ࡱ> Py{}y{} y { }  y {}y{}y{}y{}y{} !y!!{""}##$%y%%{&&m'  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry F@o@SummaryInformation(DocumentSummaryInformation8 WordDocumentH Oh+'0( H T ` l x XXXN gPlQS16-nxy Normal.dotm wangzhaoyu3@@ @(y@"Q^NMicrosoft Office Word՜.+,D՜.+,\  0R 9 (\dlKSOProductBuildVer2052-6.6.0.27680TableS8Data Cj P KSKSH;PP{$;_4-5Zx6$7D8D8$_hr1@#"4>,2h4@  m3WNoNN gPlQS Shenzhen Accord Pharmaceutical Co., Ltd. 2010 Annual Report March 2011 CONTENT IMPORTANT NOTES-----------------------------------------------------------------------------------------------------03 CHAPTER I. COMPANY PROFILE-----------------------------------------------------------------------------------04 CHAPTER II. SUMMARY OF FINANCIAL HIGHLIGHTS AND BUSINESS HIGHLIGHTS----------05 CHAPTER III. CHANGES IN SHARE CAPITAL AND PARTICULARS ABOUT SHAREHOLDERS-07 CHAPTER IV. PARTICULARS ABOUT DIRECTORS, SUPERVISORS AND SENIOR EXECUTIVES AND EMPLOYEES------------------------------------------------------------------------------------------------------11 CHAPTER V. ADMINISTRATIVE STRUCTURE-------------------------------------------------------------------18 CHAPTER VI. BRIEF INTRODUCTION OF SHAREHOLDERS GENERAL MEETING-----------------21 CHAPTER VII. REPORT OF THE BOARD OF DIRECTORS-----------------------------------------------------22 CHAPTER VIII. REPORT OF THE SUPERVISORY COMMITTEE----------------------------------------------39 CHAPTER IX. SIGNIFICANT EVENTS-------------------------------------------------------------------------------42 CHAPTER X. FINANCIAL REPORT----------------------------------------------------------------------------------63 CHAPTER XI. DOCUMENTS AVAILABLE FOR REFERENCE-----------------------------------------------181 IMPORTANT NOTES Board of Directors and the Supervisory Committee of Shenzhen Accord Pharmaceutical Co., Ltd. (hereinafter referred to as the Company) and its directors, supervisors and senior executives hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents. Chairman of the Company Mr. Shi Jinming, General Manager Mr. Yan Zhigang, Chief Financial Officer Mr. Wei Pingxiao and Financial Manager Mr. Chi Guoguang hereby confirm that the Financial Report enclosed in the Annual Report is true and complete. Director Mr. Wei Yulin,Independent Director Mr. He Zhiyi did not attend the meeting due to business but they entrusted Director Wu Aimin,Independent Director Peng Juan to attend and vote on their behalf, respectively. other directors attended the board meeting on auditing the Annual Report. No director, supervisor and senior executive would claim that he or she could not guarantee the authenticity, accuracy or completeness of the annual report s contents or that he or she holds different opinions. PricewaterhouseCoopers Zhong Tian CPAs Limited Company audited the Company s Financial Report and issued standard unqualified Report for the Company. This report has been prepared in Chinese version and English version respectively. In the event of difference in interpretation between the two versions, the Chinese report shall prevail. CHAPTER I. COMPANY PROFILE 1. Legal Name of the Company In Chinese: m3WNoNN gPlQS In English: Shenzhen Accord Pharmaceutical Co., Ltd. Abbr. of English name: Accord Pharm. 2. Legal Representative: Shi Jinming 3. Secretary of the Board of Directors: Chen Changbing Contact Address: Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province Tel: (86) 755-25875195, 25875222 Fax: (86) 755-25875147 E-mail: 0028@szaccord.com.cn 4. Registered Address: Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen Guangdong Office Address: Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen Guangdong Province Post Code: 518029 Company s Internet Web Site: http://www.szaccord.com.cn E-mail: investor@szaccord.com.cn 5. Newspapers for Disclosing the Information of the Company in the report period: Securities Times and Hong Kong Commercial Daily Internet Web Site for Publishing the Annual Report: http://www.szse.cn http://www.cninfo.com.cn The Place Where the Annual Report is Prepared and Placed: Secretariat of the Board of Directors 6. Stock Exchange Listed with: Shenzhen Stock Exchange Short Form of the Stock: AccordPharm. / Accord B Stock Code: 000028/ 200028 7. Other Information about the Company Initial registration date: August 2, 1986 Initial registration place: Shenzhen, PRC Registration date after change: December 24, 2001 Registration place after changed: Shenzhen, PRC Registered number for business license of corporation: 440301103040048 Registered number of taxation: SSD Zi No. 440301192186267 Name of the Certified Public Accountants engaged by the Company: PricewaterhouseCoopers Zhong Tian CPAs Limited Company Address:11th Floor Pricewaterhouse Coopers Center 2 Corporate Avenue 202 Hu Bin, Luwan District Shanghai 200021. PRC CHAPTER II. SUMMARY OF FINANCIAL HIGHLIGHTS AND BUSINESS HIGHLIGHTS Section I. Main business highlights Unit: RMB/ CNY 20102009Increase/decrease in this year compared with that in last year (%)2008Before adjustmentAfter adjustmentAfter adjustmentBefore adjustmentAfter adjustmentTotal operating income(RMB)13,064,428,148.6910,949,936,871.5810,997,074,919.0518.80%8,757,514,007.038,814,147,752.81Total profit(RMB)339,812,368.65260,786,881.28260,941,320.5430.23%207,908,906.63208,061,793.40Net profit attributable to shareholders of the listed company(RMB)261,116,656.70192,713,805.92192,868,245.1835.39%159,789,621.10159,942,507.87Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses(RMB)245,647,806.23190,740,616.42190,740,616.4228.79%139,335,035.00139,335,035.00Net cash flow arising from operating activities(RMB)428,159,420.65270,845,132.05273,860,877.1756.34%251,665,081.32249,718,408.15At the end of 2010At the end of 2009Increase/decrease at the end of this year compared with that at the end of last year (%)At the end of 2008Before adjustmentAfter adjustmentAfter adjustmentTotal assets(RMB)6,306,793,005.815,233,489,407.095,268,340,226.0719.71%3,944,965,333.833,981,028,605.89Owners equity attributable to shareholders of listed company(RMB)1,052,370,309.53822,666,137.68847,209,892.8324.22%659,537,950.16683,927,266.05Share capital(Share)288,149,400.00288,149,400.00288,149,400.000.00%288,149,400.00288,149,400.00 Section II. Major accounting highlights Unit: RMB/ CNY 20102009Increase/decrease in this year compared with that in last year (%)2008Before adjustmentAfter adjustmentAfter adjustmentBefore adjustmentAfter adjustmentBasic earnings per share (RMB/Share)0.910.670.6735.82%0.550.55Diluted earnings per share (RMB/Share)0.910.670.6735.82%0.550.55Basic earnings per share after deducting non-recurring gains and losses (RMB/Share)0.850.660.6628.79%0.480.48Weighted average return on equity (%)27.17%25.99%25.86%1.31%25.49%24.54%Weighted average return on equity after deducting non-recurring gains and losses (%)25.56%26.93%25.58%-0.02 %24.49%21.40%Net cash flow arising from operating activities per share (RMB/Share)1.490.940.9556.84%0.870.87At the end of 2010At the end of 2009Increase/decrease at the end of this year compared with that at the end of last year (%)At the end of 2008Before adjustmentAfter adjustmentAfter adjustmentBefore adjustmentAfter adjustmentNet asset per share attributable to shareholders of listed company (RMB/Share)3.652.852.9424.15%2.292.37 [Note]Item of deducting non-recurring gains/losses and amount Unit: RMB/ CNY Items of non-recurring gains and lossesAmountNote( If applicable)Gains and losses from the disposal of non-current assets1,969,629.82Governmental subsidy reckoned into current gains and losses, but closely relevant to the Company s business except for the governmental subsidy enjoyed in quota or ration according to the national general standards8,221,739.90Current net gains/losses of the subsidiaries from period-begin to consolidated date occurred from enterprise merger under the common control-4,607,349.97Switch back of provision for depreciation of account receivable which was singly taken depreciation test6,926,932.01Other non-operating income and expenditure except for the above items6,374,202.97Influenced amount of income tax -3,132,301.17Influenced amount of minority shareholders equity-284,003.09Total15,468,850.47- Section III. Difference in net profit as audited by Chinese and International Accounting Standard and explanation Difference in net profit as audited by Chinese and International Accounting Standard and explanation had no influences on net profit as of year 2010 and the net asset ended year 2010 of the Company. Section IV. Changes in shareholders equity and reasons in the report year Unit: RMB/ CNY ItemsShare capitalCapital reserveSurplus public reserveRetained profitMinority shareholders equityTotal shareholders equityAmount at the period-begin 288,149,400.00  31,568,488.40  17,573,057.11  509,918,947.32  55,464,963.74  902,674,856.57 Increase in the report period00 22,408,211.44  261,116,656.70  23,610,087.87 307,134,956.01 Decrease in the report period0 26,538,149.83 0 51,826,301.61 078,364,451.44 Amount at the period-end 288,149,400.00  5,030,338.57  39,981,268.55  719,209,302.41  79,075,051.61  1,131,445,361.14 Reason for change0Note 1Note 2Note 300 Note 1: Capital reserve: In 2010, the Company purchased Sinopharm TCM Co., Ltd. under the common control; in accordance with the regulations on Accounting Standards for Enterprises No. 20 - Business Combinations, while compiling the comparative statement 2009, the newly-increased consolidated units--- Sinopharm TCM Co., Ltd. Thus, capital reserve RMB5, 030,338.57 at the end of last year had an increment RMB 26,538,149.83 and adjusted to RMB 31,568,488.40, which should be listed as minus item of capital reserve after accomplishing purchase. Note 2: Surplus public reserve: Surplus public reserve in the report period increased RMB 22,408,211.44, which was withdrawn in Articles of Association by the Company. Note 3: Retained profit: Retained profit in the report period increased RMB 261,116,656.70, due to the Company made profit which increased the net profit attributable to parent company of RMB 261,116,656.70. Retained profit in the report period decreased RMB 51,826,301.61, the main reasons were: i. In accordance with Articles of Association, withdrawal of surplus public reserve RMB 22,408,211.44 made the retained profit decrease; ii. Dividend distribution made the retained profit decrease RMB 28,814,940.00; iii. The Company purchased Sinopharm TCM Co., Ltd. which considered as the transaction of enterprise merger under common control. Balance between the subsidiary s net book assets enjoyable proportion, calculated based on the holding proportion, and combination cost offsetting the owners equity. The retained profit has been adjusted with amount of RMB 603,150.17 due to the insufficient equity premium offset of the Company. CHAPTER III. CHANGES IN SHARE CAPITAL AND PARTICULARS ABOUT SHAREHOLDERS Section I. Statement of change in share capital (Ended Dec. 31, 2010, Unit: Share) Before the changeIncrease/Decrease of this time (+, -)After the changeAmountProportionNew shares issuedBonus sharesCapitalization of public reserveOthersSubtotalAmountProportionI. Restricted shares6,2860-1,572-1,5724,71401. State-owned shares2. State-owned legal person s shares3. Other domestic sharesIncluding: Domestic non-state-owned legal person s sharesDomestic natural person s shares4. Foreign sharesIncluding: Foreign legal person s sharesForeign natural person s shares5. Senior executives shares6,2860-1,572-1,5724,7140II. Unrestricted shares288,143,114100%+1,572+1,572288,144,686100%1. RMB Ordinary shares 233,257,51480.95%+1,572+1,572233,259,08680.95%2. Domestically listed foreign shares54,885,60019.05%0054,885,60019.05%3. Overseas listed foreign shares4. Others III. Total shares288,149,400100.00%00288,149,400100%Statement on changes of restricted shares Unit: Share Name of shareholdersRestricted shares at year-beginRestricted shares released in current yearIncreased restricted shares in current yearRestricted shares at year-endReason for restrictionReleasing dateChen ChangBing6,2861,57204,714Senior executives shares2011-01-01Total6,2861,57204,714   Section II. Issuance and listing of shares 1. The previous 3 years ended the report period, the Company did not issue any share and list, such as no increase issue new shares and place shares. 2. The change on shares structure of the Company: Nil Section III. About shareholders I. Ended Dec. 31, 2010, the Company had totally 15,264 shareholders, including 10,436 shareholders of A-share and 4,828 shareholder of B-share. II. Particulars about the shares held by the top ten shareholders (Ended Dec. 31, 2010): Total shareholders15,264Particulars about shares held by the top ten shareholdersNames of shareholdersNature of shareholderProportion of share heldAmount of share heldAmount of restricted shares heldShares pledged or frozenSINOPHARM GROUP CO., LTD.State-owned legal person38.33%110,459,74800ICBC GUANGFA JUFENG STOCK FUNDDomestic non-state-owned legal person3.14%9,054,310HTHK/CMG FSGUFP-CMG FIRST STATE CHINA GROWTH FDForeign legal person2.44%7,032,720ABC Greatwall Anxin Return Mixed FundDomestic non-state-owned legal person2.43%7,000,000ICBC HARVEST THEME NEW POWER STOCK INVESTMENT FUND Domestic non-state-owned legal person1.80%5,192,196ICBC BOSHI SELECTIVE STOCK FUNDDomestic non-state-owned legal person1.72%4,963,365ICBC HARVEST STRATEGY GWOTH MIX STOCK FUNDDomestic non-state-owned legal person1.71%4,920,502ICBC GUANGFA STRATEGY SELECTED MIX STOCK FUNDDomestic non-state-owned legal person1.46%4,207,399CHINA CITIC BANK MERCHANTS EXELLENT GWOTH STOCK FUNDDomestic non-state-owned legal person1.45%4,169,921ICBC E-FUND VALUE GROWTH MIX STOCK FUNDDomestic non-state-owned legal person1.39%4,000,000Particulars about shares held by the top ten unrestricted shareholdersName of shareholderAmount of unrestricted shares heldType of shareSINOPHARM GROUP CO., LTD.110,459,748RMB common shareICBC GUANGFA JUFENG STOCK FUND9,054,310RMB common shareHTHK/CMG FSGUFP-CMG FIRST STATE CHINA GROWTH FD7,032,720Domestically listed foreign shareABC Greatwall Anxin Return Mixed Fund7,000,000RMB common shareICBC HARVEST THEME NEW POWER STOCK INVESTMENT FUND5,192,196RMB common shareICBC BOSHI SELECTIVE STOCK FUND4,963,365RMB common shareICBC HARVEST STRATEGY GWOTH MIX STOCK FUND4,920,502RMB common shareICBC GUANGFA STRATEGY SELECTED MIX STOCK FUND4,207,399RMB common shareCHINA CITIC BANK MERCHANTS EXELLENT GWOTH STOCK FUND4,169,921RMB common shareICBC E-FUND VALUE GROWTH MIX STOCK FUND4,000,000RMB common shareExplanation on associated relationship or accordant action among the aforesaid shareholdersThe fund manager of ICBC HARVEST THEME NEW POWER STOCK INVESTMENT FUND and ICBC HARVEST STRATEGY GWOTH MIX STOCK FUND all refers to the Harvest Fund Management Co., Ltd., it is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies. III. The controlling shareholder of the Company Name of the controlling shareholder: Sinopharm Group Co., Ltd. Legal representative: She Lulin Date of foundation: October 6, 2008 Registered capital: RMB 2,264,568,474 Nature of economic: Limited Liability Company Business scope: industrial investment holding; management and assets reorganization entrusted by pharmaceutical enterprise; Chinese medicine, Chinese medicine tablets, chemical medicine preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic substances, toxic drugs for medical use (compatible with the business scope), vaccines wholesale, categories III: injection puncture instruments, hygienic materials & dressings, medical polymer materials and products, categories II: medical X-ray ancillary equipment and components; food marketing management (non-physical way), and domestic trade (other than special licensing), logistics and related consulting services, operating various types of goods and import and export of technology (not attached directory of import and export commodities), but excluded the import and export of goods and technology the State limits or prohibit the company. [In right of exequatur to run if refers to permission operation] IV. Particulars about the actual controller Name of the actual controller: China National Pharmaceutical Group Corporation Legal representative: She Lulin Date of foundation: Nov. 26, 1998 Registered capital: RMB 1,529,200,000 Nature of economic: enterprise  HYPERLINK "http://www.iciba.com/ownership/" \t "_blank" owned by the whole people Business scope: entrusted management and assets reorganization of pharmaceutical enterprises, consultant service of medicine industry investment project, holding exhibition and fair of surgical appliance, the wholesale of Chinese medicine, Chinese patent medicines, Chinese medicine herb in pieces, chemical material medicine, a chemical agent, antibiotics, biochemical, biological(operation period runs in right of exequatur). V. The property and controlling relationship between the actual controller of the Company and the Company is as follows:  SHAPE \* MERGEFORMAT  VI. In the report period, there existed no change in the controlling shareholder CHAPTER IV. PARTICULARS ABOUT DIRECTORS, SUPERVISORS, SENIOR EXECUTIVES AND EMPLOYEES Section I. Directors, supervisors and senior executives I. Name list of directors, supervisors and senior executives, and the attendance to board meetings NameTitleSexAgeBeginning date of office termTerminating date of office termShares held at year-beginShares held at year -endReason for changeTotal remuneration drawn from the Company in the report period (RMB 0000)(before tax)Drawing remuneration from shareholders units or other related units or notShi JinmingChairmanMale432007-09-112011-04-3000YesWei YulinDirectorMale532007-09-112011-04-3000YesFu Mingzhong DirectorFemale602008-04-252011-04-3000YesWu Ai minDirectorMale412007-09-112011-04-3000YesYan ZhigangDirector, General ManagerMale512008-12-262011-04-3000124.65NoTian WeixingDirectorFemale532010-04-162011-04-3000YesChen ShuIndependent DirectorFemale562007-09-112011-04-30008.00NoHe ZhiyiIndependent DirectorMale552010-06-282011-04-30004.00NoPeng Juan Independent DirectorFemale462007-09-112011-04-30008.00NoJiang XiuchangSupervisorMale472010-06-282011-04-3000YesGuan XiaohuiSupervisorFemale402007-09-112011-04-3000YesLin ZhaoxiongDeputy General ManagerMale432008-12-262011-04-3000101.00NoTan GuoshuDeputy General ManagerMale562007-09-112011-04-300080.05NoLiu Jun Deputy General ManagerFemale532008-12-262011-04-300086.00NoLin MinDeputy General ManagerMale462008-12-262011-04-300086.00NoLin XinyangDeputy General ManagerMale462007-09-112011-04-300064.50NoDeng Baojun Deputy General ManagerMale492010-12-292011-04-30000NoWei PingxiaoCFOMale472007-09-112011-04-300073.27NoChen ChangbingSecretary of the Board Male432007-09-112011-04-3062864714Sold39.56NoWang HuaiqinSupervisorMale532007-09-112011-04-300037.12NoTotal-----62864714-712.15- Note: The term of office of 5th Session of the Board and Supervisory Committee has expired. The Board and Supervisory Committee have held a meeting on March 18, 2011 for the approval of election of the Board and Supervisory Committee respectively. Name of the directorsPositionsDue Presence (times)Presence in person (times)Attending the meeting in way of communication (times)Entrusted presence (times)Absence (times)Whether attending the meeting in person in successive two times or notShi JinmingChairman1211010NoWei YulinDirector1211010NoFu MingzhongDirector1211010NoWu Ai minDirector1221000NoYan ZhigangDirector1221000NoTian WeixingDirector101900NoChen ShuIndependent Director1221000NoHe ZhiyiIndependent Director70610NoPeng JuanIndependent Director1221000NoII. Particulars about the position held by directors and supervisors in Shareholding Company 1. In the report period, the position held by directors, supervisors and senior executives in Shareholding Company NameUnits with position or concurrent positionRelationship with the CompanyPositionOffice termShi JinmingSinopharm Group Co., Ltd.Controlling shareholderDeputy General ManagerFrom Jan. 2009Wei YulinSinopharm Group Co., Ltd.Controlling shareholderSecretary of Party Committee, General ManagerFrom Dec. 2009Fu MingzhongSinopharm Group Co., Ltd.Controlling shareholderVice-chairwomanFrom Dec. 2009 to Nov. 2010Wu AiminSinopharm Group Co., Ltd.Controlling shareholderDeputy General ManagerFrom Nov. 2006Secretary of the BoardFrom March 2008Tian WeixingSinopharm Group Co., Ltd.Controlling shareholderMinister of Industrial Development Department From March 2008 2. In the report period, position and concurrently post of directors, supervisors and senior executives in the units barring the shareholders units NameUnits with position or concurrent positionRelationship with the CompanyPositionShi JinmingSinopharm Group Hong Kong Co., Ltd.Affiliated enterprise of the CompanyGeneral ManagerSinopharm Distribution Center Co., Ltd. Affiliated enterprise of the CompanyChairman, General ManagerSinopharm Group Guizhou Co., Ltd.Affiliated enterprise of the CompanyChairmanSinopharm Group Yunnan Co., Ltd. Affiliated enterprise of the CompanyChairmanSinopharm Group Hainan Co., Ltd.Affiliated enterprise of the CompanyChairmanSinopharm Group Hunan Co., Ltd.Affiliated enterprise of the CompanyChairmanSinopharm Group Hubei Co., Ltd.Affiliated enterprise of the CompanyChairmanA-Think Pharmaceutical Co., Ltd.Affiliated enterprise of the CompanyChairmanChina National South West Medicine Co., Ltd. Affiliated enterprise of the CompanyChairmanSinopharm Group Jiangxi Co., Ltd.Affiliated enterprise of the CompanyChairmanSinopharm Group Fuzhou Co., Ltd.Affiliated enterprise of the CompanyChairmanSinopharm Group Fujian Co., Ltd.Affiliated enterprise of the CompanyDirectorSinopharm Group Chongqing Co., Ltd.Affiliated enterprise of the CompanyDirectorWei YulinSinopharm Holding Beijing Huahong Co., Ltd. Affiliated enterprise of the CompanyChairmanSinopharm Beijing TianXing Puxin Biological Medicine Co., Ltd. Affiliated enterprise of the CompanyChairmanChina National medicines Corporation Ltd.Affiliated enterprise of the CompanyDirectorFu MingzhongSinopharm Group Hong Kong Co., Ltd.Affiliated enterprise of the CompanyChairmanChina National medicines Corporation Ltd.Affiliated enterprise of the CompanyDirectorWu AiminSinopharm Chemical Reagent Co., Ltd. Affiliated enterprise of the CompanyChairmanSinopharm Group Zhejiang Co., Ltd.Affiliated enterprise of the CompanyChairmanSinopharm Guoda Pharmacy Co., Ltd. Affiliated enterprise of the CompanyDirectorSinopharm Group Hong Kong Co., Ltd.Affiliated enterprise of the CompanyDirectorChina National medicines Corporation Ltd. Affiliated enterprise of the CompanySupervisor III. Main work experience of present directors, supervisors and senior executives: 1. Member of the Board of Directors Chairman  Mr. Shi Jinming, EMBA of Sun Yat-Sen University, studied in Shanghai University of Finance and Economics majored Commerce Economics from Sep. 1985 to July 1989. He ever worked in China Medicine (Group) Guangzhou Company from July 1989; took the turns of manager of China Medicine (Group) Guangzhou Yuexing Company, manager of medicine department of SINOPHARM Medicine Co., Ltd., deputy GM of China Medicine (Group) Guangzhou Yuexing Company and concurrently manager of Yuexing Company from Mar. 1995; he took the post of GM of Sinopharm Group (Guangzhou) Co., Ltd. from Apr. 2003 to Dec. 2006; director and GM of the Company from Feb. 2004 to Dec. 2008, took concurrently the post of chairman of Sinopharm Group (Guangzhou) Co., Ltd. from Jan. 2007, and he took the post of chairman of the 5th Board of Directors of the Company from Dec., 2008 and concurrently takes the post of deputy general manager of Sinopharm Group Co., Ltd since Jan. 2009. Director  Mr. Wei Yulin, EMBA, Licensed Pharmacist and senior economist, worked at Tianjing Pharmaceutical Company as salesman from Oct. 1976 to Nov. 1981; centre Lab Technician in Tianjin Hebei Pharmaceutical Plant from Dec. 1981 to Aug. 1984; took the turns of salesman of Leechdom Department in Sinopharm Tianjin Medicine Station, deputy general manager and general manager of pharmaceutical company in development zone from Sep. 1984 to June 1998; deputy general manager, standing deputy general manager, party secretary and general manager and chairman of Sinopharm Tianjing Co., Ltd from July 1998 to April 2006; since March 2008, he held the post of chairman of Sinopharm Logistics Co., Ltd; he was the deputy general manager of Sinopharm Group Co., Ltd. from Jan. 2003 to Dec. 2009 and the general manager(Chairman) of Sinopharm Group Co., Ltd since Dec. 2009; he was the director of the 5th board of directors of the Company since Sep. 2007. Director  Ms. Fu Mingzhong, Postgraduate, senior economist; began to work in Harbin General Pharmaceutical Factory No.2 Factory with taking the post of leader of Crystallization workshop from Oct. 1970; worked in Harbin General Pharmaceutical Factory No.3 Factory with successively taking the posts of director of injection workshop, director of Quality Management Office, director of Office, deputy factory director, member of party committee from June 1972; from March 1992, she was the director of Harbin Pharmaceutical Group LTD, general manager and party secretary of Harbin Pharmaceutical Corporation; deputy general manger and member of party committee of China National Pharmaceutical Group Corporation from Dec. 1997; successively director of China National Pharmaceutical Group General Corporation, and standing deputy general manager and member of party committee of China National Pharmaceutical Industry Corporation from Jan. 1999; chairman, member of party committee, secretary of party committee of China National Medicines Corporation Ltd from Jan. 2001 to Feb. 2008; secretary of party committee and general manager of Sinopharm Group Co., Ltd. from Feb. 2006 to Dec. 2009, vice chairman of Sinopharm Group Co., Ltd. from Dec. 2009 to Nov. 2010 ; she was the chairman of the 5th board of directors of the Company from April 2008 to Dec. 2008; director of the 5th board of directors of the Company since Dec. 2008. Director  Mr. Wu Ai min, EMBA, accountant, took the turns of senior manager of Jiangsu Property Assessment Firm, copartner of Jiangsu Renhe Property Assessment Company, financial chief supervisor and manager of investment center of Xuzhou Huaihai Food Town, and so on from Aug. 1992; takes the position of financial chief supervisor and deputy general manager(vice chairman) of Sinopharm Group Co., Ltd. from Jul. 2003 till now; from March 2008, took the post of secretary of the board of Sinopharm Group Co., Ltd.; and takes the post of director of the 5th Board of Directors of the Company from Sep. 2007. Director  Mr. Yan Zhigang, bachelor of pharmacy, MBA, chief engineer and Licensed Pharmacist, took the turns of technician, section chief of QC department, deputy GM and manager, etc. of Guizhou Medicine Company from Jul. 1983; held the position of plant manager of Shenzhen Medicinal Oil Plant, deputy GM of Shenzhen Medicine Company, deputy GM of Shenzhen Accord Pharmacy Franchise Company from Jun. 1996; from Feb. 2000 to Dec. 2008, took the post of plant manager of Shenzhen Pharmaceutical Factory, secretary of party branch and general manager of Shenzhen Zhijun Pharmaceutical Co., Ltd.; since Feb. 2000, took the post of vice-chairman of Shenzhen Main Luck Pharmaceuticals Inc.; from Jan. 2005 to Dec. 2008, he concurrently was the deputy general manager of Shenzhen Accord Pharmaceutical Co., Ltd; from Oct. 2007, he is concurrently director of Sichuan Antibiotics Industrial Institute Co., Ltd.; since Dec. 2008, he is the general manager of the Company; and takes the post of director of the 5th Board of Directors of the Company from Feb. 2009. Director  Ms. Tian Weixing, bachelor degree and Licensed Pharmacist, took the position of vice-department chief of Quality Department and Enterprise Management Department and department chief of Enterprise Planning of China national Pharmaceutical Company from 1982 to 1995 successively; took the position of vice-manager of Pharmaceutical Department, Director of Enterprise Planning Department of CAPC and Office Director of China National Pharmaceutical Group Corporation from 1995 to 1997 successively; took the marketing manager of China National Pharmaceutical Group Corporation from 1997 to 2000; took the position of Director of Planning Development Department of China National Medicines Corporation Ltd. from 2000 to 2008 and took the position of Director of Industrial Development of SINOPHARM GROUP CO., LTD. since from 2008. Independent director  Ms. Chen Shu, bachelor degree, ever worked as cadre, secretary of court, judger and vice president, etc. at People s Court of Huangling County, Shanxi province, from Oct. 1985 took the post of section chief of Law Firm of Liwan District, Guangzhou City, vice administrator of administration of justice till now; copartner and section chief of Guangzhou Law Firm from Jan. 1995; copartner and section chief of Guangzhou Jinpeng Law Firm from Feb. 1996; chief secretary of Guangzhou Lawyer Association and concurrently vice president of China National Lawyer Association and vice president of Guangdong province Lawyer Association, as well as NPC deputy of the 10th and 11th session from Mar. 2002 till now; and she takes the post of independent director of the 5th Board of Directors of the Company from Sep. 2007. Independent director  Mr. He Zhiyi, Doctor Degree of Fudan University, Post doctorate of Beijing University, Professor and PH.D adviser, work presently as the vice Dean of Antai College of Economics& Business Administration of SJTU; Worked as the professor, PH.D adviser and Dean Assistant of Guanghua Administration College of Beijing University and Office Director of Administration Case Research of Beijing University before; worked as the deputy dean of Development& Research of Poverty-zone of Beijing University, executive director of Chinese Enterprise Research Center of Beijing University, executive editor of Business Comments of Beijing University magazine, vice-chairman and secretary of the Chinese Federation for Corporate Social Responsibility, vice-chairman and secretary of CNEMA and Director of IFSAM etc. Independent director  Ms. Peng Juan, Doctor degree, associate professor, mayor research direction is finance strategy and management, marketing auditing and financing marketing. From July 1988 to July 1997, she was the instructor in Accounting Department of Shanghai Maritime University. From Aug. 1997 taught at financing and accounting department of management institute of Shanghai Jiaotong University till now, now is in charge of deputy dean and concurrently secretary of CPC; and she takes the post of independent director of the 5th Board of Directors of the Company from Sep. 2007. 2. Members of supervisors: Supervisor  Mr. Jiang Xiuchang, bachelor, senior economist, senior accountant, worked as deputy director of Information Department, deputy director of Transformation System Office, deputy director of Financial Department and deputy director of Pharmaceutical Department of China National Pharmaceutical Group Corporation from July 1986 to March 2002 successively; took the position of deputy director, director and CFO of China National Medicines Corporation Ltd. from March 2002 to April 2010 successively; took the CFO of SINOPHARM GROUP CO., LTD. since from June 2010. Supervisor  Ms. Guan Xiaohui, Master of Accounting, Certified Public Accountant and Economist; clerk of Jiangxi Sub branch of Industrial and Commercial Bank of China from July 1992 to April 2000; financing manager of business department of Shanghai Fosun Pharmaceutical(Group) Co., Ltd. From May 2000 to Jan. 2002; CFO of Shanghai Fosun Pharmaceutical Co., Ltd from Jan. 2002 to Nov. 2004; deputy CFO of Shanghai Fosun Pharmaceutical(Group) Co., Ltd from Nov. 2004. She took the supervisor of the 5th supervisory committee of the Company since Sep. 2007. Employee Supervisor  Mr. Wang Huaiqin, 3-years regular college graduate, political commissar, assistant accountant; he served in army, took the turns of soldier, amanuensis, secretariat and Platoon Sergeant from Dec. 1976 to Sep. 1983; secretary in charge of political works in team 205 of Second Architecture Engineering Company of Shenzhen Construction Group from Sep. 1983 to Aug. 1985; office director of Daily Health Products Company and concurrently chairman of Workers Union, person in charge of finance, office director of Medicinal Oil Plant, finance minister and concurrently chairman of Workers Union, section chief of Personnel Allotment Department and concurrently chairman of Workers Union of Shenzhen Medicines Production Supply Corporation from Aug. 1985 to Dec. 2000; chief of human resources department, deputy minister and concurrently chairman of Workers Union of Shenzhen Accord Pharmaceutical Co., Ltd from Dec. 2000 to June 2005; director and concurrently deputy office director of party and Masses Work Department, and the chairman of the first Workers Union of Shenzhen Accord Pharmaceutical Co., Ltd till June 2005. He took the supervisor of the 5th supervisory committee of the Company since Sep. 2007. 3. Senior executives: General Manager  Mr. Yan Zhigang, referring to the aforesaid introduction of members of directors for details. Deputy General Manger  Mr. Lin Zhaoxiong, male, born in 1967, senior MBA, Pharmacist-in-charge. He began to work in Guangzhou Medicine Industry Research Institute in July 1990; worked in Hangzhou MSD Pharmaceutical Co., Ltd from Jan. 1993 to Oct. 1997; Guangdong Huajian Pharmaceutical Co., Ltd from Nov. 1997 to Dec. 1998; worked in Sinopharm Group Guangzhou Co., Ltd. with successively taking the posts of deputy general manger and manager of Pharmacy Department, and manger of Pharmaceutical Company and majordomo of Operation Management Department from Jan. 1999 to Dec. 2003; deputy general manager of Sinopharm Group Guangzhou Co., Ltd from Jan. 2004 to Dec. 2006; from Dec. 2006 till now, he took the post of general manger of Sinopharm Group Guangzhou Co., Ltd. Deputy General Manger  Mr. Tan Guoshu, on-study postgraduate, assistant economist and political commissar, ever took the post of deputy director of Gongxiaoshe, Dalonghua, Fengshun County, manager of affiliated corporation, deputy GM of Labor Service Company, Labor Bureau, Fengshun, GM of Labor Service Company, Boned Zone, Shatoujiao District, Shenzhen, deputy GM of Shenzhen Best Machinery Electronic Company, organization charger of Labor Service Company of Shenzhen Food Headquarter, and so on; from Apr. 1996 took the post of deputy director, minister of personnel minister and GM associate, etc. of supervision administration office of Shenzhen Medicine Produce & Supply Headquarter, and concurrently GM of Shenzhen Xiannuo Medicine Company, manager of Shatoujiao Medicine Company and manager of Nanshan Medicine Company, etc. during that time; held the position of minister of talents resources department of the Company and later concurrently vice secretary of DSC of the Company from Jan. 2001, and deputy GM and later concurrently vice party secretary of the Company from Jun. 2003. Deputy General Manger  Ms. Liu Jun, Female, born in 1957, Economist, began to work in 1974; ever worked in China National Pharmaceutical Group Guangzhou Corporation with successively taking the posts of deputy dean and dean of Manager Office, deputy general manager, vice party secretary, general party secretary and chairman of Labor Union from June 1976 till now; from Oct. 2003 till now, she took the posts of general party secretary, deputy general manager and chairman of Labor Union of Sinopharm Group Guangzhou Co., Ltd. Deputy General Manger  Mr. Lin Min, born in 1964, senior MBA, Pharmaceutical Engineer, Licensed Pharmacist, worked in GuangDong Medical College from July 1986 to April 1992; took the posts of marketing minister, assistant to general manager of Guangdong Global Pharmaceutical Company Ltd. from April 1992 to Dec. 1997; deputy factory director of Manufacturing Factory of Guangdong Pharmaceutical University from Jan. 1998 to Dec. 2000; ever worked in China National Pharmaceutical Group Guangzhou Corporation with successively taking the posts of assistant to manager, deputy general manger of Pharmacy Department and deputy general manger of purchasing in Pharmaceutical Company from Jan. 2001 to Nov. 2003; supervisor of Guangzhou pharmacy sales of Sinopharm Group Guangzhou Co., Ltd from Nov. 2003 to Jan. 2005; general manager of Sinopharm Group Liuzhou Co., Ltd from March 2006 to Nov. 2007; from Jan. 2005 till now, deputy general manager of Sinopharm Group Guangzhou Co., Ltd. Deputy General Manger  Mr. Lin Xinyang, MBA, Licensed Pharmacist, from Jan. 1996 took the turns of deputy GM of Nanfang Pharm. Co., deputy GM of China Medicine Group (Guangzhou) Company Yuexing Company, general supervisor of PD of Sinopharm Group Guangzhou Company; took the post of deputy GM of Sinopharm Group Guangzhou Company from Jan. to Dec. 2004; took the post of deputy GM of the Company from Jan. 2005. Deputy General Manger  Mr. Deng Baojun, MBA, senior engineer and Licensed Pharmacist, worked as the doctor in Hospital of Personnel of 8-Bureau of Water-Electricity from July 1983 to July 1988; worked as the development personnel in Shenzhen Pharmaceutical Plant from September 1991 to May 1996; took the position of vice minister and minister of the market department and sales department respectively in Shenzhen Pharmaceutical Plant from May 1996 to September 2000; took the position of assistant of factory manager and sales majordomo in Shenzhen Pharmaceutical from September 2000 to August 2003; took the position of deputy general manager of Shenzhen Zhijun Pharmaceutical Co., Ltd. from August 2003 to December 2008; took the position as General Manager of Shenzhen Zhijun Pharmaceutical Co., Ltd. from December 2008 till now; took the position of deputy general manager and manage of pharmaceutical business department of Shenzhen Accord Pharmaceutical Co., Ltd. since from December 2010. Chief Financial Officer  Mr. Wei Pingxiao, MBA, accountant, took the turns of Financial department of State-owned Beijing Electronic Tube Plant, Modern Electronic Shenzhen Industrial Company, China Electronic Industrial Headquarter from Aug. 1985; and took the turns of deputy section chief of financial department of China Electronic Information Industry Group, financial director of AMOI, section chief of planning financial department of China Electronic Finance Leasing Company, Deputy GM of AMOI Beijing branch, financial charger of AMOI and director of its subsidiary from Apr. 1993; and hold the post of financial general supervisor of the Company since Dec. 2004. Secretary of the Board  Mr. Chen Changbing, Master Degree, ever took the post of secretary of the 3rd, 4th and 5th Board of the Directors of the Company from Dec. 2000; concurrently took the post of majordomo in Planning Investment Management Department of the Company. IV. Particulars about elections of directors, supervisors and engaging of senior executives in the report period 1. On March 20, 2010, Ms. Tian Weixing was agreed to nominate as the director candidate of 5th Board of Directors on 15th Meeting of 5th Board of Directors Meeting. And the proposal should approve by Shareholders General Meeting 2009 held on April 16, 2010. 2. On June 11, 2010, Mr. He Zhiyi was agreed to nominate as the independent director candidate of 5th Board of Directors on 17th Meeting of 5th Board of Directors Meeting. And the proposal should approve by 2nd Extraordinary Shareholders General Meeting 2010 held on June 28, 2010. 3. On June 11, 2010, Mr. Jiang Xiuchang was agreed to nominate as the supervisor candidate of 5th Board of Directors on 15th Meeting of 5th Supervisory Committee. And the proposal should approve by 2nd Extraordinary Shareholders General Meeting 2010 held on June 28, 2010. 4. On June 11, 2010, Mr. Deng Baojun was agreed to re-engage as the deputy general manager of the Company on 15th Meeting of 5th Supervisory Committee. Section II. Number of employees and professional quality At end of the year 2010, the Company (including the subsidiaries) had totally 4,187 on-the-job employees. Profession/occupation compositionEducation BackgroundProfession Number Proportion (%)EducationNumberProportion (%)Production personnel123529.50%Master degree or above1132.70%Salespersons170740.77%Bachelor degree114327.30%Technical personnel771.84%3-years regular college graduate103024.60%Financing personnel 2004.78%Polytechnic school graduate69316.55%Administrative and other personnel 96823.12%Senior high school graduate or below120828.85%Total4187100%Total4187100% CHAPTER V. ADMINISTRATIVE STRUCTURE Section I. Company Administration In the report period, strictly in accordance with the requirement from Company Law, Securities Law and CSRC and regulation documentations from Shenzhen Stock Exchange concerning the company administration, the Company continued to strength the system construction, perfected its governance structure, standardized operation and promoted company administration deeply for the purpose of standard of governance improved. In the report period, performance of the Shareholders General Meeting, Board of Directors Meeting and Supervisory Committee are still in the effective operation. The procedures of convening/holding, the proposal and decision-making concerning the above mention  Three Meetings are complied with relevant regulations strictly; The various special committee underlie the Board are in the favorable condition of operation in regulations and responsibility which provided a strong support on the scientific-decision-making towards significant business projects; the Board of the Company responsible for publicly promise, honest and diligence on its duty, supervisors can supervise and examine the Director, senior executives and financial status of the Company efficiency and independently; between the Shareholders General Meeting ,Board, Supervisory Committee and Management executives, separation responsibility have been independently, and operated in a favor condition with mutual restriction. A reasonable and efficiency administration structure of the Company has been in formed. In conclusion, in the report period, the administration of the Company meets the requirements of relevant regulations of governance on listed company. Section II. Particulars about existing non standard governance of the Company As a state-owned share controlling listed company, the Company implemented related regulations on state asset management of controlling shareholders and actual controlling shareholders. Details are as follows: No.Parties of information reported toRelationship between parties of information reported to with listed companiesSort of informationBasis of the reported informationDate or period of reporting1Sinopharm Group Co., Ltd.The 1st largest shareholderFinancial statementDemand of consolidated statement of the largest shareholderScheduled2China National Pharmaceutical Group CorporationActual controller Report of asset evaluation, etc.Management methods on State-owned equity transfer and equity investment of China National Pharmaceutical Group CorporationTemporary According to the requirements of Notice on Strengthening Supervision of Private Information Provide By Listed Companies to Majority Shareholders and Actual Share Controllers and Supplementary Notice on Strengthening Supervision of Private Information Provide By Listed Companies to Majority Shareholders and Actual Share Controllers, the board of directors as well as supervisory committee examined and passed Rules of Procedures for Implementing Inside Information Staff Reserve and Governance of Non Standard Information Disclosure in Sep. 2007, in which agreed the Company send financial reports to its majority shareholders regularly on carrying out related regulations of state-owned asset management, as well as implement secret-keeping systems and inside information staff reserve system when reserving to majority shareholders on disposition of state-owned asset and send Statistic Table of Non-public Information to Shareholders and Actual Controller to Shenzhen Securities Regulatory Bureau since from September 2007. Section III. Performance of the Independent Directors (I) The presences to the meetings of board by independent directors In year 2010, the Company held 12 meetings of board (Including the meetings by communication), and the presences to the meetings of board by independent directors were as follows: Name of independent directorsTimes are supposed to be attendedPresence in person Entrusted presenceAbsenceRemarksChen Shu121200He Zhiyi7610 (Took the office term from June 2010). Entrusted Peng Juan in written form to attend and vote oncePeng Juan121200(II) In the report period, with holding the spirit of being responsible for the medium and small shareholders, independent directors strictly performed the obligations of fairness and diligence; made their useful suggestion and opinion on the operation decision-making, lawsuits and financial management; did not have objections for the proposals examined by board of directors and other events; examined earnestly the significant events issued by independent directors and made independent judge and independent opinion in writing form on significant related transactions, routine related transactions, engagement of CPAs, etc; performed their relevant duties on protecting the legal interests of medium and small shareholders. Independent directors made important plays in the operation in special committees in board of directors. At the same time, the Company can ensure rights of knowing for independent directors and other directors. Section IV. Particulars about the Company s  Five Separations from the largest Shareholder in respect of Business, Assets, Organization, Personnel and Finance: The Company completely separated with the largest shareholder in respect of business, assets, organization, personnel and finance, and had independent and complete self-control business ability. 1. In respect of business: The Company was completely independent from the controlling shareholder in business, the Company had independent and integrated business system, and autonomous operation capacity; the Company owned independent purchase and sales system. The purchasing center, subsidiaries and production enterprises are responsible for purchasing all medicine, appliance and raw resources used in production and distributing products. Production, supply and distribution departments and R&D were separated from each other. The Company was independent legal person facing the market. 2. In respect of personnel: The largest shareholder and actual controller commended directors and managers according to legal procedures, which was no particulars about intervening appointment and removal of human resource decided by the Board of Directors and General Shareholders Meeting; the Company set independent human resource department in charge of examination, training and salary audit work of all the employees, and established each rules and regulations which the employees should obey and made employees handbook. The employees labor, human resources, salary and relevant social security including endowment insurance and medical insurance were independently managed. 3. In respect of organization: The production management and administration management was completely independent with the largest shareholder and actual controller: official organization and production management place separated with the largest shareholder; the Company set complete legal person administration organization, the board of directors, supervisory committee and manager team worked independently and took their own responsibilities according to relevant regulations of Articles of the Association. 4. In respect of assets: The Company was completed independent from its controlling shareholder in term of assets and independently operates. The Company not only possessed independent production system, auxiliary production system and complementary facilities, but also enjoyed such intangible assets as industrial property right, trademark, non-patent technology, etc. 5. In respect of finance: The Company established independent financial department and independent financing checking system; The Company independently opened account in bank, with no particulars about depositing capitals in the account of large shareholders and financial company and accounting department controlled by other related parties; The financial personnel of the Company were independent, who did not take pert-time job or draw remuneration from the largest shareholder; The Company paid tax legally and independently. Section V. Performance Valuation, Incentive and Restriction Mechanism for Senior Executives Senior executives of the Company took responsibility for the board of directors, in the report period, the board of directors implemented the performance checking mechanism that the remuneration of senior executives related with their performance checking, with achievement as direction, and made relevant reward and punishment according to target completion. The Company s relevant incentive and restriction mechanism gradually in order to further exert the enthusiasm and creativity of senior executives, urge the senior executives to perform the obligations of being honest and diligent. The Company had no incentive mechanism for senior executives such as stock option, purchase of management team and equity held by owner. Section VI. Establishment and Completeness on Internal Control System (I) Self-evaluation report of the board of directors on its internal control system The Company provided Self-Evaluation Report of Internal Control (Details could be found on Juchao Website http://www.cninfo.com.cn). (II) Independent directors independent opinions on self-evaluation of on its internal control system In 2010, the Company hire Deloitte Touche Tohmatsu,the international accounting firm, to advise on the internal control structure and drawing up the internal control manual,manual of internal control self-evaluation and other important documents,on the base of previous, the company established and perfected internal control system according to actual operations. The establishment and content of internal control system complied with relevant regulations and laws as well as relevant requirement from CSRC which formed an integrity and strictly system on internal control of the Company. Internal control system have been established perfect basically in the Company which covered the business control, accounting system control, internal auditing control, information system control and environment control etc. the above mentioned internal control system can meet the requirements from the development of the Company and management adaptation. The internal control of the Company were focused on financial management, related transaction, external guarantee and information disclosure to ensure the orderly operation for the Company, played effective functions on operation risks and protected interests for all shareholders. (III) Supervisory Committee s opinions on self-evaluation of its internal control system According to the requirement of relevant laws, regulations and standard document of Ministry of Finance, CSRC and Shenzhen Exchange, following basic principles of internal control and combined with self situation, the Company established and perfected internal control system, the administration structure of legal person was perfect, internal control system was complete, which could ensure formal and orderly operation and assets safety of the Company. In the report period, there was no particular about disobeying Guidelines for Internal Control of Listed Company issued by Shenzhen Exchange or the Company internal control system. the supervisory committee thought that, the self-evaluation of internal control was accurate, true and complete, which inflected the actual situation of the Company internal control. CHAPTER VI. PARTICULARS ABOUT THE SHAREHOLDER S GENERAL MEETING In the report period, the Company held 5 Shareholders General Meetings: I. The 1st Extraordinary Shareholder s General Meeting of 2010 The 1st Extraordinary Shareholder s General Meeting 2010 was held at the meeting hall on the 5/F of the Company, No. 15, Ba Gua Si Road, Futian District of Shenzhen on Feb. 10, 2010. The relevant notice was published on Securities Times and Hong Kong Commercial Daily dated Feb. 11, 2010. II. The 2009 Annual Shareholders General Meeting The 2009 Annual Shareholders General Meeting was held at the meeting hall on the 5/F of the Company, No. 15, Ba Gua Si Road, Futian District of Shenzhen on April 16, 2010. The relevant notice was published on Securities Times and Hong Kong Commercial Daily dated April 17, 2010. III. The 2nd Extraordinary Shareholder s General Meeting of 2010 The 2nd Extraordinary Shareholder s General Meeting was held at the meeting hall on the 5/F of the Company, No. 15, Ba Gua Si Road, Futian District of Shenzhen on June 28, 2010. The relevant notice was published on Securities Times and Hong Kong Commercial Daily dated June 29, 2010. IV. The 3rd Extraordinary Shareholder s General Meeting of 2010 The 3rd Extraordinary Shareholder s General Meeting was held at the meeting hall on the 5/F of the Company, No. 15, Ba Gua Si Road, Futian District of Shenzhen on September 3, 2010. The relevant notice was published on Securities Times and Hong Kong Commercial Daily dated September 4, 2010. V. The 4th Extraordinary Shareholder s General Meeting of 2010 The 4th Extraordinary Shareholder s General Meeting was held at the meeting hall on the 5/F of the Company, No. 15, Ba Gua Si Road, Futian District of Shenzhen on December 28, 2010. The relevant notice was published on Securities Times and Hong Kong Commercial Daily dated December 29, 2010. CHAPTER VII. REPORT OF THE BOARD Section I. General operation of the Company in the report period 2010 was the last year of the Eleventh Five-Year Plan of Accord Pharmacy, the Company actively grasped the chance brought by the new pharmacy reform surrounding closely the operation theme of Seizing Opportunity, Perfecting Distribution Network, Expanding the Industry Platform, Promoting Rapid Growth of Accord Pharmacy, deeply boost the integration of management and control, integration of distribution and operation as well as integration of industry and industry chain. The head office enhanced management and control on distribution and operation, completed the function support; perfected the network installation of distribution field, constantly optimized business structure, improved the regional marketing position; promoted the platform construction of industry field, deepened industry chain fittings, progressed quality of management. In 2010, significant growth happened in various economical standards, long-term progress occurred in various work, thus the comprehensive strength was further improved. I. Particulars and characteristic of economic operation of the Company in 2010 (I) Completion of main economic standards In 2010, Accord Pharmacy completed Total operating income RMB 13.064 billion, up 18.80% over last year; realized Total profit of RMB 0.34 billion, up 30.23% over last year. Including, the distribution business department completed main business income of RMB11.360 billion, up 19.52% over last year; realized Total profit of RMB 0.22 billion, up 50.64% over last year. Pharmacy business departmentnot included m3W-No completed main business income of RMB 1.574 billion, 14.85% up y-o-y; realized Total profit of RMB 0.16 billion, up 64.62% over last year. (II) Characteristics of economic operation in 2010: Overall economic operation in 2010 was reflected as five major characteristics: Firstly, the sales income and total profit kept a rapider growth, respectively increasing 18.71 % and 30.23% respectively over the same time of last year. The profiting space improved 0.17% over the same period of last year and profitability increased. Meeting with the standard of industry, overall development trend of the Company performed well; the net return on assets ranked a higher position, financial expense rate and management and control of inventory was better, but the distribution and operation quality are still waiting for a promotion, and ultra-red receivable wasn t improved yet; high capital cost and single financing channel added the risk of finance of the Company. Secondly, the network sink got a significant performance and the amount of customers constantly increased. Business of the new company rapidly expanded, and the amount of customers was promptly increased. Till the end of 2010, new customers increased by 2,398; while the effective members of the Good Gift of Zhijun have amounted to 10,813. Thirdly, assistance performance of external expansion got a growth, the newly established subsidiaries developed rapidly. Foshan Company, Zhanjiang Company, Dongguan Company and Meizhou Company obtained considerable improvement in sales amount. Fourthly, equal development of business and products structure, the structure was further optimized. The sales of 6 major types of products of Zhijun Pharmacy took 82.0% of total sales amount, and the products structure developed equally. The distribution products occupied 45% of the sales. Varieties structure was constantly optimized; net hospital sales business took a ratio of 51%, and the proportion was constantly ascending. Fifthly, risk controlling ability was strengthened further, assets structure was more rational. Through promotion of internal control item, the Company built a series of systemic risk controlling system, and obtained active performance. The risk assets of 2010 the Company took a ratio of 1.55% in current assets, down 0.12% over the beginning of the year. II. Main work completed in 2010 (I) Compiled the Twelfth Five-Years plan, confirmed the development direction of future Faced with the future 5 years, the Company established compiling leaders and wok team about the Twelfth Five-Years plan, and collected external talents, fully encouraged various staffs to participate in discussions, did research on and judged future development tendency of pharmacy industry, teased opportunity and challenge, and combined self-strengths and weaknesses, formulated the Twelfth Five-Years plan of Accord Pharmacy. The plan defined the position of the Company, distribution business department and pharmacy business department, as well as development goal of the Twelfth Five-Years, thus offered a direction for the future development of the Company. (II) Completed construction of operation system, improved anti-risk ability Firstly, the Company took construction of information system as important means for improving operation efficiency and effectively preventing risk. In 2010, the Company accomplished upgrading and approval of NC financial system earlier or later, realized integration of CMS system in Guangzhou and Shenzhen as well as coverage of OA system; upgrading of ERP system of Zhijun Pharmacy has been accomplished, and its up line preparation has been started. Construction and perfection of information platform forcefully supported the development of business. Secondly, the Company constantly optimized capitals calculation, improved utilization efficiency of capitals, and took supplier chain s financing as main line, expanded financing channels, ensuring the timely arrival of capitals and normal operation. Thirdly, the Company should enhance risk appraisal of upper and lower cofferdam customers of distribution through aspects of accounts receivable, gross profit, cost and inventory. Fourthly, intensified audit on internal control, completed internal control system and took effective measurements on problems found in external auditing, thus further improved risk management and control as well as estimate system of Accord Pharmacy. (III) Speed up distribution network construction, improved regional marketing position Size of the scale and the perfection degree of branches a      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxz{|}~re key factors for distribution business forming comparative advantage. In 2010, the Company laid stress on enhancing network installation in blank market, earlier or later purchased Zhanjiang Tianfeng Pharmacy, Meizhou New Special Drug and Huizhou Zhongsheng Pharmacy, and set up subsidiaries, further perfected network allocation of distribution; the Company innovated purchasing means, successfully purchased the medicine business of Nanning Pharmacy Company, and purchased Shenzhen Yanfeng Pharmacy for the second time and restructured it, further improved regional marketing position. Meanwhile, the Company earlier or later invocated Shenzhen Logistic Center, started project construction of Nanning Logistic Center, promoted partial removal and expansion projects of Liuzhou Logistic, and rebuilt home-delivery center of Dongguan, Zhanjiang and Meizhou one by one. The perfection of distribution network and completion of logistic points vigorously improved competitiveness advantage and marketing share of Accord Distribution. (IV) Further optimization of business structure and varieties structure In 2010, the Company took various measurements, constantly adjusted business structure and enhanced anti-risk ability. Direct marketing increased rapidly, sales amount reached beyond RMB 8 billion, variety structure was further optimized. At the same time, the Company optimized and integrated the purchase management, effectively promoted the all-in-one of purchase. Quantity of all-in-one variety, amount of purchase largely ascended. All-in-one variety forcefully promoted speedy development of subsidiaries, hugely improved marketing competitiveness of subsidiaries. (V)Integrated business resources, deepened all-in-one strategy of distribution and operation The Company deepened to promote all-in-one strategy of distribution and operation this year, boost Guangzhou-Shenzhen business integration, realized united allocation of variety resources, enhanced operating capacity of variety; effectively conformed the business and function of Guangxi distribution, realized the all-in-one operation of Guangxi distribution. (VI) Had eyes on future development, built development framework of industry platform In 2010, the Company paid attention to promote building of industry platform. In constant discussion and explore, the Company gradually formed development framework and thought of the Two Major Concentrations, Five Major Platforms, and focused on promoting construction of two major concentrations of R&D and marketing. In aspect of R&D, we boost the R&D cooperation and division of labor between raw materials plants and medicament, and coordinated the two corporation s to start supporting development of cefotetan disodium and faropenem and other products; strengthened external cooperation, speeded up development of new products, and got total 5 clinical certificates and 8 production certificates in the whole year. In aspect of marketing, in 2010 the industry board (Shenzhen Chinese Drugs included) realized over RMB 1.7 billion of sales amount, built 7 products with over RMB 0.7 billion of sale amount, implemented innovated marketing modes, the Zhijun Nice Gift operates well, and the effect of collecting points activities among memberships promoting sales are gradually appearing; effects of regulation on products structure was obvious, sales ratio of important products with high gross profit constantly increased, further enhanced profitability and anti-risk ability of products. At the same time, the Company set up preparation team for marketing center, made overall plan of chemicals marketing of Zhijun Pharmacy and Zhijun Wanqing. The Company laid a foundation for the Guanlan second stage of Zhijun Pharmacy, the technology transformation of the second stage of Zhijun Wanqing was completed, at the same time it went well with the land problem of Accord Pingshan, and construction of 3 bases progressed smoothly. Besides, the Company completed equity purchase of Shenzhen Chinese Drugs, and successively implemented organization frame optimization, rebuilding of marketing system. Till now, the Two Major Concentrations, Five Major Platforms has basically formed. (VII)Speeded up integration program of industry chain, gradually formed overall competitiveness advantage Competition in cephalous field has been into stage of industry chain competition. From this year on, joint of industry chain went well generally, presently 4 supporting medicines have been completed, namely cefuroxime, cefixime, cefoxitin and cefminox. The deep conduction of industry chain joint significantly improved the entire competition advantage in cephalous field. (VIII) Perfected quality management system, comprehensively improved quality of products Quality of products is the lifeline of corporate development. In 2010, the Company constantly enhanced quality control in production process, improved quality management, boost quality of products. Deepened auxiliary work of industry chain, move forward the control point of quality management; constantly completed quality management system through technology transformation, craftwork optimization and quality audit; deeply promoted fine production project, fully explored productivity, strictly grasped the quality; at the same time the final spot investigation of European Union's Authentication for lutrelef plants of Zhijun Pharmacy and American FDA Authentication for peinan plant of Zhijun Wanqing will arrive. More perfect quality management system further consolidated the competitiveness of our products in market. (IX) Innovated pattern of corporate cultural activities, promoted construction of harmony home: In 2010, the Company organized and led corporations in various regions to conduct construction activities of Party Trades and corporate culture, focused on conducting 4 months of reading activity of the Smell of Book Floating to Accord, Nice Books Recommendation to You, effectively improved work responsibility and execution ability of staffs. Meanwhile, we insisted using cultural innovation to lead reform development of corporation, declared goal and direction of corporate development, reported cultural activities and faces of staffs. The Company did well in care for staffs, practically solved actual difficulties of staffs; meanwhile actively fulfilled social responsibility, initiatively and positively participated in social utility, took part in assistance of education business and kid s welfare work, contributed the society with effort of the Company. Section II. Main business and operation results of the Company (I) Main operations: R&D and production of medicine, wholesale and chain retail of Chinese and Western medicine, Chinese herbal medicines, biological products, biological medicine, health products and medical devices. (II) Formation of income from main operations 1. Formation of income from main operations classified according to industries and products Unit: RMB 0000 Main operations classified according to industriesClassified according to industries or productsOperating incomeOperating costGross profit ratio (%)Increase/decrease in operating income over the last year (%)Increase/decrease in operating cost over the last year (%)Increase/decrease in gross profit ratio over the last year (%)Industry medicine157,093.45114,934.1926.84%19.98%23.96%-2.35%Commerce medicine wholesales1,136,469.931,070,962.215.76%20.46%19.84%0.48%Commerce medicine retail571.62525.338.10%-96.56%-95.99%-12.88%Non-medicine trade2,209.891,738.8121.32%88.56%74.32%6.43%Lease973.65612.4737.10%41.78%6.96%20.48%Subtotal1,297,318.541,188,773.018.37%18.71%18.75%-0.03%Main operations classified according to productsRespiratory antitussive medicines 18,279.51  3,910.34 78.61%-11.83%-14.46%0.66%Cef- series products 137,495.88  110,210.29 19.84%67.61%67.46%0.07%Including: the amount of related transaction 4,828.32  1,393.82 71.13%-55.36%-71.90%17.00% 2. Income from main operations classified according to areas Unit: RMB 0000 AreaIncome from main operationsIncrease/decrease in operating income over the last year (%)Domestic sales1,296,394.1418.75%Oversea sales924.40-17.90%Total1,297,318.5418.71% 3. Major suppliers and customers. Unit: RMB 0000 Total amount of purchase of the top five suppliers240,620.06Proportion in the total amount of purchase19.93%Total amount of sales of the top five sales customers74,250.22Proportion in the total amount of sales5.68% (III)Constitution of the assets and liabilities for the Company in the report period Unit: RMB 0000 Items 2010 -12 -31 2009 -12 -31 Increasing ratio in the total assetsAmountProportion in the total assets (%)AmountProportion in the total assets (%)Total assets630,679.30100.00%526,834.02100.00%0.00%Cash at bank and on hand71,178.9811.29%58,840.5711.17%0.12%Notes receivable36,916.905.85%36,302.566.89%-1.04%Accounts receivable286,682.5145.46%245,143.3546.53%-1.07%Advances to suppliers10,180.601.61%8,579.861.63%-0.02%Inventories115,632.9718.33%90,907.7517.26%1.07%Fixed assets49,255.777.81%42,839.008.13%-0.32%Construction in progress10,830.131.72%4,614.620.88%0.84%Intangible assets12,917.542.05%11,663.782.21%-0.16%Goodwill 5,355.570.85%3,415.300.65%0.20%Total liabilities517,534.7682.06%436,566.5482.87%-0.81%Short-term loans97,547.5915.47%94,418.9617.92%-2.45%Notes payable144,862.2522.97%110,495.0320.97%2.00%Accounts payable200,356.6531.77%170,614.2332.38%-0.61%Other payables34,501.135.47%24,683.534.69%0.78%Main reasons of the Y-O-Ychanges on assets liability constitute: (1) The proportion of cash at hand and on hand in total assets was 11.29%, up 0.12% over the period-beginning, the reason for change was that: firstly, sales scale enlarged, inward flood of capital at period-end increased; secondly, loan and note discount from bank increased. (2) The proportion of notes receivable in total assets was 5.85%, down 1.04% over the period-beginning, the reason for change was that: we combined increased corporations, the influence of proportion of notes receivable in total assets was weak. (3) The proportion of accounts receivable in total assets was 45.46%, down 1.07% over the period-beginning, the reason for change was that: firstly the Company paid attention to management of assets receivable and controlled its scale through credit management. Secondly, we combined increased corporations, the proportion of accounts receivable in total assets was low. (4) The proportion of advances to suppliers in total assets was 1.61%, down 0.02% over the period-beginning, but the amount of advances to suppliers at period-beginning increased RMB 16,007,400 comparing with that at period-end, the reason for change was that: the Company put more effort on supporting purchase, purchase loans payable increased. (5)The proportion of inventories in total assets was 18.33%, up 1.07% over the period-beginning, the reason for change was that: sales scale expanded, amount of inventories increased. (6) The proportion of fixed assets in total assets was 7.81%, down 0.32% over the period-beginning, but the amount of fixed assets at period-beginning increased RMB 64,167,700 comparing with that at period-end, the reason for change was that: cephalous Guer workshop of subsidiary Zhijun Pharmacy has been completed, newly built asepsis raw materials workshop of Zhijun Wanqing was partially completed, the transferred fixed assets from construction in progress was RMB 76,675,300; usage of partial fixed assets of parent company of the Company Accord Pharmacy and subsidiary Jianmin Company and Huixin Investment have been changed, transferred investment real estate from fixed assets was RMB 23,452,600. Disposal of partial fixed assets in this period made a certain influence on amount of fixed assets. (7) The proportion of construction in progress in total assets was 1.72%, up 0.84% over the period-beginning, the reason for change was that: invested more RMB 3,188,000 in cephalous guer workshop of subsidiary Zhijun Pharmacy and RMB 31,922,100 was transferred to fixed assets, thus investment in construction in progress decreased by RMB 28,734,100; asepsis raw materials workshop of Zhijun Wanqing and public construction expansion and transformation caused increased investment RMB 75,701,000 in construction in progress; Nanning logistic park of subsidiary Guangxi Chinese Medicine Logistic caused increased investment in construction in progress RMB 14,507,100. (8) The proportion of intangible assets in total assets was 2.05%, down 0.16% over the period-beginning; the reason for change was that: combined the increased corporations, proportion of intangible assets in total assets was lower. (9) The proportion of goodwill in total assets was 0.85%, up 0.20% over the period-beginning, the reason for change was that: purchase to Shenzhen Yanfeng Pharmaceutical Co., Ltd., Huizhou Sinopharm Holding Co., Ltd. and Meizhou Sinopharm Holding Co., Ltd which were under different control caused confirmed goodwill RMB 19,402,700. (10) The proportion of short-term loans in total assets was 15.47%, down 2.45% over the period-beginning, the reason for change was that: in this period the Company took more action on internal funds transfer and usage, thus met the capital demands and saved capital costs. (11) The proportion of notes payable in total assets was 22.97%, up 2% over the period-beginning, the reason for change was that: sales scale was enlarged thus usage of notes increased. (12) The proportion of accounts payable in total assets was 31.77%, up 0.61% over the period-beginning, the reason for change was that: in order to enhance cooperation with suppliers and strive for discount and other soft terms, took more actions on payment for purchase. (13) The proportion of other payables in total assets was 5.47%, up 0.78% over the period-beginning, the reason for change was that: subsidiary Zhijun Wanqing newly increased accounts for projects and equipments payable by RMB 32,878,100 in this period, withholding selling expenses newly increased RMB 6,792,400; subsidiary Zhijun Pharmacy newly increased withholding expenses by RMB 15,016,100 in this period. VI .Changes on selling and distribution expenses, administration expenses, financial expenses and income taxs. Unit: RMB 0000 Item20102009Increase/decrease ratio (%)Reason for significant changeSelling and distribution expenses43,05940,2786.90%Strength the sales in market for ration expansion; the expenses on transportation, market development and bidding were soaring y-o-y. Administration expenses 30,08825,51817.91%`$subsidiary Zhijun Wanqing and Zhijun Pharmaceutical strength their investment in R&D which makes the expenses for R&D soaring; a$the sals scale expanded due to the acquisition in the year; the increased employee makes the salary expenses soaring y-o-y; b$Sales scale enlarged makes the taxes expenses soaring y-o-y. Financial expenses 8,2545,03663.90%Business developed rapidly and capital demands increased which larger the loan amount; the interest expense has y-o-y increased due to the interest rate soaring. Investment income2,7273,258-16.30%Totally disposal income of RMB 15,469,200 was received from the equity transformation of Guangdong Accord Drug Store Co., Ltd. and Guangxi Accord Pharmaceutical Chain Co., Ltd. occurred in same period of last year. No significant equity transfer amount occurred in the period. Non-operating income2,0241,02797.08%Subordinate subsidiary Zhijun Pharmaceutical disposal out-of-date real estate in the period, subordinate subsidiary of the Company disposal the unpayable account payables with long aged account, the non-operating income increased y-o-y correspondingly. Income tax7,5596,25320.89%Profit gains a y-o-y increased caused the increase in income tax.  (V) The operation and performance analysis of the main holding companies and joint stock companies of the Company 1. Shenzhen Zhijun Pharmaceutical Co., Ltd: wholly-owned subsidiary of the Company with registration capital RMB 0.2 billion. Its main business was production for raw medicine of chemical products, processing for Chinese traditional patent medicine and R&D, production and operation of chemical material of medicine. It mainly produced medicine for respiratory system and anti-infection and the main products are isedyl cough syrup and Cefuroxime Sodium. Till Dec. 31 of 2010, total assets amounted to RMB 945,035,100, operating income RMB 1,191,606,400 of the whole year, net profit RMB 124,539,100. 2. SINOPHARM Group Guangzhou Co., Ltd.: It mainly engaged in import and export of Chinese traditional patent medicine, chemical preparations, antibiotics, bio-chemical medicine, biological medicine, diagnosis medicine, biological medicine with features of treatment and diagnosis, shaped packing food, chemical products, and various commodity and technique hold by self-support and agency with registration capital 0.4 billion yuan. Till Dec. 31 of 2010, total assets amounted to RMB 2,893,737,200, operating profit RMB 121,800,200 and net profit RMB 90,277,300. 3. SINOPHARM Group Nanning Co., Ltd.: wholly-owned subsidiary of the Company with registration capital RMB 0.1 billion. It mainly engaged in import and export of Chinese traditional patent medicine, chemical preparations, diagnosis medicine, biological medicine with features of treatment and diagnosis, and various commodity and technique hold by self-support and agency. Till Dec. 31 of 2010, total assets amounted to RMB 642,721,500, operating income RMB 1,217,520,300 of the whole year, net profit RMB 29,100,700. 4. Shenzhen Zhijun Wanqing Pharmaceutical Co., Ltd: with the registered capital of RMB 80 million with 75% equity held by the Company mainly engaged in the R&D and manufacture of raw materials and preparation of Cephalosporin. Till Dec. 31 of 2010, total assets amounted to RMB 512,192,500, net assets RMB 111,395,700, operating income RMB 509,487,300 of the whole year, net profit RMB 9,915,000. 5. Shenzhen Main Luck Pharmaceuticals INC: with the registered capital of US$ 5 million and the Company holds its 35.19% equities. Its main business covered development, research, production and operation of anticancer medicine preparations. Till Dec. 31 of 2010, total assets amounted to RMB 459,292,800, operating income RMB 468,348,600 of the whole year, net profit RMB 77,364,500. Section III. R&D investment and self-innovation I. Total investment in R&D of the Company Subordinate industrial corporations of Accord Pharmaceutical Medicine business division insisted developing model through investing more in technology to improve technologic innovation ability. Actual investment of 2010 was RMB 5,768,590, taking 3.35% of total sales amount. Detailed statement about investment in R&D of Accord Pharmaceutical Medicine business division of 2010 0Income of 2010 (RMB 0000) Actual income of 2010 (RMB 0000)Proportion of investment of R&D Zhijun Pharmacy1204373944.933.28%Zhijun Wanqing4736517893.78%Shenzhen TCM 4316.834.660.80%Total172118.85768.593.35%II. Self-innovation 1.System innovation: in 2010, Zhijun Pharmacy started to explore R&D management model, brought project responsibility system, enhanced appraisal of key points via hi-blue software. The operation went ideally, making a effective try for promotion of industrial R&D management reform of business division. 2. 2010 annual declaration of new medicines: 3 corporations of business division exerted advantage of R&D, promoted it, till 2010 1 clinical parcel and 5 production parcels had been got. Statistics of parcels of 2010 annual new medicines of various corporations of business division 0Clinical parcelsProduction parcelsZhijun PharmacyLupraph tabletCefteram pivoxil Cefdinir Dispersible TabletsZhijun WanqingNaughtNizatidine CapsulesTorasemide Cefixime tabletsShenzhen Chinese Medicine    Total15 3. Technology innovation: Under the guidance of production cost, the 3 industrial corporations brought in new techniques, and the transformation went smoothly. In 2010 we completed 5 techniques improvement, thus reduced production cost and expanded productivity. Progress of 2010 important technological transformation of various corporations of business dividend Technological transformationPredicted earnings Progress of 2010 Zhijun PharmacyTab- letting directly for Zinacef powder Production efficiency was improved 2 times, thus released productivity bottleneck of Zhijun Trial-production Cefixime Capsules marumcrbation Amount of accessories was reduced by 25%Trial-productionZhijun WanqingCombination technique innovation for Cefoxitin Solved large amount of organic solvent, improved yield coefficient by 15%, at the same time targeted energy-saving and emission-reducingTrial-productionReformation on sulfanilamidum crystallinum sterile of Cefminox Sodium Effectively reduced ignition residue whose ratio could be basically controlled within 0.1%Trial-productionShenzhen Chinese MedicineReconstruction totally on GMP of oral liquid agents plant Entirely passed GMP; productivity was expandedSmoothly passed GMPTotal5 Section IV. Working plan of the Company for 2010 I. 2011 operational ideas The Company will take over the integrate goal of the Twelfth Five-Years Plan, in accordance with new organization structure, define the duty and labor division of head-office and two business department. In 2010, the Company will focus on operational idea of the Innovate Ideas, Scientific Position, Health Operation, Leaping Development, innovate operational model, value added service and technology, enhance risk management, conduct health operation, deepen to promote integration strategy, build leader position of distribution in southern region; establish dumbbell industry platform around 4 angles, comprehensively complete annual goal of over RMB 16 billion of sales, thus realize leaping development. II. Major tasks of 2011 1. Do a good work in propagandism, taking and implementation of the Twelfth Five-Years Plan The Company will pay attention to propagandism of the Twelfth Five-Years Plan, fully make use of various platforms and channel, carry out various forms of propagandism in different levels and lines. The Company should exert subjective initiative of all the staffs, actively and initiatively ensure execution effect of plans. 2. Constantly perfect duty process and optimize organizational structure In order to promote smooth development of major tasks, we adjusted organization structure of the Company. In 2011, the Company should focus on operation and optimization of new structure, constantly perfect business procedure thus satisfy developing demands of the Twelfth Five-Years Plan. 3. Set up specific goal, effectively allocate resource In 2011, the Company will focus on staff structure optimization, making it more suitable for development of the Company; build average efficiency pattern, set up specific goal of average efficiency and constantly improve it; enhance bringing-in and appraisal of top-level talents, ensure quality growth of core talents. 4. Perfect distribution network, overtake benchmarking enterprises From 2010 distribution of Accord was faced with competition situation of surrounding heroes, the Company will further speed up network construction of distribution, promote network sinking. In 2011 we will ensure completion of distribution network, realize coverage of major targets in Guangdong and Guangxi, improve market share, overtake benchmarking enterprises, thus become top distribution brand in southern region. 5. Perfect risk management and control system, boost rapid development of subsidiaries In 2011, the Company will further perfect process system of merger and integration, ensure stable transition and speedy development of newly established subsidiaries; fully exert platform advantage of integrate operation, offer purchase, customer service, management and talent and other resource for subsidiaries, making subsidiaries larger and stronger. 6. Make the terminal market finer and more powerful, promote resource integration on basis of supply chain In 2011, the Company should take customers as guidance, boost deep coordination between business and function department; lay stress on promoting integration based on supply chain, rapidly boost business integration, thus form comparative advantage of distribution of Accord. 7. Innovate customers added value service, develop new business The Company will strengthen added value service and developing ability, vigorously promote information added value service based on supply chain integration. The project of hospitals chain will be continuously promoted and implemented in several ones in Guangzhou, Shenzhen, and Guangxi, which will form stronger demonstration effect. 8. Promote network construction of logistic, optimize logistic management and improve logistic distribution efficiency In 2011, we will constantly promote construction and optimization of logistic net points, constantly enhance logistic points management and function allocation; perfect information technology of supply chain platform, ensure electronic supervision of basic medicine; we will choose mature and integrated variety for none inventory management in areas satisfying the requirements; guided under logistic center, coordinate suppliers to conduct delivery and operation from majority warehouses. 9. Perfect internal control system, build effective and coordinated pharmacy business department In 2011, pharmacy business department will enhance management and control on industrial corporations through teasing system procedure, construction of industrial information platform as well as union of management instruments, thus it can really operate. We should fully play function of supervision, coordination and control, effectively integrate resources, lead various member corporations to conduct comprehensive cooperation in products supporting, future business development and other aspects, thus exert coordination effect of each member corporation, boost operation efficiency, build effective and coordinated pharmacy business department, realize rapid development of industry board. 10. Integrate R&D and marketing resource, build dumbbell pharmacy corporation In 2011, the Company will focus on promotion of R&D, transfer thoughts and rules of marketing center, integrate good quality resource in aspect of pharmacy business department, boost coordination and labor division of various corporations. Expand cooperation with domestic and foreign institutions in R&D, put more effort on bringing in foreign patented product, and thus accelerate development speed of new products. 11. Promote implementation of various tasks surrounding industry chain supporting In 2011, the Company should further deeply promote industry chain supporting, regulate various corporations for coordination and labor division of R&D report for approval, assist to integrate supplier resource via upline of ERP system, carry out united bringing-in and purchase of major varieties; support Euro Union Authentication for pink thread workshop and Zhijun Wanqing starts international authentication for raw materials of G workshop; should set up integrate quality sense, comprehensively boost products quality through basic construction and technology transformation as well as improving internal management, together ensure achievement of 80% targets of supporting facilities. 12. Make well with 3 major bases construction, thus lay a foundation for future development In order to deal with deficient productivity which has disturbed us for a long time, look for construction of future industry platform, the Company started planning and construction of 3 major bases. The founding of the 3 major bases will effectively improve the productivity scale of industry, thus offer condition for taking over international industry motion. At the same time we should lay stress on promoting construction of Pingshan base of Accord Pharmacy when involving in technology transformation of current project, ensure starting construction in 2011, promote supporting projects of Guanlan second phase of Zhijun Pharmacy and Zjijun Wanqing second phase according to plan, at the same time, we ll complete the establishment of project in group about Zhijun Wanqing third phase, thus offer firmed productivity for future development of industrial platform. 13. Step into new business field, boost sustainable development In 2011, the Company will make an overall plan for expansion in international main stream market of pharmacy and raw materials variety, start strategy installation of international market, accelerate the implementation of Big Health business; at the same time, we ll pick more strategy styles from the angle of industry chain, thus ensure sustainable development of corporation. Section VI. Investment and application of raised funds I. Main investment In 2010, the Company had no major external investment besides purchasing Shenzhen Yanfeng Pharmaceutical Co., Ltd., Sinopharm Holding Meizhou Co., Ltd, and Sinopharm Holding Huizhou Co., Ltd. and Sinopharm Holding Shenzhen Chinese Medicine Co., Ltd. II. Application of raised proceeds In the report period, the Company had no proceeds raised through share offering or there was no such situation that the proceeds raised through previous share offering went down to the report period for application. III. The actual progress of significant non-raised proceeds in the report period Unit: RMB 0000 Name of the projectAmount of the projectProgress of the projectEarnings of the projectNewly built Nanning Logistic Center Project14,700.0010%It was predicted that the annual operating value realized RMB 6 million and 0.15 million storage amount after completion and operation of the first phase, and total storage amount 0.2 million after the completion of the second phase. After construction of projects, logistics transfer hub of modern logistic system was formed. At that time, it will realize 0.11 million of storage amount per month in logistic storage ability, dealt with 3,000-5,000 orders daily; daily throughput is -4 million and annual one is 3-4 million; approval work zone receives 5,000 daily; over 18,000 goods allocations in parts demolition and election area; nearly ,9000 goods allocations in entire case election area; over 2,800 goods allocations in electron label shelf system.The 2nd phase project of Guanlan Base of Zhijun Pharmaceutical 25,000.000.58%1. Expanded two workshops of cephalosporin solid, increasing 1 billion pieces of annual productivity; 2. Newly built a asepsis pink powder thread production line, increasing 0.2 billion annual productivity. Newly built two workshops of cephalous solid 3,620.00100%In 2009, started to build two workshops of cephalosporin solid, and passed GMP certificate in Apr. of 2010, annual productivity was 0.175 billion pieces/grains/packs, from 2012, with the marketing of new oral cephalosporin with solid type, the annual productivity is predicted 0.5 billion pieces/grains/packs.Newly built workshop of asepsis raw materials 5,934.0099%Construction of cephalosporin asepsis crude medicine workshop will bring an annual productivity 600 tons, solving the bottleneck problem of productivity and meeting the demands of market. Newly built workshop of solvent recovery 1,744.0073%the built-up workshop of new solvent can rise the recovery from 60% to 90%, more than RMB 8 million cost can save in one year. Power supply workshop transformation project 1,470.0065%Completion of power supply workshop transformation project will improve the power supply capacity to 4,000KVA from 2,000KVA, solving energy bottleneck problem of development of the Company; at the same time it owns double electric power source, thus improve the security of production. Newly built Peinan project 4,000.0020%Approval of FDA spot of newly built Peinan project will increase the types of antibiotics, possibly exported to international market, improve the economic efficiency. Cefoxitin enzyme workshop transformation project806.0099%Completion of cefoxitin enzyme workshop transformation project possibly improves the productivity to 50 tons per year from 25 tons per year, compared with external purchased raw material, reduce production cost RMB 17.5 million per year, improve marketing competitiveness of down-stream products. Total57,274.00-- Section VII. Routine work of the Board of Directors Particulars about the meetings held by the Board of Directors of the Company in this year: 1. On January 25, 2010, the Board of Directors held the 14th meeting of the 5th session in telecommunication way, which reviewed and approved the Proposal of Purchasing Medicine Operation Business and Corresponding Assets and Liability of Nanning Pharmacy Co., Ltd. The decision of the meeting was published on Securities Times and Hong Kong Commercial Daily dated January 26, 2010. 2. On March 20, 2010, the Board of Directors held the 15th meeting of the 5th session which reviewed and approved the following proposals: (1) 2009 Annual Report of Board of Directors (2) 2009 Annual Report and Summary (3) 2009 Annual Profit Distribution Plan (4) 2009 Annual Report of Work of Independent Directors (5) 2009 Annual Report of Social Responsibility (6) 2009 Annual Self-Estimation Report of Internal Control (7) 2010 Annual Budget Plan of Operation (8) 2010 Annual Performance Appraisal Plan of Operation (9) Proposal of 2010 Annual Amount of Comprehensive Guarantee Applied form Bank and Arranging Guarantee Events (10) Proposal of 2010 Annual Daily Related Transaction between the Company and Its Subsidiaries (11)Proposal of Investing in Construction of Nanning Logistic Center (12)Proposal of Purchasing 51% Equity of Shenzhen Yanfeng Pharmacy Co., Ltd (13)Proposal of 2009 Cancellation after Verification of Non-Performing Assets (14)Proposal of Setting up Accountability System against Major Errors in Information Disclosure (15)Proposal of Management System of Submitting Information to External Units (16)Proposal of Supplementing Independent Directors (17)Proposal of Regulating Partial Directors (18)Proposal of Holding 2009 Annual General Meeting of Shareholders The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on March 23, 2010. 3. On April 26, 2010, the Board of Directors held the 16th meeting of the 5th session in telecommunication way, which reviewed and approved the 1st Seasonal Report 2010. The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on April 27, 2010. 4. On June 11, 2010, the Board of Directors held the 17th meeting of the 5th session in telecommunication way, which reviewed and approved the following proposals: (1) Proposal of Revising the Articles of Association (2) Proposal of Supplementing Independent Directors (3) Proposal of Holding 2nd Extraordinary Shareholders General Meeting of 2010 The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on June 12, 2010. 5. On June 25, 2010, the Bord held the Extraordinary Meeting of 5th session in telecommunication way, which reviewed and approved the Proposal of 100% Equity Acquisition from Huizhou Zhongsheng Pharmaceutical Co., Ltd. by Accord Pharmaceutical. The resolution was submitted to Stock Exchange for file 6.On July 20, 2010, the Board of Directors held extraordinary meeting of the 5th Board of Directors in telecommunication way, which reviewed and approved the Proposal That Shenzhen Yanfeng Pharmacy Co., Ltd Apply for Bank Comprehensive Guarantee from China Merchants Bank Anlian Branch. The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on July 22, 2010. 7. On August 16, 2010, the Board of Directors held the 18th meeting of the 5th session in telecommunication way, which reviewed and approved the following proposals: (1)2010 Semi-Annual Report and Summary (2)Proposal of Purchasing 52.61% Equity of Sinopharm Holding Shenzhen Chinese Medicine Co., Ltd (3)Proposal of Regulating 2010 Annual Line of Bank Credit and Arrange for Guarantee (4)Proposal of Shenzhen Zhijun Pharmacy Co., Ltd Changing Land Parcel Nature and Completing Project of Adding Land Parcels (5)Proposal of Regulating Staffs Composition of Strategy Committee of Board of Directors (6)Proposal of Regulating Staffs Composition of Audit Committee of Board of Directors (7)Proposal of Regulating Staffs Composition of Remuneration and Appraisal Committee of the Board of Directors (8)Proposal of Changing the Engage of Audit Institution of Annual Report (9)Notice of Holding 3rd Extraordinary Shareholders General Meeting of 2010 The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on August 18, 2010. 8. On September 9, 2010, the Bord held the Extraordinary Meeting of 5th session in telecommunication way, which reviewed and approved the Proposal of 100% Equity Acquisition from Huizhou Zhongsheng Pharmaceutical Co., Ltd. by Accord Pharmaceutical. The resolution was submitted to Stock Exchange for file. 9. On October 22, 2010, the Board of Directors held the 19th meeting of the 5th session in telecommunication way, which reviewed and approved the 2010 3rd Seasonal Report The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on October 23, 2010. 10. On November 1, 2010, the Board of Directors held the 20th meeting of the 5th session in telecommunication way, which reviewed and approved the following proposals: (1)Proposal of Increasing Registration Capital of 4 Subordinate Wholly-owned Subsidiaries (2)Proposal of Implementation of Self-Investigation and Construction of Long-acting Mechanism for Preventing Capital Occupation of Accord Pharmacy (3)Proposal of Building Management System for Preventing Large Shareholders and Related Parties Occupying Capital of Listed Companies (4)Reform Report that Accord Pharmacy 2010 Conducted Special Activity for Normalizing Basic Work of Financial Accounting The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on June 12, 2010. 11. On December 7, 2010, the Board of Directors held the 21st meeting of the 5th session in telecommunication way, which reviewed and approved the following proposals: (1)Regulation Plan for Organization Structure 2011 Accord Pharmacy (2)Proposal of Supporting Projects for Suzhou Zhijun Wanqing Pharmacy Co., Ltd (3)Proposal of Budget Regulation for Second Phase of Technology Transformation of Suzhou Zhijun Wanqing Pharmacy Co., Ltd (4)Proposal of Offering Guarantee for Fixed Assets Investment Loan of Guangxi Sinopharm Logistic Co., Ltd Applied from Guangxi Branch Bank of Communication (5)Proposal of Offering Guarantee for Line of Credit of Sinopharm Holding Liuzhou Co., Ltd Applied from Bank of Communication The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on December 9, 2010. 12. On December 29, 2010, the Board of Directors held the 22nd meeting of the 5th session in telecommunication way, which reviewed and approved the Proposal of Newly Engaging Senior Management Talent. The decisions made in meetings were published on Securities Time and Hong Kong Commercial Daily on December 31, 2010. Section VIII. Implementation of the resolutions of the Board of Directors and Shareholders General Meeting in the report period (1) Implementation of the daily related transaction made between the Company and its largest shareholders and related enterprise During the report period, the Proposal on Daily Related Transaction between the Company and Related enterprise has been examined and approved by the 2009 General Shareholders Meeting of the Company dated April 16, 2010. In 2010, the Company actually has purchased goods from the related enterprises total RMB 1,371,491,900, and RMB 1,051,843,900 for selling goods. These two occurring amounts are respectively 88.48% and 84.15% of the granted amounts authorized by the General Shareholders Meeting. (2) Implementation of the profit distribution plan 2009 Annual General Shareholders Meeting was held on April 16, 2010, in which examined and approved to send cash dividends of RMB 1.00(tax included) per every 10 shares to its all shareholders, taking the total shares 288,149,400 of the Company at the end of 2009 as the base. The Board has released the notice of Implementation of the 2009 Dividend Distribution of the Company on June 5, 2010 (published on Securities Times and Hong Kong Commercial Daily and the website http://www.cninfo.com.cn dated June 5, 2010.) the Company implemented the 2009 profit distribution plan and the dividends for public shareholders have been already sent to their accounts respectively on June 17, 2010(A-share) and June 21, 2010 (B-share). (3) Implementation of plan on issuing new shares In the report period, the Company did not implement plan on allotment and increasingly issuing new shares. Section IX. The performances of the Audit Committee of the Board of Directors In 2010, audit committee strictly performed its responsibility based on the Work System of Audit Committee of the Board of Accord Pharmaceutical, supervised the independency of auditing department as well as the implementation of internal system. In the prepared procedure of annual report, the audit committee issued written opinion respectively before the annual auditor came-by and after primary auditing opinion from annual auditing CPA, and decided the Annual Financial Accounting Report of 2010 by conference with approval by the Board. In addition, audit committee conclusion the annual auditing work of 2010 performed by Pricewaterhouse Zhongtian CPA Co., Ltd., a re-appointment proposal was submitted to the Board. I. Work of audit committee of the Board The audit committee of the Board responsible for the communication, supervises and verification work on the auditing in and out of the Company. During the annual auditing work for this year, audit committee plays its role in supervisory and protected the independency of the auditing: 1. confirmed the auditing schedule with the CPA that auditing the annual financial work of the Company by communication; 2. issued written opinion on the financial accounting statement prepared by the Company before the CPA auditing; 3. Strength communication with CPA, supervise the CPA to submitted Annual Report on schedule by urgency letter; 4. Issued written opinion on the primary auditing opinion from CPA after reviewing the enterprise financial accounting statement again; 5. The audit committee convened the Work Meeting of 2010 for the followed proposals that submitted to Board for approved as the Company s Financial Accounting Report, Conclusion Report on the Auditing Work from CPA and Re-appointment the PWC CPA Co., Ltd. as the auditing institution. II. Written opinion from Audit Committee of the Board, Conclusion Report of Annual Auditing and Resolutions 1. Written opinion of the financial accounting statement-- issued by the Company, from audit committee before annual CPA auditing According to relevant regulation of Work System of Audit Committee of the Board of Accord Pharmaceutical, the audit committee responsible for the duty of supervisor and verification during the preparation and disclosure of the annual report. After the primary auditing opinion issued by annual CPAs, the audit committee takes the opinions after reviewing the Annual Financial Accounting Statement of Accord Pharmaceutical 2010: (1) Preparation of the financial accounting statement is complied with the accounting policy of the Company. The policy were in a properly implementation and with a reasonable accounting estimation which meet the requirements of new Accounting Standard for Business Enterprises, enterprise accounting system and relevant regulations from Ministry of Finance; (2) The companies consolidated in consolidation statement and contents are in a complete-ness situation and the base of statement consolidation is accuracy; (3) Content of the financial accounting statement is objective, truth-ness, accuracy and without significant errors and omission information. Concerning the abundance of time between the reviewing date and date of report as well as the disclosure date, we required the financial department focus on the events occurred after the date of balance sheet date according to the new Accounting Standard for Business Enterprise. Guarantee the fair-ness, truth-ness and integrity. The financial accounting report may submit to annual CPA for approval. Audit Committee of the Board December 30, 2010 2. Written opinion of the financial accounting statement-- issued by the Company, from audit committee after primary auditing opinion issued by annual CPA According to relevant regulation of Work System of Audit Committee of the Board of Accord Pharmaceutical, the audit committee responsible for the duty of supervisor and verification during the preparation and disclosure of the annual report. Through the sufficient communication with annual CPAs in early period and based on the production business of the Company as well as its significant events, after the primary auditing opinion issued by annual CPAs, we reviewed the Annual Financial Accounting Statement of Accord Pharmaceutical 2010, keep the original proposal opinion with that: The Company strictly complied with the regulation of financial system of the Company and new Accounting Standard for Business Enterprises. The preparation procedure on the financial accounting statement are in a reasonable and regulated situation and reflected the assets, liabilities, equity and business results ended as December 31, 2010 fair-ness with truth-ness, accuracy and integrity content. The Financial Accounting Statement 2010 primary approved by CPAs should submit to Audit Committee for decision. Audit Committee of the Board February 18, 2011 3. Conclusion Report from Audit Committee on Annual Auditing by CPA Co., Ltd. Proposed by the 18th Meeting of 5th Board and approved by 3rd Extraordinary Shareholders General Meeting 2010, the Company appointed Pricewaterhouse Certified Public Accountants Co., Ltd as the auditing institution for financial accounting statement 2010 of the Company. On July 9, 2010, the time schedule for financial report auditing 2010 has been confirmed by communication with PWC Zhongtian CPA Co., Ltd. by audit committee. The auditors from PWC Zhongtian CPA Co., Ltd. were entered the field for auditing due to the above mentioned schedule on January 10, 2011. From January 10, 2011 to January 31, 2011, auditors completed the field auditing in various companies that in the consolidation scope. And communication continuously and fully with the managements of the Company and members of the audit committee on the statement consolidation, accounting adjustment, counting policy adoption and accounting problems need perfection that found during the auditing work. Based on the importance and prudential principle, the operation situation, financial status processing and implementation and adoption on new Accounting Standards for Business Enterprises should be fully understanding between the Company and auditors for the purpose of lay out a mature judgment on the provision of fair-ness auditing results from CPAs. The above mentioned auditing makes sure that the financial information of the Company is carried in a truth, accuracy and complete-ness way. During the period of auditing from annual auditing CPA, members of audit committee perform their responsibilities on supervision and verification according to the Work System of Audit Committee of the Board of Accord Pharmaceutical. Focus on the problems found in auditing and urge the CPA completed the preparation work in time schedule, guarantee the annual report carried in a truth, accuracy and integration way. A standard unqualified auditor s report was issued by the annual auditing CPA on schedule. We believed that the annual auditing CPA strictly complied with the regulations of Independent Auditing Criterion for Chinese Registered Accounts for auditing. The issued auditing conclusion corresponding actual situation of the Company, the auditing statement reflected real financial status of the Company dated December 31, 2010, business results of 2010 and cash flow of 2010 fair-ness and completely, with a sufficient time, reasonable personnel allocation and qualified execution. Audit Committee of the Board February 18, 2011 4. Meeting Resolution of Work 2010 from Audit Committee of Board Meeting was held on February 18, 2011 by the audit committee of the Board. Three people for legal attendance, and three people for actual attendance. Followed proposals were approved by the audit committee: (1) Pass the Financial Report of 2010 with 3 affirmative votes, 0 abstention, 0 dissenting vote; (2) Pass the Conclusion Report of auditing work 2010 on the Company from Pricewaterhouse Zhongtian CPA Co., Ltd. with 3 affirmative vote, 0 abstention, 0 dissenting vote; (3) Pass the Proposal of Re-appointment of CPAs with 3 affirmative vote, 0 abstention, 0 dissenting vote. In 2011, the Company plans to engaged Pricewaterhouse Zhongtian CPA Co., Ltd. which owns the relevant business qualification of securities and futures for accounting statement audition with one-year term. The above mentioned proposals should submit to Board for approval. Audit Committee of the Board February 18, 2011 Section X. Remuneration and appraisal committee s audit opinion on senior management persons Remuneration and appraisal committee actually fulfilled responsibility, mainly responsible for formulating appraisal standard of directors and managers and took appraisal on them, formulated and reviewed remuneration policy of directors and managers, and guided the board of directors to complete the remuneration system. Section XI. Preplan on Profit Distribution and Converting Capital Reserve into Share Capital in 2010 The 2010 Financial Settlement of the Company has been audited and confirmed by Pricewaterhouse Zhongtian Certified Public Accountants Co., Ltd. The net profit realized by the parent company in 2010 was RMB 224,082,114.41, in accordance with the regulation of Company Law and Articles of the Association, withdrawal of surplus public reserve was RMB 22,408,211.44 based on 10% of net profit, undistributed profit offset by purchasing enterprise under the common control was RMB 7,209,272.00, dividend distributed was RMB 28,814,940.00, plus the undistributed profit at year-begin RMB 234,901,348.57, the Company has profit of RMB 400,551,039.54 available for distribution for shareholders ended as Dec. 31, 2010. The 2010 Preplan Profit Distribution of the Company is: taking the total 288,149,400 shares as of Dec. 31, 2010 as the radix, cash bonus of RMB 1.2(before tax) each 10 share will be distributed to the whole shareholders. It is predicated that the distributed dividend would be RMB 34,577,928.00, and the remained profit RMB 365,973,111.54 would be transferred to the next year. The Company did not convert capital reserve into share capital in 2010. The aforementioned distribution plan should be submitted to the 2010 Annual Shareholders General Meeting for consideration and approval. 2. Particulars about the distribution of the Company in previous three years Amount of annual cash dividend of listed companies should be amount including tax and contain amount of cash dividend in middle of current year (if applicable); net profit should be calculated on basis of current year s net profit in consolidated statements attributable to shareholders of listed companies after regulation. Unit: RMB Year for bonus distributionAmount of cash bonus (tax included)Net profit attributable to shareholders of listed company in consolidated statement of bonus yearRatio of net profit attributable to shareholders of listed company in consolidated statementDistributable profit during the year200928,814,940.00192,868,245.1814.94%509,918,947.32200828,828,019.86159,894,713.2818.03%330,516,252.4120070.00126,501,853.420.00%184,074,070.88The proportion of accumulative cash bonus during recent three years in latest annual average net profit (%)36.08%Note: 1. The Company should definitely disclose amount of cash dividend and ratio of net profit in recent 3 years in form of listing. 2. Average distributable profit refers to average amount of total annual distributable profit in recent 3 years Section XII. Other disclosure events On July 13, 2010, Ministry of Finance located at Financial Ombudsman Office of Shenzhen performed a routine investigated on the 2009 annual accounting information quality of the Company. The Company submit the re-struction report to office of ombudsman for the problems esits. Concerning the involved relevant data, which makes no influenced on the consolidation balance sheet 2009, consolidation profit statement and consolidation cash flow statement, the Company have revised the involved date of same period of last year carried in the financial notes. CHAPTER VIII. REPORT OF THE SUPERVISORY COMMITTEE I. Works of the Supervisory Committee In 2010, the Supervisory Committee of Shenzhen Accord Pharmaceutical Co., Ltd. earnestly performed its duty according to the regulations of the Company Law, the Article of Association of the Company and Rules of Procedure of the Supervisory Committee. Totally 7 meetings have been held by the Supervisory Committee of the Company during the report period and followed the details: 1. The 13th Meeting of 5th Supervisory Committee was held on March 20, 2010 for the followed proposals approved: (1) Annual Report 2009 and Summary of Annual Report 2009; (2) Report of the Board of Directors 2009; (3) Report of the Supervisory Committee 2009; (4) Profit Distribution Plan 2009; (5) Social Responsibility Report 2009; (6) Self-Evaluation Report on Internal Control 2009; (7) Plan of Operation 2010; (8) Plan of Operation Performance Evaluation 2010; (9) Proposal of General Credit Limit Application to Bank and Guarantee Arrangements 2010; (10) Proposals of Daily Related Transactions between the Company, Subordinate Enterprise and Related Parties in 2010; (11) Proposal of the Establishment of China National Nanning Logistic Center; (12)Proposal of 51% Equity Acquisition from Shenzhen Yanfeng Medicine Co., Ltd.; (13) Proposal of 2009 Non-Performing Assts Verification; (14) Proposal of the Establishment of Responsibility System on Significant Errors in Annual Information Disclosure; (15) Proposal of the Establishment of Management System on Information Submit to External Units; The resolutions were published in Securities Times and Hong Kong Commercial Daily dated March 23, 2010. 2. The 14th Meeting of 5th Supervisory Committee was held on April 26, 2010 for approved the First Quarterly Report 2010. Resolutions were published in Securities Times and Hong Kong Commercial Daily dated April 27, 2010. 3. The 15th Meeting of 5th Supervisory Committee was held on June 10, 2010 for the following proposals approved: (1) Proposal of <Article of Association> Modification (2) Proposal of the Changes on Parts of the Supervisors Resolutions were published in Securities Times and Hong Kong Commercial Daily dated June 12, 2010. 4. The 16th Meeting of 5th Supervisory Committee was held on August 16, 2010 for the followed proposals approved: (1)Proposal of Election of Convener of Board of Supervisors (1) (2) 2010 Semi-Annual Report and Summary (3)Proposal of Purchase of 52.61% Equity of Sinopharm Holding Shenzhen Chinese Medicine Co., Ltd (4) Proposal of Regulation of 2010 Annual Bank Credit Line and Arrange for Guarantee (5)Proposal that Shenzhen Zhijun Pharmacy Co., Ltd Changed Land Nature and Completed Combination of Lands (6)Proposal of Re-engaging Audit Institution of Annual Report Notices of decision made in meetings have been published on Securities Times and Hong Kong Commercial Daily on August 18, 2010. 5. On October 22, 2010, the Company held the 17th meeting of the 5th Board of Directors, which reviewed and approved the 3rd Qauterly Report 2010 Notice of decision made in meetings has been published on Securities Times and Hong Kong Commercial Daily on October 23, 2010. 6. The 18th Meeting of 5th Supervisory Committee was held on November 1, 2010 for the following proposals approved: (1)Proposal of Investing More Registration Capital in 4 Wholly-Owned Subsidiaries (2)Notice of Construction of Permanent Mechanism for Preventing Capital Occupation and Implementation of Self-Investigation of Accord Pharmacy (3)Proposal of Construction of Management System of Preventing Capital Occupation of Listed Companies form Large Shareholders and Related Parties (4) Notice of Rectification of Special Activities for Normalizing Basic Work of Financial Accounting of Accord Pharmacy in 2010 Notice of decision made in meetings has been published on Securities Times and Hong Kong Commercial Daily on November 3, 2010. 7. On December 7, 2010, the Company held the 19th meeting of the 5th Board of Supervisors, which reviewed and approved the following proposals: (1)Proposal of Rectification of Organization Structure of Accord Pharmacy 2011 (2)Proposal of Supporting Projects of Suzhou Zhijun Wanqing Pharmacy Co., Ltd (3)Proposal of Regulating Budget for Partial Projects of the 2nd Technology Transformation of Suzhou Zhijun Wanqing Pharmacy Co., Ltd (4) Proposal of Offering Guarantee for Fixed Assets Investment Loan of Guangxi Sinopharm Logistic Co., Ltd from Bank of Communication Guangxi Branch (5) Proposal of Offering Guarantee for Credit Line of Sinopharm Holding Liuzhou Co., Ltd from Bank of Communication Notice of decision made in meetings has been published on Securities Times and Hong Kong Commercial Daily on December 9, 2010. II. Independent opinion on the operation of the Company issued by the Supervisory Committee In the report period, the members of the Supervisory Committee presented all meetings of the Board of the Company, performed their supervisory duty on the content and procedure of the Article of the Association carried out by the Board, and also supervised the execution of the resolutions of the Board by the operation personnel. (I) Operation by law In 2010, according to the relevant regulations of the Company Law, Securities Law, Listing Rules of Stock Market and Articles of Association, the board of directors legally managed, operated, made decisions in law and constructed and perfected internal control system. The procedures of holding shareholders meeting and meeting of the board of directors accorded with relevant regulations, and there was no behavior breaking relevant regulations and laws of the Article of Association of the Company and behavior violating the profit of the Company and shareholders when the directors and managers implemented their office duty. (II) Check on financial management of the Company In the report period, the Supervisory Committee seriously checked the financial status of the Company and thought that the financial management was standardized, the financial report objectively and truly reflected the financial status and operation achievement of the Company and the profit distribution plan for 2010 complied with the actual condition of the Company. The financial report 2010 was true and accurate, and fairly reflected the present financial status and operation achievement. The audit report with standard unqualified opinion issued by PricewaterhouseCoopers Zhong Tian CPAs Co., Ltd. was objective and just. (III) Application of raised proceeds There was no application of raised proceeds in the report period. (IV) The purchases and sales of assets In the report period, the price for the purchases and sales of assets of the Company was reasonable. There was neither secret transaction nor behavior hurting the interests of shareholders. (V) Related transaction The daily related transaction and other related transaction of the Company were equal and rational and of obedience to the market principle. There was no behavior hurting profit of non-related shareholders and the Company; the Board of the Company implemented their duty of earnest, trust and responsibility when they made the resolutions related to related transactions. The manager tier could effectively implement the resolutions of the board of directors and shareholders meeting on related transaction. There was no behavior violating laws, regulation or the Articles of Association in the process of related transaction. (VI) Self-evaluation of internal control Details could be found in Section VI (III) of Chapter V - Supervisory Committee s opinions on Self-evaluation of its Internal Control System. CHAPTER IX. SIGNIFICANT EVENTS Section  = 1 \* ROMAN I. Significant lawsuits and arbitrations (administration department) There were no significant lawsuits or arbitrations of the Company in the report period. Section  = 2 \* ROMAN II. Purchases and sales of assets 1. Purchases of assets Unit: RMB 0000 The other party of transaction or final controllerAssets purchasedPurchase datePurchase priceNet profit contributed to the Company from the purchase date to the year-end(applicable for enterprise merger under the uncommon control)Net profit contributed to the Company from the year-begin to the year-end(applicable for enterprise merger under the common control)Related transaction or notExplanation on price settingAssets rights concerned transferred ownership fully or notCredit and liability concerned shifted fully or notThe related relationship(applicable for related transaction)China National Pharmaceutical Group Corporation52.61% equity of Sinopharm TCM Co., Ltd. 2010-11-22 2,714.130.00-1,434.65YesTaking the book amount of net asset as of Dec. 31, 2009 as the reference evidence, the price was formed by open bidding in Assets and Equity Exchange.YesYesThe same final controlling shareholderShenzhen Kaijiefeng Industrial Co., Ltd.Shenzhen Yanfeng Pharmaceutical Co., Ltd controlled its 51% equity2010-04-30 2,800.78213.020.00NoTaking the book amount of net asset as of Dec. 31, 2009 as the reference evidence, the price was formed by open bidding in Assets and Equity Exchange.YesYes      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz|}~NaughtShi Xianqiang, Shi Jianwen Traditional Pharmaceutical Meizhou Co., Ltd2010-07-31 448.193.450.00NoTaking the book amount of net asset as of Mar. 31, 2010 as the reference evidence, the price was formed by open bidding in Assets and Equity Exchange.YesYesNaughtYan Minneng, Xu Jianbin Traditional Pharmaceutical Huizhou Co., Ltd2010-11-30 564.420.080.00NoTaking the book amount of net asset as of July 31, 2010 as the reference evidence, the price was formed by open bidding in Assets and Equity Exchange.YesYesNaught 2. Sales of assets Unit: RMB 0000 The other party of transaction or final controllerAssets soldSales dateSales priceNet profit contributed to the Company from the year-begin to the sales date Gains/losses from salesRelated transaction or notExplanation on price settingAssets rights concerned transferred ownership fully or notCredit and liability concerned shifted fully or notThe related relationship(applicable for related transaction)Shenzhen Jinhuo Industry Co., Ltd 0.1759% equity of GuangzhouShenzhen Joint Pharmaceutical (Group) Co., Ltd. 2010-04-2632.540.004.12NoTaking the book amount of net asset as of Dec. 31, 2008 as the reference evidence, the price was formed by open bidding in Assets and Equity Exchange.YesYesNaught Section  = 3 \* ROMAN III. Important related transactions I. Daily related transactions Unit: RMB 0000 Related partiesSell product and supply labor force to the related partiesPurchase product and accept labor force from related partiesTransaction amountProportion in the amount of the same transactionTransaction amountProportion in the amount of the same transactionSinopharm Holding Shengyang Co., Ltd.11,565.960.89%0.000.00%Guangdong Accord Drugstore Co., Ltd,9,176.020.71%103.580.01%Sinopharm Holding Hunan Co., Ltd.8,545.610.66%0.000.00%Sinopharm Holding Hubei Co., Ltd.8,328.660.64%0.000.00%Chongqing Yaoyou Pharmaceutical Co., Ltd. 7,879.490.61%382.240.03%Sinopharm Group Southwest Pharmacy Co., Ltd.6,765.470.52%74.310.01%Sinopharm Holding Beijing Co., Ltd.6,670.990.51%94.430.01%Sinopharm Holding Tianjin Co., Ltd.5,338.070.41%0.000.00%Sinopharm Group (Tianjin) Eastern Bokang Pharmaceutical Co., Ltd.4,050.690.31%0.000.00%Guangxi Accord Drugstore Chain Co., Ltd 3,204.360.25%0.000.00%Sinopharm Holding Hainan Co., Ltd.3,196.420.25%4.610.00%Sinopharm Holding Beijing Huahong Co., Ltd.2,780.680.21%0.000.00%Xinjiang Special Drugs National Pharmaceutical Co.,Ltd.2,755.040.21%2.220.00%Sinopharm Group Co., Ltd.2,576.100.20%82,082.216.80%Sinopharm Holding Yunnan Co., Ltd.2,283.940.18%0.000.00%Sinopharm Holding Henan Co., Ltd.2,201.500.17%0.000.00%Xinjiang Special Drugs Western Pharmaceutical Co., Ltd.1,852.180.14%0.000.00%Sinopharm Holding Fujian Co., Ltd.1,448.650.11%1,922.980.16%Sinopharm Holding Ningxia Co., Ltd.1,437.560.11%0.000.00%Guangdong East Uptodate & Special Medicines Co.,Ltd.1,393.300.11%809.060.07%Sinopharm Holding Shijiazhuang Co., Ltd.1,018.960.08%0.000.00%Sinopharm Holding Jiangsu Co., Ltd.964.050.07%0.000.00%Sinopharm Group Northwest Co., Ltd.930.410.07%0.000.00%Sinopharm Holding Zhejiang Co., Ltd.890.660.07%0.000.00%Sinopharm Holding Shandong Co., Ltd.848.030.07%0.000.00%Sinopharm Holding Guizhou Co., Ltd.786.700.06%34.000.00%Sinopharm Holding Shanxi Co., Ltd.781.730.06%0.000.00%China National Medicines Co., Ltd.744.830.06%14,558.781.21%Guangxi Guoda Durg Store Chain Co.,Ltd.726.120.06%0.000.00%Guangzhou Accord Drug Store Chain Co., Ltd.644.390.05%0.000.00%Sinopharm Holding Hubei Yibao Co., Ltd.346.130.03%0.000.00%Sichuan Hexin Pharmaceutical Co.,Ltd. 317.420.02%0.000.00%Sinopharm Holding Anhui Co., Ltd.276.590.02%13.950.00%Sinopharm Holding Jilin Co., Ltd.270.370.02%0.000.00%Wenzhou Biomedicin-appliances supplies co., Ltd268.790.02%0.000.00%Sinopharm Holding Inner Mongolia Co., Ltd.256.640.02%0.000.00%Sinopharm National Pharmacy Co.,Ltd.210.260.02%0.000.00%Sinopharm Holding Jiangxi Co., Ltd.203.300.02%0.000.00%Sinopharm Holding Gansu Co., Ltd.194.100.01%0.000.00%Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.166.320.01%8,977.240.74%Sinopharm Holding Fuzhou Co., Ltd.150.130.01%9.720.00%Shenzhen Accord Pharmaceutical Chain Co., Ltd150.050.01%0.000.00%Sinopharm Holding Suzhou Co., Ltd.128.600.01%11.840.00%Sinopharm Holding Shenyang Co., Ltd. Dalian Branch74.090.01%0.000.00%Shanghai Chaohui Pharmecurical Co., Ltd.69.790.01%81.380.01%China National Group Corporation of Traditional & Hebal Medical66.260.01%433.380.04%Sinopharm Holding Meiluo (Dalian) Co., Ltd63.770.00%12.460.00%Sinopharm Group Guorui Pharmaceutical Co., Ltd.63.150.00%0.000.00%Sinopharm Holding Tianjin Co., Ltd. Inner Mongolia Branch60.590.00%0.000.00%Sinopharm Holding Chongqing Co., Ltd.38.150.00%20.960.00%Guangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd.18.530.00%0.380.00%Sinopharm Group Baida Pharmaceutical Co., Ltd.2.350.00%74.900.01%Ningxia Guoda Durg Store Chain Co., Ltd.1.240.00%0.000.00%Sinopharm Holding Shenyang Co., Ltd. Changchun Branch1.200.00%0.000.00%Sinopharm Holding Sub Marketing Center Co., Ltd0.000.00%13,662.531.13%China National Pharmaceutical Industry CorporationLtd. Beijing sales branch0.000.00%607.480.05%Chengdu Rongsheng Pharmacy Co., Ltd0.000.00%510.160.04%Sinopharm Group Chemical Reagent Suzhou Co., Ltd.0.000.00%62.110.01%Sichuan Jiang You Zhong Ba Science and Technology Development Co.,Ltd. 0.000.00%51.440.00%Sinopharm Group Chemical Reagent Co., Ltd.0.000.00%41.700.00%China National Pharmaceutical Industry CorporationLtd. 0.000.00%36.020.00%Sinopharm Holding Beijing Kangchen Bio-Pharmaceutical Co., Ltd.0.000.00%21.440.00%Sinopharm Yixin Pharmacy Co., Ltd.0.000.00%6.300.00%Sinopharm Group Shanghai Medicine Device Co., Ltd.0.000.00%6.110.00%Guangdong Tianliang Medicine Co., Ltd.0.000.00%-0.280.00%Sino-Swed Pharmaceutical Corp.Ltd.0.000.00%6,042.050.50%Shenzhen Main Lusk Pharmaceutical Inc.0.000.00%2,840.490.24%Jiangsu Wanbang Pharmacy Marketing Co., Ltd.0.000.00%1,158.360.10%Qinghai Pharmaceitical (Group) Co.,Ltd.0.000.00%1,108.170.09%Sinopharm Group United Medicine Device Co., Ltd.0.000.00%806.850.07%Chongqing Haisiman Pharmaceutical Co.,Ltd.0.000.00%375.680.03%Guilin Pharmaceutical Works0.000.00%68.100.01%Guilin Pharmaceutical Co., Ltd.0.000.00%16.010.00%Shenyang Hongqi Pharmaceutical Co., Ltd.0.000.00%7.940.00%China National Pharmaceutical Foreign Trade Co., Ltd.0.000.00%-0.390.00%Shanghai Sailun Biological Technology Co.,Ltd.0.000.00%11.880.00%Yichang Humanwell Pharmaceutical Co.,Ltd.0.000.00%3.520.00%Sinopharm Qianjing Dental Technology (Beijing) Co.,Ltd.0.000.00%0.890.00%Total =SUM(ABOVE) 105,184.39 =SUM(ABOVE)*100 \# "0.00%" 8.10% =SUM(ABOVE) 137,149.19 =SUM(ABOVE)*100 \# "0.00%" 11.37% Of which: In the report period, the related transaction amount of the Company selling products and providing labor service to the controlling shareholders and its subsidiaries was RMB 966,827,600. II. Other related transactions (1) Guarantee provided for the related parties: until Dec. 31st, 2010, the contingent liability formed by the guarantee for loans of the related parties and other units provided by the Company Unit: RMB (0000) Units providing guaranteeUnits guaranteed Guarantee amount Used partBeginning day of guaranteeEnd date of guaranteeFinancial influence of the CompanyZhijun Pharmaceutical, Sinopharm GuangzhouThe Company37,500.0012,934.302010-6-212011-6-21No disadvantage influenceZhijun PharmaceuticalThe Company5,000.004,907.812010-6-12011-6-1No disadvantage influenceZhijun PharmaceuticalThe Company10,000.00385.732010-7-72011-6-23No disadvantage influenceZhijun PharmaceuticalThe Company15,000.002,624.562009-12-182010-12-18No disadvantage influenceZhijun PharmaceuticalThe Company16,000.002,015.392010-4-232010-12-31No disadvantage influenceZhijun PharmaceuticalThe Company10,000.008,605.082009-12-302010-12-30No disadvantage influenceZhijun PharmaceuticalZhijun Medical Trade3,300.00 383.96 2010-8-252011-8-24No disadvantage influenceZhijun PharmaceuticalZhijun Medical Trade2,500.00 1,103.72 2010-9-162011-9-16No disadvantage influenceThe CompanyZhijun Pharmaceutical 10,000.00 6,632.44 2009-12-302010-12-30No disadvantage influenceThe CompanyZhijun Pharmaceutical5,000.00 1,600.11 2010-6-12011-6-1No disadvantage influenceThe CompanySinopharm Guangzhou65,000.00 41,473.18 2010-3-132011-3-13No disadvantage influenceThe CompanySinopharm Guangzhou32,500.00 21,403.82 2010-4-132011-4-13No disadvantage influenceThe CompanyGuangdong Yuexing3,500.00 2,439.61 2010-4-132011-4-13No disadvantage influenceThe CompanySinopharm Guangzhou10,000.00 10,000.00 2010-9-172011-9-16No disadvantage influenceThe CompanySinopharm Guangzhou18,000.00 12,327.82 2010-6-182011-6-18No disadvantage influenceThe CompanySinopharm Guangzhou10,000.00 0.00 2010-11-232011-11-22No disadvantage influenceThe CompanySinopharm Guangzhou10,000.00 5,461.03 2010-4-302011-4-30No disadvantage influenceThe CompanySinopharm Guangzhou10,000.00 3,399.95 2010-11-52011-11-4No disadvantage influenceThe CompanySinopharm Guangzhou5,000.00 4,932.92 2010-10-262011-10-25No disadvantage influenceThe CompanySinopharm Nanning5,000.004,516.542009-12-302010-12-30No disadvantage influenceThe CompanySinopharm Nanning6,000.004,732.722010-1-132011-1-13No disadvantage influenceThe CompanySinopharm Liuzhou5,000.005,000.002009-12-302010-12-30No disadvantage influenceThe CompanyYanfeng Pharmaceutical 3,000.001,997.912010-7-272011-7-27No disadvantage influenceThe CompanyZhijun Wanqing6,000.004,009.362010-4-232011-4-22No disadvantage influenceThe CompanyZhijun Wanqing5,000.005,000.002009-12-302010-12-30No disadvantage influenceThe CompanyZhijun Wanqing6,000.002,809.122010-7-192011-12-31No disadvantage influenceThe CompanyZhijun Wanqing6,000.003,000.002010-8-12013-8-1No disadvantage influence(The above related guarantee events had been reviewed and approved in the 15th meeting of the 5th Board of Directors held on Mar. 20 of 2010, annual general meeting of shareholders held on Apr. 16 of 2010, the 5th Extraordinary Board of Directors held on July 20 of 2010, and 2010 the 3rd Extraordinary General Meeting fo Shareholders held on Sep. 3 of 2010.) (2) Subsidiary Sinopharm Holding Guangzhou Co., Ltd rented houses and equipments from Sinopharm Group Medicine Logistic Co., Ltd, and took total RMB 14.58 million of lease fees in 2010. The related lease event had been reviewed and passed on the 10th meeting of the 5th Board of Directors held on Aug. 26 of 2009. (3) Subsidiary of the Company, Yanfeng Pharmaceutical lease house to the family member of its minority shareholders Wang Yang. RMB 220,500 lent was carried in the year of 2010. (4) The Company borrowed RMB 650 million from Sinopharm Holding Co., Ltd through Bank of Communication Shanghai, and took RMB 6,217,100 of interest expense in 2010; subsidiary Sinopharm Holding Guangzhou borrowed RMB 300 million form Sinopharm Holding Co., Ltd through Shanghai Bank of Communication, taking RMB 6,368,900 of interest expenses. The related lease event had been reviewed and passed on the 15th meeting of the 5th Board of Directors held on Mar. 20 of 2010. (5) In 2010, subsidiary of the Company, Sinopharm Guangzhou Co., Ltd. beared the followed buyer discount arise of note payable discount from its affiliated companies: RMB 1,655,400 from Sinopharm Distribution Center Co., Ltd.; RMB 7,787,800 from SINOPHARM GROUP CO., LTD. and RMB 173,300 from China National Medicines Corporation Ltd. the relevant related transaction have been approved by the 15th Meeting of 5th Board of Directors held on March 20, 2010. (6) the Company and its subordianted subsidiary Sinopharm Guangzhou used the CMS system owned by Shanghai Tongyu Information Technology Co., Ltd. in the year, and beared RMB 3 million and RMB 1.8668 million expenses respectively. (7) the Company and its subordianted subsidiary Zhijun Wanqing paid exhibition expenses of RMB 80,400 and RMB 77,000 to Reed Sinopharm Exhibitions Co., Ltd. and China National Pharmaceutical Industry Corporation Ltd. respectively. (8)The Company purchased 52.61% equity of Shenzhen Chinese Medicine held by Chinese Medicine Group with RMB 27,141,300. The related transaction had been reviewed and passed on the18th meeting of the 5th Board of Directors held on Aug. 16 of 2010 (9) Subsidiary Sinopharm Holding Guangzhou Co., Ltd offered consulting service for Sinopharm Group Pharmacy Co., Ltd, intaking RMB 228,000 of consulting fees. (10) Subsidiary Huixin Investment leased houses to Guangzhou Accord Drug Store Chain Co., Ltd and Sinopharm Group United Medical Device Co., Ltd, respectively intaking RMB 394,200 and RMB 175,200 of lease charge. (11) The Company leased houses to Shenzhen Accord Chain Co., Ltd and Guangdong Accord Drug Store Co., Ltd, respectively intaking RMB 492,600 and RMB 403,000 of lease charge. (12) Subsidiary Guangxi Logistic and Sinopharm Holding Liuzhou leased houses to Guangxig Accord Drug Store Co., Ltd, respectively intaking RMB 303,800 and RMB 1,048,400 of lease charge. (13) Subsidiary Hengchang Logistic offered distribution and transport service for Guangdong Accord Drug Store Co., Ltd, Guangzhou Accord Drug Store Chain Co., Ltd, Sinopharm Holding Pharmacy Logistic Co., Ltd and Sinopharm Group Pharmacy Co., Ltd, respectively intaking RMB RMB 2,704,700, RMB 317,700, RMB 4,537,800 and RMB 2,433,100 of distribution and transport fees; subsidiary Accord Logistic offered distribution and transport service for Guangdong Accord Drug Store Co., Ltd, Guangdong Accord Drug Store Co., Ltd, intaking RMB 642,900 of distribution and transport fees. The above mentioned related transactions item(6), (9) to (13) have been approved by the 23rd Meeting of 5th Board of Directors held on March 18, 2011. III. Creditor s rights and liabilities between related parties and the Company: Unit: RMB 0000 Related partiesCapital provided for related partiesCapital provided by related parties to the CompanyOccurrence amount BalanceOccurrence amountBalanceTotal  =SUM(ABOVE) 180,675.9923,262.20 =SUM(ABOVE) 390,860.73 =SUM(ABOVE) 72,403.79 The details were as follows: Unit: RMB 0000 Related partiesCapital provided for related partiesCapital provided by related parties to the CompanyOccurrence amount BalanceOccurrence amountBalanceAccount receivable: 0.000.000.000.00Sinopharm Holding Beijing Co., Ltd7,805.062,042.520.000.00Chongqing Yaoyou Pharmaceutical Co., Ltd. 9,219.001,872.000.000.00Sinopharm Holding Hunan Co., Ltd9,998.591,865.210.000.00Sinopharm Group Southwest Pharmacy Co., Ltd7,746.151,758.290.000.00Guangdong Accord Drug Store Co., Ltd10,978.661,338.140.000.00Sinopharm Holding Beijing Huahong Co., Ltd3,253.40943.070.000.00Guangxi Accord Drug Store Chain Co., Ltd3,733.70904.290.000.00Sinopharm Holding Hubei Co., Ltd9,744.53835.000.000.00Sinopharm Holding (Tianjin) Eastern Bokang Pharmacy Co., Ltd4,739.30694.270.000.00Sinopharm Group Co., Ltd3,014.04608.570.000.00Sinopharm Holding Hainan Co., Ltd4,122.18577.000.000.00Sinopharm Holding Zhejiang Co., Ltd1,042.07510.790.000.00Sinopharm Holding Tianjin Co., Ltd6,245.54510.590.000.00Sinopharm Holding Yunnan Co., Ltd2,672.22379.560.000.00Xinjiang Special Drugs National Pharmaceutical Co.,Ltd.3,223.39376.820.000.00Sinopharm Holding Shenyang Co., Ltd13,532.22328.270.000.00Guangdong East Uptodate & Special Medicines Co.,Ltd.1,393.32279.140.000.00Sinopharm Holding Ningxia Co., Ltd2,185.28241.600.000.00Sinopharm Holding Shijiazhuang Co., Ltd1,071.29495.020.000.00Sinopharm Holding Henan Co., Ltd2,572.64225.910.000.00Xinjiang Special Drugs Western Pharmaceutical Co.,Ltd.2,167.05215.520.000.00Sinopharm Holding Fujian Co., Ltd1,916.13205.780.000.00Sinopharm Holding Guizhou Co., Ltd431.45183.640.000.00Sinopharm Holding Shanxi Co., Ltd914.62170.260.000.00China National Medicines Corporation Ltd1,114.76151.900.000.00Sinopharm Holding Jiangsu Co., Ltd1,127.94148.850.000.00Wenzhou Biomedicin-appliances supplies co., Ltd490.89108.150.000.00Guangzhou Accord Drug Store Chain Co., Ltd785.66103.140.000.00Sinopharm National Pharmacy Co., Ltd.222.9874.950.000.00Sinopharm Holding Gansu Co., Ltd227.0959.560.000.00Sinopharm Holding Jiangxi Co., Ltd389.2250.950.000.00Sinopharm Group Medicine Logistic Co., Ltd.453.7848.630.000.00Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.194.5946.340.000.00Sinopharm Group Northwest Co., Ltd1,088.5940.700.000.00Shanghai Chaohui Pharmecurical Co., Ltd. 81.6637.640.000.00Sinopharm Holding Shandong Co., Ltd992.4533.710.000.00Sinopharm Holding Meiluo (Dalian) Co., Ltd210.8030.240.000.00Sinopharm Holding Chongqing Co., Ltd281.3428.770.000.00China National Group Corporation of Traditional & Hebal Medical77.5225.920.000.00Sinopharm Holding Inner Mongolia Co., Ltd.317.3924.570.000.00Sinopharm Holding Suzhou Co., Ltd150.4623.530.000.00Sinopharm Holding Shenyang Co., Ltd Dalian Branch86.6919.140.000.00Sinopharm Holding Fuzhou Co., Ltd175.6616.950.000.00Sinopharm Holding Jilin Co., Ltd629.866.420.000.00Guangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd. 11.220.600.000.00Sinopharm Holding Anhui Co., Ltd323.610.090.000.00Shenzhen Accord Pharmaceutical Chain Co., Ltd 175.53 0.000.000.00Sinopharm Holding Tianjin Co.,Ltd. Inner Mongolia Branch0.000.000.000.00Sinopharm Group Shanghai Likang Medicines Co,. Ltd.0.000.000.000.00Sinopharm Holding Shenyang Co., Ltd. Changchun Branch 1.40 0.000.000.00Sinopharm Hubei Yibao Co., Ltd.  404.98 0.000.000.00Shanghai Sinopharm Medical Meterials Co., Ltd.  0.00- 0.000.000.00Guangxi Guoda Durg Store Chain Co., Ltd.  811.10 0.000.000.00Guangdong Tianliang Medicine Co., Ltd.  0.00- 0.000.000.00Sinopharm Group Guorui Pharmaceutical Co., Ltd. 73.88 0.000.000.00Sinopharm Group Baida Pharmaceutical Co., Ltd. 2.75 0.000.000.00Ningxia Guoda Durg Store Chain Co., Ltd. 1.45 0.000.000.00Sichuan Hexin Pharmaceutical Co., Ltd.  371.38 0.000.000.00Other accounts receivable:0.000.000.000.00Sinopharm Group Medicine Logistic Co., Ltd0.00121.500.000.00Wang Lei 90.5190.510.000.00China National Pharmaceutical Industry Corporation Lts. Guangzhou Association Company1.611.610.000.00SINOPHARM GROUP CO., LTD.0.000.000.000.00Guangdong Accord Drug Store Co., Ltd.0.000.000.000.00China National Medicines Co., Ltd. 22.80 0.000.000.00China National Group Corporation of Traditional & Hebal Medical 0.00 0.000.000.00Sino TCM Wuhan Medicine Design Institution 22.00 0.000.000.00Shenzhen Main Luck Pharmaceuticals Inc. 2.16 0.000.000.00Yang Qiaoming  0.00 0.000.000.00Accounts paid in advance:0.000.000.000.00Qinghai Pharmaceitical (Group) Co., Ltd.1,278.17540.830.000.00Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.6,647.25261.680.000.00Sinopharm Group United Medicine Device Co., Ltd.1,059.58243.560.000.00Shanghai Sailun Biological Technology Co., Ltd. 1.650.030.000.00Sinopharm Holding Beijing Kangchen Bio-Pharmaceutical Co., Ltd. 25.08 0.000.000.00Sinopharm Group Chemical Reagent Suzhou Co., Ltd. 32.58 0.000.000.00Sinopharm Group Chemical Reagent Co., Ltd. 1.80 0.000.000.00SINOPHARM GROUP CO., LTD. 0.33 0.000.000.00Sino-Swed Pharmaceutical Corp. Ltd. 97.76 0.000.000.00Sinopharm Qianjing Dental Technology (Beijing) Co., Ltd. 1.04 0.000.000.00China National Group Corporation of Traditional & Hebal Medical 0.00 0.000.000.00Chengdu Rongsheng Pharmacy Co., Ltd  596.89 0.000.000.00Sino TCM Wuhan Medicine Design Institution 12.00 0.000.000.00Reed Sinopharm Exhibitions Co., Ltd.  8.04 0.000.000.00China National Pharmaceutical Industry Corporation Ltd.  7.70 0.000.000.00Notes receivable:0.000.000.000.00Chongqing Yaoyou Pharmaceutical Co., Ltd.8,825.611,136.000.000.00Sinopharm Holding Hubei Co., Ltd7,317.08698.860.000.00Sinopharm Holding Guizhou Co., Ltd796.92684.000.000.00Sinopharm Holding Hunan Co., Ltd9,562.49406.290.000.00Sinopharm Holding Tianjin Co., Ltd244.94244.940.000.00Sinopharm Holding Henan Co., Ltd1,067.0750.000.000.00Sinopharm Holding Hainan Co., Ltd1,849.2147.470.000.00Sinopharm Holding Fuzhou Co., Ltd32.5732.570.000.00Sinopharm Holding Chongqing Co., Ltd24.2424.240.000.00Sinopharm Holding Jiangxi Co., Ltd85.8520.260.000.00Sinopharm Holding Shenyang Co., Ltd10,836.987.730.000.00Sinopharm Holding Anhui Co., Ltd42.146.910.000.00Sinopharm Holding Shandong Co., Ltd298.951.200.000.00SINOPHARM GROUP CO., LTD.  200.27 0.000.000.00China National Guorui Pharmaceutical Co., Ltd.  73.78 0.000.000.00China National Xinjiang New Special National Medicine Co., Ltd 89.26 0.000.000.00Sinopharm Holding Beijing Huahong Co., Ltd  633.56 0.000.000.00Sinopharm Holding Beijing Co., Ltd.  2,832.15 0.000.000.00Sinopharm Holding Gangsu Co., Ltd.  39.04 0.000.000.00Sinopharm Holding Hubei Yibao Co., Ltd.  169.71 0.000.000.00Sinopharm Holding Shanxi Co., Ltd.  25.00 0.000.000.00Sinopharm HoldingYunnan Co., Ltd. 70.44 0.000.000.00Sinopharm HoldingZhejiang Co., Ltd.  76.70 0.000.000.00Xinjiang Special Drugs Western Pharmaceutical Co.,Ltd. 300.00 0.000.000.00Sinopharm Group Baida Pharmaceutical Co., Ltd.0.000.000.000.00Guangdong Tianliang Medicine Co., Ltd.0.000.000.000.00Shanghai Chaohui Pharmecurical Co., Ltd. 44.01 0.000.000.00Sichuan Hexin Pharmaceutical Co., Ltd.  230.61 0.000.000.00Accounts payable:0.000.000.000.00Sinopharm Group Co., Ltd0.000.00187,425.4310,959.88Sinopharm Holding Sub Marketing Center Co., Ltd0.000.0010,928.261,697.85China National Medicines Co., Ltd.0.000.0034,593.711,165.01Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.0.000.0028,123.001,026.77Sino-Swed Pharmaceutical Corp. Ltd. 0.000.00971.60971.60Main Luck 0.000.00421.56421.56Jiangsu Wanbang Pharmacy Marketing Co., Ltd0.000.00 2,576.53 208.32China National Group Corporation of Traditional & Hebal Medical0.000.00145.23105.05Chongqing Yaoyou Pharmaceutical Co., Ltd.0.000.00870.56100.62Sinopharm Group United Medicine Device Co., Ltd0.000.002,183.0096.37Chongqing Haisiman Pharmaceutical Co., Ltd.0.000.00808.1192.77Sinopharm Holding Beijing Co., Ltd0.000.00193.5160.93Guangdong East Uptodate & Special Medicines Co.,Ltd.0.000.001,810.6451.09Sinopharm Holding Guizhou Co., Ltd0.000.0048.8535.88Shanghai Chaohui Pharmecurical Co., Ltd.0.000.00185.5234.59Sichuan Jiang You Zhong Ba Science and Technology Development Co.,Ltd.0.000.0059.8234.13Sinopharm Group Medicine Logistic Co., Ltd0.000.00115.9012.82Sinopharm Holding Suzhou Co., Ltd0.000.0027.7112.01China National Pharmaceutical Industry CorporationLtd. Beijing sales branch0.000.0029.8611.99Sinopharm Holding Meiluo (Dalian) Co., Ltd0.000.0093.2210.75Sinopharm Holding Fujian Co., Ltd0.000.004,454.007.01Guilin Pharmaceutical Works0.000.00146.835.25Sinopharm Holding Hainan Co., Ltd0.000.008.985.17Shanghai Sailun Biotechnology Co., Ltd.0.000.005.045.04Sinopharm Group Southwest Pharmacy Co., Ltd0.000.00156.933.81Yichang Humanwell Pharmaceutical Co., Ltd. 0.000.003.343.34Sinopharm Yixin Pharmacy Co., Ltd0.000.002.952.95China National Pharmaceutical Industry CorporationLtd. 0.000.0079.902.87Shenyang Hongqi Pharmaceutical Co., Ltd.0.000.0018.591.86Sinopharm Group Shanghai Medicine Device Co., Ltd0.000.0013.721.84Jiangsu Wanbang Bio-Chemical Medicine Co., Ltd. 0.000.000.001.49Sinopharm Group Chemical Reagent Suzhou Co., Ltd.0.000.00173.451.45Sinopharm Group Beijing Medicine Device Co., Ltd0.000.000.000.88Guangdong Tianliang Medicine Co., Ltd.0.000.001.060.68Guilin Pharmaceutical Co., Ltd.0.000.0034.750.68Sinopharm Group Chemical Reagent Co., Ltd.0.000.0093.960.51Guangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd.0.000.000.980.38Sinopharm Holding Jiangsu Co., Ltd0.000.000.000.37Sinopharm Holding Anhui Co., Ltd0.000.0032.200.31China Otsuka Pharmaceutical Co., Ltd. 0.000.000.210.21Shanghai Fosun Long March Medical Science Co., Ltd. 0.000.000.180.18China National Pharmaceutical Industry Corporation Lts. Guangzhou Association Company0.000.000.130.13Guangdong Accord Drug Store Co., Ltd0.000.00117.020.10Shanghai Fosun Pharmaceutical Co., Ltd. 0.000.000.000.02Sinopharm Qianjing Dental Technology (Beijing) Co., Ltd.0.000.000.010.01China Sinopharm Foreign Trade Co., Ltd.0.000.00-0.98-0.98Other accounts payable:0.000.000.000.00Shenzhen Kaijiefeng Industrial Co., Ltd. 0.000.00481.09481.09Sinopharm Holding Co., Ltd0.000.000.00389.39Sinopharm Group Pharmacy Holding Shanghai Co., Ltd0.000.000.00166.04Shanghai Chaohui Medicines Co., Ltd.0.000.000.000.02Notes payable:0.000.000.000.00Sinopharm Holding Co., Ltd0.000.0027,266.7821,009.56China National Medicines Co., Ltd.0.000.002,826.421,240.95Sinopharm Holding Sub-Marketing Center Co., Ltd0.000.001,318.26531.22Sinopharm Holding Fujian Co., Ltd0.000.00503.61503.61Jiangsu Wanbang Pharmacy Marketing Co., Ltd0.000.00510.69224.08Chongqing Haisiman Pharmaceutical Co., Ltd.0.000.00258.9853.32Main Luck 0.000.0038.8438.84Sinopharm Group Baida Pharmaceutical Co., Ltd.0.000.0034.8934.89Guilin Pharmaceutical Works0.000.0013.6513.65Guilin Pharmaceutical Co., Ltd.0.000.002.582.58Accounts received in advance0.000.000.000.00Sinopharm HoldingGuizhou Co., Ltd0.000.00537.00537.00Interest payable:0.000.000.000.00Sinopharm Group Co., Ltd0.000.00112.6722.00Short-term loan0.000.000.000.00Sinopharm Group Co., Ltd0.000.0080,000.0030,000.00Total =SUM(ABOVE) 180,675.9923,262.20 =SUM(ABOVE) 390,860.73 =SUM(ABOVE) 72,403.79 Of which: In the report period, the occurring amount which the Company provided funds to the controlling shareholder and its subsidiaries was RMB1,437,161,100 and the balance was RMB 1,813,400. In the report period, the Company has not provided non-operating capital for the controlling shareholder and its subsidiaries. Section IV. Important contracts and implementation I. Significant contracts (I) There was no signed external investment contract or financial expenditure which had not been implemented or completely implemented. (II) There was no signed let contract with big amount being implemented or in preparation to implement. (III) The signed equipment purchase contract with big amount was being implemented or in preparation to implement. 83461900 yuan will be paid for equipments purchase contract signed by subsidiaries of the Company Shenzhen Zhijun Pharmaceutical Co., Ltd, Sinopharm Group Nanning Co., Ltd and Guangxi Traditional Medicine Logistic Co., Ltd, and this account belonged to the necessary expenditure for the normal operation of the Company. (IV) The signed lease contract and financial influence which was being implemented or in preparation to implement. As to the house property leased by the subsidiary of the Company, the account payable agreed in the lease contract could be found in the following table, and this account belonged to the necessary expenditure for the normal operation of the Company: PeriodLease amount payableWithin a year 25,648,3001 to 2 years 10,577,6002 to 3 years 8,835,100Above 3 years 77,502,300Total 122,563,300(V) There was no signed merger agreement being implemented or in preparation to implement. (VI) There was no signed reorganization plan being implemented or in preparation to implement. (VII) There was no other significant financial commitment. (VIII) Implementation of commitment in the past. All commitments had been implemented according to contact. II. Significant guarantee Unit: RMB 0000 Particulars about the external guarantee of the Company (Barring the guarantee for the controlling subsidiaries)Name of the Company guaranteedDisclosure date and number of related notices of guarantee amount Guarantee amountActual date of happening (Date of signing agreement)Actual line of creditGuarantee typeGuarantee termComplete Implementation or notGuarantee for related party (Yes or not)Shenzhen Accord Pharmaceutical Co., Ltd.2010-3-20 2010-0737,500.002010-06-2112,934.30Guaranty2010.06.21-2011.06.21NoYesShenzhen Accord Pharmaceutical Co., Ltd.2010-3-20 2010-075,000.002010-06-014,907.81Guaranty2010.06.01-2011.06.01NoYesShenzhen Accord Pharmaceutical Co., Ltd.2010-3-20 2010-0710,000.002010-07-07385.73Guaranty2010.07.07-2011.06.23NoYesShenzhen Accord Pharmaceutical Co., Ltd.2009-08-26 2009-21 2010-3-20 2010-0715,000.002009-12-182,624.56Guaranty2009.12.18-2010.12.18NoYesShenzhen Accord Pharmaceutical Co., Ltd.2010-3-20 2010-0716,000.002010-04-232,015.39Guaranty2010.04.23-2010.12.31NoYesShenzhen Accord Pharmaceutical Co., Ltd.2009-08-26 2009-21 2010-3-20 2010-0710,000.002009-12-308,605.08Guaranty2009.12.30-2010.12.30NoYesShenzhen Zhijun Medical Trade Co., Ltd. 2010-3-20 2010-073,300.002010-08-25383.96Guaranty2010.08.25-2011.08.24NoYesShenzhen Zhijun Medical Trade Co., Ltd.2010-8-16 2010-222,500.002010-09-16 1,103.72Guaranty2010.09.16-2011.09.16NoYesTotal external guarantee amount approved in reporting period(A1)74,300.00Total actual external guarantee amount approved in reporting period(A2)125,771.92Total external guarantee amount approved at the end of reporting period(A3)99,300.00Total actual balance of external guarantee amount approved at the end of reporting period(A4)32,960.55Guarantee of the Company for the controlling subsidiariesName of the Company guaranteedDisclosure date and number of related notices of guarantee amount Guarantee amountActual date of happening (Date of signing agreement)Actual line of creditGuarantee typeGuarantee termComplete Implementation or notGuarantee for related party (Yes or not)Shenzhen Zhijun Pharmaceutical Co., Ltd.2009-08-26 2009-21 2010-3-20 2010-0710,000.002009-12-306,632.44Guaranty2009.12.30-2010.12.30NoYesShenzhen Zhijun Pharmaceutical Co., Ltd.2010-3-20 2010-075,000.002010-06-011,600.11Guaranty2010.06.01-2011.06.01NoYesSinopharm Holding Guangzhou Co., Ltd 2009-08-26 2009-21 2010-3-20 2010-0765,000.002010-03-1341,473.18Guaranty2010.3.13-2011.3.13NoYesSinopharm Holding Guangzhou Co., Ltd2010-3-20 2010-0732,500.002010-04-13 21,403.82Guaranty2010.4.13-2011.4.13NoYesGuangdong Yuexing Pharmaceutical Co., Ltd.2010-3-20 2010-073,500.002010-04-132,439.61Guaranty2010.4.13-2011.4.13NoYesSinopharm Holding Guangzhou Co., Ltd2010-8-16 2010-2210,000.002010-09-1710,000.00Guaranty2010.9.17-2011.9.16NoYesSinopharm Holding Guangzhou Co., Ltd2010-3-20 2010-0718,000.002010-06-1812,327.82Guaranty2010.6.18 -2011.6.18NoYesSinopharm Holding Guangzhou Co., Ltd2010-3-20 2010-0710,000.002010-11-230.00Guaranty2010.11.23-2011.11.22NoYesSinopharm Holding Guangzhou Co., Ltd2010-3-20 2010-0710,000.002010-04-305,461.03Guaranty2010.4.30-2011.4.30NoYesSinopharm Holding Guangzhou Co., Ltd2010-3-20 2010-0710,000.002010-11-053,399.95Guaranty2010.11.5-2011.11.4NoYesSinopharm Holding Guangzhou Co., Ltd2010-8-165,000.002010-10-264,932.92Guaranty2010.10.26-2011.10.25NoYesSinopharm Holding Nanning Co., Ltd2009-08-26 2009-21 2010-3-20 2010-075,000.002009-12-304,516.54Guaranty2009.12.30-2010.12.30NoYesSinopharm Holding Nanning Co., Ltd2010-3-20 2010-076,000.002010-01-134,732.72Guaranty2010.1.13-2011.1.13NoYesSinopharm Holding Liuzhou Co., Ltd2009-08-26 2009-21 2010-3-20 2010-075,000.002009-12-305,000.00Guaranty2009.12.30-2010.12.30NoYesShenzhen Yanfeng Pharmaceutical Co., Ltd. 2010-7-20 2010-183,000.002010-07-271,997.91Guaranty2010.7.27-2011.7.27NoYesSuzhou Zhijun Wanqing Pharmaceutical Co., Ltd.2010-3-20 2010-076,000.002010-04-234,009.36Guaranty2010.04.23-2011.04.22NoYesSuzhou Zhijun Wanqing Pharmaceutical Co., Ltd.2009-08-26 2009-21 2010-3-20 2010-075,000.002009-12-305,000.00Guaranty2009.12.30-2010.12.30NoYesSuzhou Zhijun Wanqing Pharmaceutical Co., Ltd.2010-3-20 2010-076,000.002010-07-192,809.12Guaranty2010.07.19-2011.12.31NoYesSuzhou Zhijun Wanqing Pharmaceutical Co., Ltd.2010-3-20 2010-076,000.002010-08-013,000.00Guaranty2010.08.01-2013.08.1NoYesTotal guarantee amount for subsidiaries approved in reporting period196,000.00Total actual guarantee amount for subsidiaries approved in reporting period1,448,417.92Total guarantee amount for subsidiaries approved at the end of reporting period221,000.00Total actual balance of guarantee amount for subsidiaries approved at the end of reporting period140,736.53Total guarantee of the CompanyTotal the former two items Total guarantee amount approved in reporting period270,300.00Total actual guarantee amount approved in reporting period1,574,189.84Total guarantee amount approved at the end of reporting period320,300.00Total actual balance of guarantee amount approved at the end of reporting period173,697.08Proportion of the total actual guarantee amount in net assets of the Company165.05%Including:Line of credit for shareholders, actual controller and its related parties0.00The debts guarantee amount provided for the guaranteed parties whose assets-liability ratio exceed 70% directly or indirectly131,993.75Proportion of total line of credit in net assets of the Company exceed 50%121,078.56Total amount of the aforesaid three guarantees253,072.31Explanations on possibly bearing joint and several liquidating responsibilities for undue guarantees Naught Note:  Guarantee of the Company for the controlling subsidiaries carried aboved mention statement including the guarantee only for subsidiaries. Other situations as guarantee for other enterprise, guarantee for other enterprise by susbsidiaries and guarantee for another subsidiary by the subsidiaries were carried in  external guarantee of the Company . Among which, the external guarantee amount of subsidiaries calculated with the external guarantee amount times the share equity proportion of such subsidiary held by the Company. III. Entrustment of cash assets management In the report period, the Company had not entrusted others to manage cash assets, nor had it done so in previous periods and lasted into this report period. Section V. Commitments of the Company or shareholders holding over 5% shares of the Company Shareholders and actual controllers or other relevant parties holding over 5% equity of the Company had no committee events in reporting period or lasting to reporting period. Section VI. Engagement of Certified Public Accountants I. Engagement of Certified Public Accountants On Aug. 16 of 2010, the 18th meeting of the 5th board of directors decided to re-hire Pricewaterhouse Zhongtian CPA Company Limited as 2010 annual audit institution of the Company, which was passed on the 3rd extraordinary general meeting of shareholders held on Sep. 3 of 2010. Relevant notice was respectively published on Securities Times and Hong Kong Commercial Daily on Aug. 18 of 2010 and Sep. 4 of 2010. II. Remuneration paid to Certified Public Accountants The auditing fees the Company paid to the Certified Public Accountants for the Annual Report 2010 totaled to RMB 1.25 million(business tax and surchange included), and the fees for the business trips the Certified Public Accountants took for the Company s auditing affairs had been paid by the Company. III. Years of auditing service the audit institutions had provided for the Company Since initially signing audit business agreement in 2010, PricewaterhouseCoopers Zhong Tian CPAs Co., Ltd. has provided auditing service consistently for the Company for 1 year. Section  = 7 \* ROMAN VII. Other important events In the report period, the Company, the board of directors, supervisory committee, senior executives, shareholders, and actual controllers did not be inspected or administratively punished by CSRC, not be prohibited by security market, cognized as improper to be punished by other administrative department or be publicly criticized by Stock Exchange. Section VIII. In the report period, the received research and interview of the Company In the report period, the Company respectively received the research of investors from Fund Company and Securities Company. In the reception, according to the regulations of Guideline on Fair Information Disclosure for Listed Companies promulgated by Shenzhen Stock Exchange, the Company had not disclosed or leaked non-public significant information to specific parties privately, selectively or in advance. This guaranteed the equality for the information disclosure of the Company. Activities form of receiving research, communication and interview in the report period The received dateThe received placeThe received wayThe received partiesContents discussed and materials supplied2010-10-29 Accord Pharmaceutical BuildingOn-the-spot investigationsAnxin Securities Got to know the reform development of pharmaceutical industry, no materials were supplied. 2010-11-08 Accord Pharmaceutical BuildingOn-the-spot investigationsSW Securities, Taishin Investment TrustGot to know the reform development of pharmaceutical industry, no materials were supplied. 2010-11-09 Accord Pharmaceutical BuildingOn-the-spot investigationsTianzhi Funds Got to know the reform development of pharmaceutical industry, no materials were supplied. 2010-11-28 Accord Pharmaceutical BuildingOn-the-spot investigationsYifangda Fund, China Merchants Securities, Dacheng Fund, Zhongtou Securities, China Post Fund, Everbright PramericaGot to know the reform development of pharmaceutical industry, no materials were supplied. 2010-12-15Accord Pharmaceutical BuildingOn-the-spot investigationsAnxin Securities, UBS SDIC FundGot to know the reform development of pharmaceutical industry, no materials were supplied. Section IX. Explanation on change of accounting policy, accounting estimation and calculating method compared with the latest annual report (I) Change of accounting policy There was no change of accounting policy in the report period. (II) Change in accounting estimation There was no change of accounting estimation in the report period. Section  = 9 \* ROMAN X. Significant accounting errors, corrected amount, the reason and influence In the report period, there were no significant accounting errors and corrections. Section  = 10 \* ROMAN XI. Explanation on change of consolidated scope compared with the latest annual report 1. Newly-increased consolidated units in this year were 4 ones, the reasons were: Sinopharm TCM Co., Ltd., Shenzhen Yanfeng Medicine Co., Ltd, Sinopharm Meizhou Co., Ltd and Sinopharm Huizhou Co., Ltd. were purchased by the Company in 2010. In prepared the comparative statement of 2009, the Sinopharm TCM Co., Ltd. was newly for added due to combining the enterprise under same control. Section  = 10 \* ROMAN XII. Index for information notice on significant events No.Disclosure dateEvents disclosed12010-01-26Notice of Acquisition the Medical Business of Nanning Medical Co., Ltd. and relevant assets and liabilities; Notice of Holding the 1st Extraordinary Shareholders General Meeting of 201022010-02-11Attorney Opinion Letter of 1st Extraordinary Shareholders General Meeting of 2010; Resolution of 1st Extraordinary Shareholders General Meeting of 201032010-03-23Social Responsibility Report of 2009; Notice of Daily Related Transactions between the Company, Subordinate enterprise and Related Parties; Notice of External Investment; Notice of General Credit Limit Application to Bank in 2010 and Guarantee Arrangement; Notice of 51% Equity Acquisition from Shenzhen Yanfeng Medicine Co., Ltd and Capital Increased; Activities Report of Independent Directors 2009; Notice of Opinions from Independent Directors; Responsibility System on Significant Errors in Annual Information Disclosure; Management System of the Information Delivered to External Units( March 2010); Independent Opinions on Director Appointment; Full-Tex of Annual Report 2009 and Summary of Annual Report 2009; Self-Evaluation Report of Internal Control 2009; Verification Report on the Capital Contact with Related Parties; Resolutions of the 13th Meeting of 5th Supervisory Committee; Resolutions of the 15th Meeting of 5th Board of Directors; Auditing Report of 2009; Notice of Holding the Shareholders General Meeting of 2009; Notice of Independent Director Resignation 42010-04-17Resolutions of the Shareholders General Meeting of 2009 Attorney Opinion Letter of Shareholders General Meeting 200952010-04-27First Quarterly Report of 201062010-06-05Implementation Notice of Profit Distribution of 200972010-06-12Statement of the Candidate of Independent Director (HE ZHI YI) ; Notice of Holding the 2nd Extraordinary Shareholders General Meeting of 2010; Resolutions of the 15th Meeting of 5th Supervisory Committee; Resolutions of the 17th Meeting of 5th Board of Directors; Statement on the Nomination of Independent Director 82010-06-29Article of Association (June 2010) Resolutions of the 2nd Extraordinary Shareholders General Meeting 2010; Attorney Opinion Letter of 2nd Extraordinary Shareholders General Meeting 201092010-07-22Notice of Guarantee for Controlling Subsidiary 102010-08-18Financial Report of Semi- Annual Report 2010; Adjustment of Bank Credit Limit for 2010 and Guarantee Arrangement; Resolutions of the 16th Meeting of 5th Supervisory Committee; Resolutions of the 18th Meeting of 5th Board of Directors; Full-Text of Semi-Annual Report 2010 and Summary of Semi-Annual Report 2010; Notice of Holding the 3rd Extraordinary Shareholders General Meeting of 2010; Notice of 52.61% Equity Acquisition from Sinopharm TCM Co., Ltd. 112010-08-19Notice of Re-registration on Industry Classification 122010-09-04Attorney Opinion Letter of 3rd Extraordinary Shareholders General Meeting of 2010; Resolution of 3rd Extraordinary Shareholders General Meeting of 2010; 132010-09-09Notice of Strategic Co-operation Frame Agreement signed between China national Pharmaceutical Corp. and Shenzhen People s Government 142010-10-14Notice of Progress of Equity Acquisition 152010-10-23Third Quarterly Report of 2010162010-11-03Capital Increase to Four Subordinate Wholly-owned Subsidiaries of the Company; Resolution of 20th Meeting of 5th Board; Management System on Capital Occupying Prevention to Largest Shareholders and Related Parties (November 2010) Resolution of 18h Meeting of 5th Supervisory Committee; 172010-12-09Resolutions of the 19th Meeting of 5th Supervisory Committee; Resolutions of the 21st Meeting of 5th Board of Directors; Notice of Guarantee for Controlling Subsidiary from the Company Notice of Holding the 4th Extraordinary Shareholders General Meeting of 2010;182010-12-29Resolution of 4th Extraordinary Shareholders General Meeting of 2010; Attorney Opinion Letter of 4th Extraordinary Shareholders General Meeting of 2010;192010-12-30Independent Opinions on Re-appointment of Executive Managers of the Company from Independent Directors; Resolutions of the 22nd Meeting of 5th Board of Directors;The aforesaid events had been disclosed on Securities Times, Hong Kong Commercial Daily and the website http://www.cninfo.com.cn. CHAPTER X. FINANCIAL REPORT Section I. Auditors Report PwC ZT Shen Zi (2011) No.10022(Page 1 of 2)To the Shareholders of Shenzhen Accord Pharmaceutical Co., Ltd.:We have audited the accompanying consolidated financial statements of Shenzhen Accord Pharmaceutical Co., Ltd. (the  Company ) and its subsidiaries (together, the  Group ), which comprise the consolidated and company balance sheets as at 31 December 2010, the consolidated and company income statements, the consolidated and company cash flows statements and the consolidated and company statements of changes in owners equity for the year then ended and notes to these financial statements.Management s Responsibility for the Financial Statements The management of the Company is responsible for the preparation of these financial statements in accordance with the Accounting Standards for Business Enterprises. This responsibility includes: 1) designing, implementing and maintaining internal control relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error; 2) selecting and applying appropriate accounting policies; and 3) making accounting estimates that are reasonable in the circumstances.Auditor s Responsibility Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the China Auditing Standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity s preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.  PwC ZT Shen Zi (2011) No.10022(Page 2 of 2)We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.Opinion In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Group and the Company as of 31 December 2010 and the financial performance and cash flows of the Group and the Company for the year then ended in accordance with the Accounting Standards for Business Enterprises.PricewaterhouseCoopers Zhong Tian CPAs Limited Company Shanghai, the People s Republic of China 18 March 2011Certified Public Accountant of China CHEN GENG TAO, Certified Public Accountant of China TANG ZHEN FENG ASSETSNotesConsolidatedCompany31 December 201031 December 200931 December 201031 December 2009Current assetsCash at bank and on handV(1)711,789,775.66588,405,672.15135,498,819.87125,541,203.80Notes receivableV(2)369,169,030.47363,025,601.605,038,459.891,758,275.85Accounts receivableV(3), XIII(1)2,866,825,102.782,451,433,461.71282,597,465.23301,349,886.88Advances to suppliersV(4)101,806,030.9285,798,584.953,798,560.901,042,226.64Dividends receivableV(5)-8,271,829.94--Other receivablesV(6), XIII(2) 43,110,999.74  63,596,027.23557,324,957.67379,622,614.20InventoriesV(7)1,156,329,658.80909,077,496.35117,829,120.3096,332,120.70Total current assets 5,249,030,598.37 4,469,608,673.931,102,087,383.86905,646,328.07Non-current assetsLong-term equity investmentsV(8), XIII(3) 85,275,251.0658,334,840.951,272,402,665.15642,597,981.98Investment propertiesV(10)87,293,333.7657,973,532.9712,033,619.617,572,670.36Fixed assetsV(11)492,557,743.43428,390,030.2135,677,614.0128,578,457.35Construction in progressV(12)108,301,338.1246,146,183.50253,886.24253,886.24Intangible assetsV(13)129,175,366.09116,637,778.2928,837,698.0229,653,420.36Development costsV(13)2,580,662.85235,375.01--GoodwillV(14)53,555,677.0934,153,027.89--Long-term prepaid expensesV(15)19,811,611.247,456,046.959,161,222.49184,277.86Deferred income tax assetsV(16)31,083,592.2412,871,196.242,958,699.75-Other non-current assetsV(18)48,127,831.5636,533,540.13--Total non-current assets1,057,762,407.44 798,731,552.141,361,325,405.27708,840,694.15TOTAL ASSETS6,306,793,005.815,268,340,226.072,463,412,789.131,614,487,022.22 LIABILITIES AND OWNER S EQUITYNotesConsolidatedCompany31 December 201031 December 200931 December 201031 December 2009Current liabilitiesShort-term loansV(19)975,475,884.21944,189,604.46349,183,556.07347,023,220.37Notes payableV(20)1,448,622,490.721,104,950,330.28227,394,114.09167,985,468.09Accounts payableV(21)2,003,566,517.621,706,142,277.91238,636,669.29246,909,317.09Advances from customersV(22)100,322,387.2182,498,031.5548,490.627,015,577.03Employee benefits payableV(23)127,191,717.25110,138,050.7622,612,110.6321,952,780.15Taxes payableV(24)39,720,311.7236,717,779.362,957,612.62122,667.32Interests payableV(25)2,122,314.90589,050.00596,047.97361,845.00Other payablesV(26) 345,011,293.80246,835,253.81874,380,433.82263,570,295.56Current portion of long-term loansV(27)-30,000,000.00--Total current liabilities5,042,032,917.43 4,262,060,378.131,715,809,035.111,054,941,170.61Non-current liabilitiesLong-term loansV(28)30,000,000.0030,000,000.00-- Long-term payables40,777.8046,019.40--Payables for specific projectsV(29)4,755,000.002,555,000.001,320,000.001,320,000.00Deferred income tax liabilitiesV(16)22,709,093.7025,525,421.763,773,319.003,773,319.00Other non-current liabilitiesV(30)75,809,855.7445,478,550.21--Total non-current liabilities133,314,727.24 103,604,991.375,093,319.005,093,319.00Total liabilities5,175,347,644.674,365,665,369.501,720,902,354.111,060,034,489.61OWNERS EQUITYShare capitalV(31)288,149,400.00288,149,400.00288,149,400.00288,149,400.00Capital surplusV(32)5,030,338.57 31,568,488.4013,828,726.9313,828,726.93Surplus reserveV(33)39,981,268.5517,573,057.1139,981,268.5517,573,057.11Undistributed profitsV(34)719,209,302.41509,918,947.32400,551,039.54234,901,348.57Total equity attributable to equity holders of the Company1,052,370,309.53847,209,892.83742,510,435.02554,452,532.61Minority interestV(35)79,075,051.6155,464,963.74--Total owners' equity1,131,445,361.14902,674,856.57742,510,435.02554,452,532.61TOTAL LIABILITIES AND OWNERS EQUITY6,306,793,005.815,268,340,226.072,463,412,789.131,614,487,022.22 The accompanying notes form an integral part of these financial statements. Legal representative: Principal in charge of accounting : Head of accounting department: ItemsNotesConsolidatedCompanyYear ended 31 December 2010Year ended 31 December 2009Year ended 31 December 2010Year ended 31 December 2009SalesV(36) ,XIII(4)13,064,428,148.6910,997,074,919.051,793,332,482.651,643,866,356.16Less:Cost of salesV(36),XIII(4)(11,925,655,507.94)(10,041,207,840.07)(1,703,659,976.45)(1,562,600,505.75)Taxes and surchargesV(37)(19,918,513.42)(15,870,831.05)(2,537,599.61)(1,276,051.88)Selling and distribution expensesV(38)(430,588,573.47)(402,780,881.44)(55,411,427.41)(49,720,215.81)Administration expensesV(39)(300,875,369.90)(255,178,530.07)(36,690,738.84)(46,318,174.91)Financial expenses  netV(40)(82,538,641.49)(50,356,642.60)(25,081,726.33)(3,035,528.61)Asset impairment lossesV(41)(9,217,962.21)(12,330,073.25)5,826,408.97(3,643,443.09)Add:Investment incomeV(42),XIII(5)27,265,825.1132,577,605.29241,256,657.31194,681,096.90Including: Share of profits of associates 27,224,583.8120,878,151.3523,078,755.1717,186,060.02Operating profit 322,899,405.37251,927,725.86217,034,080.29171,953,533.01Add:Non-operating incomeV(43)20,244,943.9310,271,959.886,830,676.013,931,661.39Less:Non-operating expensesV(44)(3,331,980.65)(1,258,365.20)(322,844.62)(154,623.30)Including: Loss on disposal of non-current assets(548,476.80)(544,477.77)(10,332.02)(16,973.47) Total profit339,812,368.65260,941,320.54223,541,911.68175,730,571.10Less:Income taxes expensesV(45)(75,587,949.59)(62,527,277.15)540,202.73-Net profit264,224,419.06198,414,043.39224,082,114.41175,730,571.10 Including: (Net losses)/net profit of the acquiree entity in a business combination involving enterprises under common control before the combination date(8,757,555.55)263,508.02-- Attributable to equity holders of the Company261,116,656.70192,868,245.18224,082,114.41175,730,571.10Minority interest3,107,762.365,545,798.21--Earnings per shareV(46)Basic earnings per share0.910.67 N(u N(uDiluted earnings per share0.910.67 N(u N(uOther comprehensive income----Total comprehensive income264,224,419.06198,414,043.39224,082,114.41175,730,571.10Attributable to equity holders of the Company261,116,656.70192,868,245.18224,082,114.41175,730,571.10Minority interest3,107,762.365,545,798.21-- The accompanying notes form an integral part of these financial statements. Legal representative: Principal in charge of accounting :Head of accounting department: ItemsNotesConsolidatedCompanyYear ended 31 December 2010Year ended 31 December 2009Year ended 31 December 2010Year ended 31 December 2009I. Cash flows from operating activities:Cash received from sales of goods or rendering of services13,371,120,839.9412,006,759,276.412,000,448,923.571,586,303,501.03Refund of taxes and surcharges1,011,514.12766,339.85--Cash received relating to other operating activitiesV(47)(a)40,506,959.1430,146,665.1333,946,251.4342,365,406.95Sub-total of cash inflows13,412,639,313.2012,037,672,281.392,034,395,175.001,628,668,907.98Cash paid for goods and services(12,071,170,836.94)(10,792,536,493.55)(1,814,811,040.08)(1,578,692,564.42)Cash paid to and on behalf of employees(369,596,005.66)(317,574,769.18)(32,286,351.44)(35,442,437.59)Payments of taxes and surcharges(289,543,090.68)(227,174,658.46)(24,337,680.93)(21,012,066.83)Cash paid relating to other operating activitiesV(47)(b)(254,169,959.27)(426,525,483.03)(68,362,099.93)(119,308,513.34)Sub-total of cash outflows(12,984,479,892.55)(11,763,811,404.22)(1,939,797,172.38)(1,754,455,582.18)Net cash flows from operating activitiesV(48)(a) XIII(6)(a)428,159,420.65273,860,877.1794,598,002.62(125,786,674.20)II. Cash flows from investing activitiesCash received from disposal of investments--45,000,000.00-Cash received from returns on investments8,271,829.94 3,618.16120,525,780.70157,015,678.55Net cash received from disposal of fixed assets, intangible assets and other long-term assets8,584,335.706,924,402.4366,884.115,243,565.12Cash received from disposal of subsidiaries and other business units325,415.0059,988,453.43-65,613,100.00Cash received relating to other investing activities--527,181,026.96-Sub-total of cash inflows17,181,580.6466,916,474.02692,773,691.77227,872,343.67Cash paid to acquire fixed assets, intangible assets and other long-term assets(177,992,154.66)(103,671,283.81)(24,348,271.94)(3,523,755.18)Cash paid to acquire investments--(593,660,000.00)(30,750,000.00)Net cash paid to acquire subsidiaries and other business unitsV(48)(b)(127,971,282.96)(112,284,233.53)(65,675,390.00)(256,327,901.88)Cash paid relating to other investing activitiesV(47)(c)-(8,100,000.00)(688,107,915.16)(5,000,000.00)Sub-total of cash outflows(305,963,437.62)(224,055,517.34)(1,371,791,577.10)(295,601,657.06)Net cash flows from investing activities(288,781,856.98)(157,139,043.32)(679,017,885.33)(67,729,313.39) ItemsNotesConsolidatedCompanyYear ended 31 December 2010Year ended 31 December 2009Year ended 31 December 2010Year ended 31 December 2009III. Cash flows from financing activitiesCash received from capital contributions9,800,000.00---Including: Cash received from capital contributions by minority shareholders of subsidiaries9,800,000.00---Cash received from loans711,726,701.181,524,036,889.20970,000,000.00703,710,793.61Cash received relating to other financing activitiesV(47)(d)950,000,000.00-1,018,500,644.34505,816,825.31Sub-total of cash inflows1,671,526,701.181,524,036,889.201,988,500,644.341,209,527,618.92Cash repayments of borrowings(704,180,953.09)(1,264,359,623.02)(1,010,000,000.00)(436,859,302.49)Cash payments for interest expenses and distribution of dividends or profits(106,597,670.36)(87,440,842.08)(69,084,760.92)(43,410,324.18)Including: Cash payments for dividends or profit to minority shareholders of subsidiaries-(4,900,000.00)--Cash payments relating to other financing activitiesV(47)(e)(900,000,000.00)(95,000,000.00)(310,038,384.64)(477,570,384.51)Sub-total of cash outflows(1,710,778,623.45)(1,446,800,465.10)(1,389,123,145.56)(957,840,011.18)Net cash flows from financing activities(39,251,922.27)77,236,424.10599,377,498.78251,687,607.74IV. Effect of foreign exchange rate changes on cash and cash equivalents(440.37)(3,389.48)--V. Net increase in cash and cash equivalents100,125,201.03193,954,868.4714,957,616.0758,171,620.15Add: Cash and cash equivalents at beginning of the period582,750,672.15388,795,803.68120,541,203.8062,369,583.65VI. Cash and cash equivalent at end of the periodV(48)(d) XIII(6)(c)682,875,873.18582,750,672.15135,498,819.87120,541,203.80 The accompanying notes form an integral part of these financial statements. . Legal representative: Principal in charge of accounting :Head of accounting department: ItemsNotesAttributable to the shareholders of the CompanyMinority interestTotal owners equityShare capitalCapital surplusSurplus reserveUndistributed profitsAs at 31 December 2008288,149,400.0031,624,522.449,303,064.31330,460,963.4121,383,463.30 680,921,413.46Business combination under common controlIV(3)(d)- 26,538,149.83-(2,148,833.94)-24,389,315.89As at 1 January 2009288,149,400.0058,162,672.279,303,064.31328,312,129.4721,383,463.30705,310,729.35Increase/(decrease)Net profit---192,868,245.185,545,798.21198,414,043.39Other comprehensive income------Capital contribution by owners- Business combination under non-common control----33,460,202.2333,460,202.23- Others-(26,568,683.87)(9,303,064.31)(4,497,799.33)-(40,369,547.51)Appropriation- Transfer to surplus reserveV(33)--17,573,057.11(17,573,057.11)--- DividendsV(34)---(28,828,019.86)(4,900,000.00)(33,728,019.86)- OthersV(32)-(25,500.00)-39,637,448.97(24,500.00)39,587,448.97 As at 31 December 2009288,149,400.0031,568,488.4017,573,057.11509,918,947.3255,464,963.74902,674,856.57 ItemsNotesAttributable to the shareholders of the CompanyMinority interestTotal owners equityShare capitalCapital surplusSurplus reserveUndistributed profitsAs at 31 December 2009288,149,400.005,030,338.5717,573,057.11511,913,342.0055,464,963.74878,131,101.42Business combination under common controlIV(3)-26,538,149.83-(1,994,394.68)-24,543,755.15As at 1 January 2010288,149,400.0031,568,488.4017,573,057.11509,918,947.3255,464,963.74902,674,856.57Increase/(decrease)Net profit---261,116,656.703,107,762.36264,224,419.06Other comprehensive income------Capital contribution by owners- Capital injection----20,502,325.5120,502,325.51- OthersIV(3)-(26,538,149.83)-(603,150.17)-(27,141,300.00)Appropriation- Transfer to surplus reserve--22,408,211.44(22,408,211.44)--- Dividends---(28,814,940.00)-(28,814,940.00)As at 31 December 2010288,149,400.005,030,338.5739,981,268.55719,209,302.4179,075,051.611,131,445,361.14 The accompanying notes form an integral part of these financial statements. . Legal representative: Principal in charge of accounting :Head of accounting department: ItemsNotesShare capitalCapital surplusSurplus reserveUndistributed profitsTotal owners equityAs at 1 January 2009288,149,400.002,508,769.9412,781,301.82121,657,269.56425,096,741.32Increase/(decrease)Net profit---175,730,571.10175,730,571.10Other comprehensive income-----Capital contribution by owners- Others-11,319,956.99(12,781,301.82)(16,085,415.12)(17,546,759.95)Appropriation- Transfer to surplus reserve--17,573,057.11(17,573,057.11)-- Dividends---(28,828,019.86)(28,828,019.86)As at 31 December 2009288,149,400.0013,828,726.9317,573,057.11234,901,348.57554,452,532.61As at 1 January 2010288,149,400.0013,828,726.9317,573,057.11234,901,348.57554,452,532.61Increase/(decrease)Profit for the year---224,082,114.41224,082,114.41Other comprehensive income-----Capital contribution by owners- OthersIV(3)---(7,209,272.00)(7,209,272.00)Appropriation- Transfer to surplus reserve--22,408,211.44(22,408,211.44)-- Dividends---(28,814,940.00)(28,814,940.00)As at 31 December 2010288,149,400.0013,828,726.9339,981,268.55400,551,039.54742,510,435.02 The accompanying notes form an integral part of these financial statements. . Legal representative: Principal in charge of accounting :Head of accounting department: IGeneral informationShenzhen Accord Pharmaceutical Co., Ltd. ( the Company ), formerly known as Shenzhen Health Mineral Water Co., Ltd., was approved by the People s Government of Shenzhen with SFBF (1993) No.356 document to establish on February 1, 1993 through stock restructure as a company limited by shares. In March 1993, with the approval from the Shenzhen Branch of the People s Bank of China, the Company issued 30 million A-shares (including 16.5 million public shares, 3.5 million employee shares and 10 million corporation shares) and 20 million B-shares. After this issuance, the Company s share capital was Rmb105 million. Through transfer of capital surplus to share capital and bonus issues for years, the share capital of the Company increased to       !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|~Rmb288,149,400 up to December 31, 2010. The employee shares, domestic public shares and foreign public shares have all been listed on the Shenzhen Stock Exchange. In November 2000, the Company entered into an Assets Exchange Agreement with Shenzhen Investment Management Company, the original main shareholder of the Company, to exchange all the assets and liabilities of the Company as of August 31, 2000 for Shenzhen Investment Management Company s 100% equity interests in 11 pharmaceutical companies and certain properties as well as 51% equity interests in Shenzhen Tefa Modern Computer Co., Ltd. On December 29, 2000, the above assets exchange proposal was approved by shareholder s voting in the second extraordinary general meeting in 2000. The transaction was completed on January 8, 2001. On June 18, 2001, the Company changed its name to Shenzhen Accord Pharmaceutical Co., Ltd., and belongs to the pharmaceutical manufacturing industry. On February 18, 2004, the Company s original main shareholder, Shenzhen Investment Management Company, entered into a Stock Transfer Agreement with Sinopharm Group Co., Ltd. (formerly known as Sinopharm Group Medicine Holding Co., Ltd, hereinafter referred to as  Sinopharm Group ) to transfer its 43.33% shares in the Company to Sinopharm Group. The legal procedures of the above equity transfer were completed on December 9, 2004. At the same time, as approved by GZCQ (2004) No.525 document from the State-owned Assets Supervision and Administration Commission of the State Council and ZJGSZ (2004) No.94 document from the China Securities Regulatory Commission, the nature of these shares was transferred from state-owned stock to state-owned legal entity stock and Sinopharm Group became the top shareholder of the Company. On April 14, 2006, the Company s proposal on reformation of segregated stocks was approved. To gain liquidity for the restricted stocks of the Company, the holders of the restricted stocks of the Company agreed to pay the following consideration: based on the stock registration as of April 27, 2006, the Company issued bonus shares on April 28, 2006 at the ratio of 3 shares to every 10 A-shares to liquidated A-share holders which went public on the same day. After this bonus issue, the total number of shares of the Company remained unchanged with corresponding changes in the composition of share holdings. As at December 31, 2010, there were 288,149,400 shares in total and all are shares without selling restriction. The Company is registered with Shenzhen Administration for Industry & Commerce. Its business license number is 440301103040048 and the serial number of the license is N24657. The operation period of the Company is from August 2, 1986 to August 2, 2036. The registered capital of the Company is Rmb288,149,400. The legal representative of the Company is Shi Jinming. IGeneral information (continued)The approved scope of business of the Company and its subsidiaries (together  the Group ) includes wholesale of Chinese patent drugs, raw materials for chemical medicine, chemical material drugs, antibiotics, bio-chemical drugs and biological products (including vaccines); trade of health food; research, development and consultation services of pharmaceutical packaging materials and pharmaceutical industry products; investment on setting up entities (application on projects separately); domestic trading and supplies (excluding solely licensed, solely controlled or monopolized products); category III disposable bacterial-free medical treatment instruments; equipments and instruments for operation units, emergency units and diagnosis units, medical macromolecule materials and products, clinical check up and analysis apparatus and diagnosis reagents, medical sutures and bonds, oral section materials, medical assay and basic equipments and instruments; category II medical electronic equipment, medical X-ray appurtenances and parts, medical ultrasonic instruments and relevant equipments, antisepsis and antibacterial equipments and instruments, medical sanitation materials and dressings; import and export business (excluding the items banned by laws, administrative regulations, or the State Council. The restricted items can only be traded after obtaining a license).These financial statements were authorised for issue by the board of directors of the Company on 18 March 2011. IISummary of significant accounting policies and accounting estimates(1)Basis of preparationThe Group adopted the Accounting Standards for Business Enterprises (comprising one basic standard and 38 specific standards) promulgated by the Ministry of Finance on 15 February 2006, the application guidance and interpretation to the Accounting Standards for Business Enterprises and other relative regulations subsequently promulgated by Ministry of Finance (here in after collectively as referred to the  CAS ). The rules of Compilation Rules for Information Disclosures by Companies That Offer Securities to the Public No.15 - General Provisions for Financial Reports(2010 revised edition) promulgated by China Securities Regulatory Commission has adopted as well. (2)Statement of compliance with the Accounting Standards for Business EnterprisesThe financial statements of the Company for the year ended 31 December 2010 are in compliance with the Accounting Standards for Business Enterprises, and truly and completely present the financial position as of 31 December 2010 and the operating results, cash flows and other information for the year then ended of the Group and the Company.(3)Accounting periodThe Company s accounting year starts on 1 January and ends on 31 December.(4)Recording currencyThe recording currency is Renminbi (RMB). IISummary of significant accounting policies and accounting estimates (continued)(5)Business combinations(a)Business combinations involving enterprises under common controlThe consideration paid and net assets obtained by the absorbing party in a business combination are measured at the carrying amount. The difference between the carrying amount of the net assets obtained and the carrying amount of the consideration paid for the combination is treated as an adjustment to capital surplus (capital premium). If the capital surplus (capital premium) is not sufficient to be offset, the remaining balance is adjusted against retained earnings.Costs directly attributable to the combination are included in profit or loss in the period in which they are incurred.(b)Business combinations involving enterprises not under common controlThe cost of combination and identifiable net assets obtained by the acquirer in a business combination are measured at fair value at the acquisition date. Where the cost of the combination exceeds the acquirer s interest in the fair value of the acquiree s identifiable net assets, the difference is recognised as goodwill; where the cost of combination is lower than the acquirer s interest in the fair value of the acquiree s identifiable net assets, the difference is recognised in profit or loss for the current period. Costs directly attributable to the combination are included in profit or loss in the period in which they are incurred. (6)Preparation of consolidated financial statementsThe consolidated financial statements comprise the financial statements of the Company and all of its subsidiaries.Subsidiaries are consolidated from the date on which the Group obtains control and are de-consolidated from the date that such control ceases. For a subsidiary that is acquired in a business combination involving enterprises under common control, it is included in the consolidated financial statements from the date when it, together with the Company, come under common control of the ultimate controlling party. The portion of the net profits realised before the combination date is presented separately in the consolidated income statement.In preparing the consolidated financial statements, where the accounting policies and the accounting periods are inconsistent between the Company and subsidiaries, the financial statements of subsidiaries are adjusted in accordance with the accounting policies and accounting period of the Company. For subsidiaries acquired from a business combination involving enterprises not under common control, the individual financial statements of the subsidiaries are adjusted based on the fair value of the identifiable net assets at the acquisition date.All significant inter-group balances, transactions and unrealised profits are eliminated in the consolidated financial statements. The portion of a subsidiary s equity and the portion of a subsidiary s net profits and losses for the period not attributable to Company are recognised as minority interests and presented separately in the consolidated financial statements within equity and net profits respectively. IISummary of significant accounting policies and accounting estimates (continued)(7)Cash and cash equivalentsFor the purpose of the cash flow statement, cash and cash equivalents comprise cash on hand, call deposits with banks and short-term and highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (8)Foreign currency translationForeign currency transactions are translated into RMB using the exchange rates prevailing at the dates of the transactions. At the balance sheet date, monetary items denominated in foreign currencies are translated into RMB using the spot exchange rates on the balance sheet date. Exchange differences arising from these translations are recognised in profit or loss for the current period, except for those attributable to foreign currency borrowings that have been taken out specifically for the acquisition or construction of qualifying assets, which are capitalised as part of the cost of those assets. Non-monetary items denominated in foreign currencies that are measured at historical costs are translated at the balance sheet date using the spot exchange rates at the date of the transactions. The effect of exchange rate changes on cash is presented separately in the cash flow statement. (9)Financial Instruments(a)Financial assets(i)ClassificationFinancial assets are classified into the following categories at initial recognition: financial assets at fair value through profit or loss, receivables, available-for-sale financial assets and held-to-maturity investments. The classification of financial assets depends on the Group s intention and ability to hold the financial assets. The Group currently holds the financial assets including receivables. Receivables, including notes receivables, accounts receivable and other receivables, are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market (ii)Recognition and measurementFinancial assets are recognised at fair value on the balance sheet when the Group becomes a party to the contractual provisions of the financial instrument. Receivables are measured at amortised cost using the effective interest method. (iii)Impairment of financial assetsThe Group assesses the carrying amounts of receivables at each balance sheet date. If there is objective evidence that a financial asset is impaired, the Group shall determine the amount of impairment loss. If there is objective evidence that the value of the financial asset recovered and the recovery is related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed and the amount of reversal is recognised in profit or loss.(iv)Derecognition of financial assetsFinancial assets are derecognised when: i) the contractual rights to receive the cash flows from the financial assets have expired; or ii) all substantial risks and rewards of ownership of the financial assets have been transferred; or iii) the control over the financial asset has been waived even if the Group does not transfer or retain nearly all of the risks and rewards relating to the ownership of a financial asset. IISummary of significant accounting policies and accounting estimates (continued)(9)Financial Instruments (continued)(a)Financial assets(continued)(iv)Derecognition of financial assets(continued)On derecognition of a financial asset, the difference between the carrying amount and the aggregate of consideration received, is recognised in the income statement. (b)Financial liabilitiesFinancial liabilities are classified into the following categories at initial recognition: the financial liabilities at fair value through profit or loss and other financial liabilities. The financial liabilities in the Group mainly comprise of other financial liabilities, including payables and borrowings. Payables comprise notes payable, accounts payable and other payables, which are recognised initially at fair value and measured subsequently at amortised cost using the effective interest method.Borrowings are recognised initially at fair value, net of transaction costs incurred, and subsequently carried at amortised costs using the effective interest method.Other financial liabilities are classified as the short-term borrowings if they mature within one year (one year included); others are classified as non-current liabilities; Non-current liabilities due for repayment within one year since the balance sheet day are classified as current portion of non-current liabilities.A financial liability (or a part of financial liability) is derecognised when and only when the obligation specified in the contract is discharged or cancelled. The difference between the carrying amount of a financial liability (or a part of financial liability) extinguished and the consideration paid is recognised in the income statement.(10)ReceivablesReceivables comprise notes receivable, accounts receivable and other receivables. Accounts receivable arising from sale of goods or rendering of services are initially recognised at fair value of the contractual payments from the buyers or service recipients. (a)Receivables with significant amount are subject to separate impairment assessmentReceivables that are individually significant are subject to separate impairment assessment. If there is objective evidence that the Group will not be able to collect the full amount under the original terms, a provision for impairment of that receivable is established at the difference between the carrying amount of that receivable and the present value of its estimated future cash flows.Debtors with significant balance refer to those with individual amount over RMB5 million.A provision on receivable accounts with significant amount is established at the difference between the carrying amount of that receivable and the present value of its estimated future cash flows. IISummary of significant accounting policies and accounting estimates (continued)(10)Receivables (continued)(b)Recognition and provision of bad debt provision on receivable accounts within similar credit risk groupReceivables that are not individually significant and those receivables that have been individually evaluated for impairment and have been found not impaired are combined into certain groups based on their credit risk characteristics. The impairment losses are determined based on the historical loss experience for the groups of receivables with the similar credit risk characteristics and taking into consideration of the current circumstances. The basis of similar credit risk group: the ageing of receivables A provision for impairment of the receivables is made based on the ageing of receivables at the following percentage:Rate for accounts receivablesRate for other receivables Within 1 year--1 to 2 years5%5%2 to 3 years10%10%More than 3 years20%20%(c)Receivables that are not individually significant but subject to separate impairment assessmentIf there is objective evidence that the Group will not be able to collect the full amount under the original terms, then the Group would separately assess the provision of the receivables. A provision for impairment of that receivable is established at the difference between the carrying amount of that receivable and the present value of its estimated future cash flows.(d)When the Group transfers the accounts receivable to financial institutions without recourse, the net amount of proceeds received from the transaction after the carrying amounts of the accounts receivable and related taxes is recognised in profit or loss for the current period. (11)Inventories(a)ClassificationInventories include raw materials, work in progress, finished goods and turnover materials, and are presented at the lower of cost and net realisable value.  IISummary of significant accounting policies and accounting estimates (continued)(11)Inventories (continued)(b)Determination of costCost is determined on the weighted average method. The cost of finished goods and work in progress comprises raw materials, direct labour and an allocation of all production overhead expenditures incurred based on normal operating capacity.(c)The determination of net realisable value and the method of provisions for impairment of inventoriesProvisions for declines in the value of inventories are determined at the excess amount of the carrying value of the inventories over their net realisable value. Net realisable value is determined based on the estimated selling price in the ordinary course of business, less the estimated costs to completion and estimated costs necessary to make the sale and related taxes.(d)The Group adopts the perpetual inventory system.(e)Amortization method for low cost consumables and packaging materialsTurnover materials include low cost consumables and packaging materials, which are expensed when issued. (12)Long-term equity investmentsLong-term equity investments comprise the Company s long-term equity investments in its subsidiaries and the Group s long-term equity investments in its associates.Subsidiaries are all entities over which the Company is able to control. Associates are all entities over which the Group has significant influence, but not control, on their financial and operating policies.Investments in subsidiaries are measured using the cost method in the Company s financial statements, and adjusted by using the equity method when preparing the consolidated financial statements. Interests in associates are accounted for using the equity method.(a)Initial recognitionLong-term equity investments accounted for using the cost method are measured at the initial investment costs. Investments in associates are accounted for using the equity method. Where the initial investment cost exceeds the Group s share of the fair value of the investee s identifiable net assets at the time of acquisition, the investment is initially measured at cost. Where the initial investment cost is less than the Group s share of the fair value of the investee s identifiable net assets at the time of acquisition, the difference is included in profit or loss for the current period and the cost of the long-term equity investment is adjusted upwards accordingly. IISummary of significant accounting policies and accounting estimates (continued)(12)Long-term equity investments (continued)(b)Subsequent measurement Long-term equity investments accounted for using the cost method are measured at the initial investment costs. Investment income is recognised in profit or loss for the cash dividends or profit distribution declared by the investees.Under the equity method of accounting, the Group recognises the investment income according to its share of net profit or loss of the investee. The Group discontinues recognising its share of net losses of an investee after the carrying amount of the long-term equity investment together with any long-term interests that, in substance, form part of the investor s net investment in the investee are reduced to zero. However, if the Group has obligations for additional losses and the criteria with respect to recognition of provisions under the accounting standards on contingencies are satisfied, the Group continues recognising the investment losses and the provisions. For changes in owners equity of the investee other than those arising from its net profit or loss, the Group records its proportionate share directly into capital surplus, provided that the Group s proportion of shareholding in the investee remains unchanged. The carrying amount of the investment is reduced by the Group s share of the profit distribution or cash dividends declared by an investee. The unrealised profits or losses arising from the intra-group transactions amongst the Group and its investees are eliminated in proportion to the Group s equity interest in the investees, and then based which the investment gain or losses are recognised. The loss on the intra-group transaction amongst the Group and its investees, of which the nature is asset impairment, is recognised in full, and the related unrealised loss is not eliminated.(c)Definition of control and significant influence over the investeesControlling power means the power over the firm s financial and operational decision-making, and can obtain profit from the operation of such firm. At considering of substantial control or major influence of a firm, the potential voting right factors such as current convertible bonds or executable subscription options have been considered.Major influence means the power to participate in decision-making but cannot control or collectively control the same. (d)Impairment of long-term equity investments The carrying amount of long-term equity investments in subsidiaries and associates is reduced to the recoverable amount when the recoverable amount is less than the carrying amount (Note II (20)). (13)Investment propertiesInvestment properties, including land use rights that have already been leased out buildings that are held for the purpose of lease and buildings that is being constructed or developed for future use for leasing, are measured initially at cost. Subsequent expenditures incurred in relation to an investment property is included in the cost of the investment property when it is probable that the associated economic benefits will flow to the Group and its cost can be reliably measured; otherwise, the expenditures are recognised in profit or loss in the period in which they are incurred. IISummary of significant accounting policies and accounting estimates (continued)(13)Investment properties (continued)The Group adopts the cost model for subsequent measurement of the investment properties. Buildings and land use rights are depreciated or amortised to their estimated net residual values over their estimated useful lives. The estimated useful lives, the estimated net residual values expressed as a percentage of cost and the annual depreciation (amortisation) rates of the investment properties are as follows:Estimated useful livesEstimated residual valueAnnual depreciation (amortisation) rateBuildings20-35 years5%2.71% to 4.75%Land use rights30-50 years-2.00% to 3.33%When an investment property is transferred to an owner-occupied property, it is reclassified as fixed asset or intangible asset at the date of the transfer. When an owner-occupied property is transferred for earning rentals or for capital appreciation, the fixed asset or intangible asset is reclassified as investment property at its carrying amount at the date of the transfer.The estimated useful life, net residual value of the investment property and the depreciation (amortisation) method applied are reviewed and adjusted as appropriate at each year-end.An investment property is derecognised on disposal or when the investment property is permanently withdrawn from use and no future economic benefits are expected from its disposal. The net amount of proceeds from sale, transfer, retirement or damage of an investment property after its carrying amount and related taxes and expenses is recognised in profit or loss for the current period.The carrying amount of investment properties is reduced to the recoverable amount when the recoverable amount is less than the carrying amount (Note II (20)). (14)Fixed assets(a)RecognitionFixed assets comprise buildings, machinery and equipment, motor vehicles, computer and electronic equipment, office equipment and leasehold improvements.Fixed asset is recognised when it is probable that the economic benefits associated with the fixed asset will flow to the Group and its cost can be reliably measured. Fixed assets purchased or constructed by the Group are initially measured at cost at the time of acquisition. Fixed assets contributed by state-owned shareholders during the company reorganisation were recorded based on the valuation amount approved by the state-owned assets supervision and management department.Subsequent expenditures incurred for a fixed asset are included in the cost of the fixed asset when it is probable that the associated economic benefits will flow to the Group and the related cost can be reliably measured. The carrying amount of the replaced part is derecognised. All the other subsequent expenditures are recognised in profit or loss in the period in which they are incurred. IISummary of significant accounting policies and accounting estimates (continued)(14)Fixed assets (continued)(b)DepreciationFixed assets are depreciated using the straight-line method to allocate the cost of the assets to their estimated residual values over their estimated useful lives. For the fixed assets that have been provided for impairment loss, the related depreciation charge is prospectively determined based upon the adjusted carrying amounts over their remaining useful lives.The estimated useful lives, the estimated residual values expressed as a percentage of cost and the annual depreciation rates are as follows:Estimated useful livesEstimated residual valueAnnual depreciation rateBuildings20-35 years5%2.71% to 4.75%Machinery and equipment10-14 years5%6.79% to 9.5%Motor vehicles5-10 years5%9.5% to 19%Other5-10 years5%9.5% to 19%Leasehold improvementsWithin 5 years-Above 20%The estimated useful life, the estimated net residual value of a fixed asset and the depreciation method applied to the asset are reviewed, and adjusted as appropriate at least at each year-end. (c)The carrying amount of fixed assets is reduced to the recoverable amount when the recoverable amount is less than the carrying amount (Note II (20)). (d)DisposalA fixed asset is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The amount of proceeds from disposal on sale, transfer, retirement or damage of a fixed asset net of its carrying amount and related taxes and expenses is recognised in profit or loss for the current period.(15)Construction in progressConstruction in progress is measured at actual cost. Actual cost comprises construction costs, installation costs, borrowing costs that are eligible for capitalisation and other costs necessary to bring the fixed assets ready for their intended use. Construction in progress is transferred to fixed assets when the assets are ready for their intended use, and depreciation begins from the following month. The carrying amount of construction in progress is reduced to the recoverable amount when the recoverable amount is less than the carrying amount (Note II (20)). The borrowing costs that are directly attributable to the acquisition and construction of a fixed asset that needs a substantially long period of time of acquisition and construction for its intended use commence to be capitalised and recorded as part of the cost of the asset when expenditures for the asset and borrowing costs have been incurred, and the activities relating to the acquisition and construction that are necessary to prepare the asset for its intended use have commenced. The capitalisation of borrowing costs ceases when the asset under acquisition or construction becomes ready for its intended use, the borrowing costs incurred thereafter are recognised in profit or loss for the current period. Capitalisation of borrowing costs is suspended during periods in which the acquisition or construction of a fixed asset is interrupted abnormally and the interruption lasts for more than 3 months, until the acquisition or construction is resumed. IISummary of significant accounting policies and accounting estimates (continued)(16)Borrowing costsFor a borrowing specific for the acquisition, construction or production activities for preparing an asset eligible for capitalisation, the to-be-capitalised borrowing costs shall be determined according to the actual borrowing costs incurred less any income earned on the unused borrowing fund as a deposit in the bank or as a temporary investment.For the other borrowings related to acquisition, construction and production of a qualifying asset, the amount of to-be-capitalised borrowing costs shall be the lower of the actual borrowing costs incurred and the amount of qualifying asset not financed by specific borrowings multifying capitalisation rate. The capitalisation rate is the weighted average interest rate of these borrowings. (17)Intangible assetsIntangible assets include land use rights, computer softwares, technology patents and trademarks, which initially recognised at cost. Intangible assets contributed by state-owned shareholders during the company reorganisation were recorded based on the valuation amount approved by the state-owned assets supervision and management department.(a)Land use rightsA land use right granted by government with a infinite useful life would not be amortised. Other land use rights are amortised on the straight-line basis over their approved useful period of 30 to 50 years.If the purchase costs of land use rights and the buildings located thereon cannot be reliably allocated between the land use rights and the buildings, all of the purchase costs are recognised as fixed assets.(b)Computer softwaresComputer softwares purchased by the Group are initially measured at cost, which are amortised on the straight-line basis over their approved useful period of 3 to 5 years.(c)Trademarks and proprietary technology Trademarks are amortised on the straight-line basis over their effective periods as stipulated by law of 5 to 10 years. Proprietary technology are amortised on the straight-line basis over their effective useful period of 5 years.(d)Periodical review of useful life and amortisation methodFor an intangible asset with a finite useful life, review and adjustment on its useful life and amortisation method are performed at each year-end. For an intangible asset without a definite useful life, review and adjustment on its useful life are performed at each year-end. IISummary of significant accounting policies and accounting estimates (continued)(17)Intangible assets (continued)(e)Research and developmentThe expenditure on an internal research and development project is classified into expenditure on the research phase and expenditure on the development phase based on its nature and whether there is material uncertainty that the research and development activities can form an intangible asset at end of the project.Expenditure on the research phase is recognised in profit or loss in the period in which it is incurred. Expenditure on the development phase is capitalised only if all of the following conditions are satisfied: it is technically feasible to complete the intangible asset so that it will be available for use; management intends to complete the intangible asset, and use or sell it; it can be demonstrated how the intangible asset will generate economic benefits; adequate technical, financial and other resources to complete the development and the ability to use or sell the intangible asset; and the expenditure attributable to the intangible asset during its development phase can be reliably measured.Other development expenditures that do not meet the conditions above are recognised in profit or loss in the period in which they are incurred. Development costs previously recognised as expenses are not recognised as an asset in a subsequent period. Capitalised expenditure on the development phase is presented as development costs in the balance sheet and transferred to intangible assets at the date that the asset is ready for its intended use. (f)ImpairmentThe carrying amount of intangible assets is reduced to the recoverable amount when the recoverable amount is less than the carrying amount (Note II (20)). (18)Long-term prepaid expensesLong-term prepaid expenses include the expenditure for improvements to fixed assets under operating leases, and other expenditures that have been made but should be recgonised as expenses over more than one year in the current and subsequent periods. Long-term prepaid expenses are amortised on the straight-line basis over the expected beneficial period and are presented at actual expenditure net of accumulated amortisation. (19)Governmental medical reserve funds and specially approved reserving materialsAppointed by the PRC Government, China National Pharmaceutical Group Corporation ( CNPGC") is responsible for purchasing, allocating and providing the governmental medical reserves, which include the medical products, traditional Chinese medicine and medical appliances for nation-wide emergency rescue and disaster relief. Appointed by the Government of Guangxi Province, Sinopharm Medicine Holding Nanning Co., Ltd. ( Sinopharm Nanning ), a subsidiary of the Group, is responsible for purchasing, allocating and providing the medical reserves, which include the medical products needed for common disease and emergencies triggered by major disasters, epidemics and other situations in Guangxi Province. In accordance with the regulation of CNPGC, as being the enterprise who bears the obligation for specially approved medical reserving materials, the medical reserve funds received from the PRC Government or local government are recognised in other Non-current liabilities. The Group reserves the specially approved medical reserving materials according to the reserve program (by category and by quantity), applies dynamic management and recognises in other non-current assets.  IISummary of significant accounting policies and accounting estimates (continued)(20)Impairment of long-term assetsFixed assets, construction in progress, intangible assets with finite useful lives, Long-term prepaid expenses and investment properties measured using the cost model and long-term equity investments in subsidiaries, joint ventures and associates are tested for impairment if there is any indication that an asset may be impaired at the balance date. If the result of the impairment test indicates that the recoverable amount of the asset is less than its carrying amount, a provision for impairment and an impairment loss are recognised for the amount by which the asset s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset s fair value less costs to sell and the present value of the future cash flows expected to be derived from the asset. Provision for asset impairment is determined and recognised on the individual asset basis. If it is not possible to estimate the recoverable amount of an individual asset, the recoverable amount of a group of assets to which the asset belongs is determined. A group of assets is the smallest group of assets that is able to generate independent cash inflows. Goodwill that is separately presented in the financial statements and intangible assets with infinite useful lives are tested at least annually for impairment, irrespective of whether there is any indication that it may be impaired. In conducting the test, the carrying value of goodwill is allocated to the related asset groups or groups of asset groups which are expected to benefit from the synergies of the business combination. If the result of the test indicates that the recoverable amount of an asset group or group of asset groups, including the goodwill allocated, is lower than its carrying amount, the corresponding impairment loss is recognised. The impairment loss is first deducted from the carrying amount of goodwill that is allocated to the asset group or group of asset groups, and then deducted from the carrying amounts of other assets within the asset groups or groups of asset groups in proportion to the carrying amounts of other assets.Once the above asset impairment loss is recognised, it will not be reversed for the value recovered in the subsequent periods. (21)Employee benefitsEmployee benefits mainly include wages or salaries, bonuses, allowances and subsidies, staff welfare, social security contributions, housing funds, labour union funds, employee education funds and other expenditures incurred in exchange for service rendered by employees.  If the Group terminates the labor relationship with an employee prior to the expiration of the relevant labor contract or makes a severance package proposal with the purpose of encouraging voluntary redundency, and provided that the Group has drafted a formal plan for the termination of labour relationships or has put forward a proposal for voluntary layoffs and intends to execute it forthwith, and the Group may not retract plans for termination of labour relationships or layoff proposals ex parte, the Group shall recognise the liabilities to be incurred due to severance pay, and shall at the same time record them in the income statement. Except for compensation paid for termination of employment, employee benefits are recognised as salaries and wages payable in the accounting period in which an employee has rendered service, as costs of assets or expenses to whichever the employee service is attributable.(22)Profit distributionCash dividends distribution is recognised as a liability in the period in which it is approved by the annual shareholders meeting. IISummary of significant accounting policies and accounting estimates (continued)(23)Revenue recognitionThe amount of revenue is determined in accordance with the fair value of the consideration received or receivable for the sale of goods and services in the ordinary course of the Group s activities. Revenue is shown net of value-added tax, rebates, discounts and returns. Revenue is recognised when the economic benefits associated with the transaction will flow to the Group, the related revenue can be reliably measured, and the specific revenue recognition criteria have been met for each type of the Group s activities as described below:(a)Sale of goodsRevenue from the sale of goods is recognized when significant risks and rewards of ownership of the goods are transferred to the buyer, the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold, and it is probable that the economic benefit associated with the transaction will flow to the Company and the relevant revenue and costs can be measured reliably. (b)Rendering of servicesThe Group provides freight service and storage service to external parties. The freights are recognized as revenue right after the goods are transported to the place of delivery according to contracts or agreements, received and confirmed by the purchasers. The storage charges are recognized as revenue on the basis of services provided during the storage period.  (c)Transfer of asset use rightsInterest income is recognised on a time-proportion basis using the effective interest method.Income from an operating lease is recognised on a straight-line basis over the period of the lease. (24)Government grantsGovernment grants are the monetary asset the Group receives from the government for free, including tax refund, government subsidies, etc.Grants from the government are recognised when there is a reasonable assurance that the grants will be received and the Group will comply with all attached conditions. Government grants are measured at the amounts received or receivable.Government grants relating to assets are recognised as deferred income and are credited to the income statement on a straight-line basis over the expected lives of the related assets. Government grants relating to income, which is used to compensate the expenses/costs incurred in future, are recognised as deferred income and then credited to the income statement over the period necessary to match them with the expenses that they are intended to compensate. Government grants relating to income, which is used to compensate the expenses/costs incurred in the past, are credited to the income statement directly. IISummary of significant accounting policies and accounting estimates (continued)(25)Deferred tax assets and deferred tax liabilitiesDeferred tax assets and deferred tax liabilities are calculated and recognised based on the differences arising between the tax bases of assets and liabilities and their carrying amounts (temporary differences). Deferred tax asset is recognised for the deductible losses that can be carried forward to subsequent years for deduction of the taxable profit in accordance with the tax laws. No deferred tax liability is recognised for a temporary difference arising from the initial recognition of goodwill. No deferred tax asset or deferred tax liability is recognised for the temporary differences resulting from the initial recognition of assets or liabilities due to a transaction other than a business combination, which affects neither accounting profit nor taxable profit (or deductible loss). At the balance sheet date, deferred tax assets and deferred tax liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled.Deferred tax assets are only recognised for deductible temporary differences, deductible losses and tax credits to the extent that it is probable that taxable profit will be available in the future against which the deductible temporary differences, deductible losses and tax credits can be utilised.Deferred tax assets and liabilities are offset when: the deferred taxes are related to the same tax payer within the Group and the same taxation authority; and, that tax payer has a legally enforceable right to offset current tax assets against current tax liabilities. Deferred tax liabilities are recognised for temporary differences arising from investments in subsidiaries and associates, except where the Group is able to control the timing of the reversal of the temporary difference, and it is probable that the temporary difference will not reverse in the foreseeable future. When it is probable that the temporary differences arising from investments in subsidiaries, joint ventures and associates will be reversed in the foreseeable future and that the taxable profit will be available in the future against which the temporary differences can be utilised, the corresponding deferred tax assets are recognised.  (26)Operating leasesLeases where a significant portion of the risks and rewards of ownership are retained by the leaser are classified as operating leases. Lease payments under an operating lease are recognised on a straight-line basis over the period of the lease, and are either capitalised as part of the cost of related assets or charged as an expense. (27)Segment informationThe Group identifies operating segments based on the internal organisation structure, management requirements and internal reporting system, and discloses segment information of reportable segments which is determined on the basis of operating segments.An operating segment is a component of the Group that satisfies all of the following conditions: (1) the component is able to earn revenues and incur expenses from its ordinary activities; (2) whose operating results are regularly reviewed by the Group s management to make decisions about resources to be allocated to the segment and to assess its performance, and (3) for which the information on financial position, operating results and cash flows is available to the Group. If two or more operating segments have similar economic characteristics and satisfy certain conditions, they are aggregated into one single operating segment. IISummary of significant accounting policies and accounting estimates (continued)(28)Changes in significant accounting policiesThe Group has no changes in significant accounting policies in 2010. (29)Critical accounting estimates and judgmentsThe Group continually evaluates the critical accounting estimates and key judgments applied based on historical experience and other factors, including expectations of future events that are believed to be reasonable.(a)Critical accounting estimates and key assumptionsThe critical accounting estimates and key assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are outlined below:(i)Accounting estimates on impairment of goodwillThe Group tests annually whether goodwill has suffered any impairment. The recoverable amount of asset groups and groups of asset groups is the present value of the future cash flows expected to be derived from them. These calculations require use of estimates (Note V (14)).If management revises the gross margin that is used in the calculation of the future cash flows of asset groups and groups of asset groups, and the revised gross margin is lower than the one currently used, the Group would need to recognise further impairment against goodwill and fixed assets.If management revises the pre-tax discount rate applied to the discounted cash flows, and the revised pre-tax discount rate is higher than the one currently applied, the Group would need to recognise further impairment against goodwill and fixed assets.If the actual gross margin/pre-tax discount rate is higher/lower than management s estimates, the impairment loss of goodwill previously provided for is not allowed to be reversed by the Group.(ii)Income taxesThe Group is subject to income taxes in numerous jurisdictions. There are many transactions and events for which the ultimate tax determination is uncertain during the ordinary course of business. Significant judgment is required from the Group in determining the provision for income taxes in each of these jurisdictions. The Group recognises income taxes in each jurisdiction based on estimates. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made. IISummary of significant accounting policies and accounting estimates (continued)(29)Critical accounting estimates and judgments (continued)(iii)Accounting estimates on impairment of accounts receivableIn accordance with the Group s accounting policy (note II (10)), the Group s management tests annually whether receivables have suffered any impairment, Impairment of receivables has been assessed by taking into account the customers credit history and financial position together with the current market conditions. Even if the Group s management has made bad debt provision for the expected loss at its best estimate, there is a possibility that changes in customers financial position or market conditions will alter the result.(iv)Accounting estimates on impairment of inventoriesIn accordance with the Group s accounting policy (Note II (11) (c)), the Group s management estimates the net realizable value of the inventory. Net realisable value is determined based on the estimated selling price in the ordinary course of business, less the estimated costs to completion and estimated costs necessary to make the sale and related taxes. Even if the Group s management has made stock provision for the expected impairment at its best estimate, there is a possibility that changes in market conditions will alter the result.(v)Accounting estimates on impairment of long-term assetsIn accordance with the Group s accounting policy (note II (20)), the Group s management tests annually whether long term assets with an indication of impairment have suffered any impairment, including fixed assets, construction in progress, intangible assets with finite useful lives, Long-term prepaid expenses and investment properties measured using the cost model and long-term equity investments in subsidiaries and associates. The calculation of present value of projection cash flows of these long-term assets requires the use of accounting estimate which is similar to the impairment test of goodwill.It is reasonably possible that outcomes based on current experience within the next financial year would be significantly different, which will result in a significant impact on the carrying amount of those long-term assets described above. IIITaxation(1)The types and rates of taxes applicable to the Group are set out below:TypeTaxable baseTax rateEnterprise income tax( EIT )Taxable income15%022% or 25%Value added tax ( VAT )Taxable value added amount (Tax payable is calculated using the taxable sales amount multiplied by the effective tax rate less deductible VAT input of current period)0%03%013% or 17%Business tax Rental income, storage income and etc.5%Business taxFreight income3%City maintenance and construction taxVAT and business tax 1% or 7%Education surchargeVAT and business tax3% or 4%(2)Tax preferencesThe company, Shenzhen Zhijun Pharmaceutical Trade Co., Ltd. ( Zhijun Trade ), Shenzhen Accord Pharmaceutical Materials Co., Ltd. ( Accord Material ), Shenzhen Jianmin Pharmaceutical Co., Ltd. ( Jianmin Pharm ), Shenzhen Accord Pharmaceutical Logistics Co., Ltd. ( Accord Logistics ), Shenzhen Yanfeng Medical Co., Ltd. ( Yanfeng Medical )and Sinopharm Shenzhen Medicine Co., Ltd ( Shenzhen Medicine ), qualify as foreign investment manufacturing enterprises established in a special economic zone. As approved by the tax authorities, the aforesaid companies original applicable enterprise income tax rates are 15%. Under relevant requirements of the Corporate Income Tax Law and Guo Fa [2007]39, the enterprise income tax rate applicable to those companies will increase gradually to 25% within 5 years from 2008 to 2012. Their applicable income tax rate for the current year is 22% (Year 2009: 20%). In 2008, Shenzhen Zhijun Pharmaceutical Co., Ltd. ( Zhijun Pharm ) and Suzhou Zhijun Wanqing Pharmaceutical Co., Ltd. ( Suzhou Wanqin ), subsidiaries of the Company, separately obtained the certificate of High and New Technology Enterprises with effective period of 3 years. Under the relevant regulations of article 28 of the Corporate Income Tax Law, the applicable tax rates for Zhijun Pharm and Suzhou Wanqin are 15%(Year 2009: 15%). IVBusiness combinations and consolidated financial statements(1)Subsidiaries(a)Subsidiaries acquired under common control The holding type of investmentPlace of registrationNature of businessRegistered capital ( Rmb 0000)Principal activitiesEnterprise TypeLegal Repres-entativeZhijun PharmDirectShenzhenManufacturing20,000.0Original chemical medicine manufacture, Chinese patent medicine processing, chemical raw material of medicine, the imports and exports business which transacted according to examined and approved certificateLimited companyYan Zhigang Jianmin PharmDirectShenzhenCommercial500.0Wholesale of chemical agent, antibiotics agent, chemical and biological agent, blood products, raw material of chemical product, Chinese medicine and diagnosis productsLimited companyLin XinyangShenzhen Medicine Trade Co., Ltd. (Shenzhen Trade ) (i)DirectShenzhenCommercial188.0Wholesale and retail of drugs and textiles--Accord Material DirectShenzhenCommercial600.0Chinese patent medicine, western medicine, medicine treatment apparatusLimited companyJiao QiZhijun TradeDirectShenzhenCommercial189.0Purchase and sale of Chinese traditional medicinal materials, Chinese patent medicine, chemical raw material for medical treatment, antibiotic preparation, chemical medicine preparation etc.Limited companyDeng Baojun Accord Logistics DirectShenzhenService100.0Storage service, convey, liquidation of cargo external package and common transportation of roadLimited companyLin Min IVBusiness combinations and consolidated financial statements (continued)(1)Subsidiaries (continued)(a)Subsidiaries acquired under common control(continued)Guangdong Accord Pharmaceutical Vocational Skills Training Center ( Training Center ) DirectShenzhenService3.0Training serviceNon-EnterpriseTan GuoshuSinopharm Medicine Holding Guangzhou Co., Ltd. ( Sinopharm Guangzhou )DirectGuangzhouCommercial40,000.0Chinese patent medicine, chemical medicine preparation, antibiotics, biochemical medicine, biological products, diagnosis medicine, treatment diagnosis biological products, finalized packing food, chemical products, self-support and surrogate the imports and exports of various merchandise and skills.Limited companyShi Jinming Guangdong Accord Hengxing Pharmaceutical Co., Ltd. (Hengxing Pharm') DirectGuangzhouCommercial2,000.0Drugs, medical apparatus salesLimited companyLin Zhaoxiong Guangxi Accord Pharmaceutical Co., Ltd.( Guangxi Accord )DirectNanningCommercial500.0Drug salesLimited companyZhou RuiliSinopharm Medicine Holding Liuzhou Co., Ltd. ( Sinopharm Liuzhou )DirectLiuzhouCommercial2,053.1Chinese traditional medicinal materials, Chinese patent medicine, Chinese traditional medicine in pieces, chemical raw material, chemical medicine preparation, antibiotics, biochemical drugs, psychotropic drugs, chemical raw material drug and its preparation. (that involving specific examination and approve should be operated based on the scope that checked and ratified by the license)Limited companyLin Zhaoxiong IVBusiness combinations and consolidated financial statements (continued)(1)Subsidiaries (continued)(a)Subsidiaries acquired under common control(continued) The holding type of investmentPlace of registrationNature of businessRegistered capital (Rmb 0000)Principal activitiesEnterprise TypeLegal Repres-entativeGuangxi Accord Chinese Herbal Pieces Co., Ltd. ( Guangxi Chinese Herbal Pieces ) IndirectLiuzhouManufacturing200.0Manufacturing and sales of Chinese herbal piecesLimited companyZhu WenhuiGuangdong Huixin Investment Co., Ltd. ( Huixin Investment ) DirectGuangzhouService500.0Project investment, property management and leasing, medical information consultancy, car park managementLimited companyShi JinmingSinopharm Medicine Holding Foshan Co., Ltd. ( Sinopharm Foshan ) DirectFoshanCommercial200.0Drug salesLimited companyLin XinyangGuangdong Yuexing Pharmaceutical Co., Ltd. ( Yuexing Pharm ) DirectGuangzhouCommercial3,000.0Sales of medicine and medical treatment apparatusLimited companyLuo QinGuangdong Hengchang Logistics Co., Ltd. ( Hengchang Logistics ) DirectGuangzhouService500.0Storage loading and unloadingLimited companyLin MinSinopharm Nanning DirectNanningCommercial10,000.0Drug salesLimited companyLin ZhaoxiongGuangxi Sinopharm Logistics Co., Ltd. ( Guangxi Logistics ) IndirectNanningService710.0Storage loading and unloading, consultation serviceLimited companyLin ZhaoxiongShenzhen Medicine (iv)DirectShenzhenManufacturing5,000.0Manufacturing of granules, lotion, tablet, capsule, oral liquid and mixture, and syrup; manufacturing and sale of hair products, bath foam and cosmetics, and detergent (antibiosis washing liquid); manufacturing of plastic bottle; manufacturing and sale of health food.Limited companyDeng Baojun IVBusiness combinations and consolidated financial statements (continued)(1)Subsidiaries (continued)(a)Subsidiaries acquired under common control(continued)Year-End balance of investment (Rmb 0000)Other assets constitute investment in substanceEquity interest held (%)Voting rights held (%)Consolidated or notMinority interests (Rmb 0000)Loss shared by minority interestsZhijun Pharm23,706.2-100100Yes--Jianmin Pharm5,348.3-100100Yes--Shenzhen Trade(i)847.9-100100Yes--Accord Material816.7-100100Yes--Zhijun Trade373.4-100100Yes--Accord Logistics101.9-100100Yes--Training Center3.0-100100Yes--Sinopharm Guangzhou48,388.8-100100Yes--Hengxing Pharm1,714.2-100100Yes--Guangxi Accord498.8-100100Yes--Sinopharm Liuzhou2,220.6-5151Yes2,307.4-Guangxi Chinese Herbal Pieces (ii)--51100Yes--Huixin Investment6,441.7-100100Yes--Sinopharm Foshan699.5-100100Yes--Yuexing Pharm4,345.9-100100Yes--Hengchang Logistics559.6-100100Yes--Sinopharm Nanning10,404.9-100100Yes--Guangxi Logistics(iii)--100100Yes--Shenzhen Medicine(iv)4,808.1-100100Yes--(i)Shenzhen Trade ceased its operation in 2003. (ii)Guangxi Chinese Herbal Pieces, a wholly owned subsidiary of Sinopharm Liuzhou, is indirectly held of 51% in equity by the Company.(iii)Guangxi Logistics, a wholly owned subsidiary of Sinopharm Nanning, is indirectly held of 100% in equity by the Company.(iv)Shenzhen Medicine originally was an associate of the Company, with an equity interest held of 47.39%. In 2010, the Company acquired the remaining 52.61% equity of Shenzhen Medicine from Sinopharm, the ultimate shareholders. As a result, Shenzhen Medicine became a subsidiary of the Company. IVBusiness combinations and consolidated financial statements (continued)(1)Subsidiaries (continued)(b)Subsidiaries acquired not under common control The holding type of investmentPlace of registrationNature of businessRegistered capital (Rmb 0000)Principal activitiesEnterprise TypeLegal Repres-entativeSuzhou WanqinDirectSuzhouManufacturing8,000.00Production and sales of general raw materials of medicine, raw medicine and preparation of cephalosporin; do export business of production and technology of the CompanyLimited companyShi Jinming Dongguan Accord Pharmaceutical Co., Ltd. ( Dongguan Accord )DirectDongguanCommercial280.00Wholesales of Chinese traditional medicinal materials, Chinese patent medicine, Chinese traditional medicine in pieces, chemical raw material; sales of daily general merchandise and heath protection foodLimited companyLin XinyangSinopharm Medicine Holding Zhanjiang Co., Ltd. ( Sinopharm Zhanjiang )DirectZhanjiangCommercial60.00Wholesale of medicineLimited companyLin XinyangYanfeng MedicalDirectShenzhenCommercial3,000.00Wholesale of medicineLimited companyLin ZhaoxiongSinopharm Medicine Holding Meizhou Co., Ltd. ( Sinopharm Meizhou )DirectMeizhouCommercial120.00Wholesale of medicineLimited companyYang YanSinopharm Medicine Holding Huizhou Co., Ltd. ( Sinopharm Huizhou )DirectHuizhouCommercial700.00Wholesale of medicineLimited companyYang Yan Year-end balance of investment ( Rmb 0000)Other assets constitute investment in substanceEquity interest held (%)Voting rights held (%)Consolidated or notMinority interests (Rmb 0000)Loss shared by minority interestsSuzhou Wanqin13,425.0-7575Yes3,445.5-Dongguan Accord274.2-100100Yes--Sinopharm Zhanjiang137.0-100100Yes--Yanfeng Medical3,504.85-5151Yes2,154.6-Sinopharm Meizhou313.7-100100Yes--Sinopharm Huizhou444.4-100100Yes-- IVBusiness combinations and consolidated financial statements (continued)(2)New subsidiaries included in the scope of consolidation in the current year:Net assets as at 31 December 2010Net profit/(loss) after acquisitionUnder common control - Shenzhen Medicine (Note IV(3))32,261,842.89 (5,588,987.73)Not under common control - Yanfeng Medical (Note IV(4)(a))43,971,665.762,130,185.12 - Sinopharm Meizhou (Note IV(4)(b)) 2,905,580.8334,500.29 - Sinopharm Huizhou (Note IV(4)(c))  4,721,814.07798.74 (3)Business combination involving entities under common controlIdentifying a business combinationCommon control partyShenzhen MedicineShenzhen Medicine and the Company are ultimately controlled by CNPGC both before and after the business combination, and that control is not transitory.CNPGCShenzhen Medicine originally was an associate of the Company, with an equity interest held of 47.39%. In 2010, the Company acquired the remaining 52.61% equity of Shenzhen Medicine from Sinopharm, the ultimate shareholders. (a)Consideration for the business combinations and book value for the acquired net assets are as follows. Cost of combination -Cash paid27,141,300.00Original investment cost17,918,802.62Consideration in total45,060,102.62Less: book value for the acquired net assets (b)(37,850,830.62)Amount adjusted to undistributed profits7,209,272.00 (b)The carrying amounts of assets and liabilities of Shenzhen Medicine at the date of the combination and 31 December 2009 are as follows:Carrying amount22 November 201031 December 2009Cash at bank and on hand17,342,363.108,933,758.67Notes receivable17,220.003,605,849.21Accounts receivable12,304,192.4512,906,517.04Advances to suppliers631,448.06152,045.87Other receivables218,971.3715,420,621.45Inventories4,819,329.255,143,108.77Fixed assets9,765,606.709,609,822.70Intangible assets486,511.96405,342.64Long-term prepaid expenses1,132,579.11738,383.65Less:Accounts payable(4,036,233.19)(4,598,417.43)Advances from customers-(637,436.18)Accrued payroll and welfare benefits(2,574,212.62)(2,742,008.80)Taxes payable(122,148.96)(389,830.55)Other payables(2,134,796.61)(1,939,370.87)Net assets acquired37,850,830.6246,608,386.17 IVBusiness combinations and consolidated financial statements (continued)(3)Business combination involving entities under common control (continued)(c)Revenue, net profit and cash flows of Shenzhen Medicine for the period from the date of combination and for the year ended 31 December 2009 are as follows:For the period from 1 January 2010 to date of combination2009Sales40,191,560.8947,138,047.47Net (loss)/profit(8,757,555.55)263,508.02Cash flows from operating activities(4,648,700.04)(1,984,254.88)Net cash flows8,408,604.432,344,239.68(d)Impact on opening balances Based on the balances of owners equity of Shenzhen Medicine as at 1 January 2009, the Group increases its capital surplus with RMB26,538,149.83 and decreased retained earnings with RMB2,148,833.94(note V(34)(a)) as at 1 January 2009 respectively. At the consolidation date, the Group reversed its capital surplus RMB26,538,149.83(note V(32)) and retained earnings RMB603,150.17 (note V(34)(b)) according to the total consideration of RMB27,141,300.00. (4)Business combination involving entities not under common controlGoodwillCalculation of GoodwillYanfeng Medical(a)16,868,644.87Where the cost of the combination exceeds the acquirer s interest in the fair value of the acquiree s identifiable net assets, the difference is recognised as goodwill.Sinopharm Meizhou(b)1,610,819.66Sinopharm Huizhou(c)923,184.67 Details of costs and goodwill recognised are as follows:Yanfeng MedicalSinopharm      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~ MeizhouSinopharm HuizhouCost of combination - Cash paid24,848,500.003,137,330.004,444,200.00Cash payable3,159,300.001,344,570.001,200,000.00Total cost of combination28,007,800.004,481,900.005,644,200.00Less: Fair value of the identifiable net assets acquired(11,139,155.13)(2,871,080.34)(4,721,015.33)Goodwill16,868,644.871,610,819.66923,184.67(a)Yanfeng Medical On 6 April 2010, the Company acquired 51% of Yanfeng Medical s equity interest from Shenzhen Kaijiefeng Co., Ltd.( Kaijiefeng ). On 30 April 2010, the Company obtained the controlling rights of Yanfeng Medical in substance.  IVBusiness combinations and consolidated financial statements (continued)(4)Business combination involving entities not under common control (continued)(a)Yanfeng Medical(continued)(i)The carrying amounts of assets and liabilities of Yanfeng Medical at the date of the combination are as follows:Carrying amountAcquisition Date31 December 2009Cash at bank and on hand2,492,754.1311,938,563.01Accounts receivable64,986,966.0257,819,604.77Advances to suppliers-215,128.61Other receivables3,429,471.266,593,848.65Inventories13,355,611.4911,869,988.39Fixed assets2,849,473.803,070,713.07Less: short-term loans(21,257,359.13)(22,180,953.09)accounts payable(41,123,745.76)(43,850,880.48)advances from customers(1,698.68)(504,609.97)taxes payable(665,690.87)(2,856,187.65)other payables(2,224,301.62)(273,734.67)Net assets21,841,480.6421,841,480.64Less: minority interest(10,702,325.51)-Net assets acquired11,139,155.1321,841,480.64 As the fair value of Yanfeng Medical s identifiable net assets was nearly the same with its book value on purchase date, the Company used its book value to calculate goodwill directly. Consideration paid24,848,500.00Less: cash at bank and on hand from acquiree(2,492,754.13)Net cash outflows for the acquisition22,355,745.87(ii)Revenue, net profit and cash flows of Yanfeng Medical for the period from 1 January 2010 to the date of combination to 31 December 2010 are as follows:Sales212,974,206.13Net profit2,130,185.12Cash flows from operating activities7,519,041.48Net cash flows20,337.83 (b)Sinopharm Meizhou On 30 June 2010, the Company acquired 100% equity interest of Sinopharm Meizhou from Mr. Shi Zhiqiang and Mr. Shi Jianwen. The effective date of obtaining the controlling rights was 31 July 2010. Consideration paid in cash 3,137,330.00Less: Cash at bank and on hand from acquiree(2,716,880.99)Net cash outflows for the acquisition420,449.01 IVBusiness combinations and consolidated financial statements (continued)(4)Business combination involving entities not under common control (continued)(c)Sinopharm Huizhou On 10 September 2010, the Company acquired 100% of Sinopharm Huizhou s equity interest from Mr. Yan Minneng and Mr. Xu Jianbin. The effective date of obtaining the controlling rights was 30 November 2010.Consideration paid in cash4,444,200.00Less: Cash at bank and on hand from acquiree(2,412,332.55)Net cash outflows for the acquisition2,031,867.45 (5)Business combination involving operating unit not under common controlGoodwillCalculation of GoodwillNanning Medical Co., Ltd. Medical( Nanning Medical )- trading business-Where the cost of the combination exceeds the acquirer s interest in the fair value of the business acquired s identifiable net assets, the difference is recognised as goodwill. (a)On 28 February 2010, the Group acquired trading business of Nanning Medical. The cost of consideration is recognised on the carrying amount of net assets up to 28 February 2010. Details of consideration and goodwill recognised are as follows:Cost of combination - Cash paid64,330,110.00Cash payable9,824,621.08Total cost of combination74,154,731.08Less: Fair value of the identifiable net assets acquired(74,154,731.08)Goodwill- (b)The carrying amounts of assets and liabilities of Nanning Medical Business at the date of the combination are as follows:Purchase dateFair valueCarrying amountAccounts receivable 107,446,767.52 107,446,767.52Other receivables 302,000.00 302,000.00Inventories 28,101,231.84 28,101,231.84Less: Accounts payable (61,695,268.28) (61,695,268.28)Net assets acquired 74,154,731.0874,154,731.08The Group recognised accounts receivable, other receivables and accounts payable at the amount agreed by all the related party involved. Inventories recognised base on the quantities count and market prices, considering the physical condition as well. VNotes to the consolidated financial statements(1)Cash at bank and on hand31 December 201031 December 2009Cash on hand 146,710.56  335,820.91 Cash at bank 682,729,162.62  470,647,654.89 Other cash balances 28,913,902.48  117,422,196.35 711,789,775.66588,405,672.15As at 31 December 2010, except a deposit of USD which was equivalent to RMB17,977.46(31 December 2009: RMB18,513.57), all other cash at bank and on hand are in RMB. Other cash balances of RMB28,617,918.88(31 December 2009: RMB112,301,177.34) represents deposits of the Group for the purpose of applying for bank acceptance notes.(2)Notes receivable31 December 201031 December 2009Trade acceptance notes 212,196,387.14 161,273,604.35Bank acceptance notes 156,972,643.33 201,751,997.25 369,169,030.47 363,025,601.60(a)Pledged notes receivableAs at 31 December 2010, notes receivable of RMB2,530,302.00 (31 December 2009: Nil) is pledged as collateral for the Group s short-term borrowings of RMB2,400,000.00 (31 December 2009: Nil (Note V(19) (a)); other notes receivable of RMB14,170,035.00 (31 December 2009: Nil) is pledged for the purpose of applying for bank acceptance notes of RMB15,553,416.40. The top five pledged notes receivable is listed as below.IssuerIssue dateExpiry dateAmountSinopharm Holding Guizhou Co., Ltd.28 October 201028 April 20116,840,000.00Shanghai Haikuoquanjiao Pharmaceutical Co. Ltd.9 October 20109 January 20111,672,578.00Hainan Hemei Pharmaceutical Co. Ltd.27 October 201027 January 20111,336,905.00Jinan iron & steel Co. Ltd.26 September 201026 March 20111,000,000.00Shandong Kanghui Pharmaceutical Co. Ltd.27 August 201027 February 20111,000,000.0011,849,483.00 (b)Endorsed undue notes receivableAs at 31 December 2010, the Group endorsed the undue notes receivable of RMB578,715,918.12. The top five notes receivable are analysed as below.IssuerIssue dateExpiry dateAmountSinopharm Holding Shenyang Co., Ltd.17 November 201017 February 20115,412,360.00Nanjing Medicine Hefei TianXing Co. Ltd.22 December 201022 March 20114,565,547.36Sinopharm Holding Hunan Co., Ltd19 November 201019 February 20114,494,355.26Guangdong Jiuzhoutong Pharmaceutical Co. Ltd.8 November 20108 February 2011 3,518,466.03Sinopharm Holding Tianjin Co., Ltd23 November 201023 February 2011 2,760,000.0020,750,728.65 VNotes to the consolidated financial statements (continued)(2)Notes receivable (continued)(c)Discounted undue notes receivableAs at 31 December 2010, notes receivable including undue trade acceptance notes of RMB84,612,337.66 (31 December 2009: RMB172,208,736.97), and undue bank acceptance notes of RMB136,610,378.69 (31 December 2009: RMB199,716,470.06) have been discounted.(d)The Group has no notes receivable which need to be reclassified as accounts receivable. (3)Accounts receivable31 December 201031 December 2009Accounts receivable2,901,694,647.442,478,465,807.01Less: provision for bad debts (note V(17))(34,869,544.66)(27,032,345.30)2,866,825,102.782,451,433,461.71(a)The ageing of accounts receivable and related provision for bad debts are analysed below:31 December 201031 December 2009AmountProvision for bad debtsAmountProvision for bad debtsWithin 1 year2,868,265,213.09(3,649,047.87)2,457,149,498.27  (7,842,585.38)1 to 2 years18,451,303.03(16,242,365.47) 2,188,326.59 (61,777.77)2 to 3 years--1,157,860.00(1,157,860.00)Over 3 year14,978,131.32(14,978,131.32)17,970,122.15(17,970,122.15)2,901,694,647.44(34,869,544.66)2,478,465,807.01(27,032,345.30) (b)The accounts receivable and related provision for bad debts by category are analysed below: 31 December 201031 December 2009Carrying amountBad debt provisionCarrying amountBad debt provisionamount% of total balanceamountrateamount% of total balanceamountrateindividually significant are subject to separate impairment assessment53,290,932.841.84%(23,655,876.26)44.39%89,304,191.983.61%(9,934,325.99)11.12%receivable accounts within similar credit risk group2,833,143,282.4397.64%(111,099.82)0.004%2,349,896,516.9294.81%(61,777.77)0.003%individually not significant but individually evaluated for impairment15,260,432.170.52%(11,102,568.58)72.75%39,265,098.111.58%(17,036,241.54)43.39%2,901,694,647.44100%(34,869,544.66)1.20%2,478,465,807.01100.00%(27,032,345.30)1.09% VNotes to the consolidated financial statements (continued)(3)Accounts receivable (continued)(c)As at 31 December 2010, impairment provision for accounts receivable individually significant are analysed as below.Carrying amountBad debt provisionRateAssessment for impairmentGuangdong Liyuan Pharmaceutical Co. Ltd.15,686,460.93 (15,686,460.93) 100.00%Disputed receivable with higher risk of recoverability.BeiHai People's Hospital15,288,208.17(1,528,820.82)10.00%Disputed receivable with higher risk of recoverability.LiuZhou Municipal LiuTie Central Hospital9,068,898.12(210,838.78)2.32%Disputed receivable with higher risk of recoverability.NanNing Second People's Hospital7,797,344.32(779,734.43)10.00%Disputed receivable with higher risk of recoverability.NanNing Medicine Wholesale Center5,450,021.30(5,450,021.30)100.00%Ageing over 5 years.53,290,932.84(23,655,876.26) (d)Provisions for impairment of the receivables which have a similar risk group are analysed below:31 December 201031 December 2009Carrying amountBad debt provisionCarrying amountBad debt provisionamount% of total balanceamountrateamount% of total balanceamountrateWithin 1 year2,830,921,285.8099.92%- -2,348,660,961.5299.95%--1 to 2 years2,221,996.630.08%(111,099.82)5.00%1,235,555.400.05%(61,777.77)5.00%2,833,143,282.43100.00%(111,099.82)0.004%2,349,896,516.92100.00%(61,777.77)0.003% (e)As at 31 December 2010, accounts receivable individually not significant but individually evaluated for impairment are analysed below:Carrying amountBad debt provisionRateAssessment for impairmentGuangXi JiaZhao Pharmaceutical Co. Ltd.etc.9,528,110.02(9,528,110.02)100.00%Ageing is above 3 years.ShenZhen Ophthalmology Hospital1,914,912.37(169,434.82)8.85%Uncertainty in recoverabilityShenZhen NanShan District SheKou Hospital907,806.04(250,000.00)27.54%Uncertainty in recoverabilityShenZhen Bao'An District GuanLan Hospital904,110.15(64,972.60)7.19%Uncertainty in recoverabilityAnHui Province FuYang KangTai Pharmaceutical Co. Ltd.730,851.19(93,687.19)12.82%Uncertainty in recoverabilityHuiZhou QuanYi Pharmaceutical Franchise Co. Ltd.443,692.12(443,692.12)100.00%Uncertainty in recoverabilityJiangYin KaiHong Pharmaceutical Co. Ltd.354,600.00(354,600.00)100.00%Uncertainty in recoverabilityAnHui BoYang Medicine supplied center Co. Ltd.307,777.68(71,760.00)23.32%Uncertainty in recoverabilitySuZhou KangXin Pharmaceutical Co. Ltd.23,580.00(15,480.00)65.65%Uncertainty in recoverabilityJiangSu WeiKang Pharmaceutical Co. Ltd.19,200.00(7,380.00)38.44%Uncertainty in recoverabilityHeBei AiPu Herbs&Pharmaceutical Co. Ltd.4,800.00(4,800.00)100.00%Uncertainty in recoverabilityJiangSu Province YanCheng Pharmaceutical Co. Ltd.120,992.60(98,651.83)81.54%Uncertainty in recoverability15,260,432.17(11,102,568.58) VNotes to the consolidated financial statements (continued)(3)Accounts receivable (continued)(f)Accounts receivable, which have been fully or partly made impairment provision already, recovered in current year is listed below:Reason for recoverabilityOriginal assessment for providing impairmentRecovered bad debt provisionsRecovered amountShenZhen Health Food I&E Co. Ltd.ETc.Amount received Disputed amount with uncertainty in recoverability6,926,932.016,926,932.01The Guangxi Zhuang Autonomous Region Pharmaceutical Co. Ltd. Etc.Amount received Long ageing with higher risk in recoverability936,137.00936,137.007,863,069.017,863,069.01 (g)Accounts receivable written off in current year are analysed as below:Nature of the receivableAmountReasonRelated party transaction or notShiJiaZhuang Medicine Purchased&supplied center etc.Receivable for medicine sold 1,775,833.87No amount would be recovered after the lawsuitNo (h)Accounts receivable due from shareholders with more than 5% (including 5%) of the Company s equity interest are analysed as below:31 December 201031 December 2009Sinopharm Group(Note VII(6))6,085,670.424,044,001.00 (i)As at 31 December 2010, the top five accounts receivable by customer are analysed as below:Relationship with the GroupAmountAgeing% of the total accounts receivableThe Third Affiliated Hospital of ZhongShan UniversityThird party 47,863,207.06 Within 1 year 1.65%GuangDong Province People's HospitalThird party 37,134,849.79 Within 1 year 1.28%The First Affiliated Hospital of GuangXi Medical University Third party 33,497,211.98 Within 1 year 1.15%The First Affiliated Hospital of ZhongShan UniversityThird party 28,953,661.82 Within 1 year 1.00%The Southern Hospital of Southern Medical UniversityThird party 28,400,843.26 Within 1 year 0.98%175,849,773.916.06% (j)Accounts receivable due from related partyAs at 31 December 2010, there are accounts receivable of RMB186,420,123.66 due from related party (31 December 2009: RMB231,188,100.00), which is 6.42% of the total accounts receivable (31 December 2009: 9.33%) (Note VII(6)).(k)In 2010, accounts receivable of RMB212,476,188.14 are derecognized given that irrevocable factoring contracts agreed with financial institute(2009: RMB58,600,000.00). VNotes to the consolidated financial statements (continued)(3)Accounts receivable (continued)(l) As at 31 December 2010, accounts receivable of RMB30,941,730.97 is pledged as collateral for the Group s short-term borrowings of RMB27,847,557.88 (31 December 2009: Nil) (Note V(19)(a)). (4)Advances to suppliers(a)The ageing of advances to suppliers is analysed below:31 December 201031 December 2009amount% of total balanceamount% of total balanceWithin 1 year98,067,411.72 96.33%82,220,250.0095.83%1 to 2 years202,384.25 0.20%3,577,434.954.17%2 to 3 years3,536,234.95 3.47%900.00-101,806,030.92100.00%85,798,584.95100.00%As at 31 December 2010, advances to suppliers of RMB3,738,619.20 with ageing over 1 years (31 December 2009: RMB3,578,334.95) mainly represented prepayment for patent.(b)As at 31 December 2010, the top five advances to suppliers by customer are analysed below:Relationship with the GroupAmountProportionAgeingReason for unsettlementShangHai NuoHua Trading Co. Ltd.Third party17,346,548.3517.04%Within 3 monthsAdvances for imported VATYunNan BaiYao Group Co. Ltd.Third party11,963,198.0011.75%Within 3 monthsAdvances for procurementQingHai Pharmaceutical Co. Ltd.Third party5,408,378.675.31%Within 1 yearAdvances for procurementGuangZhou Outsel Trading Co. Ltd.Third party5,086,261.305.00%Within 1 yearAdvances for procurementShenWei Pharmaceutical (HaiNan) Co. Ltd.Third party4,159,128.004.09%Within 3 monthsAdvances for procurement43,963,514.3243.19%(c)Advances due from related partyAs at 31 December 2010, there are advances of RMB10,460,996.03 due from related party (31 December 2009: RMB18,805,100.00), which is 10.28% of the total advances to suppliers (31 December 2009: 21.92%), and no bad debt provision was provided (31 December 2009: Nil). (Note VII(6)). VNotes to the consolidated financial statements (continued)(5)Dividends receivable31 December 2009Decreases31 December 2010Shenzhen Wanle Medical Co., Ltd. ( Wanle Medical )(Note V(8)(a))8,271,829.94(8,271,829.94)-(6)Other receivables31 December 201031 December 2009Deposit10,238,481.8711,550,534.72Purchase rebate9,502,788.6911,489,381.96Receivable of equity transaction(c) 8,980,000.00 8,980,000.00Petty cash advance to employees7,195,539.528,224,565.98Receivable due from related party(i)2,136,200.0024,139,225.00Others22,847,234.4119,965,076.0060,900,244.4984,348,783.66Less: provision for bad debts (Note V(17))(17,789,244.75)(20,752,756.43)43,110,999.7463,596,027.23(a)The ageing of other receivables and related provision for bad debts are analysed below:31 December 201031 December 2009Within 1 year41,876,178.3660,794,541.011 to 2 years1,179,247.561,197,290.302 to 3 years1,052,432.85246,105.80Over 3 years16,792,385.7222,110,846.5560,900,244.4984,348,783.66 (b)Other receivables and related provision for bad debts by category are analysed below: 31 December 201031 December 2009Carrying amountBad debt provisionCarrying amountBad debt provisionamount% of total amountamountrateamount% of total amountamountrateIndividually significant are subject to separate impairment assessment8,980,000.0014.75%(8,980,000.00)100.00%8,980,000.0010.65%(8,980,000.00)100.00%Receivable accounts within similar credit risk group43,215,849.7170.96%(104,849.97)0.24%63,880,867.5075.73%(577,039.76)0.90%Individually not significant but individually evaluated for impairment8,704,394.7814.29%(8,704,394.78)100.00%11,487,916.1613.62%(11,195,716.67)97.46%60,900,244.49100.00%(17,789,244.75)29.21%84,348,783.66100.00%(20,752,756.43)24.60% VNotes to the consolidated financial statements (continued)(6)Other receivables (continued)(c)As at 31 December 2010, impairment provision for other receivables individually significant are analysed as below.AmountBad debt provisionRateAssessment for impairmentShenzhen Yinghai Technology investment Co., Ltd. 8,980,000.00  (8,980,000.00)100%Uncertainty in recoverability(d)Provisions for impairment of the receivables which have a similar risk group are analysed below: 31 December 201031 December 2009Carrying amountBad debt provisionCarrying amountBad debt provisionamount% of total amountamountrateamount% of total amountamountrateWithin 1 year41,876,178.3696.90%-0.00%60,630,641.0594.91%- 0.00%1 to 2 years1,015,347.602.35%(50,767.38)5.00%322,633.000.51%(16,131.65)5.00%2 to 3 years107,821.600.25%(10,782.16)10.00%246,105.800.39%(24,610.58)10.00%Over 3 year216,502.150.50%(43,300.43)20.00%2,681,487.654.20%(536,297.53)20.00%43,215,849.71100.00%(104,849.97)0.24%63,880,867.50100.00%(577,039.76)0.90% (e)As at 31 December 2010, other receivables individually not significant but individually evaluated for impairment are analysed below:AmountBad debt provisionRateAssessment for impairmentShenZhen Health Food I&E Co. Ltd.1,157,860.00(1,157,860.00)100%Uncertainty in recoverabilityYiZhouShi People's Hospital etc.4,874,988.57(4,874,988.57)100%Aged over 3 years, high risk in recoverabilityGuangXi Autonomous Region People's Hospital800,000.00(800,000.00)100%Aged over 3 years, high risk in recoverabilityService fee etc.1,871,546.21(1,871,546.21)100%Long ageing and high risk in recoverability8,704,394.78(8,704,394.78) VNotes to the consolidated financial statements (continued)(6)Other receivables (continued)(f)Other receivables written off in current year are analysed as below:NatureAmountReason for written offRelated party transaction or notGuangXi BanZhou Company Limited By Share etc.Withdrawal for the procurement1,210,483.66No amount would be recovered after the lawsuitNo(g)Other receivables due from shareholders with more than 5% (including 5%) of the Company s equity interest are analysed as below:31 December 201031 December 2009AmountBad debt provisionAmountBad debt provisionSinopharm Group(note VII(6))--731,846.06- (h)As at 31 December 2010, the top five other receivables by customer are analysed below:Relationship with the GroupAmountAgeing% of the total other receivableShenZhenShi YingHai Technology&Investment Co. Ltd.Third party 8,980,000.00 Over 5 years14.75%Bayer Health Food Co. Ltd.Third party 4,963,936.12 Within 1 year8.15%ZheJiang TianYuan Biological Pharmaceutical Co. Ltd.Third party 2,457,548.51 Within 1 year4.04%LiuZhouShi Housing Provident Fund Management Center- Specific Account for Housing FundThird party 1,991,298.98 Over 5 years3.27%GuangXi Autonomous Region Housing system Reformed DepartmentThird party 1,904,439.38 4 to 5 years3.13% 20,297,222.9933.33% (i)Other receivables due from related partyAs at 31 December 2010, there are other receivables of RMB2,136,200.00 due from related party (31 December 2009: RMB24,139,225.00), which is 3.51% of the total other receivables(31 December 2009: 28.62%), without any bad debt provided (31 December 2009: Nil). (note VII(6)). VNotes to the consolidated financial statements (continued)(7)Inventories(a)Inventories by category are analysed as below:31 December 201031 December 2009Book valueProvisionNet book ValueBook valueProvisionNet book ValueRaw materials165,679,203.91(3,358,112.02)162,321,091.89104,213,488.59(2,039,571.51)102,173,917.08Packaging materials655,633.83-655,633.83311,542.41-311,542.41Consigned processing materials1,366,855.16-1,366,855.163,114,494.76-3,114,494.76Finished goods877,562,151.03(4,961,799.59)872,600,351.44735,669,492.92(6,446,155.71)729,223,337.21Goods in transition75,453,155.42(2,006,680.46)73,446,474.9655,577,275.70(635,513.76)54,941,761.94Work in progress45,068,088.99-45,068,088.9918,545,109.18-18,545,109.18Low cost consumables871,162.53-871,162.53767,333.77-767,333.771,166,656,250.87(10,326,592.07)1,156,329,658.80918,198,737.33(9,121,240.98)909,077,496.35 (b)Provision for declines in value of inventories is analysed as below:31 December 2009IncreasesDecreases31 December 2010ReversalWritten offRaw materials2,039,571.511,366,250.70-(47,710.19)3,358,112.02Finished goods6,446,155.717,711.54(777,778.95)(714,288.71)4,961,799.59Goods in transition635,513.761,371,166.70--2,006,680.469,121,240.982,745,128.94(777,778.95)(761,998.90)10,326,592.07 (8)Long-term equity investments31 December 201031 December 2009Associates - Without quoted price (a) 85,275,251.0658,050,667.25Other long-term equity investments (b)-284,173.70 85,275,251.0658,334,840.95The Group has no liquidity restriction on its long-term equity investments. VNotes to the consolidated financial statements (continued)(8)Long-term equity investments (continued)(a)AssociatesIncreases/(Decreases)Accounting methodOriginal investment cost31 December 2009Additional investment costShare of profit of associateProfit/Cash dividends declared by associateOther changes in equity31 December 2010Equity interest held (%)Voting rights held (%)Explanation for the inconsistence between equity interest held and voting rights heldNote V(42)Wanle MedicalEquity method4,457,400.0058,050,667.25-27,224,583.81--85,275,251.0635.1933.33Board of the directors is the highest decision making organization, which is formed by 3 shareholders of Wanle Medical evenly,  (b)Other long-term equity investmentsAccounting methodOriginal investment cost31 December 2009Increases/(Decreases)31 December 2010Equity interest heldVoting rights heldImpairment(%)(%)ShenZhen China Associate GuangShen Pharmaceutical Company Limited By ShareCosting method284,173.70284,173.70(284,173.70)---- (9)Investment in associatesEquity interest held Voting rights held 31 December 2010For the year ended 31 December 2010Total assetsTotal liabilitiesNet assetsRevenuesNet profit(%)(%)Wanle Medical35.1933.3459,292,775.96227,923,839.96231,368,936.00468,348,634.5677,364,546.20 VNotes to the consolidated financial statements (continued)(10)Investment properties31 December 2009Current year additionsCurrent year disposals31 December 2010Cost107,608,544.2860,099,709.41(1,793,491.23)165,914,762.46Buildings104,375,970.5547,913,729.58(1,793,491.23)150,496,208.90Land use rights3,232,573.7312,185,979.83-15,418,553.56Accumulated depreciation/ amortisation(49,635,011.31)(29,830,673.12)844,255.73(78,621,428.70)Buildings(49,176,032.53)(28,750,373.35)844,255.73(77,082,150.15)Land use rights(458,978.78)(1,080,299.77)-(1,539,278.55)Net book value57,973,532.9787,293,333.76Buildings55,199,938.0273,414,058.75Land use rights2,773,594.9513,879,275.01In 2010, the amount of depreciation expense and amortization were RMB9,498,256.09 (2009: RMB2,921,646.13), and no provision for impairment was provided (2009: Nil).In 2010, the Group changed the use of buildings with net book value of RMB348,061.25 (cost of RMB489,797.80) to owner-occupied properties, and therefore, such investment properties were transferred to fixed assets at the dates of transfers.In 2010, the Group changed the use of buildings with net book value of RMB23,452,582.40 (cost of RMB42,899,850.79) and land use rights with net book value of RMB11,300,831.22 (cost of RMB12,185,979.86) to lease-out properties, and therefore, such assets were transferred from fixed assets and intangible assets to investment properties at the dates of transfers.In 2010, the Group disposed of investment properties with net book value of RMB601,174.25 (cost of RMB 1,303,693.43) and recognised a gain of RMB2,984,999.68. VNotes to the consolidated financial statements (continued)(11)Fixed assets31 December 2009Current year additionsCurrent year disposals31 December 2010Cost688,012,581.97148,766,811.47(53,437,579.63)783,341,813.81Buildings312,195,700.2628,312,215.44(48,217,180.48) 292,290,735.22Machinery and equipment214,912,021.2076,714,989.38(558,908.23)291,068,102.35Motor vehicles39,703,709.9016,510,547.56(2,867,823.59)53,346,433.87Other 105,339,510.9116,141,052.48(1,439,421.33)120,041,142.06Leasehold improvements15,861,639.7011,088,006.61(354,246.00) 26,595,400.31Current year other additionsCurrent year depreciationCurrent year disposalsAccumulated depreciation(258,322,551.76)(141,736.55)(57,419,738.59)26,399,956.52(289,484,070.38) Buildings(93,160,551.94)(141,736.55)(10,443,588.70)22,050,403.74(81,695,473.45) Machinery and equipment(89,382,653.00)-(21,149,248.86)474,274.49(110,057,627.37)Motor vehicles(19,416,613.07)-(5,574,265.63)2,510,951.02(22,479,927.68)Other (49,467,827.20)-(17,256,878.54)1,341,891.07(65,382,814.67)Leasehold improvements(6,894,906.55)-(2,995,756.86)22,436.20(9,868,227.21) Carrying value429,690,030.21493,857,743.43Buildings219,035,148.32210,595,261.77Machinery and equipment125,529,368.20181,010,474.98Motor vehicles20,287,096.8330,866,506.19Other 55,871,683.7154,658,327.39Leasehold improvements8,966,733.1516,727,173.10Provision for impairment loss(1,300,000.00)--(1,300,000.00)Buildings(1,300,000.00)--(1,300,000.00)Machinery and equipment----Motor vehicles----Other ----Leasehold improvements----Net book value428,390,030.21492,557,743.43Buildings217,735,148.32209,295,261.77Machinery and equipment125,529,368.20181,010,474.98Motor vehicles20,287,096.8330,866,506.19Other 55,871,683.7154,658,327.39Leasehold improvements8,966,733.1516,727,173.10 VNotes to the consolidated financial statements (continued)(11)Fixed assets (continued)In 2010, details of the amount of depreciation expense charged is below:31 December 201031 December 2009Cost of goods sold31,740,044.2826,588,421.81Selling expenses3,338,028.185,115,957.87General and administrative expenses18,848,850.4321,248,340.58Research and development expenses3,492,815.70480,044.1457,419,738.5953,432,764.40In 2010, fixed assets transferred from construction in progress were RMB76,675,258.73(2009: RMB16,196,140.32). (12)Construction in progress31 December 201031 December 2009Asepsis Materials Plant Project 20,828,473.64 5,204,063.10 Nanning Logistics Center Project14,507,130.59 -Menstruum Recycling Plant Project12,773,423.00 -Power Station Improvement Project9,625,754.12 -Cefoxitin Plant Improvement Project8,055,862.00 -Chebei Project6,915,595.20 6,750,695.20 Multifunctional Warehouse project6,847,719.64 -Peinan Project8,084,242.403,911,064.47Cephalo Plant II Project-28,734,111.57 Zhijun Zhiyao Guanglan Stage II Project1,441,384.55456,232.55Reconstruction of Wastewater Treatment Project and others 14,513,077.86  663,189.10 Greening Design Programme and others 4,708,675.12  426,827.51 108,301,338.1246,146,183.50 VNotes to the consolidated financial statements (continued)(12)Construction in progress (continued)Changes of construction in progress in 2010 are below:Name of projectBudget of project31 December 2009Current year additionsTransfer to fixed assets during current year31 December 2010Cost up to date out of budget (%)Construction progress (%)Accumulated capitalised borrowing costBorrowing cost capitalised in 2010Weighted average interest rate (%)Financed byAsepsis Materials Plant Project 59,340,000.005,204,063.1054,144,395.90(38,519,985.36)20,828,473.649999151,356.86151,356.865.04Working capital and loansNanning Logistics Center Project147,000,000.00-14,507,130.59-14,507,130.591010738,779.67738,779.674.94Working capital and loans from related partyMenstruum Recycling Plant Project17,440,000.00-12,773,423.00-12,773,423.007373---Working capitalPower Station Improvement Project14,700,000.00-9,625,754.12-9,625,754.126565---Working capital Cefoxitin Plant Improvement Project8,060,000.00-8,055,862.00-8,055,862.009999---Working capital Chebei Project11,810,000.006,750,695.20164,900.00-6,915,595.2000---Working capital Multifunctional Warehouse Project10,670,000.00-6,847,719.64-6,847,719.646464---Working capital Peinan Project40,000,000.003,911,064.47 4,173,177.93 -8,084,242.40 2020---Working capital Cephalo Plant II project36,200,000.0028,734,111.573,187,954.86(31,922,066.43)-1001001,563,300.00611,550.004.86Working capital and loansZhijun Zhiyao Guanglan Stage II Project250,000,000.00456,232.55985,152.00-1,441,384.550.580.58---Working capital Reconstruction of Wastewater Treatment Project and others24,606,541.20663,189.1018,973,884.00(5,123,995.24)14,513,077.868080---Working capital Greening Design Programme and others-426,827.515,391,059.31(1,109,211.70)4,708,675.12-----Working capital 619,826,541.2046,146,183.50138,830,413.35(76,675,258.73)108,301,338.12 VNotes to the consolidated financial statements (continued)(13)Intangible assets31 December 2009Current year additionsCurrent year decreases31 December 2010Cost167,574,605.4839,939,149.92(12,185,979.86)195,327,775.54Land use rights104,808,837.9237,222,525.98(12,185,979.86)129,845,384.04Computer software10,284,984.231,916,623.94-12,201,608.17Proprietary technology52,283,933.33800,000.00-53,083,933.33Trademarks196,850.00--196,850.00Accumulated amortization(50,936,827.19)(16,100,730.90)885,148.64(66,152,409.45)Land use rights(23,755,277.38)(2,235,869.97)885,148.64(25,105,998.71)Computer software(6,522,280.69)(1,587,899.23)-(8,110,179.92)Proprietary technology(20,552,500.86)(12,239,036.10)-(32,791,536.96)Trademarks(106,768.26)(37,925.60)-(144,693.86)Net book value116,637,778.29129,175,366.09Land use rights81,053,560.54104,739,385.33Computer software3,762,703.544,091,428.25Proprietary technology31,731,432.4720,292,396.37Trademarks90,081.7452,156.14In 2010, the amount of amortization expense was RMB16,100,730.90(2009: RMB12,272,751.72).As at 31 December 2010, the carrying amount of land use right located on Ping Shan of Longgang district was RMB26,811,850.95 (initial cost : RMB30,020,106.63). The land is still pending for development due to the change of functional planning of the industrial park by the government. As a result, the Bureau of Planning, Land and Resources of Shenzhen Municipality has recognised it as vacant land. The Company is in the process of applying administrative re-examination and appeals the bureau to withhold the title of vacant land. According to the Company s plan, the land will be developed as Shenzhen Accord Ping Shan pharmaceutical centre specializing in manufacturing and R&D. Expenditures on research and development incurred in 2010 are listed as below:31 December 2009Current year additions31 December 2010Development costs235,375.012,345,287.842,580,662.85Expenditures on research and development incurred in 2010 amount to RMB55,176,057.07 (2009: RMB33,961,185.22) in total, of which RMB52,830,769.23 (2009: RMB33,725,810.21) is recognised in profit or loss for the current period, RMB2,345,287.8 (2009: RMB235,375.01) is recognised as development costs. The development costs accounted for 4.25% (2009: 0.69%)) of the total expenditures on research and development incurred in 2010. VNotes to the consolidated financial statements (continued)(14) Goodwill31 December 2009Current year additions31 December 2010Goodwill34,153,027.8919,402,649.20 53,555,677.09Less: provision for impairment (a)---34,153,027.8919,402,649.20 53,555,677.09Goodwill recognised in 2010 arose from acquisition of 51% of the equity interests in Yanfeng Medical, 100% of the equity interests in Sinopharm Meizhou and 100% of the equity interests in Sinopharm Huizhou (Note IV (4)).ImpairmentThe goodwill allocated to the asset groups and groups of asset groups are summarised by operating segments as follows:31 December 201031 December 2009 Pharmaceutical distribution-Yanfeng Medical16,868,644.87-Sinopharm Meizhou1,610,819.66-Sinopharm Huizhou923,184.67-Sinopharm Zhanjiang282,135.55282,135.55Dongguan Accord1,499.021,499.02Pharmaceutical manufacturing -  Suzhou Wanqin33,869,393.3233,869,393.32 53,555,677.0934,153,027.89The recoverable amount of asset groups and groups of asset groups is calculated using the estimated cash flows determined according to the five-year budget approved by management. The cash flows beyond the five-year period are calculated based on the following estimated growth rates.The main assumptions applied in calculating discounted future cash flows are as follows:Pharmaceutical distributionPharmaceutical manufacturingGross margin 6%15%Discount rate15%12%Management determines budgeted gross margin based on past experience and forecast on future market development. The discount rates used by management are the pre-tax interest rates that are able to reflect the risks specific to the related asset groups and groups of asset groups. The above assumptions are used to assess the recoverable amount of each asset group and group of asset groups within the corresponding operating segment. As at 31 December 2010, management of the Group considered there was no impairment to goodwill recognised after the impairment assessment. VNotes to the consolidated financial statements (continued) (15)Long-term prepaid expenses31 December 2009Current year additionsCurrent year amortisation31 December 2010Leasehold improvements6,219,765.91 16,000,514.28(3,610,360.02)18,609,920.17Others1,236,281.04 298,833.78(333,423.75)1,201,691.077,456,046.95 16,299,348.06(3,943,783.77)19,811,611.24 (16)Deferred income tax assets and deferred income tax liabilities(a)Deferred income tax assets31 December 201031 December 2009Deferred income tax assetsDeductible temporary differencesDeferred income tax assetsDeductible temporary differencesProvision for accounts receivable4,745,194.3819,246,624.261,435,756.105,953,219.63Provision for other receivables2,739,278.5212,089,435.27319,768.642,006,658.37Provision for declines in value of inventories1,711,016.7710,089,072.641,188,969.566,103,884.42Provision for fixed assets impairment174,571.68698,286.70181,351.17725,404.66Accrued expenses5,541,124.1731,872,047.072,931,780.7417,785,204.93Accrued payroll10,948,931.1453,300,710.616,540,926.8929,036,924.20Deferred revenue4,722,984.1328,751,822.73131,431.03876,206.90Others500,491.452,723,589.31141,212.11564,848.4431,083,592.24158,771,588.5912,871,196.2463,052,351.55(b)Deferred income tax liabilities31 December 201031 December 2009Deferred income tax liabilitiesDeductible temporary differencesDeferred income tax liabilitiesDeductible temporary differencesBusiness combination involving entities not under common control4,817,694.4232,117,962.85 6,509,229.0043,394,860.06Changes in fair value14,118,080.2856,472,321.1115,242,873.7660,971,495.02Others3,773,319.00 15,093,276.00 3,773,319.0015,093,276.0022,709,093.70103,683,559.9625,525,421.76119,459,631.08 VNotes to the consolidated financial statements (continued)(16)Deferred income tax assets and deferred income tax liabilities (continued)(c)As at 31 December 2010, the Group has not recognised deferred tax assets in respect of deductible losses and other deductible temporary differences are listed as below.31 December 201031 December 2009Deductible losses(i)34,682,363.786,725,785.99Other deductible temporary differences6,307,666.932,732,243.0240,990,030.719,458,029.01For those loss making subsidiaries, the Group does not recognize deferred tax assets arising from accumulated losses amounting to RMB34,682,363.78 which are tax deductible under the tax law within 2011 to 2015. The reason of un-recognition is mainly due to the uncertainty in: a) obtaining available taxable profit in the future which will be used against the deductible tax loss; and b) successfully getting the approval from the in-charge tax bureau. In addition, similar to consideration of uncertainty of a) mentioned above, the Group does not recognize the deferred tax assets arising from deductable temporary differences amounting RMB6,307,666.93, including accrual of sale commission and unpaid payroll, either.  (i)As at 31 December 2010, the unrecognised deferred tax assets in respect of deductible losses will be expired as follows:Year31 December 201031 December 20092011-199,236.1420122,255,000.052,255,000.052013201,029.87201,029.8720142,672,990.114,070,519.93201529,553,343.75-34,682,363.786,725,785.99 (17)Provision for asset impairment31 December 2009IncreasesDecreases31 December 2010ReversalWritten offBad debt provision47,785,101.7317,712,952.70(9,852,947.49)(2,986,317.53)52,658,789.41Including: Provision for accounts receivable27,032,345.3017,610,456.73(7,997,423.50)(1,775,833.87)34,869,544.66Provision for other receivables20,752,756.43102,495.97(1,855,523.99)(1,210,483.66)17,789,244.75Provision for declines in value of inventories9,121,240.982,745,128.94(777,778.95)(761,998.90)10,326,592.07Provision for fixed assets impairment1,300,000.00---1,300,000.0058,206,342.7120,458,081.64(10,630,726.44)(3,748,316.43)64,285,381.48 VNotes to the consolidated financial statements (continued)(18)Other non-current assets31 December 201031 December 2009Medical reserve fund48,127,831.5636,533,540.13 (19)Short-term loans(a)CategoryCurrency31 December 201031 December 2009Entrusted loans(Note VII (6))RMB300,000,000.00250,000,000.00Guaranteed loans(i)RMB118,348,996.2557,443,266.96Unsecured loans(ii)RMB442,266,992.42264,821,130.47Pledged loans(iii)RMB30,247,557.88-Discounted notesRMB84,612,337.66371,925,207.03 975,475,884.21  944,189,604.46 (i)As at 31 December 2010, bank loans of RMB118,348,996.25 (31 December 2009: 57,443,266.96) are guaranteed by Sinopharm Group.(ii)As at 31 December 2010, unsecured loans of RMB442,266,992.42(31 December 2009: RMB264,821,130.47) are guaranteed by the Company and its subsidiaries. (iii)As at 31 December 2010, bank borrowings of RMB30,247,557.88 (31 December 2009: Nil) are secured by current assets, including notes receivable with a carrying amount of RMB2,530,302.00(Note V(2)(a)) and accounts receivable with a carrying amount of RMB30,941,730.97 (Note V (3)(l)).As at 31 December 2010, the weighted average interest rate of short-term borrowings is 4.93% per annum (31 December 2009:4.58%).(b)As at 31 December 2010, there were no expired bank loans (31 December 2009: Nil). (20)Notes payable31 December 201031 December 2009Trade acceptance notes 336,739,137.60 348,860,174.45Bank acceptance notes 1,111,883,353.12 756,090,155.831,448,622,490.721,104,950,330.28As at 31 December 2010, notes receivable of RMB1,448,622,490.72 would be expired within 1 year (31 December 2009: RMB1,104,950,330.28). VNotes to the consolidated financial statements (continued)(21)Accounts payable31 December 201031 December 2009Accounts payable2,003,566,517.621,706,142,277.91 (a)Accounts payable due from shareholders with more than 5% (including 5%) of the Company s equity interest are analysed as below:31 December 201031 December 2009Sinopharm Group(Note VII (6))109,598,841.4989,246,550.04(b)Accounts payable due to related partyAs at 31 December 2010, there are accounts payable of RMB171,555,542.58 due to related party (31 December 2009: RMB144,346,600.00), which accounts for 8.56% of the total accounts payable(31 December 2009: 8.46%).(Note VII(6)).(c) As at 31 December 2010, accounts payable of RMB60,550,672.66 (31 December 2009: RMB66,246,814.61) were aged over 1 year, which were mainly for medicine procurement. Before the financial statement is approved, no such long aged accounts payable have been settled. (22)Advances from customers31 December 201031 December 2009Advances from customers100,322,387.2182,498,031.55As at 31 December 2010, there are advances of RMB5,370,000.00 due to related party (31 December 2009: Nil), which accounts for 5.35% of the total accounts payable(31 December 2009: Nil). (Note VII(6)). As at 31 December 2010, advances from customers of RMB2,379,071.02 (31 December 2009: RMB1,872,088.36) were aged over 1 year. Before the financial statement is approved, no such long aged advances have been settled. VNotes to the consolidated financial statements (continued)(23)Employee benefits payable31 December 2009Current year additionsCurrent year reductions31 December 2010Wages and salaries, bonuses, allowances and subsidies86,891,988.17295,716,403.54(279,295,918.57)103,312,473.14Staff welfare500,000.0025,280,617.14(25,608,441.14)172,176.00Social security contributions944,120.8833,348,861.04(32,867,042.87)1,425,939.05Including: Medical insurance110,417.208,133,991.80(8,082,421.71)161,987.29Basic pensions,790,241.2921,369,137.75(21,175,491.57)983,887.47Supplemental pensions,-1,743,100.00(1,567,520.00)175,580.00Unemployment insurance29,558.31809,616.96(759,361.65)79,813.62Work injury insurance5,065.09523,542.88(519,816.10)8,791.87Maternity insurance8,838.99769,471.65(762,431.84)15,878.80Housing funds543,205.329,593,075.22(9,754,492.38)381,788.16Labor union funds and employee education funds8,160,285.159,488,746.33(8,375,474.47)9,273,557.01Compensation for employee dismission4,212,977.06448,993.57(1,184,223.57)3,477,747.06Early retirement benefits7,843,024.24617,795.18(1,731,561.83)6,729,257.59Others1,042,449.9413,211,620.06(11,835,290.76)2,418,779.24110,138,050.76387,706,112.08(370,652,445.59)127,191,717.25As at 31 December 2010, there are no payroll payables in arrears. Most part of the payroll payables would be paid out in the coming year 2011. (24)Taxes payable 31 December 201031 December 2009Enterprise income tax payable35,944,942.6924,612,308.00Value-added-tax payable(5,010,377.31)3,170,577.34Business tax payable1,380,716.941,470,714.51City maintenance and construction tax payable537,550.82495,947.05Real estate tax payable399,097.44390,791.68Stamp duty tax payable1,094,469.16669,629.79Land use rights83,178.55189,448.22Individual income tax payable2,411,409.522,311,912.95Educational surcharge payable235,523.80369,697.57Rivers management fee2,152,879.391,768,478.55Anti-flood fund469,902.57148,805.72Others21,018.151,119,467.9839,720,311.7236,717,779.36 VNotes to the consolidated financial statements (continued)(25)Interests payable31 December 201031 December 2009Interests payable2,122,314.90589,050.00 (26)Other payables31 December 201031 December 2009Accrued selling expenses148,869,382.91124,351,840.74Payables for construction in progress48,899,435.3412,562,793.93Amount collected on behalf of third party32,338,391.7410,519,288.13Deposit14,037,304.365,136,038.04Others100,866,779.4594,265,292.97345,011,293.80 246,835,253.81 (a)Other payables due to shareholders with more than 5% (including 5%) of the Company s equity interest are analysed as below:31 December 201031 December 2009Sinopharm Group(Note VII (6))3,893,939.65 3,333,939.65(b)Other payables due to related partyAs at 31 December 2010, there are other payables of RMB10,365,391.15 due to related party (31 December 2009: RMB22,446,400.00), which accounts for 3.00% of the total other payables (31 December 2009: 9.09%). (Note VII(6)).(c) As at 31 December 2010, other payables of RMB61,897,416.02 (31 December 2009: RMB47,055,011.76) were aged over 1 year, which were mainly for accrued selling expenses. Before the financial statement is approved, other payables of RMB11,572,136.60 have been paid out (Note X(1)). VNotes to the consolidated financial statements (continued)(27)Current portion of long-term loans31 December 201031 December 2009Current portion of long-term loans - Pledged bank loans-30,000,000.00 (28)Long-term loansCurrency31 December 201031 December 2009Pledged loansRMB-30,000,000.00Unsecured loansRMB30,000,000.00-30,000,000.0030,000,000.00As at 31 December 2010, long-term loans of RMB30,000,000.00(31 December 2009: Nil) are guaranteed by Suzhou Wanqin, a subsidiary of the Company. Interest is payable every month and the principal is due for repayment on 5 September 2013.(a)Details for top five long-term loans are as followings.Borrowing dateRepayment dateCurrencyInterest rate per annum (%)31 December 201031 December 2009Agricultural Bank of China6 September 20105 September 2013RMB5.26510,000,000.00-Agricultural Bank of China13 October 20105 September 2013RMB5.26510,000,000.00-Agricultural Bank of China16 December 20105 September 2013RMB5.26510,000,000.00-China Merchants Bank Anlian Branch30 April 200921 July 2013RMB4.865-30,000,000.0030,000,000.0030,000,000.00(b)The long-term borrowings are repayable as follows: 31 December 201031 December 2009Between 1 to 2 years-30,000,000.00Between 2 to 5 years30,000,000.00-30,000,000.0030,000,000.00As at 31 December 2010, the weighted average interest rate of long-term borrowings is 5.040%( per annum (31 December 2009: 4.865%). VNotes to the consolidated financial statements (continued)(29)Payables for specific projects31 December 2009AdditionReclassification31 December 2010Others1,600,000.00-(800,000.00)800,000.00Government grants for ERP system construction955,000.00--955,000.00Industrial technology funds-3,000,000.00-3,000,000.002,555,000.003,000,000.00(800,000.00)4,755,000.00(30)Other non-current liabilities31 December 201031 December 2009Deferred income(Note a)30,382,512.43876,206.90Medical reserve funds (Note b)45,427,343.3144,602,343.3175,809,855.7445,478,550.21(a)Deferred income31 December 201031 December 2009Government grants related to assets- R&D library (in progress)5,000,000.00-- Medical R&D center II (in progress)5,000,000.00-- Shared logistics center(completed)4,102,107.25-- Other projects(in progress)2,277,489.70876,206.90Promotion rewards program14,002,915.48-30,382,512.43876,206.90(b)Certain medical reserves funds were received by the Group from the PRC government for it to purchase medical products (including medicines) required to respond to major disasters, epidemics and other emergencies. VNotes to the consolidated financial statements (continued)(31)Share capital31 December 2009Movement31 December 2010New issue Bonus issue Capitalisation of surplus reserveOthersTotalListed shares without restriction of trading:A shares, listed233,263,800.00-----233,263,800.00B shares, listed54,885,600.00-----54,885,600.00288,149,400.00-----288,149,400.0031 December 2008Movement31 December 2009New issue Bonus issue Capitalisation of surplus reserveOthersTotalListed shares without restriction of trading:A shares, listed149,283,973.00---83,979,827.0083,979,827.00233,263,800.00B shares, listed54,885,600.00-----54,885,600.00204,169,573.00---83,979,827.0083,979,827.00288,149,400.00Listed shares with restriction of trading:A shares held by the State 83,979,827.00---(83,979,827.00)(83,979,827.00)-288,149,400.00-----288,149,400.00 VNotes to the consolidated financial statements (continued)(32)Capital surplus31 December 2009Current year reductions31 December 2010(Note IV (3)(a))Share premiumBusiness combination under common control (Note a)26,538,149.83(26,538,149.83)-Other Capital surplusShare of changes in equity other than profits of investees2,380,016.57-2,380,016.57Transfer of capital surplus recognised under the previous accounting system2,650,322.00-2,650,322.0031,568,488.40(26,538,149.83)5,030,338.5731 December 2008Current year reductions31 December 2009Share premiumBusiness combination under common control (Note a)53,106,833.70(26,568,683.87)26,538,149.83Other Capital surplusShare of changes in equity other than profits of investees2,405,516.57(25,500.00)2,380,016.57Transfer of capital surplus recognised under the previous accounting system2,650,322.00 -2,650,322.0058,162,672.27(26,594,183.87)31,568,488.40(a)In 2010, business combination involving Shenzhen Medicine (2009: Sinopharm Nanning) under common control led to changes in capital surplus of RMB26,538,149.83 (2009: RMB26,568,683.87).(33)Surplus reserve31 December 2009Current year additionsCurrent year reductions31 December 2010Statutory surplus reserve17,573,057.1122,408,211.44-39,981,268.5531 December 2008Current year additionsCurrent year reductions31 December 2009Statutory surplus reserve9,303,064.3117,573,057.11(9,303,064.31)17,573,057.11In accordance with the Company Law of PRC and the Company s constitution, the Company should appropriate 10% of net profit for the year to the statutory surplus reserve, and the Company can cease appropriation when the statutory surplus reserve accumulated to more than 50% of the registered capital. The statutory surplus reserve can be used to make up for the loss or increase the paid in capital after approval from the appropriate authorities. According to a resolution at the Board of Directors, the Company appropriated 10% of net profit, amounting to RMB 22,408,211.44 for the year 2010, (2009: 10% of the net profit for year, amounting to RMB 17,573,057.11) to the statutory surplus reserve. VNotes to the consolidated financial statements (continued)(34)Undistributed profits20102009AmountAppropriation rateAmountAppropriation rateOpening balance of retained earnings(before adjusted)511,913,342.00330,460,963.41Changes from business combination under common control (a)(1,994,394.68)(2,148,833.94)Opening balance of retained earnings(after adjusted)509,918,947.32328,312,129.47Add:net profit attributable to the shareholders of the company261,116,656.70192,868,245.18Less: appropriation of statutory surplus reserve (Note V(33))(22,408,211.44)10%(17,573,057.11)10%Dividends (d)(28,814,940.00)(28,828,019.86)Other outflow (b)(603,150.17)(4,497,799.33)Add: other inflow (c)-39,637,448.97Ending balance of retained earnings719,209,302.41509,918,947.32 (a)In 2010, changes from business combination under common control was RMB1,994,394.68(2009: RMB2,148,833.94) (Note IV (3)(d)).(b)The transferred out amount in  others represented the impact from acquisition of Shenzhen Medicine in year the 2010 (Note IV (3)(d)) (2009: business combination of Sinopahrm Nanning). The acquisition is defined as business combination involving entities under common control. Thus, difference between the carrying amount of the net assets obtained by the combining party and the carrying amount of the consideration paid by it, shall be adjusted against the owners equity. As the account capital surplus is not sufficient to be offset, the retained earnings have been adjusted.(c)The transferred in amount in  others represented the impact from disposal of two significant loss subsidiaries in 2009. Before the adoption of accounting standards on 1 January 2007, super loss from subsidiaries was presented as  unrecognised investment loss directly in the consolidated account, other than recognised in net profit. Therefore, gain from disposal of significant loss subsidiaries whose loss incurred before year 2007 and not recognised in the income statement, was taken into retained earnings instead of profit of current year directly.(d)Pursuant to the resolution at the General Meeting on 16 April 2010, cash dividends of RMB28,814,940.00 (RMB1 per 10 shares) was paid based on the issued shares of 288,149,400.Pursuant to the resolution of board of directors of the company on 18 March 2011, cash dividends of RMB34,577,928.00 (RMB1.2 per 10 shares) was proposed based on the issued shares of 288,149,400. This proposed dividend is subject to the approval of General Meeting (Note X(2)). (35)Minority InterestMinority interests are analysed as below:31 December 201031 December 2009Sinopharm Liuzhou23,073,890.8720,873,364.99Suzhou Wanqin34,455,044.5334,591,598.75Yanfeng Medical21,546,116.21-79,075,051.6155,464,963.74 VNotes to the consolidated financial statements (continued)(36)Sales and cost of sales20102009Revenue of main operations12,973,185,381.0210,928,536,536.97Other operating income91,242,767.6768,538,382.0813,064,428,148.6910,997,074,919.0520102009Cost of main operations(11,887,730,086.45)(10,010,662,507.45)Other operating expenses(37,925,421.49)(30,545,332.62)(11,925,655,507.94) (10,041,207,840.07)(a)Revenue and cost of main operationsRevenue and cost of main operations analysed by industries are set out below:20102009Revenue of main operationsCost of main operationsRevenue of main operationsCost of main operationsPharmaceutical manufacturing1,570,934,485.12(1,149,341,920.41)1,309,366,784.86(927,211,288.86)Pharmaceutical distribution11,364,699,335.20(10,709,622,065.79)9,434,644,471.39(8,936,621,292.50)Retail pharmacy5,716,159.30(5,253,317.09)165,938,081.44(131,128,956.20)Logistics and freights22,098,929.36(17,388,130.15)11,719,900.13(9,974,941.07)Rental and other income9,736,472.04(6,124,653.01)6,867,299.15(5,726,028.82)12,973,185,381.02(11,887,730,086.45)10,928,536,536.97(10,010,662,507.45) (b)Other operating income and expenses20102009Other operating incomeOther operating expensesOther operating incomeOther operating expensesSales of raw materials35,396,390.57(31,295,631.57)37,338,215.56(27,895,413.78)Rental income16,146,125.91(3,332,435.53)11,360,309.76(1,379,172.70)Rendering of services32,942,310.75(1,290,011.24)19,376,838.05(1,122,658.42)Income from disposal of investment properties 4,415,151.77(1,430,152.09)--Others2,342,788.67(577,191.06)463,018.71(148,087.72)91,242,767.67(37,925,421.49)68,538,382.08(30,545,332.62) VNotes to the consolidated financial statements (continued)(36)Sales and cost of sales (continued)(c)Top five customers are analysed as follows:The sales to top five customers of the Group amounted to RMB742,502,202.03 (2009: RMB740,672,201.72), which accounted for 5.68% (2009: 6.74%) of the total revenue from main operations. Details are set out below:Sales% of total sales of the GroupGuangDong Province People's Hospital212,901,694.56 1.63%The First Affiliated Hospital of GuangXi Medical University 158,286,301.88 1.21%Shenzhen People's Hospital128,339,169.28 0.98%The Guangxi Zhuang Autonomous People s Hospita127,315,445.71 0.97%Sinopharm Holding Shenyang Co., Ltd.115,659,590.600.89%742,502,202.035.68%(37)Tax and surcharges 20102009Business tax8,554,262.19 5,900,691.24City maintenance and construction tax5,913,573.72 5,051,480.81Educational surcharge4,892,414.31 4,718,139.45Others558,263.20 200,519.55 19,918,513.42 15,870,831.05 (38)Selling and distribution expenses20102009Employees payroll and welfare benefits150,330,866.04139,815,123.36Transportation charges67,900,327.0657,408,495.73Promotion and marketing expenses49,850,966.8037,952,380.50Conference expenses22,835,768.7810,325,885.54Travel allowances18,241,288.2317,522,362.72Entertainment expenses16,924,293.6014,862,440.23Advertising expenses16,337,186.8017,562,817.80Storage expenses14,445,518.2117,496,248.23Tendering expenses12,948,548.892,349,950.42Office allowances11,703,372.5213,351,348.97Rental expenses6,609,943.8916,725,959.80Depreciation expenses3,338,028.185,115,957.87Others39,122,464.4752,291,910.27430,588,573.47402,780,881.44 VNotes to the consolidated financial statements (continued)(39)Governance and administrative expense20102009Employees payroll and welfare benefits119,851,546.31106,295,948.95Research and development expenses52,830,769.2333,725,810.21Depreciation expenses18,848,850.4321,248,340.58Taxations17,731,453.458,813,663.25Amortisation of intangible assets16,100,730.9012,272,751.72Entertainment expenses9,805,471.715,917,094.82Office allowances8,833,351.188,835,208.82Conference expenses6,246,454.326,965,704.73Vehicle management expenses5,996,637.524,867,071.81Maintenance and other charges4,859,112.743,492,973.73Travel allowances4,775,407.483,572,675.97Utilities4,678,618.333,527,041.15Consulting fees4,593,484.163,248,486.08Rental expenses4,194,543.512,569,054.02Others21,528,938.6329,826,704.23300,875,369.90255,178,530.07 (40)Financial expenses - net20102009Interest expenses79,315,995.2647,077,841.54Less: interest income(4,088,163.10)(4,508,432.69)Exchange gains (712,362.46)(172,231.40)Others8,023,171.797,959,465.1582,538,641.4950,356,642.60 (41)Assets impairment losses20102009Bad debts7,235,906.595,613,539.97Declines in values of inventories1,982,055.626,716,533.289,217,962.2112,330,073.25 (42)Income tax expenses20102009Share of profit of investees under equity method (Note a)27,224,583.8120,878,151.35Profit / cash dividends declared by investees under cost method-3,618.16Income from disposal of long-term equity investments41,241.3011,695,835.7827,265,825.1132,577,605.29The investment income from long-term investment under equity method represented the profit from Wanle Medical. The increase was due to improved business performance of that associate.There is no significant restriction on the remittance of investment income to the Group. V Notes to the consolidated financial statements (continued)(43)Non-operating income20102009Gain on disposal of fixed assets2,476,865.32 145,754.97Government grants (Note a)8,427,739.90 7,599,783.30Others9,340,338.71 2,526,421.6120,244,943.93 10,271,959.88Non-operating income is wholly classified as non-recurring pro      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxz{|}~fit and loss. (a)Government grants20102009NoteGovernment grants for medicine reserve expenses3,776,825.603,812,590.20Subsidy for medical reserveGovernment grants for technical improvement2,474,992.752,045,300.00Subsidy for technical improvement of high and new technology enterprisesGovernment grants for R&D expenses200,000.001,000,000.00Subsidy for R&D expenditure for enterprises located in Bao An district ShenzhenOthers1,975,921.55741,893.10Cash reward for contribution to taxation and patent8,427,739.907,599,783.30(44)Non-operating expenses20102009Losses on disposal of non-current assets548,476.80544,477.77Including: disposal of fixed assets525,809.86544,477.77 disposal of intangible assets22,666.94-Donation273,786.00-Others2,509,717.85713,887.433,331,980.651,258,365.20Non-operating cost is wholly classified as non-recurring profit and loss.(45)Income taxes expenses20102009Current income tax96,616,673.6566,047,144.40Deferred income tax(21,028,724.06)(3,519,867.25)75,587,949.5962,527,277.15 VNotes to the consolidated financial statements (continued)(45)Income taxes expenses (continued)The reconciliation from income tax calculated based on applicable tax rates and total profit presented in the consolidated financial statements to the income tax expenses is listed below:20102009Total profit339,812,368.65260,941,320.54Income tax expenses calculated at applicable tax rates84,953,092.1665,235,330.14Differences in preferential tax rates of certain companies(14,953,582.37)(9,934,608.78)Income not subject to tax(6,806,145.95)(5,219,537.84)Expenses not deductible for tax purposes6,811,445.295,790,591.45Tax losses for which no deferred income tax asset was recognised3,288,042.951,066,778.65Others2,295,097.515,588,723.53Income taxes75,587,949.5962,527,277.15(46)Earnings per share(a)Basic earnings per shareBasic earnings per share is calculated by consolidated net profit attributable to shareholders of the Company dividing by the weighted average number of ordinary shares in issue:20102009Consolidated net profit attributable to shareholders of the Company261,116,656.70192,868,245.18Weighted average number of ordinary shares in issue288,149,400.00288,149,400.00Basic earnings per share 0.910.67Including:Basic earnings per share on going 0.910.67(b)Diluted earnings per shareDiluted earnings per share is calculated by dividing the consolidated net profit attributable to shareholders of the Company by the weighted average number of ordinary shares in issue, which both should be adjusted for the effects of all potential dilutive factors. The Company has no potential outstanding ordinary shares (2009: nil), the diluted earnings per share equals the basic earnings per share. VNotes to the consolidated financial statements (continued)(47)Cash received relating to other operating activities(a)Cash received relating to other operating activities 20102009Government grants8,427,739.907,596,783.30Interest income4,088,163.103,593,204.20Others27,991,056.1418,956,677.6340,506,959.1430,146,665.13(b)Cash paid relating to other operating activities20102009Storage and transportation expenses82,345,845.2774,146,644.44Entertainment expenses26,729,765.3121,198,245.55Rental expenses10,804,487.4016,994,946.52Advertising expenses16,337,186.8016,746,873.88Bank charges7,310,273.227,941,568.36Others110,642,401.27289,497,204.28254,169,959.27 426,525,483.03  (c)Cash paid relating to other investing activities20102009Payment for acquisition of minority interests-5,000,000.00Deposit for land bidding-3,100,000.00-8,100,000.00 (d)Cash received relating to other financing activities20102009Entrusted loans borrowed from Sinopharm950,000,000.00- (e)Cash payments relating to other financing activities20102009Repayment of entrusted loans lent by Sinopharm900,000,000.0095,000,000.00 VNotes to the consolidated financial statements (continued)(48)Supplementary information of cash flow statements(a)Supplementary information of cash flow statementsReconciliation of net profit to cash flows from operating activities20102009Net profit264,224,419.06198,414,043.39Add: Provision for assets impairment9,217,962.2112,330,073.25  Depreciation of fixed assets and investment properties66,917,994.6856,354,410.53 Amortisation of intangible assets16,100,730.9012,272,751.72  Amortisation of long-term prepaid expenses3,943,783.775,511,501.81 (Gains)/Losses on disposal of fixed assets, intangible assets and other non-current assets(1,928,388.52)398,830.30 Financial expenses79,316,531.3747,081,231.02 Investment income(27,265,825.11)(32,577,605.29)Increase of deferred tax assets(18,212,396.00) (1,251,326.99)Decrease of deferred tax liabilities(2,816,328.06) (2,268,540.26)Increase of inventory(207,071,490.97) (150,045,021.51)Increase in operating receivables(305,425,666.81) (635,086,338.31)Increase in operating payables574,416,996.61762,726,867.51 Increase in operating cash with restriction(23,258,902.48)-Net cash flow from operating activities428,159,420.65273,860,877.17 Movement of cash 20102009Cash at end of year682,875,873.18582,750,672.15 Less: cash at beginning of year(582,750,672.15)(388,795,803.68)Net increase in cash 100,125,201.03193,954,868.47 VNotes to the consolidated financial statements (continued)(48)Supplementary information of cash flow statements (continued)(b)Acquisition of subsidiaries and operating unit20102009The consideration of acquisition 139,429,931.08149,340,643.10Consideration settled in cash123,901,440.00148,803,790.00Less: cash and cash equivalents in the subsidiaries and business acquired(7,621,967.67)(36,519,556.47)Add: cash paid for prior year acquisition11,691,810.63-Net cash outflow on acquisition of the subsidiaries and business127,971,282.96112,284,233.53 Net assets acquired from the business combination involving entities and operating unit under non common control20102009Current assets234,630,541.72493,763,840.28Non-Current assets3,315,658.23156,784,810.98Current liabilities(134,357,892.56)(453,571,864.94)Non-Current liabilities-(26,258,762.06)Minority interest(10,702,325.51)-92,885,981.88170,718,024.26(c)Net proceeds from disposal of subsidiaries 20102009Consideration from disposal-76,074,000.00Cash received from the disposal-76,074,000.00Less: cash held by subsidiaries-(16,085,546.57)Net cash received from disposal-59,988,453.43Net assets of subsidiaries20102009Current assets-169,274,494.08Non-Current assets-21,718,956.48Current liabilities-(171,388,135.05)Non-Current liabilities---19,605,315.51 VNotes to the consolidated financial statements (continued)(48)Supplementary information of cash flow statements (continued)(d)Cash and cash equivalents31 December 201031 December 2009Cash at end of year682,875,873.18582,750,672.15Including: Cash in hand146,710.56335,820.91Call deposits with banks682,729,162.62470,647,654.89Other cash and cash equivalents -111,767,196.35Restricted cash28,913,902.485,655,000.00Cash at bank and on hand711,789,775.66588,405,672.15 VISegment informationThe reportable segments of the Group are the business units that provide different products or service, or operate in the different areas. Different businesses or areas require different technologies and marketing strategies, the Group, therefore, separately manages the production and operation of each reportable segment and evaluates their operating results respectively, in order to make decisions about resources to be allocated to these segments and to assess their performance. The Group identified 2 reportable segments as follows: - Pharmaceutical distribution, which is mainly engaged in distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores and clinics; - Pharmaceutical manufacturing, which is mainly engaged in the manufacture and sale of medicine.Inter-segment transfers are measured by reference to sales to third parties. The assets and liabilities are allocated based on the operations of the segment and the physical location of the asset. The liabilities are allocated based on the operations of the segment. Expenses indirectly attributable to each segment are allocated to the segments based on the proportion of each segment s revenue. VISegment information (continued)(a)Segment information as at and for the year ended 31 December 2010 is as follows:Pharmaceutical distributionPharmaceutical manufacturingEliminationTotalRevenue from external customers11,429,075,204.471,635,352,944.22-13,064,428,148.69Inter-segment revenue643,455.9020,363,024.64(21,006,480.54)-Interest income2,611,888.977,238,731.29(5,762,457.16)4,088,163.10Interest expense(81,503,577.03)(3,574,875.39)5,762,457.16(79,315,995.26)Share of profit of associates27,224,583.81--27,224,583.81Impairment (3,584,354.21)(5,633,608.00)-(9,217,962.21)Depreciation and Amortisation(28,585,216.11)(58,377,293.24)-(86,962,509.35)Gross profit 288,159,127.81133,966,014.45(82,312,773.61)339,812,368.65Income taxes(52,368,403.09)(23,219,546.50)-(75,587,949.59)Net profit235,790,724.72110,746,467.95(82,312,773.61)264,224,419.06Total Assets5,265,741,439.431,561,062,548.05(520,010,981.67)6,306,793,005.81Total liabilities(4,294,108,883.88)(1,021,238,760.79)140,000,000.00(5,175,347,644.67)Long-term equity investment in associates85,275,251.06--85,275,251.06Additions to non-current assets other than long-term equity investments103,340,658.48128,749,786.71-232,090,445.19 VISegment information (continued)(b)Segment information as at and for the year ended 31 December 2009 is as follows:Pharmaceutical distributionPharmaceutical manufacturingEliminationTotalRevenue from external customers9,548,200,236.371,448,874,682.68-10,997,074,919.05Inter-segment revenue243,214.1317,059,707.05(17,302,921.18)-Interest income3,892,089.342,536,255.13(1,919,911.78)4,508,432.69Interest expense(42,549,607.68)(6,448,145.64)1,919,911.78(47,077,841.54)Share of profit of associates20,878,151.35--20,878,151.35Impairment (12,144,104.88)(185,968.37)-(12,330,073.25)Depreciation and Amortisation(46,769,531.40)(27,369,132.66)(74,138,664.06)Gross profit 228,760,421.65118,822,281.85(86,641,382.96)260,941,320.54Income taxes(43,381,171.92)(19,146,105.23)-(62,527,277.15)Net profit185,379,249.7399,676,176.62(86,641,382.96)198,414,043.39Total Assets4,405,022,732.551,138,631,279.79(275,313,786.27)5,268,340,226.07Total liabilities(3,649,387,935.31)(756,277,434.19)40,000,000.00(4,365,665,369.50)Long-term equity investment in associates58,050,667.25--58,050,667.25Additions to non-current assets other than long-term equity investments145,170,807.7629,917,358.68-175,088,166.44 VIIRelated party relationships and significant related party transactions (1)The parent company  (a)General information of the parent company:Enterprise TypePlace of registrationLegal representativePrincipal businessSinopharm GroupCompany limited by sharesShanghaiShe LulinDistribution and retail of medicines and pharmaceutical products to The Company s ultimate controlling equity holder is CNPGC.(b)Registered capital and changes in registered capital of the parent company31 December 2009AdditionDecrease31 December 2010(Rmb 0,000)(Rmb 0000)(Rmb 0000)(Rmb 0000)Sinopharm Group226,456.84--226,456.84 (c)The proportions of equity interests and voting rights in the Company held by the parent company:31 December 201031 December 2009% interest held % voting rights% interest held % voting rightsSinopharm Group38.3338.3338.3338.33(2)Subsidiaries of the CompanyThe general background and other related information of the subsidiaries is set out in Note IV.(3)AssociatesEnterprise TypePlace of registrationLegal representativePrincipal businessRegister capital% interest held% voting rightsWanle MedicalForeign capitalShenzhenYan ZhigangMedicine manufactureUSD 500.00 million 35.19%33.33%(4)Other related parties Relationship with the CompanyShanghai Tongyu Information Technology Co., Ltd.Controlled by Sinopharm GroupSinopharm Yixin Pharmacy Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Yunnan Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Inner Mongolia Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Sub Marketing Center Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Beijing Huahong Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Beijing Kangchen Bio-Pharmaceutical Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Beijing Co., Ltd.Controlled by Sinopharm GroupSinopharm National Pharmacy Co.,Ltd.Controlled by Sinopharm GroupSinopharm Holding Tianjin Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Tianjin Co.,Ltd. Inner Mongolia BranchControlled by Sinopharm GroupSinopharm Group (Tianjin) Eastern Bokang Pharmaceutical Co., Ltd.Controlled by Sinopharm Group VIIRelated party relationships and significant related party transactions (continued)(4)Other related parties (continued)Relationship with the CompanySinopharm Holding Ningxia Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Anhui Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Shandong Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Shanxi Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Jiangsu Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Jiangxi Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Shengyang Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Shenyang Co., Ltd. Dalian BranchControlled by Sinopharm GroupSinopharm Holding Shenyang Co., Ltd. Changchun BranchControlled by Sinopharm GroupSinopharm Holding Jilin Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Henan Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Zhejiang Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Hainan Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Hubei Yibao Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Hubei Xinlong Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Hubei Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Hunan Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Gansu Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Shijiazhuang Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Fuzhou Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Fujian Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Suzhou Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Guizhou Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Chongqing Co., Ltd.Controlled by Sinopharm GroupSinopharm Group Shanghai Likang Medicines Co,. Ltd.Controlled by Sinopharm GroupSinopharm Group Chemical Reagent Suzhou Co., Ltd.Controlled by Sinopharm GroupSinopharm Group Medicine Logistic Co., Ltd.Controlled by Sinopharm GroupSinopharm Group Medicine Logistic Co., Ltd. Guangzhou BranchControlled by Sinopharm GroupSinopharm Group Guorui Pharmaceutical Co., Ltd.Controlled by Sinopharm GroupChina National Medicines Co., Ltd.Controlled by Sinopharm GroupSinopharm Group Northwest Co., Ltd.Controlled by Sinopharm GroupSinopharm Group Southwest Pharmacy Co., Ltd.Controlled by Sinopharm GroupNingxia Guoda Durg Store Chain Co., Ltd.Controlled by Sinopharm GroupGuangdong Accord Drug Store Co., Ltd.Controlled by Sinopharm GroupGuangdong East Uptodate & Special Medicines Co.,Ltd.Controlled by Sinopharm GroupGuangzhou Accord Drug Store Chain Co., Ltd.Controlled by Sinopharm GroupGuangxi Accord Drug Store Chain Co., Ltd.Controlled by Sinopharm GroupGuangxi Guoda Durg Store Chain Co.,Ltd.Controlled by Sinopharm GroupGuangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd.Controlled by Sinopharm GroupXinjiang Special Drugs National Pharmaceutical Co.,Ltd.Controlled by Sinopharm GroupXinjiang Special Drugs Western Pharmaceutical Co.,Ltd.Controlled by Sinopharm GroupWenzhou Biomedicin-appliances supplies co., LtdControlled by Sinopharm GroupShenzhen Accord Pharmaceutical Chain Co., LtdControlled by Sinopharm GroupSinopharm Holding Meiluo (Dalian) Co., LtdControlled by Sinopharm GroupSinopharm Group Chemical Reagent Co., Ltd.Controlled by Sinopharm GroupShanghai Shyndec Pharmaceutical Co., Ltd.Controlled by Sinopharm GroupSinopharm Holding Tianjin Co.,Ltd. Tangshan BranchControlled by Sinopharm GroupSinopharm Group Pharmacy Holding Shanghai Co., LtdControlled by Sinopharm GroupSinopharm Qianjing Dental Technology (Beijing) Co.,Ltd.Controlled by Sinopharm GroupWanle MedicalAssociate of the CompanyShanghai Sailun Biological Technology Co.,Ltd.Associate of Sinopharm GroupYichang Humanwell Pharmaceutical Co.,Ltd.Associate of Sinopharm GroupQinghai Pharmaceitical (Group) Co.,Ltd.Associate of Sinopharm GroupShanghai Sinopharm Medical Meterials Co.,Ltd.Controlled by CNPGCShenzhen National Medical Equlpment & Supplies I/E Shenzhen CorporationControlled by CNPGCChina National Medical Equipment Industry CorportationControlled by CNPGCChina Sinopharm Foreign Trade Co.,Ltd.Controlled by CNPGCChina National Pharmaceutical Industry CorporationLtd. Controlled by CNPGC VIIRelated party relationships and significant related party transactions (continued)(4)Other related parties (continued)Relationship with the CompanyChina National Pharmaceutical Industry Corporation Ltd. Beijing sales branchControlled by CNPGCSinopharm United Engineering CorporationControlled by CNPGCChina National Group Corporation of Traditional & Hebal MedicalControlled by CNPGCSichuan Jiang You Zhong Ba Science and Technology Development Co.,Ltd.Controlled by CNPGCReed Sinopharm Exhibitions Co.,Ltd.Controlled by CNPGCSinopharm Group Shanghai Medicine Device Co., Ltd.Controlled by CNPGCSinopharm Group Beijing Medicine Device Co., Ltd.Controlled by CNPGCSinopharm Group Baida Pharmaceutical Co., Ltd.Controlled by CNPGCSinopharm Group United Medicine Device Co., Ltd.Controlled by CNPGCGuang dong South National Pharmaceutical Foreign Trade Co.,Ltd.Controlled by CNPGCGuangdong Tianliang Medicine Co., Ltd.Controlled by CNPGCChengdu Rongsheng Pharmacy Co., Ltd.Controlled by CNPGCChina National Pharmaceutical Industry Corporation Lts. Guangzhou Association CompanyAssociate of CNPGCChina Otsuka Pharmaceutical Co.,Ltd.Associate of CNPGCSino-Swed Pharmaceutical Corp.Ltd.Associate of CNPGCYangqiaomingMinority interest of subsidiaryWangleiMinority interest of subsidiaryKaijiefeng Controlled by WangleiWangyangRelatives of WangleiShanghai Fosun Pharmaceutical (Group) Co., Ltd.("Fosun Pharm")Shareholders have significant influence on Fosun PharmShanghai Fosun Pharmaceutical Co., Ltd.Subsidiary of Fosun PharmShanghai Fosun Long March Medical Science Co., Ltd.Subsidiary of Fosun PharmShanghai Chaohui Pharmecurical Co., Ltd.Subsidiary of Fosun PharmGuilin Pharmaceutical Co., Ltd.Subsidiary of Fosun PharmGuilin Pharmaceutical WorksSubsidiary of Fosun PharmJiangsu Wanbang Pharmacy Marketing Co., Ltd.Subsidiary of Fosun PharmJiangsu Wanbang Bio-Chemical Medicine Co., Ltd.Subsidiary of Fosun PharmShenyang Hongqi Pharmaceutical Co., Ltd.Subsidiary of Fosun PharmChongqing Haisiman Pharmaceutical Co.,Ltd.Subsidiary of Fosun PharmChongqing Yaoyou Pharmaceutical Co.,Ltd.Subsidiary of Fosun PharmSichuan Hexin Pharmaceutical Co.,Ltd. Subsidiary of Fosun PharmShenyang Hongqi Pharmaceutical Co.,Ltd.Subsidiary of Fosun Pharm VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions(a)Purchase of goodsRelated partyPricing policies20102009Amount% of same transaction Amount% of same transaction  Sinopharm GroupMarket price82,082.216.80%57,881.62 4.94%China National Medicines Co., Ltd.Market price14,558.781.21%11,433.17 0.98%Sinopharm Holding Sub Marketing Center Co., Ltd.Market price13,662.531.13%42,220.20 3.60%Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.Market price8,977.240.74%4,322.77 0.37%Sino-Swed Pharmaceutical Corp.Ltd.Market price6,042.050.50%5,453.72 0.47%Wanle MedicalMarket price2,840.490.24%2,301.980.20%Qinghai Pharmaceitical (Group) Co.,Ltd.Market price1,108.170.09%-  - Sinopharm Holding Fujian Co., Ltd.Market price1,922.980.16%- -Jiangsu Wanbang Pharmacy Marketing Co., Ltd.Market price1,158.360.10%733.700.06%Guangdong East Uptodate & Special Medicines Co.,Ltd.Market price809.060.07%1,164.220.10%Sinopharm Group United Medicine Device Co., Ltd.Market price806.850.07%895.360.08%China National Pharmaceutical Industry CorporationLtd. Beijing sales branchMarket price607.480.05%43.100.00%Chengdu Rongsheng Pharmacy Co., Ltd.Market price510.160.04%--China National Group Corporation of Traditional & Hebal MedicalMarket price433.380.04%463.24 0.04%Chongqing Yaoyou Pharmaceutical Co.,Ltd.Market price382.240.03%21.780.00%Chongqing Haisiman Pharmaceutical Co.,Ltd.Market price375.680.03%140.130.01%Guangdong Accord Drug Store Co., Ltd.Market price103.580.01%1.38 0.00%Sinopharm Holding Beijing Co., Ltd.Market price94.430.01%-  - Shanghai Chaohui Pharmecurical Co., Ltd.Market price81.380.01%12.710.00%Sinopharm Group Baida Pharmaceutical Co., Ltd.Market price74.900.01%-  - Sinopharm Group Southwest Pharmacy Co., Ltd.Market price74.310.01%137.850.01%Guilin Pharmaceutical WorksMarket price68.100.01%87.43-Sinopharm Group Chemical Reagent Suzhou Co., Ltd.Market price62.110.01%29.830.00%Sichuan Jiang You Zhong Ba Science and Technology Development Co.,Ltd.Market price51.440.00%10.870.00%Sinopharm Group Chemical Reagent Co., Ltd.Market price41.700.00%18.270.00%China National Pharmaceutical Industry Corporation Ltd. Market price36.020.00%44.010.00%Sinopharm Holding Guizhou Co., Ltd.Market price34.000.00%--Sinopharm Holding Beijing Kangchen Bio-Pharmaceutical Co., Ltd.Market price21.440.00%--Sinopharm Holding Chongqing Co., Ltd.Market price20.960.00%--Guilin Pharmaceutical Co., Ltd.Market price16.010.00%24.580.00%Sinopharm Holding Anhui Co., Ltd.Market price13.950.00%--Sinopharm Holding Meiluo (Dalian) Co., LtdMarket price12.460.00%--To next page137,084.4511.37%127,441.9210.86% VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions (continued)(a)Purchase of goods (continued)Related partyPricing policies20102009Amount% of same transaction Amount% of same transaction continued137,084.4511.37%127,441.9210.86%Shanghai Sailun Biological Technology Co.,Ltd.Market price11.880.00%- - Sinopharm Holding Suzhou Co., Ltd.Market price11.840.00%86.180.01%Sinopharm Holding Fuzhou Co., Ltd.Market price9.720.00%--Shenyang Hongqi Pharmaceutical Co., Ltd.Market price7.940.00%9.860.00%Sinopharm Yixin Pharmacy Co., Ltd.Market price6.300.00%--Sinopharm Group Shanghai Medicine Device Co., Ltd.Market price6.110.00%12.920.00%Sinopharm Holding Hainan Co., Ltd.Market price4.610.00%--Yichang Humanwell Pharmaceutical Co.,Ltd.Market price3.520.00%--Xinjiang Special Drugs National Pharmaceutical Co.,Ltd.Market price2.220.00%5.850.00%Sinopharm Qianjing Dental Technology (Beijing) Co.,Ltd.Market price0.890.00%-- Guangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd.Market price0.380.00%--Sinopharm Holding Hunan Co., Ltd.Market price- 0.00%667.960.06%Sinopharm Group Northwest Co., Ltd.Market price- 0.00%112.820.01%Sinopharm Holding Zhejiang Co., Ltd.Market price- 0.00%4.340.00%Sinopharm National Pharmacy Co.,Ltd.Market price-0.00%114.450.01%Guangdong Tianliang Medicine Co., Ltd.Market price(0.28)0.00%95.280.01%China Sinopharm Foreign Trade Co.,Ltd.Market price(0.39)0.00%2,653.570.23%Sinopharm Group Medicine Logistic Co., Ltd.Market price--177.360.02%Sinopharm Group Medicine Logistic Co., Ltd. Guangzhou BranchMarket price--9.640.00%Sinopharm Qianjing Dental Technology (Beijing) Co.,Ltd.Market price--17.870.00%Shanghai Shyndec Pharmaceutical Co., Ltd.Market price--21.440.00%Sinopharm Holding Jiangsu Co., Ltd.Market price--0.160.00%Total137,149.1911.37%131,431.6211.21% VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions (continued)(b)Sales of goods Related partyPricing policies20102009Amount% of same transaction Amount% of same transaction Sinopharm Holding Shengyang Co., Ltd.Market price11,565.960.89%25,228.89 2.31%Guangdong Accord Drug Store Co., Ltd.Market price9,176.020.71%3,724.94 0.34%Sinopharm Holding Hunan Co., Ltd.Market price8,545.610.66%8,161.09 0.75%Sinopharm Holding Hubei Co., Ltd.Market price8,328.660.64%9,221.12 0.84%Chongqing Yaoyou Pharmaceutical Co.,Ltd.Market price7,879.490.61%5618.160.51%Sinopharm Group Southwest Pharmacy Co., Ltd.Market price6,765.470.52%7,615.76 0.70%Sinopharm Holding Beijing Co., Ltd.Market price6,670.990.51%5,974.61 0.55%Sinopharm Holding Tianjin Co., Ltd.Market price5,338.070.41%5,969.04 0.55%Sinopharm Group (Tianjin) Eastern Bokang Pharmaceutical Co., Ltd.Market price4,050.690.31%1,920.90 0.18%Guangxi Accord Drug Store Chain Co., Ltd.Market price3,204.360.25%1,767.58 0.16%Sinopharm Holding Hainan Co., Ltd.Market price3,196.420.25%--Sinopharm Holding Beijing Huahong Co., Ltd.Market price2,780.680.21% 1,926.68 0.18%Xinjiang Special Drugs National Pharmaceutical Co.,Ltd.Market price2,755.040.21%286.21 0.03%Sinopharm GroupMarket price2,576.100.20%2,089.17 0.19%Sinopharm Holding Yunnan Co., Ltd.Market price2,283.940.18%227.57 0.02%Sinopharm Holding Henan Co., Ltd.Market price2,201.500.17%1,600.62 0.15%Xinjiang Special Drugs Western Pharmaceutical Co.,Ltd.Market price1,852.180.14%130.92 0.01%Sinopharm Holding Fujian Co., Ltd.Market price1,448.650.11%-0.00%Sinopharm Holding Ningxia Co., Ltd.Market price1,437.560.11%1,711.890.16%Guangdong East Uptodate & Special Medicines Co.,Ltd.Market price1,393.300.11%2,696.230.25%Sinopharm Holding Shijiazhuang Co., Ltd.Market price1,018.960.08%--Sinopharm Holding Jiangsu Co., Ltd.Market price964.050.07%656.190.06%Sinopharm Group Northwest Co., Ltd.Market price930.410.07%538.530.05%Sinopharm Holding Zhejiang Co., Ltd.Market price890.660.07%448.820.04%Sinopharm Holding Shandong Co., Ltd.Market price848.030.07%--Sinopharm Holding Guizhou Co., Ltd.Market price786.700.06%--Sinopharm Holding Shanxi Co., Ltd.Market price781.730.06%508.610.05%China National Medicines Co., Ltd.Market price744.830.06%557.860.05%Guangxi Guoda Durg Store Chain Co.,Ltd.Market price726.120.06%612.910.06%Guangzhou Accord Drug Store Chain Co., Ltd.Market price644.390.05%70.970.01%Sinopharm Holding Hubei Yibao Co., Ltd.Market price346.130.03%1,897.180.17%Sichuan Hexin Pharmaceutical Co.,Ltd. Market price317.420.02%128.750.01%Sinopharm Holding Anhui Co., Ltd.Market price276.590.02%228.38 0.02%Sinopharm Holding Jilin Co., Ltd.Market price270.370.02%--Wenzhou Biomedicin-appliances Supplies co., Ltd.Market price268.790.02%--Sinopharm Holding Inner Mongolia Co., Ltd.Market price256.640.02%--Sinopharm National Pharmacy Co.,Ltd.Market price210.260.02%171.780.02%Sinopharm Holding Jiangxi Co., Ltd.Market price203.300.02%--Sinopharm Holding Gansu Co., Ltd.Market price194.100.01%--To next page104,130.178.03%91,691.368.42% VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions (continued)(b)Sales of goods (continued)Related partyPricing policies20102009Amount% of same transaction Amount% of same transaction Continued104,130.178.03%91,691.368.42%Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.Market price166.320.01%24.380.00%Sinopharm Holding Fuzhou Co., Ltd.Market price150.130.01%--Shenzhen Accord Pharmaceutical Chain Co., Ltd.Market price150.050.01%3,282.850.30%Sinopharm Holding Suzhou Co., Ltd.Market price128.600.01%125.150.01%Sinopharm Holding Shenyang Co., Ltd. Dalian BranchMarket price74.090.01%66.270.01%Shanghai Chaohui Pharmecurical Co., Ltd.Market price69.790.01%113.460.01%China National Group Corporation of Traditional & Hebal MedicalMarket price66.260.01%36.120.00%Sinopharm Holding Meiluo (Dalian) Co., LtdMarket price63.770.00%--Sinopharm Group Guorui Pharmaceutical Co., Ltd.Market price63.150.00%--Sinopharm Holding Tianjin Co.,Ltd. Inner Mongolia BranchMarket price60.590.00%130.090.01%Sinopharm Holding Chongqing Co., Ltd.Market price38.150.00%-0.00%Guangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd.Market price18.530.00%19.640.00%Sinopharm Group Baida Pharmaceutical Co., Ltd.Market price2.350.00%73.080.01%Ningxia Guoda Durg Store Chain Co., Ltd.Market price1.240.00%11.400.00%Sinopharm Holding Shenyang Co., Ltd. Changchun BranchMarket price1.200.00%-- Guangdong Tianliang Medicine Co., Ltd.Market price--648.550.06%Sinopharm Group Medicine Logistic Co., Ltd.Market price--419.630.04%Sinopharm Holding Tianjin Co.,Ltd. Tangshan BranchMarket price--(2.44)(0.00%)Sinopharm Holding Sub Marketing Center Co., Ltd.Market price--(131.72)(0.01%)Shanghai Sinopharm Medical Meterials Co.,Ltd.Market price--147.610.01%Sinopharm Holding Hubei Xinlong Co., Ltd.Market price--8.540.00%Yichang Humanwell Pharmaceutical Co.,Ltd.Market price--53.440.00%Sinopharm Group Shanghai Likang Medicines Co,. Ltd.Market price--34.640.00%Total105,184.398.10%96,752.058.87% VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions (continued)(c)LeaseThe Group as leaser: LeasersLesseesType of assets use for Contract beginning dateContract terminated date Rental incomeHuixin InvestmentGuangzhou Accord Drug Store Chain Co., Ltd.Building1 January 201031 December 201039.42Huixin InvestmentSinopharm Group United Medicine Device Co., Ltd.Building1 August 200931 July 201017.52The CompanyShenzhen Accord Pharmaceutical Chain Co., LtdBuilding1 June 200931 December 201249.26The CompanyGuangdong Accord Drug Store Co., Ltd.Building1 June 200931 December 201040.30Guangxi LogisticsGuangxi Accord Drug Store Chain Co., Ltd.Building1 July 200931 December 201230.38Sinopharm LiuzhouGuangxi Accord Drug Store Chain Co., Ltd.Building1 July 200931 December 2012104.84281.72Rental income received from related parties is negotiated by both parties involved in the lease and by making reference to the market price. The Group as lessee: LesseesLeasersType of assets use forContract beginning dateContract terminated date Lease expensesSinopharm Guangzhou Sinopharm Group Medicine Logistic Co., Ltd.Building1 June 201031 December 2011708.00Sinopharm Guangzhou Sinopharm Group Medicine Logistic Co., Ltd.Equipment1 June 201031 December 2011750.00Yanfeng MedicineMr. Wang YangBuilding1 July 200930 June 201122.051,480.05Lease charges paid to related parties are negotiated by both parties involved in the lease and by making reference to the market price. VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions (continued) (d)Guarantees provided GuarantorGuaranteeAmountBeginning date of guarantee contractMaturity date of guarantee contract Guarantee obligation expiredThe CompanySinopharm Guangzhou41,473.1813 March 201013 March 2011No The CompanySinopharm Guangzhou21,403.8213 April 201013 April 2011No The CompanySinopharm Guangzhou12,327.8218 June 201018 June 2011No The CompanySinopharm Guangzhou5,461.0330 April 201030 April 2011No The CompanySinopharm Guangzhou4,932.9226 October 201025 October 2011No The CompanySinopharm Guangzhou10,000.0017 September 201016 September 2011No The CompanySinopharm Guangzhou3,399.955 November 20104 November 2011No The CompanyYuexing Medicine2,439.6113 April 201013 April 2011No The CompanyZhijun Pharm6,632.4430 December 200930 December 2010No The CompanyZhijun Pharm1,600.111 June 20101 June 2011No The CompanySuzhou Wanqin2,809.1219 July 201031 December 2011No The CompanySuzhou Wanqin5,000.0030 December 200930 December 2010No The CompanySuzhou Wanqin4,009.3623 April 201022 April 2011No The CompanySuzhou Wanqin3,000.001 August 20101 August 2013No The CompanySinopharm Nanning4,732.7213 January 201013 January 2011No The CompanySinopharm Nanning4,516.5430 December 200930 December 2010No The CompanySinopharm Liuzhou5,000.0030 December 200930 December 2010No The CompanyYanfeng Medicine1,997.9127 July 201027 July 2011No Zhijun PharmZhijun Trade383.9625 August 201024 August 2011No Zhijun PharmZhijun Trade1,103.7216 September 201016 September 2011No Zhijun PharmThe Company8,605.0830 December 200930 December 2010No Zhijun PharmThe Company2,015.3923 April 201031 December 2010No Zhijun PharmThe Company4,907.811 June 20101 June 2011No Zhijun PharmThe Company2,624.5618 December 200918 December 2010No Zhijun PharmThe Company385.737 July 201023 June 2011No Zhijun Pharm , Sinopharm GuangzhouThe Company12,934.3021 June 201021 June 2011No Sinopharm GroupSinopharm Guangzhou5,632.5517 September 201028 September 2011No Sinopharm GroupSinopharm Guangzhou10,153.0010 September 201010 September 2011No Sinopharm GroupThe Company11,184.9018 September 201018 September 2011No Sinopharm GroupSinopharm Nanning1,213.4515 October 200931 October 2010No Sinopharm GroupSinopharm Nanning650.0010 March 201010 March 2011No 202,530.98 VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions (continued)(e)FinancingAmount (Rmb 0,000)Effective date Maturity date2010Borrowed from-Sinopharm Group22,000.00 1 March 201031 March 2010Sinopharm Group15,000.00 25 May 201024 November 2010Sinopharm Group15,000.00 25 November 201024 May 2011Sinopharm Group13,000.00 1 March 201031 March 2010Sinopharm Group10,000.00 27 May 201026 November 2010Sinopharm Group10,000.00 22 November 201022 May 2011Sinopharm Group5,000.00 21 February 20101 August 2010Sinopharm Group5,000.00 5 August 20101 February 201195,000.002009Borrowed from-Sinopharm Group15,000.0011 December 200931 May 2010Sinopharm Group10,000.00 11 December 200931 May 201025,000.00(f)Remuneration of key management2010 (Rmb 0,000)2009 (Rmb 0,000)Remuneration of key management655.03540.61 (g)Interest expensesRelated partyType of transaction2010 (Rmb 0,000)2009 (Rmb 0,000)Sinopharm GuangzhouSinopharm GroupInterest paid for the entrusted loans636.8925.52The CompanySinopharm GroupInterest paid for the entrusted loans621.7138.27Sinopharm GuangzhouSinopharm GroupCharges of discounted notes payable778.78259.53Sinopharm GuangzhouSinopharm Holding Sub Marketing Center Co., Ltd.Charges of discounted notes payable165.54458.72Sinopharm GuangzhouChina National Medicines Co., Ltd.Charges of discounted notes payable17.3343.282,220.25825.32 VIIRelated party relationships and significant related party transactions (continued)(5)Related party transactions (continued) (h)Rendering of serviceRelated partyType of transaction2010 (Rmb 0,000)2009 (Rmb 0,000)Hengchang LogisticsSinopharm Group Medicine Logistic Co., Ltd.Dispatching and transportation charges 453.78 - Hengchang LogisticsGuangdong Accord Drug Store Co., Ltd.Dispatching and transportation charges 270.47 22.02 Hengchang LogisticsChina National Medicines Co., Ltd.Dispatching and transportation charges 243.31 - Accord LogisticsGuangdong Accord Drug Store Co., Ltd.Dispatching and transportation charges 64.29 36.32 Hengchang LogisticsGuangzhou Accord Drug Store Chain Co., Ltd.Dispatching and transportation charges 31.77 - Sinopharm GuangzhouChina National Medicines Co., Ltd.Consultation fees22.80- 1,086.4258.34(i)Other serviceRelated partyType of transaction2010 (Rmb 0,000)2009 (Rmb 0,000)The CompanyShanghai Tongyu Information Technology Co., Ltd.CMS system maintenance 300.00458.00Sinopharm GuangzhouShanghai Tongyu Information Technology Co., Ltd.CMS system maintenance 186.68-Suzhou WanqinReed Sinopharm Exhibitions Co.,Ltd.Exhibition charges8.04-Suzhou WanqinChina National Pharmaceutical Industry Corporation Ltd. Exhibition charges7.70-502.42458.00 (6)Accounts receivable from and payables to related parties31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Notes receivableChongqing Yaoyou Pharmaceutical Co.,Ltd.1,136.00- Sinopharm Holding Hubei Co., Ltd.698.861,136.00 Sinopharm Holding Guizhou Co., Ltd.684.00-Sinopharm Holding Hunan Co., Ltd.406.292,168.22 Sinopharm Holding Tianjin Co., Ltd.244.94-Sinopharm Holding Henan Co., Ltd.50.00-Sinopharm Holding Hainan Co., Ltd.47.47-Sinopharm Holding Fuzhou Co., Ltd.32.57-Sinopharm Holding Chongqin Co., Ltd.24.24-Sinopharm Holding Jiangxi Co., Ltd.20.26-Sinopharm Holding Shengyang Co., Ltd.7.73 5,037.66 Sinopharm Holding Anhui Co., Ltd.6.91-Sinopharm Holding Shangdong Co., Ltd.1.20-Sinopharm Group- 249.57 Sinopharm Group Baida Pharmaceutical Co., Ltd.- 80.00 Guangdong Tianliang Medicine Co., Ltd.- 6.90 3,360.478,678.35 VIIRelated party relationships and significant related party transactions (continued)(6)Accounts receivable from and payables to related parties (continued)31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Accounts receivableSinopharm Holding Beijing Co., Ltd.2,042.52 1,750.05 Chongqing Yaoyou Pharmaceutical Co.,Ltd.1,872.001,480.01Sinopharm Holding Hunan Co., Ltd.1,865.21 1,633.59 Sinopharm Group Southwest Pharmacy Co., Ltd.1,758.29 1,865.25 Guangdong Accord Drug Store Co., Ltd.1,338.14 1,762.41 Sinopharm Holding Beijing Huahong Co., Ltd.943.07 635.40 Guangxi Accord Drug Store Chain Co., Ltd.904.29 901.38 Sinopharm Holding Hubei Co., Ltd.835.00 1,643.74 Sinopharm Group (Tianjin) Eastern Bokang Pharmaceutical Co., Ltd.694.27 379.01 Sinopharm Group608.57 404.40 Sinopharm Holding Hainan Co., Ltd.577.00 -Sinopharm Holding Zhejiang Co., Ltd.510.79 11.12 Sinopharm Holding Tianjin Co., Ltd.510.59 595.22 Sinopharm Holding Shijiazhuang Co., Ltd.495.02 -Sinopharm Holding Yunnan Co., Ltd.379.56 271.53 Xinjiang Special Drugs National Pharmaceutical Co.,Ltd.376.82 335.09 Sinopharm Holding Shengyang Co., Ltd.328.27 6,003.55 Guangdong East Uptodate & Special Medicines Co.,Ltd.279.14 330.30 Sinopharm Holding Ningxia Co., Ltd.241.60 134.40 Sinopharm Holding Henan Co., Ltd.225.91 106.05Xinjiang Special Drugs Western Pharmaceutical Co.,Ltd.215.52 229.50Sinopharm Holding Fujian Co., Ltd.205.78 -Sinopharm Holding Guizhou Co., Ltd.183.64 -Sinopharm Holding Shanxi Co., Ltd.170.26 119.76 China National Medicines Co., Ltd.151.90 253.53 Sinopharm Holding Jiangsu Co., Ltd.148.85 145.48 Wenzhou Biomedicin-appliances Supplies co., Ltd108.15 -Guangzhou Accord Drug Store Chain Co., Ltd.103.14 9.62 Sinopharm National Pharmacy Co.,Ltd.74.95 101.44 Sinopharm Holding Gansu Co., Ltd.59.56 -Sinopharm Holding Jiangxi Co., Ltd.50.95 -Sinopharm Group Medicine Logistic Co., Ltd.48.63 176.00Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.46.34 4.55Sinopharm Group Northwest Co., Ltd.40.70 93.44Shanghai Chaohui Pharmecurical Co., Ltd.37.648.06Sinopharm Holding Shandong Co., Ltd.33.71 -Sinopharm Holding Meiluo (Dalian) Co., Ltd.30.24 -To next page18,496.0221,383.88 VIIRelated party relationships and significant related party transactions (continued)(6)Accounts receivable from and payables to related parties (continued)31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Accounts receivable Continued18,496.0221,383.88Sinopharm Holding Chongqing Co., Ltd.28.77 -China National Group Corporation of Traditional & Hebal Medical25.92 36.12 Sinopharm Holding Inner Mongolia Co., Ltd.24.57 -Sinopharm Holding Suzhou Co., Ltd.23.53 9.36Sinopharm Holding Shenyang Co., Ltd. Dalian Branch19.14 23.64 Sinopharm Holding Fuzhou Co., Ltd.16.95 -Sinopharm Holding Jilin Co., Ltd.6.42 -Guangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd.0.60 -Sinopharm Holding Anhui Co., Ltd.0.09 45.98Shenzhen Accord Pharmaceutical Chain Co., Ltd-963.68Sinopharm Holding Hubei Yibao Co., Ltd.-326.29Sinopharm Holding Tianjin Co.,Ltd. Inner Mongolia Branch-17.12Guangxi Guoda Durg Store Chain Co.,Ltd.-151.80Sinopharm Group Shanghai Likang Medicines Co,. Ltd.-12.71Shanghai Sinopharm Medical Meterials Co.,Ltd.-132.26Guangdong Tianliang Medicine Co., Ltd.-15.9718,642.0123,118.81Other receivablesSinopharm Group Medicine Logistic Co., Ltd.121.50121.50Wang Lei90.51-China National Pharmaceutical Industry Corporation Lts. Guangzhou Association Company1.61-Sinopharm Group-73.18Guangdong Accord Drug Store Co., Ltd.-0.17Yang Qiaoming-717.25China National Group Corporation of Traditional & Hebal Medical-1,501.82213.622,413.92Advances to suppliersQinghai Pharmaceitical (Group) Co.,Ltd.540.83559.16Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.261.681,303.66Sinopharm Group United Medicine Device Co., Ltd.243.5615.69Shanghai Sailun Biological Technology Co.,Ltd.0.03-China National Group Corporation of Traditional & Hebal Medical-2.001,046.101,880.51Except receivables due from Guangxi Guoda Durg Store Chain Co.,Ltd. which have been fully provide the bad debt provision, there is no recoverability risk in related to receivables due from other related party. Therefore, no provision has been provided for. VIIRelated party relationships and significant related party transactions (continued)(6)Accounts receivable from and payables to related parties (continued)31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Notes payableSinopharm Group21,009.56 14,693.08 China National Medicines Co., Ltd.1,240.95 2,969.82 Sinopharm Holding Sub Marketing Center Co., Ltd.531.22 14,813.28 Sinopharm Holding Fujian Co., Ltd.503.61 - Jiangsu Wanbang Pharmacy Marketing Co., Ltd.224.0896.15Chongqing Haisiman Pharmaceutical Co.,Ltd.53.3222.12Wanle Medical38.8444.85Sinopharm Group Baida Pharmaceutical Co., Ltd.34.89-Guilin Pharmaceutical Works13.65-Guilin Pharmaceutical Co., Ltd.2.58-Sinopharm Holding Hunan Co., Ltd.- 367.94 Guangxi Accord Drug Store Chain Co., Ltd.- 1.18 China Sinopharm Foreign Trade Co.,Ltd.- 455.71 Sinopharm Group United Medicine Device Co., Ltd.- 376.55 Shenzhen National Medical Equlpment & Supplies I/E Shenzhen Corporation- 4.19 23,652.7033,844.87Accounts payableSinopharm Group10,959.888,924.66 Sinopharm Holding Sub Marketing Center Co., Ltd.1,697.852,612.69 China National Medicines Co., Ltd.1,165.01991.82 Guang dong South National Pharmaceutical Foreign Trade Co.,Ltd.1,026.77307.96 Sino-Swed Pharmaceutical Corp.Ltd.971.60-Wanle Medical 421.56529.25Jiangsu Wanbang Pharmacy Marketing Co., Ltd.208.32170.13China National Group Corporation of Traditional & Hebal Medical105.05179.96 Chongqing Yaoyou Pharmaceutical Co.,Ltd.100.6211.44Sinopharm Group United Medicine Device Co., Ltd.96.37(52.44)Chongqing Haisiman Pharmaceutical Co.,Ltd.92.7773.77Sinopharm Holding Beijing Co., Ltd.60.932.86 Guangdong East Uptodate & Special Medicines Co.,Ltd.51.0993.48 Sinopharm Holding Guizhou Co., Ltd.35.88- Shanghai Chaohui Pharmecurical Co., Ltd.34.5913.57Sichuan Jiang You Zhong Ba Science and Technology Development Co.,Ltd.34.139.20 Sinopharm Group Medicine Logistic Co., Ltd.12.8245.85 Sinopharm Holding Suzhou Co., Ltd.12.0145.30 China National Pharmaceutical Industry CorporationLtd. Beijing sales branch11.999.30 Sinopharm Holding Meiluo (Dalian) Co., Ltd10.75- Sinopharm Holding Fujian Co., Ltd.7.01- Guilin Pharmaceutical Works5.2511.90Sinopharm Holding Hainan Co., Ltd.5.17- To next page17,127.4213,980.70 VIIRelated party relationships and significant related party transactions (continued)(6)Accounts receivable from and payables to related parties (continued)31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Accounts payable Continued17,127.4213,980.70Shanghai Sailun Biological Technology Co.,Ltd.5.04-Sinopharm Group Southwest Pharmacy Co., Ltd.3.813.56 Sinopharm Holding Chongqing Co., Ltd.-- Yichang Humanwell Pharmaceutical Co.,Ltd.3.340.96Sinopharm Yixin Pharmacy Co., Ltd.2.95- China National Pharmaceutical Industry Corporation Ltd. 2.8711.31 Shenyang Hongqi Pharmaceutical Co., Ltd.1.861.87Sinopharm Group Shanghai Medicine Device Co., Ltd.1.844.54 Jiangsu Wanbang Bio-Chemical Medicine Co., Ltd.1.491.49Sinopharm Group Chemical Reagent Suzhou Co., Ltd.1.457.21 Sinopharm Group Beijing Medicine Device Co., Ltd.0.880.88 Guangdong Tianliang Medicine Co., Ltd.0.681.98 Guilin Pharmaceutical Co., Ltd.0.683.87Sinopharm Group Chemical Reagent Co., Ltd.0.51- Guangxi Wuzhou Hua Wu Traditional & Herbal Co.,Ltd.0.380.28 Sinopharm Holding Jiangsu Co., Ltd.0.370.37 Sinopharm Holding Anhui Co., Ltd.0.31- China Otsuka Pharmaceutical Co.,Ltd.0.21-Shanghai Fosun Long March Medical Science Co., Ltd.0.18- China National Pharmaceutical Industry Corporation Lts. Guangzhou Association Company0.13-Guangdong Accord Drug Store Co., Ltd.0.100.04 Shanghai Fosun Pharmaceutical Co., Ltd.0.020.02Sinopharm Qianjing Dental Technology (Beijing) Co.,Ltd.0.010.01Sinopharm Holding Tianjin Co., Ltd.0.00 - Sinopharm Holding Hubei Yibao Co., Ltd.-0.67 Sinopharm National Pharmacy Co.,Ltd.-41.03 China Sinopharm Foreign Trade Co.,Ltd.(0.98)350.91 Sinopharm Group Medicine Logistic Co., Ltd. Guangzhou Branch-9.64 Shenzhen National Medical Equlpment & Supplies I/E Shenzhen Corporation-0.35 Shanghai Shyndec Pharmaceutical Co., Ltd.-8.58 17,155.5514,434.67 VIIRelated party relationships and significant related party transactions (continued)(6)Accounts receivable from and payables to related parties (continued)31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Other payablesMr. Yang Qiaoming-1,664.23Kaijiefeng481.09-Sinopharm Group389.39333.39Sinopharm Group Pharmacy Holding Shanghai Co., Ltd166.04 166.04Shanghai Chaohui Pharmecurical Co., Ltd.0.020.01Sinopharm Group Medicine Logistic Co., Ltd. Guangzhou Branch-80.971,036.542,244.64Advances from customersSinopharm Holding Guizhou Co., Ltd.537.00-Interests payableSinopharm Group22.00-Entrusted loansSinopharm Group30,000.0025,000.00Other non-current liabilitiesSinopharm Group3,506.183,506.18 (7)Commitment with related partiesUndertaking contracted for at the balance sheet date but not recognised in balance sheet are anaylsed as follows:31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Lease-As a lesseeSinopharm Group Medicine Logistic Co., Ltd.2,308.50-Mr. Wang Yang18.90-2,327.40--As a leaser Sinopharm Group United Medicine Device Co., Ltd.- 17.52 Guangzhou Accord Drug Store Chain Co., Ltd.22.22 - Shenzhen Accord Pharmaceutical Chain Co., Ltd.93.91 86.56 Guangxi Accord Drug Store Chain Co., Ltd.64.14 32.07 180.27 136.15 Guarantee- Guaranteed by related partySinopharm Group14,816.1011,996.56 VIIIContingenciesAs at 31 December 2010, there is no material contingency of the Group.IXCommitments(1)Capital commitmentsCapital expenditures contracted for at the balance sheet date but not recognised in balance sheet are anaylsed as follows:31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Buildings, machinery and equipment8,346.195,658.26 (2)Operating lease commitmentsThe future minimum lease payments due under the signed irrevocable operating leases contracts are summarised as follows:31 December 201031 December 2009(Rmb 0,000)(Rmb 0,000)Within one year 2,564.832,171.40Between 1 and 2 years1,057.76715.00Between 2 and 3 years883.51729.90Over 3 years7,750.239,448.4012,256.3313,064.70(3)Execution of commitments of prior yearsThe Group has fulfilled the commitments as of 31 December 2009 according to the relevant contracts. XSubsequent events after the balance sheet date(1)Major subsequent events after the balance sheet dateItemContentInfluence to financial performance of the GroupOther payable imbursement(Note V(26)(c))Imbursement of large amount other payables aging over 1 yearAsset and liability reduce RMB 11,572,136.60 simultaneously (2)Profit appropriation after the balance sheet dateAmountProposed dividends (a)34,577,928.00(a)In accordance with the resolution at the Board of Directors meeting dated on 18 March 2011, Board of Directors proposed a dividend in the amount of RMB 34,577,928.00 to the shareholders, which is not recorded as liability in the financial statements for the current year (Note V(34)). XIBusiness combinationNote IV(3) and Note IV(4). XIIFinancial instrument and riskThe Group's activities expose it to a variety of financial risks: market risk (primarily interest rate risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.(1)Market risk- Interest rate riskThe Group's interest rate risk arises from long-term interest bearing borrowings from bank. Financial liabilities issued at floating rates expose the Group to cash flow interest rate risk. Financial liabilities issued at fixed rates expose the Group to fair value interest rate risk. The Group determines the relative proportions of its fixed rate and floating rate contracts depending on the prevailing market conditions. As at 31 December 2010, the Group s long-term interest bearing borrowings were mainly RMB-denominated with floating rates, amounting to RMB 30,000,000.00(31 December 2009: RMB 30,000,000.00) ( Note V(27), (28)). Increases in interest rates will increase the cost of new borrowing and the interest expenses with respect to the Group s outstanding floating rate borrowings, and therefore could have a material adverse effect on the Group s financial position. The Group s finance department at its headquarters continuously monitors the interest rate position of the Group and makes decisions with reference to the latest market conditions. The Group may enter into interest rate swap agreements to mitigate its exposure to interest rate risk. During 2010 and 2009, the Group did not enter into any interest rate swap agreements.For the year ended 31 December 2010, if interest rates on the floating rate borrowings had been 10% higher/lower while all other variables had been held constant, the Group s net profit would have increased/decreased by approximately RMB 5,948,699.65 (2009: approximately RMB 3,556,452.56).(2)Credit riskCredit risk is managed on a Group basis. Credit risk mainly arises from cash at bank and on hand, accounts receivable, other receivables, notes receivable etc.The Group expects that there is no significant credit risk associated with cash at bank since they are deposited at state-owned banks and other medium or large size listed banks. Management does not expect that there will be any significant losses from non-performance by these counterparties.In addition, the Group has policies to limit the credit exposure on accounts receivable, other receivables and notes receivable. The Group assesses the credit quality of and sets credit limits on its customers by taking into account their financial position, the availability of guarantee from third parties, their credit history and other factors such as current market conditions. The credit history of the customers is regularly monitored by the Group. In respect of customers with a poor credit history, the Group will use written payment reminders, or shorten or cancel credit periods, to ensure the overall credit risk of the Group is limited to a controllable extent. XIIFinancial instrument and risk (continued)(3)Liquidity riskCash flow forecasting is performed by each subsidiary of the Group and aggregated by the Group s finance department in its headquarters. The Group s finance department at its headquarters monitors rolling forecasts of the Group's short-term and long-term liquidity requirements to ensure it has sufficient cash and securities that are readily convertible to cash to meet operational needs, while maintaining sufficient headroom on its undrawn committed borrowing facilities from major financial institution so that the Group does not breach borrowing limits or covenants on any of its borrowing facilities to meet the short-term and long-term liquidity requirements. The financial assets and liabilities of the Group at the balance sheet date are analysed by their maturity date below at their undiscounted contractual cash flows :31 December 2010Within 1year1 to 2 years2 to 5 yearsOver 5 yearsTotalFinancial assets -Cash at bank and on hand711,789,775.66---711,789,775.66Notes receivable369,169,030.47---369,169,030.47Accounts receivable2,901,694,647.44---2,901,694,647.44Other receivables60,900,244.49---60,900,244.494,043,553,698.06---4,043,553,698.06Financial liabilities -Short-term loans988,829,073.69---988,829,073.69Notes payable1,448,622,490.72---1,448,622,490.72Accounts payable2,003,566,517.62---2,003,566,517.62Other payables345,011,293.80---345,011,293.80Long-term loans1,601,437.501,601,437.5031,190,034.24-34,392,909.244,787,630,813.331,601,437.5031,190,034.24-4,820,422,285.0731 December 2009Within 1year1 to 2 years2 to 5 yearsOver 5 yearsTotalFinancial assets -Cash at bank and on hand588,405,672.15---588,405,672.15Notes receivable363,025,601.60---363,025,601.60Accounts receivable2,478,465,807.01---2,478,465,807.01Other receivables84,348,783.66---84,348,783.663,514,245,864.42---3,514,245,864.42Financial liabilities -Short-term loans951,340,994.51---951,340,994.51Notes payable1,104,950,330.28---1,104,950,330.28Accounts payable1,706,142,277.91---1,706,142,277.91Other payables246,835,253.81246,835,253.81Current portion of long-term loans30,477,212.05---30,477,212.05Long-term loans1,458,000.0030,802,898.63--32,260,898.634,041,204,068.5630,802,898.63--4,072,006,967.19(4)Financial instruments not measured at fair valueFinancial assets and liabilities not measured at fair value mainly represent receivables, short-term loans, payables and long-term loans. The carrying amount of financial assets and liabilities not measured at fair value is a reasonable approximation of their fair value. XIIINotes to the main items of financial statement of the Company(1)Accounts receivable31 December 201031 December 2009Accounts receivable283,766,551.16304,920,272.90Less: provision for bad debts(1,169,085.93)(3,570,386.02)282,597,465.23301,349,886.88(a)The ageing of accounts receivable is analysed below:31 December 201031 December 2009Within 1 year282,597,465.23303,762,412.901 to 2 years1,169,085.93-2 to 3 years-1,157,860.00283,766,551.16304,920,272.90(b)The accounts receivable and related provision for bad debts by category are analysed below:31 December 201031 December 2009Carrying amountBad debt provisionsCarrying amountBad debt provisionsamount% of total balanceamountrateamount% of total balanceamountrateIndividually significant are subject to separate impairment assessment----56,246,800.6518.45%(1,398,400.03)2.49%Receivable accounts within similar credit risk group282,597,465.2399.59%--230,346,333.7275.54%--Individually not significant but individually evaluated for impairment1,169,085.930.41%(1,169,085.93)100%18,327,138.53 6.01%(2,171,985.99)11.85%283,766,551.16100%(1,169,085.93)0.41%304,920,272.90100%(3,570,386.02)1.17% (c)As at 31 December 2010, there are no receivables individually significant which subject to separate impairment assessment.(d)Provisions for impairment of the receivables which have a similar risk group are analysed below:31 December 201031 December 2009Carrying amountBad debt provisionCarrying amountBad debt provision amount% of total balanceamountrateamount% of total balanceamountrateWithin 1 year282,597,465.23100%--230,346,333.72100%-- XIIINotes to the main items of financial statement of the Company (continued)(1)Accounts receivable (continued)(e)As at 31 December 2010, accounts receivable individually not significant but individually evaluated for impairment are analysed below:Per bookBad debt provisions% of provisionReasonGuangdong Liyuan Pharmaceutical Co. Ltd.1,169,085.93(1,169,085.93)100.00%Uncertainty in recoverability (f)As at 31 December 2010, there is no accounts receivable due from shareholders who holds more than 5% (including 5%) shares of the Company (31 December 2009: nil). (g)As at 31 December 2010, the top five accounts receivable by customer are analysed as below:Relationship with the CompanyAmountAgeing% of the total accounts receivableShenzhen People s HospitalThe third party 22,520,251.06 Within 1 year7.94%Shenzhen Second People s HospitalThe third party 22,146,809.79 Within 1 year7.80%Peking University Shenzhen HospitalThe third party 19,029,794.33 Within 1 year6.71%Shenzhen Traditional Chinese Medicine HospitalThe third party 10,882,131.24 Within 1 year3.83%Shenzhen Longgang Center HospitalThe third party10,580,440.84 Within 1 year3.73% 85,159,427.2630.01% (h)Accounts receivable due from related partyAs at 31 December 2010, there are accounts receivable of RMB12,968,480.21 due from related party (31 December 2009: RMB22,054,101.07), which is 4.57% of the total accounts receivable (31 December 2009: 7.23%), without any bad debt provided (31 December 2009: Nil). (i)In 2010, accounts receivable of RMB41,373,696.51 are derecognized given that irrevocable factoring contracts agreed with financial institute(2009: Nil). (2)Other receivables31 December 201031 De      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRcTUVWXYZ[\]^_`ab1 defghijklmnopqrstuvwxyz|}~cember 2009Amounts due from subsidiaries (note h)554,781,312.21376,151,397.05Receivable from equity transaction8,980,000.008,980,000.00Compensation receivables1,157,860.003,004,579.90Borrowings due from employees2,095,749.562,781,073.96Others528,280.50397,943.70567,543,202.27391,314,994.61Less: provision for bad debts(10,218,244.60)(11,692,380.41)557,324,957.67 379,622,614.20 XIIINotes to the main items of financial statement of the Company (continued)(2)Other receivables (continued)(a)The ageing of other receivables is analysed as follows:31 December 201031 December 2009Within 1 year557,121,075.32379,172,379.711 to 2 years214,613.00149,776.502 to 3 years69,653.9511,992,838.40Over 3 years10,137,860.00-567,543,202.27 391,314,994.61  (b)Other receivables and related provision for bad debts by category are analysed below:31 December 201031 December 2009Carrying amountBad debt provisionCarrying amountBad debt provisionamount% of total amountamountrateamount% of total amountamountrateIndividually significant are subject to separate impairment assessment8,980,000.001.58%(8,980,000.00)100.00%8,980,000.002.29%(8,980,000.00)100.00%Receivable accounts within similar credit risk group557,335,688.3298.20%(10,730.65)0.00%379,330,414.7196.94%--Individually not significant but individually evaluated for impairment1,227,513.950.22%(1,227,513.95)100.00%3,004,579.900.77%(2,712,380.41)90.27%567,543,202.27100.00%(10,218,244.60)1.80%391,314,994.61100.00%(11,692,380.41)2.99% (c)As at 31 December 2010, impairment provision for other receivables individually significant is analysed as below.AmountBad debt provisionRateAssessment for impairmentShenzhen Yinghai Technology Investment Co., Ltd. 8,980,000.00  (8,980,000.00)100%Uncertainty in recoverability (d)Provisions for impairment of the receivables which have a similar risk group are analysed below:31 December 201031 December 2009Carrying amountBad debt provisionCarrying amountBad debt provision amount% of total amountamountrateamount% of total amountamountrateWithin 1 year557,121,075.3299.96%-379,330,414.71100%--1 to 2 years214,613.000.04%(10,730.65)5.00%---557,335,688.32100%(10,730.65)0.00%379,330,414.71100%-- XIIINotes to the main items of financial statement of the Company (continued)(2)Other receivables(continued)(e)As at 31 December 2010, other receivables individually not significant but individually evaluated for impairment are analysed below:AmountBad debt provisionRateAssessment for impairmentShenZhen Health Food I&E Co. Ltd.1,157,860.00(1,157,860.00)100%Uncertainty in recoverabilityOthers69,653.95(69,653.95)100%Aged over 3 years, high risk in recoverability1,227,513.95(1,227,513.95) (f)As at 31 December 2010, there is no amount due from shareholders who holds more than 5% (including 5%) shares of the Company (31 December 2009: nil).(g)As at 31 December 2010, the top five other receivables by customer are analysed below:Relationship with the CompanyAmountAgeing% of the total other receivableHengxing MedicineSubsidiary 126,148,469.44 Within 1 year22.23%Cueing MedicineSubsidiary 104,710,116.42 Within 1 year18.45%Sinopharm ZhanjiangSubsidiary 88,000,000.00 Within 1 year15.51%Sinopharm NanningSubsidiary 53,478,000.00 Within 1 year9.42%Guangxi LogisticsSubsidiary 46,928,739.37 Within 1 year8.27% 419,265,325.2373.87%(h)Other receivables due from related parties are analysed as below:As at 31 December 2010, there are other receivables of RMB554,781,312.21 due from related party (31 December 2009: RMB371,545,137.13), which is 97.75% of the total other receivables (31 December 2009: 94.95%), without any bad debt provided (31 December 2009: Nil). (3)Long-term equity investments31 December 201031 December 2009Investments in subsidiaries (note a) 1,194,816,640.78570,171,910.40Investments in associates (note b)85,275,251.0680,115,298.271,280,091,891.84650,287,208.67Less: provision for impairment of long-term equity investments (note c)(7,689,226.69)(7,689,226.69)1,272,402,665.15642,597,981.98The long-term equity investments of the Company are not subject to restriction on conversion into cash. XIIINotes to the main items of financial statement of the Company (continued)(3)Long-term equity investments (continued)(a)SubsidiariesAccounting methodOriginal investment cost31 December 2009Increases/(decreases) in investment cost31 December 2010Equity interest held (%)Voting rights held (%)Zhijun PharmCost method73,903,284.8773,903,284.87131,000,000.00 204,903,284.87100100Jianmin PharmCost method45,054,911.0445,054,911.04-45,054,911.04100100Accord MaterialCost method5,400,000.006,450,875.93- 6,450,875.93100100Accord LogisticsCost method900,000.001,019,062.68- 1,019,062.68100100Sinopharm GuangzhouCost method58,283,114.6885,440,323.63350,000,000.00 435,440,323.63100100Zhijun TradeCost method3,006,866.423,006,866.42-3,006,866.42100100Guangdong Hengxing'Cost method8,421,544.0815,763,288.00-15,763,288.00100100Training centerCost method30,000.0030,000.00- 30,000.00100100Guangxi AccordCost method4,987,919.714,987,919.71-4,987,919.71100100Sinopharm LiuzhouCost method21,407,965.7921,407,965.79- 21,407,965.795151Dongguan AccordCost method2,742,000.002,742,000.00- 2,742,000.00100100Huixin InvestmentCost method109,416,937.72109,416,937.72(45,000,000.00)64,416,937.72 100100Hengchang LogisticsCost method1,269,502.301,136,006.214,460,000.00 5,596,006.21 100100Yuexing MedicineCost method16,459,326.2716,459,326.2727,000,000.00 43,459,326.27 100100Sinopharm FoshanCost method6,995,065.516,995,065.51-6,995,065.51 100100Suzhou WanqinCost method134,250,000.00134,250,000.00- 134,250,000.00 7575Sinopharm NanningCost method33,048,985.2833,048,985.2871,000,000.00104,048,985.28 100100Sinopharm ZhanjiangCost method1,369,864.651,369,864.65-1,369,864.65100100Yanfeng MedicalCost method38,207,800.00-38,207,800.0038,207,800.005151Sinopharm MeizhouCost method4,481,900.00 -4,481,900.00 4,481,900.00 100100Shenzhen MedicineCost method37,850,830.38-37,850,830.3837,850,830.38100100Sinopharm HuizhouCost method20,939,177.19-5,644,200.005,644,200.00100100Shenzhen TradeCost method7,689,226.697,689,226.69-7,689,226.69100100570,171,910.40624,644,730.381,194,816,640.78 XIIINotes to the main items of financial statement of the Company (continued)(3)Long-term equity investments (continued) (b)AssociatesMovementAccounting methodInitial investment cost31 December 2009Addition or Decrease in investmentShare of profit or lossDividend declaredOther movement31 December 2010Equity interest held (%)Voting rights held (%)Explanation for the inconsistence between equity interest held and voting rights heldShenzhen MedicineEquity method20,939,177.1022,064,631.02-(4,145,828.64)-(17,918,802.38)---Wanle MedicalEquity method4,457,400.0058,050,667.25-27,224,583.81--85,275,251.0635.1933.33Board of the directors is the highest decision making organization, which is formed by 3 shareholder of Wanle Medical evenly80,115,298.27-23,078,755.17-(17,918,802.38)85,275,251.06 XIIINotes to the main items of financial statement of the Company (continued)(3)Long-term equity investments (continued)(c)Provision for impairment of long-term equity investments31 December 2009Current year additionsCurrent year disposals31 December 2010SubsidiaryShenzhen Trade7,689,226.69--7,689,226.69(4)Sales and cost of sales20102009Revenue of main operations1,787,456,473.46 1,639,973,980.99Other operating income5,876,009.19 3,892,375.171,793,332,482.65 1,643,866,356.1620102009Cost of main operations(1,701,399,246.71)(1,561,909,346.42)Other operating expenses(2,260,729.74)(691,159.33)(1,703,659,976.45)(1,562,600,505.75)(a)Revenue and cost of main operationsAnalysed by industry:20102009Revenue of main operationsCost of main operationsRevenue of main operationsCost of main operationsPharmaceutical distribution1,787,456,473.46(1,701,399,246.71)1,639,973,980.99(1,561,909,346.42) (b)Other operating income and expenses 20102009Other operating incomeOther operating expensesOther operating incomeOther operating expensesRental income4,958,762.51(1,729,321.74)3,227,734.98(517,116.90)Rendering of services917,246.68(531,408.00)664,640.19(174,042.43)5,876,009.19(2,260,729.74)3,892,375.17(691,159.33) XIIINotes to the main items of financial statement of the Company (continued)(4)Sales and cost of sales (continued)(c)Top five customers are analysed as follows:The sales to the top five customers of the Company totaling to RMB674,334,141.82 (2009: RMB372,388,968.44), which accounted for 37.60% (2009: 22.71%) of the total revenue from main operations. Details are set out below:Sales% of total revenue from main operations Jianmin Pharm 285,505,786.18 15.92%Shenzhen People s Hospital 128,339,169.28 7.16%Shenzhen Second People s Hospital 103,142,776.29 5.75%Peking University Shenzhen Hospital 90,129,966.32 5.03%Guangdong Accord Drug Store Co., Ltd  67,216,443.75 3.75%674,334,141.8237.61%(5)Investment income20102009Cash dividends declared by subsidiaries (a) 218,177,902.14  162,881,375.97 Share of profit in an associated company (b)23,078,755.17 17,186,060.02 Income from disposal of long-term investments- 14,613,660.91 241,256,657.31194,681,096.90 There is no significant restriction on the investment income remittance to the Company. (a)Cash dividends declared by subsidiariesInvestment income from the top five investees are analysed as below:20102009Reason of FluctuationSinopharm Guangzhou120,225,327.94 66,867,908.99 Profit increased comparing 2009Zhijun Pharm81,419,952.44 85,812,844.18 Profit decreased comparing 2008Yuexing Medicine6,098,357.24  1,779,217.80 Acquired in 2009Huixin Investment3,997,155.94 -Acquired in 2009Sinopharm Nanning3,442,647.29 -Acquired in 2009215,183,440.85154,459,970.97(b)Share of profit /(loss) in an associated company20102009Reason of FluctuationShenzhen Medicine(4,145,828.64)109,068.76 Loss in 2010Wanle Medical27,224,583.8117,076,991.26 Profit increased comparing 200923,078,755.1717,186,060.02  XIIINotes to the main items of financial statement of the Company (continued)(6)Notes to cash flow statement(a)Reconciliation of net profit to cash flows from operating activities20102009Net profit 224,082,114.41175,730,571.10Add: Provision for assets impairment (5,826,408.57)3,643,443.09Depreciation of fixed assets5,822,592.795,574,016.72Amortisation of intangible assets1,563,165.211,362,935.94Amortisation of long-term prepaid expenses279,493.3791,779.96Gains on disposal of fixed assets, intangible assets and other long-term assets(40,359.54)(26,374.40)Financial expenses25,134,269.4514,904,449.32Investment income(241,256,657.31)(194,681,096.90)Increase in deferred income tax assets(2,958,699.75)-Increase in inventories(19,546,026.53)(4,169,753.52)Decrease/(increase) in operating receivables 15,185,638.02(253,178,282.38)Increase in operating payables 92,158,881.07124,961,636.87Net cash flows from operating activities 94,598,002.62(125,786,674.20)(b)Net increase in cash20102009Cash at end of year135,498,819.87120,541,203.80Less: cash at beginning of year(120,541,203.80)(62,369,583.65)Net increase in cash and cash equivalents14,957,616.0758,171,620.15(c)Cash and cash equivalents20102009Cash at bank and on hand 135,498,819.87125,541,203.80Less: restricted other cash balance-(5,000,000.00)Cash at end of year135,498,819.87120,541,203.80 INon-routine items20102009Gains on disposal of non-current assets1,969,629.8211,301,538.13Government grants8,221,739.907,596,783.30Net profit gained for the period from 1 January 2010 to the date of combination under common control(4,607,349.97)3,494,394.60Receivables impairment reversal by individual assessment6,926,932.01352,626.03Other non-operating income/(expenses), net6,374,202.971,643,141.4018,885,154.7324,388,483.46Tax impact of above non-routine items(3,132,301.17)(19,711,604.76)Share of minority interests of above non-routine items after tax(284,003.09)(2,549,249.94)15,468,850.472,127,628.76Basis of preparationAccording to the  Information Disclosures Requirement Interpretation for Listed Companies No.1 - non-routine gain and loss , non-routine gain and loss represent those gain or loss that are not related to the daily operation of the Group or even if being related to the daily operation, separate disclosure of these items will help a better understanding of results and profitability of the Group s operation by considering their nature and frequency. IIReturn on equity and earnings per shareWeighted average return on equity (%)Earnings per shareBasic earnings per shareDiluted earnings per share201020092010200920102009Consolidated net profit attributable to the shareholders of the Company27.1725.860.910.670.910.67Consolidated net profit attributable to the shareholders of the Company, excluding non-routine items25.5625.580.850.660.850.66 IIINotes for significant fluctuation of major accounts in financial statementsFluctuation with 30% or above, and balance accounting for 5% or above of total assets or transaction accounting for 10% or above of profit before tax are analysed as below:(1)Consolidated Balance SheetNotes31 December 201031 December 2009Fluctuation%ConsolidatedConsolidatedCash at bank and on hand1.1711,789,775.66588,405,672.15123,384,103.5121%Notes receivable1.2369,169,030.47363,025,601.606,143,428.872%Accounts receivable1.32,866,825,102.782,451,433,461.71415,391,641.0717%Dividends receivable1.4-8,271,829.94(8,271,829.94)-100%Other receivables1.543,110,999.7463,596,027.23(20,485,027.49)-32%Inventories1.61,156,329,658.80909,077,496.35247,252,162.4527%Long-term equity investments1.785,275,251.0658,334,840.9526,940,410.1146%Investment properties1.887,293,333.7657,973,532.9729,319,800.7951%Fixed assets1.9492,557,743.43428,390,030.2164,167,713.2215%Construction in progress1.10108,301,338.1246,146,183.5062,155,154.62135%Development costs1.112,580,662.85235,375.012,345,287.84996%Goodwill1.1253,555,677.0934,153,027.8919,402,649.2057%Long-term prepaid expenses1.1319,811,611.247,456,046.9512,355,564.29166%Deferred income tax assets1.1431,083,592.2412,871,196.2418,212,396.00141%Other non-current assets1.1548,127,831.5636,533,540.1311,594,291.4332%Short-term loans1.16975,475,884.21944,189,604.4631,286,279.753%Notes payable1.171,448,622,490.721,104,950,330.28343,672,160.4431%Accounts payable1.182,003,566,517.621,706,142,277.91297,424,239.7117%Interests payable1.192,122,314.90589,050.001,533,264.90260%Other payables1.20345,011,293.80246,835,253.8198,176,039.9940%Current portion of long-term loans1.21-30,000,000.00(30,000,000.00)-100%Payables for specific projects1.224,755,000.002,555,000.002,200,000.0086%Other non-current liabilities1.2375,809,855.7445,478,550.2130,331,305.5367%Capital surplus1.245,030,338.5731,568,488.40(26,538,149.83)-84%Surplus reserve1.2539,981,268.5517,573,057.1122,408,211.44128%Undistributed profits1.26719,209,302.41509,918,947.32209,290,355.0941%Minority interest1.2779,075,051.6155,464,963.7423,610,087.8743% IIINotes for significant fluctuation of major accounts in financial statements (continued)(1)Consolidated Balance Sheet (continued)1.1Increase in cash and bank was due to that more subsidiaries contribute to the business performance. 1.2Increase in notes receivable was mainly due to increase of sales.1.3Increase in accounts receivable was mainly due to increase of sales.1.4Decrease in dividend receivable was mainly due to withdraw the dividend from associate.1.5Decrease in other receivable was mainly due to withdraw the borrowing from associate. 1.6Increase in inventory was mainly due to the increase of sales and the consolidated range increased.1.7Increase in long-term equity investments was mainly attributable to the profit increased of the associate.1.8Increase in Investment properties was mainly due to reclassification of fixed assets.1.9Increase in fixed assets was due to a number of constructions in progress were completed in the year. 1.10Increase in construction in progress was due to addition of construction cost of major projects.1.11Increase in development costs was due to part of R&D expenses capitalized.1.12Increase in goodwill was caused by acquisition of the new company.1.13Increase in long-term prepaid expenses was mainly represented the expenditures on leasehold improvements.1.14Increase in deferred income tax assets was mainly caused by the timing difference of unpaid payroll.1.15Increase in other non-current assets was mainly due to the special reserve medicine increased.1.16Increase in short-term loans was mainly caused by the loan borrowed from bank increased and also the borrowing from new subsidiary.1.17Increase in notes payable was mainly due to the increased purchase.1.18Increase in accounts payable was mainly due to the increased purchase.1.19Increase in interest payable was mainly due to the loan and interest rate increased.1.20Increase in other payable was mainly due to the increasing provision of selling expenses and payable for purchasing engineering equipment for new production line. 1.21Decrease in current portion of long-term loans was mainly due to pay back the expired borrowing.1.22Increase in grant payable was mainly due to more grants from the government.1.23Increase in other non-current liabilities resulted from medicine reserve fund received from government, other government grants and fair value of rewards program.1.24Decrease in capital surplus was caused by business combination involving entities under common control.1.25Increase in surplus reserve was mainly due to the provision of legal surplus reserve.1.26Increase in retained earnings was mainly due to the increased profit.1.27Increase in minority interests was mainly because the net assets of minority shareholders increased by acquiring new company. IIINotes for significant fluctuation of major accounts in financial statements (Continued)(2)Consolidated Income StatementNotes20102009Fluctuation%ConsolidatedConsolidatedSales2.113,064,428,148.6910,997,074,919.052,067,353,229.6419%Cost of sales2.211,925,655,507.9410,041,207,840.071,884,447,667.8719%Selling and distribution expenses2.3430,588,573.47402,780,881.4427,807,692.037%General and administrative expenses2.4300,878,002.90255,178,530.0745,699,472.8318%Financial expenses - net2.582,538,641.4950,356,642.6032,181,998.8964%Non-operating income2.620,244,943.9310,271,959.889,972,984.0597%Non-operating expenses2.73,331,980.651,258,365.202,073,615.45165%Income tax expenses2.875,587,949.5962,527,277.1513,060,672.4421%2.1Increase in sales was mainly contributable by increased market capacity of the existing products.2.2Increase in cost of sales was mainly due to the sales volume increased.2.3Selling expenses increased in line with the growth of performance of the Group.2.4Administrative expenses increased were mainly due to the payroll and R&D increased.2.5Increase in financial expenses was mainly due to the interest rate and the loan borrowed increased.2.6Non-operating incomes resulted from disposal of fixed assets and payables written off.2.7Non-operating expenses resulted from penalty, compensation for lawsuit and others.2.8Increase in income taxes was due to profit growth in current year. CHAPTER XI. DOCUMENTS FOR REFERENCE 1. Accounting Statement carrying the signatures and seals of the legal representative, financial chief and person in charge of accounting; 2. Original of Auditors Report carrying the seals of Certified Public Accountants, and signatures and seals of the CPAs; 3. Originals of all the documents and notifications of the Company ever disclosed in the report period in Securities Times and Hong Kong Commercial Daily designated by CSRC; 4. Original of the Annual Report carrying the signature of the Chairman of the Board. 5. The Place Where the document placed: Office of Secretariat of the Board of Directors, Accord Pharm Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen. Chairman of the Board: Shi Jinming Board of Directors of Shenzhen Accord Pharmaceutical Co., Ltd. March 22, 2010 Shenzhen  h^h` ho(.H^H\`\ H)^\`\ .^\`\ .4^4\`\ 4) ^ \`\  .| ^| \`\ | . ^ \`\  )^\`\ .h^h`. ^` OJQJo(^` OJQJo(^Jo p^p` pOJQJo( @ ^@ ` @ OJQJo(^` OJQJo(^Jo ^` OJQJo( ^` OJQJo(^` OJQJo(^Jo P^P` POJQJo( (^(0`0 (o(0 ^` OJQJo(^` OJQJo(^Jo p^p` pOJQJo( @ ^@ ` @ OJQJo(^` OJQJo(^Jo ^` OJQJo( ^` OJQJo(^` OJQJo(^Jo P^P` POJQJo(  eF`Fcke a$$1$CJKHmH sH nHtH_Hv`v h 10 & Fdh8$7$1$$@&9D5$H$]$CJOJPJKHmH sH nHtH_Hd`dh 2d,a$$1$$@&*CJOJ PJQJ 5hmH sH nHtH_Hv`vh 3!XD<YDa$$1$$@&2CJOJ PJQJ ^J aJ5mH sH nH tH _H\d`d.h 4dTa$$1$$@&*CJOJPJQJ>*hmH sH nHtH_HR`Rh 5!dtXD"YD$$@&CJaJ5\$A`$9؞k=W[SOJoJ Char Char7CJOJ PJ QJ hmH sH LoL yblFhe,g Char CJPJaJmH sH nHtH_H$o$big1CJ8o!8 Char Char10nH tH 2o12eg Char CJaJKH:oA:da1B*`JphCJOJQJ>*^oQ^ Char Char310CJOJPJQJ^JaJKHmH sH nHtH_H$oa$msoins`oq` Char Char52CJOJ PJQJ ^J aJ5mH sH nH tH _H\)`uxRoR@ Char Char4#CJPJ5KHmH sH nHtH_HNoNT Char Char2 CJPJKHmH sH nHtH_H6o6 Char Char9nH tH 6o6 short_text1CJaJLoL2 Char Char CJPJKHmH sH nHtH_HZoZ Char Char12*CJOJ PJQJ 5hmH sH nHtH_H$*`$>\l_(uH*RoR Char Char6$CJOJPJKHmH sH nHtH_H@o@ Char Char13CJOJQJh0o!0f14b1CJaJ5\6X`16:_B*`Jph356\]\oA\KChar Char Char(CJOJPJQJKHmH sH nHtH_HVoQVA Char Char8'CJOJ PJ QJ hmH sH nHtH_H.U`a.cB*`Jph>*NoqN; Char Char1 CJPJKHmH sH nHtH_HJoJ ech~gV CharCJaJKHfH q FoFB Char Char3PJmH sH nH tH _H6V`6]vcB* `J ph>*.o.webdict15\('`(ybl_(uCJaJdodLevel 1 - 1 Char Char"CJOJ QJ ^J aJ5nH tH \ZoZ Char Char11*CJOJPJQJ>*hmH sH nHtH_HHC`Hckee,g)ۏ/dG$@&H$WD`5ToTDl N~cke"0dG$H$VDX^ v OJQJaJToTHeader1'1a$$G$&dP 9r CJT `"Tu2a$$G$ 9r  CJPJKHmH sH nHtH_H,o2,yblFhe,g13CJDoDCM144dfB*`JphCJOJPJ6o6..5B*`JphOJPJDobDFooter6a$$G$ 9r CJaJNoNCM37d%B*`JphOJPJ^JaJnH tH DoDCM178dB*`JphCJOJPJ$o$ Char9RoRCM16 :YD%B*`JphOJPJ^JaJnH tH F`F'yblFhe,g; CJPJKHmH sH nHtH_HdodDefault<8$7$1$H$-B*`JphCJOJPJmH sH nHtH_HHoHDlN~cke=dG$H$VDV^OJQJ&o&write>@o@Revision?mH sH nH tH _HNB`Nckee,g@a$$#CJPJ5KHmH sH nHtH_HhP`h%ckee,g 2Ad,a$$1$]'CJOJ PJ QJ hmH sH nHtH_HF+`"F)>\le,g Ba$$1$PJmH sH nH tH _HhR`2hckee,g)ۏ 2)CdG$@&H$VD3k^kWD`6fH q zoBzxl31GDdXD[$dYD\$a$$9D1$&dP'dQCJOJQJKHoRxl33XEdXD[$dYD\$a$$9D1$%dO&dP'dQCJOJQJKH0ob0p0F1$ OJQJo(@L`@egG8$7$9D5$H$CJPJ5KH6 `6"}_ 1Hda$$G$H$*j`QR*ybl;NI5\dS`dckee,g)ۏ 3&JdG$H$VD^WD`6fH q JZ`J$~e,gK(CJOJPJQJKHmH sH nHtH_Hoxl24iLdXD[$dYD\$a$$9D1$$dN%dO&dP'dQCJOJQJaJKH&o& CharMbQ`bckee,g 3$Nd,a$$1$]  CJOJ QJ KHmH sH LoLCM124 OXYD\$B*`JphCJOJPJpop Body Text 31$Pda$$9D8$7$1$$5$H$B*`JphCJPJKH^o^font6!QdXD[$dYD\$a$$1$CJOJQJ^JaJKHo""Char Char Char Char Char Char CharRdYDa$$1$CJOJQJ^JKHnH tH 8Y`28ech~gVS-D M f`Bfu w'Ta$$G$&dP 9r  CJPJKHmH sH nHtH_H*`R*ybleW[Ua$$ob- Char Char Char Cha Accord Pharmaceutical Co., Ltd. 2010 Annual Report  PAGE 23 Shenzhen Accord Pharmaceutical Co., Ltd. 2010 Annual Report  PAGE 72 -  PAGE 93 - 7h,g-NV]NON gPlQS ObhDl 2001t^12g31e (dyr+RhfY '^USMO:NNl^CQ) PAGE 114 7h,g ND]NON gPlQS [Updated on 1 March 2002] {tB\cOvROo` (dyr+RhfY ёUSMO:NNl^CQ)  PAGE \* MERGEFORMAT - 101 -  PAGE \* MERGEFORMAT - 105 - 7h,g-NV]NON gPlQS ObhDl 2001t^12g31e (dyr+RhfY '^USMO:NNl^CQ) PAGE 114  PAGE \* MERGEFORMAT - 115 -  PAGE \* MERGEFORMAT - 116 - 7h,g-NV]NON gPlQS ObhDl 2001t^12g31e (dyr+RhfY '^USMO:NNl^CQ) PAGE 114  PAGE \* MERGEFORMAT - 119 -  PAGE \* MERGEFORMAT - 120 -  PAGE \* MERGEFORMAT - 172 - 7h,g ND]NON gPlQS [Updated on 1 March 2002] {tB\cOvROo` (dyr+RhfY ёUSMO:NNl^CQ) 7h,g ND]NON gPlQS [Updated on 1 March 2002] {tB\cOvROo` (dyr+RhfY ёUSMO:NNl^CQ) 7h,g ND]NON gPlQS [Updated on 1 March 2002] {tB\cOvROo` (dyr+RhfY ёUSMO:NNl^CQ) Shenzhen Accord Pharmaceutical Co., Ltd. 2010 Annual Report  PAGE 181 PAGE  zOO^NR@b gPlQS2007t^7g26eHr PAGE 1 ,{ 1 u qQ 121 u The State-owned Assets Supervision & Administration Commission of the State Council China National Pharmaceutical Group Corporation Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Qishen Investment Management Co., Ltd. Sinopharm Industry Investment Co., Ltd. Sinopharm Group Co., Ltd. Shenzhen Accord Pharmaceutical Co., Ltd. 100% 100% 51% 2.77% 69.40% 27.71% 38.33% National Council for Social Security Fund Public Shareholders 49% 0.12%  "rtvɿukfaWME=CJOJQJ5CJOJQJ5CJOJPJQJ5CJOJPJQJ5CJaJCJaJCJOJPJQJ5CJOJPJQJ5CJOJPJQJ5CJ OJPJQJ5CJHOJPJQJ5CJ,OJQJaJ,CJ,OJQJaJ,CJOJQJ5CJ4OJQJ50JCJOJQJ5CJ4OJQJ5CJ4OJQJ5OJQJmHsHnHtHUCJ4OJQJ5CJ OJQJ5CJ OJQJ5ǿwog_WOG?CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5     x  ǿ}wpjc\VOI 5aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5aJ\CJaJ5\CJaJ5\CJaJ5\CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5   4 6 VZflnrt *68ztpjf`ZTP5aJ 5aJ\ 5o(aJ 5o(aJ5aJ 5o(aJ5aJ 5aJ\ 5o(aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5o(aJ5aJ 5o(aJ5aJ 5aJ\5aJ 5o(aJ5aJ 5aJ\ 5o(aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5o(aJ\fjlpr$2468:<>@|tld\TLCJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5 5o(aJ\ 5o(aJ5aJ 5o(aJ5aJ 5aJ\ 5o(aJ 5o(aJ5aJ 5o(aJ5aJ 5o(aJ5aJ 5aJ\ 5o(aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5aJ\ 5o(aJ\ 5o(aJ5aJ 5o(aJ@BDFHJLNPRTVXZ\^`bdǿwnf^QHCJaJmH sH CJaJmH sH nHtHCJaJ5\CJaJ5\CJo(aJ5\CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5<D^jtL Ŀ}snhcCJaJ CJo(aJCJaJCJOJQJaJ5CJaJCJaJCJaJmH sH CJaJo(o(o(o(o(o(o(o(CJaJ CJaJ] CJaJ]CJaJCJaJnHtHCJaJCJaJCJaJmH sH CJaJmH sH nHtHCJaJCJaJmH sH nHtH$$L  Ƽ|tld\TLF CJaJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJaJ5CJOJQJaJ]CJOJQJaJCJOJQJaJ5 CJaJ5CJaJ CJo(aJCJaJ CJo(aJ2 4 d f !!!d!f!ŽzupkfaZTN CJaJ5 CJaJ5 CJOJQJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJOJQJ5 CJaJ5 CJaJ5CJo(aJ5CJo(aJ5CJo(aJ5CJo(aJ5CJo(aJ5CJo(aJ5CJo(aJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5f!h!!!""""""##V#X#Z#($*$$$$ %"%%%%%%|&~&&&j'l'Ŀ{toje`[VCJaJCJaJCJaJCJaJCJaJCJaJ CJOJQJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJo(aJCJaJCJaJCJaJ CJOJQJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ5 CJaJ5 CJOJQJ l'''f(h((((")$)))))) *"*^*j*v*x***.+0++++pa\WRMHCJaJCJaJCJaJCJaJCJaJCJaJ6fHq CJaJ6fHq B*`JphCJaJB*`JphCJaJB*`JphCJPJaJB*`JphCJaJCJaJCJaJOJQJCJaJCJaJCJaJCJaJCJaJCJaJ CJOJQJCJaJCJaJCJaJCJaJCJaJCJaJ+,,r,,,--4-B-N-R-Z------.teUC3CJo(aJ6fHq "CJo(aJ6H*fHq CJo(aJ6fHq CJaJ6fHq CJaJ6fHq CJo(aJ6fHq CJaJ6fHq CJo(aJ6fHq CJaJ6fHq CJo(aJ6fHq CJaJ6fHq CJaJCJaJCJaJCJCJaJCJaJCJ..n.p.r.t.v.x.z.|.~...../ / /R/T/p/r/t/|/~//}wmc^YTOJECJaJCJaJCJaJCJaJCJaJCJaJCJOJQJaJ5CJOJQJaJ5 CJaJ5 CJaJ5 CJaJ5CJaJ5nHtH CJaJ5OJQJOJQJOJQJOJQJOJQJOJQJOJQJOJQJCJaJ6fHq CJaJ6fHq CJo(aJ6fHq CJo(aJ6fHq // 000000@0B0b0d000000011(1*1L1N1p1r1~111111žzupkfa\WRCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ@CJaJ CJaJ@CJaJ CJaJ@CJaJ CJaJ@ CJaJ@ CJaJ@ CJaJ@ CJaJ@CJaJCJaJCJaJCJaJCJaJ CJaJ@CJaJ11122$2&2B2D2P2R2n2p2x2~222222 3332343P3R3n3p3|3~3333344|wrpnha CJaJ@ CJaJ\o(o(CJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ@ CJaJ\o(o(o(o(CJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ@$444444444444444555$5&5B5F555555556 666Ŀ{vqlgb]XCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ@CJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJo(aJCJaJCJaJCJaJCJaJCJaJ CJo(aJCJaJ CJo(aJCJaJ CJo(aJCJaJ CJo(aJCJaJCJaJ 64666R6V6X6r6|6~6666T7V7p7z7~777777777778;}vohaZUPKFCJaJCJaJCJaJCJaJ CJaJ@ CJaJ@ CJaJ@ CJaJ@ CJaJ@CJaJCJaJCJaJCJaJCJaJ@fH q CJaJCJaJ@fH q CJaJCJaJCJaJ@fH q CJaJCJaJCJaJ@fH q CJaJCJaJCJaJCJaJCJaJ8884868V8X8x8z8888888H9R9T9t9v99999999999&:(:D:F:~ytoje`[VCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ@CJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ@!F:b:d::::::::::;;:;<;>;F;H;P;R;;;;;;; < <,<.<N<P<r<t<<<<ý{xsnidaaJ@aJ@aJ@aJ@aJaJ@aJ@aJ@aJ@aJ@aJaJaJaJaJaJ@aJaJaJaJaJaJCJCJ CJaJ5 CJaJ5CJ5CJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ%<<<<<<<= ==== =$=p=r=z=|===========Z>\>d>f>n>p>x>z>>>>>>>>>>>?~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.????? ?,?.?:?>?????@@@@ @"@.@0@<@@@@@@@@@@@@@AA AAA,A4A6ARAZA\A}zwaJaJ@aJaJaJ@aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ,\A BB*B2B6B8B:B\B^B~BBBBBBBBpCCCCCCCCCCCCCCCCFDHDDD E"E.EzwtqnkaJaJaJCJCJCJaJCJaJCJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ@aJ@aJ@aJ@aJ@aJaJ@aJ@aJ@aJ@aJ@aJaJaJaJaJ@aJaJ@aJ(.E0EXE\EEEEEEGGGGGGGHHHHHHHHHHHHIIIIIlJnJrJxJzJJJJJJJJJJJRKTKjKlKpKzK|K~KKKKKKKo(o(o(aJaJaJaJaJaJo(o(o(aJo(o(o(o(aJo(aJaJaJaJaJ=KKKKKKc@ccccccccccccddTdVdbdddtdvddd·zwrojPJCJCJPJB*`JphCJPJaJB*`JphCJaJB*`JphCJPJaJB*`JphCJaJB*`JphCJPJaJB*`JphCJaJB*`JphCJPJo(aJ5B*`JphCJPJaJ5B*`JphCJaJ5CJB*`JphCJaJ5\#ddddddddddddddddeee e4e6e8e:ee@eBeDeFeJeeeeeeeeeeeeeeeeeeeeeeePJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJ4ebfdfffhfjflfnfpfrftfxffffffffffffffffffffgggVgXgZg\g^g`gbgdgfghglggg~{xuPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJ.gggggggggggghhh h hhhhh*h,h6h8h:h>hlhnhhhhhhhhhhhhhhhhiiii*i,i.i0i2i>i@iLiNidifiPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJ:firiviiiiiiiiiiiiiij jjj\j^j`jbjdjfjhjjjljnjrjjjjjjjjjjjjjjjjjjjjjjjjjj kPJPJmH sH PJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJPJ8 kkkklknkkkkkkkDlFlllllmm$m(mDmFmPmRm\m^m`mbmlmnmmmmmmmmmmmmmmmmmmmmmmmNnPnCJOJQJaJ5\CJOJQJaJ5\CJ5PJo(PJo(PJPJPJPJPJo(o(PJPJo(o(CJCJPJCJ7Pnzo|ooo(p*pppppqqJqLqqq"r$r0r4rrrrrss2s4s\s^ssssstt8tÿ~{xurolifc`aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJCJOJQJaJCJOJQJaJ CJaJ5 CJaJ5CJ5 CJaJ5CJ5 CJaJ5CJ5 CJaJ5CJOJQJaJ5\CJOJQJaJ5\CJaJCJaJCJaJCJaJ%8t:tFtHt^t`tbtdtftjttttttuuuuuxuzuuuuuuuuu vvv`vbvlvnvvvvvvv:w}}}}~~H~P~R~d~f~~~~~$(hj|~ ,0vĀ,.@Bbfȁʁ|CJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ0J#B*`JphaJaJaJ:JLʆ̆ TVȇTV68|~ȑʑý{vmd^XRJCJaJ5\ CJaJ5 CJaJ5 CJaJ5CJOJQJaJCJOJQJaJCJaJCJaJ0J#B*`JphCJaJCJaJ CJaJ5 CJaJ5 CJaJh CJaJhCJaJ CJaJ5CJaJ5\ CJaJ5 CJaJ5 CJaJ5CJOJQJaJCJOJQJaJCJaJCJaJCJaJCJaJCJaJCJaJ |~ 2468:<ܗޗº}wqnj]OB*`JphCJaJ5\B*`JphCJaJ5CJ5CJ CJaJ5 CJaJ5CJCJU jUCJCJUUCJCJCJUCJPJCJ CJaJ5 CJaJ5 CJaJ5 CJaJ5CJaJ5\CJaJ5\CJaJ5\U"0J&B*`JphCJaJ5>*\UCJaJ5\CJaJ5\CJaJ5\Uv™ęƙΙЙڙܙ&(fhö}ume]UMJGDAaJaJaJaJCJOJaJ\CJOJaJ\CJOJaJ\CJOJaJ\CJOJaJ\CJOJaJ\CJOJaJ\CJOJaJ\CJ5B*`JphCJPJaJB*`JphCJPJaJB*`JphCJaJB*`JphCJPJaJB*`JphCJaJ5B*`JphCJaJ5 B*`JphCJaJ5mH sH  B*`JphCJaJ5mH sH h̚Κnp48NP`bjlpr÷~{xurnkgd`\XaJo(aJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJ CJaJ\ CJaJ\ CJaJ\ CJaJ\ CJaJ\ CJaJ\CJOJQJaJ5\CJOJQJaJ5\CJOJQJaJ5\CJOJQJaJ5\CJOJQJaJ5\CJOJQJaJ5\ ƜȜ؜ڜ  "(,FHXZfhln~zwaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ-ĝԝ֝ޝ $(>@rt|~ÿ|yaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJ.ƞȞ̞О $&,.246:<>@BDFHNRbd¿~{xuaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJo(aJaJaJaJaJaJo(aJaJo(aJaJo(aJ.ğƟȟ̟ΟПҟԟ֟؟ڟ$&.046JLRTXZ\`bdfhjln¿~{xaJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJo(aJo(aJaJo(aJaJo(aJaJaJaJaJaJaJ-ntvz~ʠ̠РҠ 68LNVX\^rtz|ÿ|xuaJo(aJaJaJaJaJaJaJaJaJ mH sH aJaJaJaJaJaJo(aJaJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJ,ΡСܡޡ "&@Bnpxz~}zwaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJ mH sH aJaJaJaJaJaJaJaJaJaJo(aJaJo(aJ-¢ĢȢ̢ 46<>BDFJLNPRTV`bfjz~{xuaJaJaJo(aJo(aJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJo(aJaJaJaJo(aJo(aJaJo(aJaJo(aJaJaJaJ-z|ңԣڣܣDFNPTVjlrtxz|}zvaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJo(aJaJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJ.  "$&(*,68<@XZ¿|yvspaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJo(aJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJ CJOJaJ CJOJaJaJaJo(aJo(aJaJaJaJ,¥ĥƥȥʥ̥ΥХҥ֥ڥ "(*.0268:<>@BLNRVrt¿{tqaJ CJOJaJ CJOJaJaJaJo(aJo(aJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJo(aJaJaJaJaJo(aJaJo(aJaJo(aJ,ȦʦЦҦ֦ئڦަ *,@BJLPRfhnptvx|~¾{xtqmjaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJB*`JphCJaJmH sH B*`JphCJaJmH sH aJaJaJaJo(aJo(aJaJaJaJaJo(aJaJo(aJaJo(aJaJaJaJaJaJaJaJaJ)~ħƧΧЧҧԧ&*(*ܩީ  &(8zCJaJCJaJCJaJCJaJCJaJCJaJCJaJo(H*aJaJo(aJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJo(aJaJaJaJ/8:HJnp~ڪܪ "@BΫҫ .0@þqkfaCJaJCJaJCJaJCJaJB*`JphCJaJB*`JphCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ&@BFHJLPRTVXZ^bz|¬ҬԬجڬܬެ "$&(,CJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ6,.0246:>VXhjnprtvxz|~­ĭȭʭ̭έҭԭ֭حڭܭ "$&(*,.0248CJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ68<NPxz~RT8:BD԰ְLN|~¼zwtqncCJOJQJ^JaJaJaJaJaJ OJQJaJ OJQJaJCJOJQJ^JaJ5CJOJQJ^JaJ5aJ\aJ\5aJ5aJ5aJ5aJ5aJ 5aJ\ CJaJ5 CJaJ5 CJaJ5 CJaJ5CJaJCJaJCJaJCJaJCJaJ&ȱ̱ޱBDزڲ <>\^ܳ޳ƽypg^[XURaJaJaJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJ CJaJ5 CJaJ5aJaJCJOJPJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJaJ5 CJaJ5aJaJ CJaJ5 CJaJ5CJOJPJaJ CJOJaJCJOJQJ^JaJ޳ :<X\^`bʴ̴.0Ǿxurg\SJACJOJPJaJCJOJPJaJCJOJPJaJCJOJQJ^JaJCJOJQJ^JaJaJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJCJOJQJ^JaJCJOJQJ^JaJضڶ8:tvַ24RVXļ}tmd[RI@CJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJaJ\aJ\ CJaJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5CJaJ5\B*`JphCJPJaJB*`JphCJaJB*`JphCJPJaJB*`JphCJPJaJCJOJPJaJX&*,\npʹιй\^n|ulcZQH?CJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ0JCJOJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJnrtBTV>Ļ~ulc\SJACJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJ>@PTVRT@xof]VMD;CJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ@BRVX(:<п¹|sjcZQJA0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ,.>BTV BĻ|sjaXOF=CJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJCJOJPJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJBDLN^bd&Ľ~ulcZSJACJOJPJaJCJOJPJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJ CJOJaJCJOJPJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJ&(rtbdtxz zqh^ULC:CJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJo(aJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ  "Vhj hj(*rt&Ļ~ulf`[VPK>0J#B*`JphCJaJCJaJ CJaJ6CJaJCJaJ CJaJ5 CJaJ5CJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJCJOJPJaJ CJOJaJCJOJPJaJCJOJPJaJCJOJPJaJ0JCJOJaJ CJOJaJCJOJPJaJCJOJPJaJ CJOJaJ&jz@T`bNP ^`Lʻwre`SN?0J&B*`JphCJaJ>*CJaJ0J#B*`JphCJaJCJaJ0J#B*`JphCJaJCJaJ0J#B*`JphCJaJCJaJ0J#B*`JphCJaJCJaJ CJaJ6 CJaJ5 CJaJ5CJaJ5H* CJaJ50J#B*`JphCJaJ5 CJaJ5CJaJ56CJaJCJaJ CJaJH*CJaJ0J#B*`JphCJaJCJaJ>H|$(PR *. ſyske_YTG0J#B*`JphCJaJCJaJ CJaJ6 CJaJ5 CJaJ5CJaJ5H* CJaJ50J#B*`JphCJaJ5 CJaJ50J#B*`JphCJaJ5 CJaJ5CJaJ56 CJaJ5 CJaJ5CJaJ5H* CJaJ5CJaJ56CJaJCJaJ CJaJH*CJaJ CJaJH*CJaJ0J#B*`JphCJaJCJaJ "fx~BF f$`RV.x¼~xpjd_ZTOI CJo(aJCJaJ CJaJ6CJaJCJaJ CJaJ5 CJaJ5CJaJ5H* CJaJ50J&B*`JphCJaJ5>* CJaJ5CJaJ56OJaJOJaJ OJaJ6OJaJ56OJPJaJ6 CJaJ5 CJaJ5CJaJ5H* CJaJ5CJaJ5H* CJaJ5CJaJ5H* CJaJ5CJaJ56CJaJj l  PTjltv ^pŽtn_YQB0J#B*`JphCJaJ5CJaJ5\ CJaJ50J#B*`JphCJaJ5 CJaJ50J#B*`JphCJaJ5 CJaJ5CJaJ56 CJaJ5 CJaJ5CJaJ56 CJaJ5 CJaJ5 CJaJ5 CJaJ5CJaJ5H* CJaJ5CJaJ56 CJaJ5 CJaJ5CJaJ5H* CJaJ5CJaJ56CJaJCJaJz!|!!**L***&.(.l...../&/0"0115¼~oiZTE? CJaJ50J#B*`JphCJaJ5 CJaJ50J#B*`JphCJaJ5 CJaJ50J#B*`JphCJaJ5 CJaJ50J#B*`JphCJaJ5 CJaJ50J#B*`JphCJaJ5 CJaJ5CJaJ56 CJaJ5 CJaJ50J#B*`JphCJaJ5 CJaJ5CJaJ56 CJaJ5 CJaJ5CJaJ56 CJaJ5 CJaJ555$6D6X699\9^9`99@@4A F"FvFFFFFGG>H@HBH"I$II}wrlgb]XSNCJaJCJaJCJaJCJaJCJaJCJaJ CJaJH*CJaJ CJaJH*CJaJ CJaJH*CJaJ CJaJ6 CJaJ5 CJaJ5CJaJ560J#B*`JphCJaJ0J#B*`JphCJaJCJaJ CJo(aJCJaJ CJaJ6CJaJCJaJ0J#B*`JphCJaJCJaJ CJaJ6 CJaJ5IIJJ0J4J,K.KKK*L.LHLLLLLfMhM(N,N^NbN|NNNNOOpPtPPPPþ}wrmhb]WRCJaJ CJaJH*CJaJ CJaJH*CJaJCJaJCJaJ CJaJH*CJaJ CJaJH*CJaJ CJaJH*CJaJ CJaJH*CJaJCJaJCJaJ CJaJH*CJaJ CJaJH*CJaJ CJaJH*CJaJ CJaJH*CJaJCJaJCJaJ CJaJH*CJaJ CJaJH*CJaJ CJaJH* PPP6Q8Q RRPRRRzR~RRRRRRRRRRRSS.S0S8S:SFSHStSvS|S~Sÿyvrnjfb_[WSaJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\aJB*`JphCJaJB*`JphCJaJB*`JphCJaJB*`JphCJaJB*`JphCJaJB*`JphCJaJaJ\aJ\aJ\aJ\aJ\aJ\aJaJaJaJCJaJCJaJ CJaJ5 CJaJ5CJaJCJaJ ~SSSSSSSSSSSSSSST T$T&T0T2TrTtT|T~TTTTTTTTTUU U UUUbU¾|xtplhaJ\aJ\aJ\aJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\aJ\aJ\aJ\aJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\aJaJ\aJ\'bUdUjUlUxUzUUUUUUUUUUUUUV VVVV V"VhVjVlVVVYYtbvbccczrolifc`]CJCJCJCJCJCJCJOJQJaJ5OJQJaJ5OJQJaJ5CJOJQJaJ5CJOJQJaJ5CJOJQJ5aJ\aJ\aJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\aJaJ\aJ\aJ\aJ\aJ\$cBdDdeeee4f6fffff«ybK<-0JB*`JphOJQJaJ0JB*`JphOJQJaJ,0J*B*`JphaJ6>*fHq ,0J*B*`JphaJ6>*fHq 00J*B*`JphPJaJ6>*fHq 00J*B*`JphPJaJ6>*fHq ,0J*B*`JphaJ6>*fHq ,0J*B*`JphaJ6>*fHq 0JB*`JphOJQJaJ OJQJaJOJQJaJ5OJQJaJ5 fgtgxgzg|ggggggghοt]F/,0J*B*`JphaJ6>*fHq ,0J*B*`JphaJ6>*fHq ,0J*B*`JphaJ6>*fHq /0J*B*`JphaJ6>*H*fHq ,0J*B*`JphaJ6>*fHq 0JOJPJ CJOJaJ 0JOJPJ 0JOJPJ0JB*`JphOJQJaJ0JB*`JphOJQJaJ!0JB*`JphOJPJQJaJ!0JB*`JphOJPJQJaJ hhhhhhhhii&i(ihijiƷt]F70 0JOJPJ0J*B*`JphOJaJ>*,0J*B*`JphaJ6>*fHq ,0J*B*`JphaJ6>*fHq 00J*B*`JphPJaJ6>*fHq 6fHq aJ 0JOJPJ 0JOJPJ0JB*`JphOJQJaJ0JB*`JphOJQJaJ!0JB*`JphOJPJQJaJ!0JB*`JphOJPJQJaJ,0J*B*`JphaJ6>*fHq jij^j`jrjvjxjXqqrrrrrrvsxsssttuuŶyqje^YSN?<9aJaJ0JB*`JphOJQJaJCJaJ CJo(aJCJaJ 0JCJaJCJaJ 0JCJaJ0JCJaJ50JCJaJ5 OJQJaJ OJQJaJ OJQJaJOJQJaJ6 OJQJaJ!0JB*`JphCJOJPJQJ0JB*`JphOJQJaJ0JB*`JphOJQJaJ!0JB*`JphOJPJQJaJCJOJQJaJ!0JB*`JphOJPJQJaJu`ubuuuuuuuuuuuuuuuuuuuu vvvvvvvvvv}tkbYPCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKH CJOJPJ CJOJPJ CJOJPJCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKHaJ mH sH aJ mH sH aJaJaJaJaJaJaJaJaJvnvvvvvwwww w wwwwLwj~l~n~46h؅څ܅ȿ~xrlf`[HCCJaJ%0JB*`JphCJOJPJQJaJOJaJ OJaJ6 CJaJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5 CJaJ5$0JB*`JphCJOJQJaJ5CJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKHCJOJPJKH CJOJPJ CJOJPJ CJOJPJ CJOJaJ CJOJPJ܅68tv8:ln "TVFHJ`–ҙ̚Lſ~vojc^WRK 0JCJaJCJaJ 0JCJaJCJaJ 0JCJaJCJaJ 0JCJaJ0JCJaJ50JCJaJ5 CJaJ50JCJaJ5 CJaJ5CJaJCJaJCJaJ CJaJ6 CJaJ6CJaJCJaJ CJaJ6 CJaJ6 CJaJ5 CJaJ5CJaJ56CJaJ56 CJaJ5 CJaJ5 CJaJ6 CJaJ6L@B$&\zupke`ZUD?CJaJ!0JB*`JphCJOJQJaJCJaJ CJo(aJCJaJ CJo(aJCJaJCJaJCJaJ$0JB*`JphCJOJQJaJ5!0JB*`JphCJOJQJaJ OJPJaJ!0JB*`JphCJOJQJaJCJaJCJaJ!0JB*`JphCJOJQJaJCJaJCJaJCJaJ 0JCJaJ 0JCJaJCJaJ 0JCJaJCJaJ\^z|~"пwpid^YRKF@ CJaJH*CJaJ 0JCJaJ 0JCJaJCJaJ CJaJH*CJaJ 0JCJaJ 0JCJaJ%0JB*`JphCJOJPJQJaJ0JCJaJ5\0JCJaJ5\0JCJaJ5 CJaJ5%0JB*`JphCJOJPJQJaJ!0JB*`JphCJOJQJaJ!0JB*`JphCJOJQJaJCJaJCJaJCJaJCJaJCJaJCJaJ"\TVX`@pr|¹,.8<v{upib]WRCJaJ CJaJH*CJaJ 0JCJaJ 0JCJaJCJaJ CJaJH*CJaJCJaJ 0JCJaJ 0JCJaJCJaJ CJaJH*CJaJ 0JCJaJ 0JCJaJCJaJ CJaJH*CJaJCJaJ 0JCJaJ 0JCJaJ 0JCJaJ 0JCJaJCJaJCJaJ 0JCJaJ 0JCJaJCJaJvtvx~Ƽ@>@BDF ĿziXRLF@ CJaJ5 CJaJ5 CJaJ5 CJaJ5!0JB*`JphCJOJQJaJ!0JB*`JphCJOJQJaJ!0JB*`JphCJOJQJaJ 0JCJaJ 0JCJaJCJaJCJo(aJH* CJo(aJCJaJ 0JCJaJ 0JCJaJCJaJ CJaJH*CJaJ!0JB*`JphCJOJQJaJ!0JB*`JphCJOJQJaJ 0JCJaJ 0JCJaJ   (2JLTV .^`HJtvdf02Ž~{xurolifCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJB*`JphCJCJCJCJCJCJCJOJPJo(CJOJQJo(CJOJCJOJQJo(CJOJCJOJQJo(CJCJCJCJCJCJ CJaJ5(VXPRH#J####z%|%%%&&'''''¿|wrokaJaJCJaJCJaJCJaJCJaJCJaJCJaJCJCJCJaJ CJaJ5 CJaJ5 CJaJ5CJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJPJCJCJCJCJCJCJCJCJPJCJCJ)''(( ("(N(P(((>)@)))))))******,*8*:*F*J*****************+ +,+.+:+<+F+H+V+X+f+h+v+z++++aJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ<++++++++++++,,,,",$,0,2,>,@,J,L,X,\,l,n,,,,,,,,,,,,,,,:->---------------..6.8.R.T.`.o(o(o(aJaJo(o(o(o(o(o(aJaJaJo(aJaJaJaJ@`.b.n.p.|.~.....////*/,/:/HbHHHxIIKKKKKLLLLMMMMMM¿zuojOJPJ OJPJo(OJPJ OJPJo(OJPJOJOJPJOJPJOJOJo(OJOJo(OJOJo(OJOJPJOJOJPJOJOJOJOJo(OJOJo(OJOJPJOJOJo(OJOJPJOJPJOJPJOJOJo(OJOJo(OJ'MMNNNOOOOOOOOPPXP\P^PdPfP"Q*QFRNRSSSSSSSSSS4T`@`B`H`J```````aaaa:alaaaaabb"b$b,b.b6b8bnbpbb}zwtqnkhaJaJaJaJaJaJaJaJaJCJaJCJaJCJaJ CJo(aJCJaJ CJo(aJCJaJ CJo(aJOJPJOJPJOJOJo(OJOJo(OJOJo(OJOJo(OJOJo(OJOJo(OJOJo(OJOJo(OJOJo(OJOJo((bbbbbbc cccc&d*dZd\dhdjdvdxddddeeefffgg*g,g6g8gyrkhe`[KHaJKHaJaJaJ CJaJKH CJaJKH QJaJKHKHaJKHaJ QJaJKHKHaJKHaJ QJaJKHKHaJKHaJKHaJKHaJKHaJKHaJaJaJ CJaJKH CJaJKHKHaJKHaJKHaJKHaJKHaJKHaJaJaJo(aJaJ!8gBgDgPgRgggghh`hfhhhhhhhhhhhh`ifiviiiiƾ}unf_WP QJaJKHQJo(aJKH QJaJKHQJo(aJKH QJaJKHQJo(aJKH QJaJKHKHaJKHaJKHaJKHaJKHaJKHaJaJaJ CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHKHaJKHaJKHaJKHaJijjkk>k@kJkLkVkXkdkfkhk8lLlTlZl~llllmm`mdmxmzmmm½zrkc[XUPKKHaJKHaJaJaJCJo(aJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHKHaJKHaJKHaJKHaJKHaJKHaJaJaJ CJaJKHQJo(aJKH QJaJKHQJo(aJKHmmmmmmmm$n(n*n oooooo pprss ssź{pg\SH?B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJPJB*`JphOJB*`JphOJo(B*`JphOJB*`JphOJPJo(B*`JphOJPJCJaJCJaJB*`JphOJPJCJo(aJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHKHaJKHaJKHaJKHaJss>sFsHsJsPsRsXsZsssssssssssø|sh_TI<B*`JphOJPJo(B*`JphOJPJB*`JphOJPJB*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(st"wwwwwwwwwwwwwwwwwʽyncVK>3B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJo(B*`JphOJB*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJo(B*`JphOJ0JB*`JphOJaJB*`JphOJwxxxxxxx$x&x(x,xpxxxy{n{v{Ȼype\QH=B*`JphOJo(B*`JphOJB*`JphOJaJB*`JphOJB*`JphOJo(B*`JphOJB*`JphOJaJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJB*`JphOJB*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJo(B*`JphOJv{{{{{{{{|||*|0|2|4|8|X|h||ƻyncVMB9B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJB*`JphOJB*`JphOJPJo(B*`JphOJPJB*`JphOJo(B*`JphOJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJo(B*`JphOJB*`JphOJPJo(|||&},}>}F}r}x}}}}V~^~p~~~~~~ø|of[PC:B*`JphOJB*`JphOJPJo(B*`JphOJPJB*`JphOJo(B*`JphOJB*`JphOJPJo(B*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(~~~~~~.:HJLøvkbWJ?2B*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJB*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJB*`JphOJPJB*`JphOJB*`JphOJPJo(B*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(B*`JphOJB*`JphOJo(ځ܁4:<BDFLNPȻwn[NA41CJB*`JphOJPJ5B*`JphOJPJ5B*`JphOJPJo(%B*`JphOJo(fHq B*`JphOJB*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJB*`JphOJPJo(B*`JphOJPJB*`JphOJPJo(B*`JphOJPJB*`JphOJB*`JphOJPJ̄ք؄ڄ܄ބ(*,46vxچ܆Ƚ{peZQHB*`JphCJB*`JphCJB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHCJaJ CJaJ CJCJaJ CJaJ CJaJ CJCJo(CJCJo(CJCJo(CJCJ$&02:<FJdfrt~żypg^ULC8B*`JphCJKHB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJKHB*`JphCJKHB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJKHB*`JphCJKHB*`JphCJB*`JphCJB*`JphCJB*`JphCJƇʇPRƋȋʋ܋Ҍ֌ǾzuhcVIB*`JphCJaJKHB*`JphCJaJKHCJaJB*`JphCJaJKHCJaJB*`JphCJaJKHB*`JphCJaJKH CJnHtH CJnHtHCJ CJnHtHCJCJCJCJCJCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJB*`JphCJKH46:<>@vzĽ~qdWJ=0B*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKH OJQJaJ OJQJaJB*`JphOJQJaJB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKH̍Ѝҍԍ֍HJNPxsfYL?2B*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHCJaJB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKH CJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJPTXbdfhjnp|~FHJ˾~wpc`SF9B*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHCJB*`JphCJaJKH CJnHtH CJnHtH CJnHtH CJnHtHCJ CJnHtHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHB*`JphCJaJKHΑґDF"&(hjܓ~sh]RG@BFHޘlnTVȽ~xrjd^XPJD CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \B*`JphOJaJ5B*`JphOJaJ5B*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHB*`JphCJKHVޡpr"$(*vx$&¯įjl  ýyske_YSKCJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ ̹ιйrtv{umga[UO CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \ CJaJ \ CJaJ \ CJaJ \ CJaJ \vxXZ~tv~jlnx02XZ>@RTXZ\ľ|wtqo(o(o(o(aJaJaJaJaJaJaJaJCJ\CJCJCJCJo(CJ0JaJ0JaJ 0JaJ\ 0JaJ\CJCJCJCJCJCJ5CJ5CJ5 CJaJ \ CJaJ \ CJaJ \ CJaJ \CJo(aJ \,bdFJTXtrvfj46FHNP8:o(o(o(o(o(o(o(o(H*o(o(o(D26"$&(*.0LNbdLNbdVX&(CJCJCJCJCJCJCJCJCJCJCJCJCJCJH*CJCJH*CJCJCJCJCJCJH*CJCJH*CJ0JaJ0JaJ0JCJaJ50JCJaJ5CJ51^`<>"$~fh4BLN`lptn}zwtCJCJCJCJo(CJCJH*CJCJo(CJCJH*CJCJH*CJCJo(CJCJCJCJo(CJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJ,n| "08:@B$&~          : ý~{wtpmCJCJH*CJCJo(CJCJCJCJCJCJH*CJCJCJCJH*CJCJCJCJo(CJCJ\CJ\ CJH*\CJ\ CJaJ\CJ\CJ\CJ\CJ\CJCJCJo(CJCJH*CJCJH*CJCJo(CJCJCJCJo(): > @ N   < >   LNhjvzTĿ}zvsolifb_CJCJH*CJCJCJCJo(CJCJo(CJCJCJaJ CJo(aJCJaJ CJaJH*CJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ\CJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ\ CJaJ\CJCJCJo(CJCJH*$TVx 26>Bÿ|xuqCJH*CJCJH*CJCJo(CJCJCJCJo(CJCJCJCJCJCJCJCJCJCJCJCJH*CJCJH*CJCJo(CJCJo(CJCJCJCJo(CJCJo(CJCJCJCJH*CJCJH*CJCJH*CJCJ+Bv x !!" "@#B#<$>$ %%&%(%<%P%%%%%&&''''((())),,,,,D,{vpkCJaJ CJo(aJCJaJ CJo(aJCJaJ0JaJCJaJCJaJ0JaJ CJaJ5 CJaJ5CJCJCJo(CJCJCJCJH*CJCJH*CJCJo(CJCJCJCJo(CJCJCJCJCJCJCJCJCJCJCJCJCJ'D,P,R,^,,,,,,,,,,-----,1111b3d333334444455þ{vqlic] CJaJ5 CJaJ5CJCJaJCJaJCJaJCJaJCJaJCJaJ CJo(aJCJaJ CJo(aJCJaJ0JaJCJaJ0JaJCJaJCJaJCJaJCJaJCJaJCJo(CJCJo(CJaJCJCJo(CJCJo(CJCJaJ CJo(aJCJaJ CJo(aJ"552;4;;;==>>??~@@AACCDDEE IIKKM MNbQdQzR|RSSSNXPXRXt[v[V\X\h]j]¿}zvCJo(CJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJ5-j]l]^ ^.^2^L^P^^^*`,`iillRqTqjrlrnrrrttRuTuvvyyyyyzzz{{{{P~R~T~|wq 0Jo(aJ0JaJCJCJ5CJ5CJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJo(CJo(CJCJCJCJCJCJCJCJCJCJH*CJCJH*CJCJH*CJCJCJCJo(+T~V~X~Z~$&(Ā8R҃.Ph Fbއ:FĿ~{vqkd_X 0JCJaJCJaJ 0JCJaJ CJaJ\CJaJCJaJCJCJaJCJ CJaJ\CJaJ CJaJ\CJCJaJCJaJCJCJaJCJCJaJCJCJaJCJCJaJCJCJaJCJCJaJ CJaJ\CJ0JCJaJ50JCJaJ5 0Jo(aJ 0Jo(aJ 0Jo(aJ"FHZ\^ΌЌڍ܍ގ$&24PT\^xzƏΏЏ؏ڏ $aJaJaJaJaJaJaJaJaJaJaJaJaJCJPJ CJPJ CJaJCJaJCJaJ CJaJKH 0JCJaJ 0JCJaJ6 BDHJ"<HƔLRHbЖԖږ r~ÿ}yuqCJo(CJo(CJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJ5CJ5CJ5CJCJPJPJPJo(+ Z\TVXjn:<bddfJLfhP¿}zwtqnkCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJCJH*CJCJH*CJCJ 0JCJaJ 0JCJaJ 0JCJaJ 0JCJaJ0JCJaJ50JCJaJ5(      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|~PRܥޥئܦjl24FJdh¿}zvsCJCJo(CJCJCJo(CJCJo(CJCJCJo(CJCJo(CJCJCJH*CJCJH*CJCJCJCJCJCJCJCJCJCJH*CJCJH*CJCJCJCJCJCJH*CJCJH*CJCJCJCJCJCJ+TVXZ\(*,.0̮ ,0¯ʯ̯ʰ̰ް¿}zwtpCJH*CJCJCJCJo(CJCJo(CJCJo(CJCJo(CJCJH*CJCJH*CJCJH*CJCJo(CJCJCJCJo(CJCJCJCJo(CJCJo(CJCJCJo(CJCJo(CJCJCJo(CJCJo(CJCJCJo(*L^VXZ\^tvxz|z"VX¾{xtqnCJCJCJo(CJCJo(CJCJCJH*CJCJH*CJCJo(CJCJCJCJo(CJCJCJCJo(CJCJo(CJCJCJo(CJCJo(CJCJCJo(CJCJo(CJCJCJo(CJCJo(CJCJCJo(CJCJH*CJ+XZ\^pt(*,.2ʽ̽`bvx zupkf0JaJ0JaJ0JaJ0JaJ0JaJCJaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJCJo(CJo(CJCJo(CJCJCJCJo(CJCJo(CJCJCJo(CJCJo(CJCJCJH*CJCJo(CJCJo(CJCJCJo(CJCJo(' ".`bdz|~D,.0@þ}wsmgaY0JCJaJ5 CJaJ5 CJaJ5 CJaJ5CJ5 CJaJ50JaJ0JaJCJaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJ0JaJCJaJ0JaJCJaJ @B^`bdBD`ǿzrjbXPHC0JaJ0JCJaJ50JCJaJ50JCJo(aJ50JCJaJ50JCJaJ5CJaJ5U0JCJaJ5mHsHnHtHUCJaJ50JCJaJ5CJaJ5U0JCJaJ5 0JCJaJ 0JCJaJ 0JCJaJ0JCJaJ50JCJaJ5CJaJ5U0JCJaJ5mHsHnHtHUCJaJ50JCJaJ5CJaJ5U`b$&8:BDxz*,pr BDJLRTz|¿o(aJaJo(o(^JaJaJaJKHaJaJKHaJaJKHaJaJKHaJaJKHaJaJKHaJaJaJaJaJaJaJaJaJCJaJ5\3HJ ,0`b&(.068DaJo(o(aJo(o(aJEDHJPnp  "$:<:<tvVX"${aJaJaJaJKHaJaJKHaJaJKHaJaJKHaJaJaJaJKHaJaJaJaJaJaJaJaJaJCJaJ5\0JaJ 0JCJaJ 0JCJaJ0JCJo(aJCJ/$*,8<>NPlntv02 $&JL48zupkfa\YaJPJaJPJaJPJaJPJaJPJaJPJaJPJaJPJaJaJPJaJPJaJPJaJPJaJaJPJaJCJaJ0J 0JCJaJ 0JCJaJ 0JCJaJ 0JCJaJ CJaJU0JCJaJmHsHnHtH UCJaJ 0JCJaJ CJaJU 0JCJaJCJaJ!"$02<@$&04xoB*`JphaJB*`JphaJB*`JphaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ*.0:<FHRV.0:<DFPT~{xurolifcaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJB*`JphaJB*`JphaJB*`JphaJB*`JphaJB*`JphaJB*`JphaJB*`JphaJ& ^`pr|~hjz| ",.6~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.68BFZnxz&(26xz 02<>FHRV¿}zwaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJ-V "24>@HJTXLN^`jltv~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.DFRT^`hjtx>@LNXZbdnr24~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.4@BLNVXbf68DFPRZ\fjBDPR\^fh~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.hrv:<HJTV`blpDFRT^`hjtx~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.HJVXbdlnx|8:FHRT\^hl"&~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.&jlxz(,pr~  "$,.8<}zwaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ->@JLVXdfptZ\fhrt|~   ",0z~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.z| ",.68BF$ & . 0 : < D F P T        ~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.    L N V X b d v x     ( * 4 6 B D N R           . 0 8 : D F P R \ `    ~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.         t v ~         ",.8:DH<>FHRT\^~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.^hlLNVXbdnpz~FHPR\^npz~}zwaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ- \^fhrt  $(|~¿|yvsaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJo(aJQJ aJaJaJaJaJaJaJaJaJo(aJQJ aJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJ, VX`blnxzrt|~  "$.2|yvaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJ-"$,.8:BDNR\^`z|ÿ~solhaJUaJaJUmHsHnHtHaJUaJaJaJUaJaJUmHsHnHtHaJUaJaJaJUaJaJUmHsHnHtHaJUaJaJaJUaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ'NP\^bd.0  *,NPbdxqnkheb_\YR CJaJKHaJaJaJaJaJaJaJaJ CJmHsH CJmHsHCJaJmHsH CJaJH* 0JCJaJ 0J"CJaJ0J"CJaJ5 0JCJaJ0JCJaJH* 0JCJaJ 0JCJaJ 0JCJaJ CJPJ aJCJaJ CJo(aJCJaJ CJmHsHaJaJUmHsHnHtHaJUaJaJ bdz|,.DFVXZ\hƿzsleXQ CJaJKHCJaJKHHh CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJaJaJaJaJ CJaJKHhjz|(*:<NPxung`YRK CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH    N R | ~           !!F!H!^!`!r!t!!xung`YRK CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH!!!!!!!!""<">"N"P"t"v""""""""#(#*#:#<#b#d#ž|yrohaZSL CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKHaJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKHaJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHd#v#x#######$$$$B$D$X$Z$n$p$$$$$$$$$"%$%xqng`YRK CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH$%4%6%F%H%z%~%%%%%%%%%%%&&D&H&^&`&&&&&&&xqng`YRK CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH&&&&&'','.'P'R'd'f'v'x'''''''''((0(2(D(Ľ{tmjc\UN CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKHD(F(^(`(r(t(((((((())),).)@)B)t)x))))))))xqjg`YRJCJo(aJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH))))* *<*@*V*X*~**********+ +"+$+J+L+`+b+r+~wpif_XQJ CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKHCJo(aJKHr+t+++++++++,,*,,,<,>,V,X,l,n,,,,,,,,,-xqjg`YRK CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH----.-0-b-f-|-~----------- .$.:.<.^.`.p.r..xqjg`YRK CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH..........,/./>/@/P/R/d/f/x/z/////////Ľ~{tmf_XQJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH/0 0000020d0h0~000000000000 1$1:1<1X1Z1j1Ľ~wtmf_XQJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHj1l1|1~11111111122$2&26282H2J2Z2\222`5b5d566V7Z7Ľ~wpmfc_[XTQMCJH*CJCJo(CJCJo(CJo(CJ CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHaJ CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKH CJaJKHZ7\7|777788T8n89 9>9@9F9r9x94:::>:@:F:H:::: ;;;;;;;l<p<<<<<<(=.=¾|xtpmCJCJo(CJo(CJo(CJCJH*CJCJH*CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJo(CJo(CJCJo(CJCJo(CJCJo(CJo(CJCJH*CJCJo().===?????@ @@*@.@@@@@@@@A"AAAAB:BRBVBXB`BfB$C*CCC&D(D*D0Dǿ{xtphdCJo(CJOJQJo(CJo(CJo(CJCJo(CJCJo(CJCJo(CJo(CJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJOJQJo(CJo(CJo( CJo(H*CJo( CJo(H*CJo(CJCJo(CJCJo(CJCJo(CJCJo('0DDEEEEEEEFFFGG"G$GRGTG\GHHHHHHHHHHIJJJJ J&J.J0JXJZJbJpKvK}zwsplCJo(CJCJo(CJCJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJCJo(CJCJo(CJCJo(CJo(CJCJH*CJCJo(CJCJo(CJCJo(CJ*vK~KKKKKKKKKKKKMMMMMMNNNNN N*N0N4N6NNNNTNXNZN`NbNOOOPNP}zvsolCJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJo(CJCJOJQJo(CJo(CJCJCJo(CJCJo(CJCJo(CJCJo(CJ)NPPPRPTPPPPQQ Q$Q(QQQQ"R$RRRRRRSSSSSSSSSSSSSSƿ~ytoje`[CJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJCJaJCJaJ 0JCJaJ 0JCJaJCJo(CJo(CJo( CJo(H*CJo( CJo(H*CJo(CJCJo(CJCJo(CJCJo(CJo(#STTTT2T4T6THTJTLTfThT|T~TTTTTTTTTTTT~UUUUUUNVRVTVxVzVVVVVVVV~{xuroaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJCJCJaJCJCJCJCJUmHsHnHtHUUUmHsHnHtHUU B*`Jph B*`Jph B*`JphUmHsHnHtHUUCJaJ+VVVVVVWWWWXWZWjWlW|W~WWWWWWWWW XXXX X$XdXfXvXxXXXXXXXXXY YYY$Y~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.$Y&Y.Y2YzY|YYYYYYYYY ZZZ Z,Z.Z6Z8Z@ZDZZZZZZZZZZZ [[[ [,[.[6[8[@[D[[[[~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.[[[[[[[[$\&\6\8\D\F\N\P\X\\\\\\\\\\\\\] ]0]2]>]@]H]J]R]V]]]]]]]]]]~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.]]^^&^(^4^6^>^@^H^L^^^^^^^^^^^8_:_L_N_Z_\_d_f_n_r_______````V`X`h`j`v`~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.v`x```````````aaaaTaVafahatava~aaaaaa b bbb"b$b,b0brbtbbbbbbbbbb~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.bbbb c cccc"cdcfcrctcccccccccccd dddd dddfdvdxddddddddde eee e~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ. e"e*e.eeeeeeeeeeeffffff$f&f.f2frftfffffffffffffgg ggggpgrg~g~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.~gggggggg h"h.h0h:hj@jHjLjjjjjjjjjjjDkFkPkRk\k^kfkhkpktkkkkkkkkkkklJlLlVl~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.VlXl`lbljlnllllllllllmBmDmPmRm\m^mfmhmpmtmmmmmmmmmmmJnLnNnXnZnbndnlnnnvnzn~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.znnnnnnnnnnnDoFovoxooooooop ppppp&p(p0p4ppppppppppp0q2qnqpqxqzq~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.zqqqqqqqrrrr"r$r,r0rrrrrrrrrrrLsNsssssssssssBtDtLtNtVtXt`tdttt~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.ttuu uuuu u|u~uuuuuuuuu,v.vjvlvtvvv~vvvvvvww w wwww"wVwXw`wbwjwlwtwvw~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.vw~wwwwwwwwwwxxxx$x&x0x2x:x@HL~ƂȂЂ҂ڂނ$&`bjltv~02:<DFNRЄ҄"$,.6}zwaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ-6:ȅʅ҅ԅ܅46prz|܆ކ$&.08< 02:<D~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.DFNPX\ˆ҈Ԉ܈ވ*,<>JLTV^bĉƉΉЉ؉܉.0<>FHP~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJB*`JphaJaJaJaJaJaJ,PTȊ̊  *,46>B  (,tv~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.  ^`rt|~ԍ֍HJVX`bjltx~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.ҎԎ܎ގVX02lnvx "*,46>BVfȑʑ}zwaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ-ʑґԑܑޑ02lnvx&(02:>P`“ē̓Γ֓ؓ&~{wtaJo(aJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJ-&(bdlnvxΔД   (,ԕ֕ޕRT\^fhprz~ʖ̖Ԗ֖¿}zwaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJ-֖ޖFH02:<DFNRtv~ҘԘܘޘ~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.rt|~ .2Ěƚؚښ68@BJLXZfj~|yvaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ- <>JN̜Μ֜؜RT\^fhtvú~{xurolaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJB*`JphaJB*`JphaJB*`JphaJB*`JphaJaJaJaJaJaJaJaJaJaJaJaJ)  prz| &*z|~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.|8:BDLNXZdhơȡСҡޡ02:<DFPR\` ~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.$(|~"XZbdlnz|ʤ̤Ԥ֤ޤDFNP~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.PXZbdlpƥȥХҥڥܥLNVX`bjltxĦƦΦЦئڦVX`bjlvx~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.ԧ֧ާdfnpxz$&~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.&.08< tv~ &(04xz~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.z^`hjrt|~ȮʮҮԮܮޮ~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.<>FHPR^`hlƯȯЯүگܯXZbdlnvxҰ԰ܰް0¿}zwaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJo(aJaJaJaJaJaJaJaJaJaJaJaJaJaJ-02:<DFNPX\±ıбұޱ "*,46BF²ʲ̲زܲ$&.08:B~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.BDLPlnvx̳γֳس PRZ\dfvx"dfn~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.npxz"xzȶʶҶԶ޶JLTV^`jlv~{xuaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ.vzķƷзҷܷ (*24<>FJĸҸ"&HJRT\^fhpaJaJaJaJaJaJaJaJaJo(o(^JaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ5ptȹʹԹع  "TV^`hj|~ҺԺֺ~wurUU B*`Jph B*`Jph B*`JphUmHsHnHtHUUaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJaJ, "<>PRVXzƼؼؽڽܽBDFvxVX<>ľ}xsnid_ZCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ 0JCJaJ 0JCJaJCJaJ CJo(aJ CJo(aJCJaJ CJo(aJCJaJ CJo(aJCJaJCJUmHsHnHtHUUUmHsHnHtH# (*8:@BHLdftv|~žwphaZWTaJaJ CJaJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHaJaJ CJaJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHaJaJ CJaJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHaJaJaJaJaJaJCJdf<>rtTXƾ~ytolgb]XUaJCJaJCJaJCJaJCJaJCJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHaJaJ CJaJKH CJaJKHCJo(aJKH CJaJKHCJo(aJKH CJaJKHX<> "LN*,@BPTVfh*,@BRTdfo(o(aJaJaJaJaJaJaJaJaJaJaJaJaJB*`JphaJaJaJaJ<*,@BNP`b8:LNbdtv8:LNbdtv*,:<^`rto(o(o(o(o(o(o(o(F:<^`pr24\^np`bfhj|~  "&o(aJaJo(aJaJo(aJo(aJaJo(aJaJo(aJo(aJaJo(aJaJ=Z\lndh,.>@PR|~o(o(o(o(aJaJaJaJaJaJaJaJaJaJaJaJaJB*`JphaJaJaJaJaJo(aJo(aJaJo(aJaJo(aJ6*,<>NPz| "46JL^`pr*,BDVXhj,.BDTo(o(o(o(GTVfh$&:<NP`b02DFVX(*24DFprvx~o(o(G*,<>dfjlrv  02XZ^`fj>@DFLP*,VX\^do(o(o(o(Gdh  DFJLRV  02\^bdjn "24Z\`bhl"&(o(o(o(o(o(o(F(8:dfjlrv .0DFVXhj&(8:NP\`brt 02BDXZjl|~@aJo(o(o(o(o(o(F@BVX   &*bdfjlrtx|"$(o(o(aJo(o(o(o(aJaJaJaJo(o(aJaJaJaJaJo(o(o(o(aJaJaJaJo(o(aJaJaJ:(<@ | 6<xo(aJaJo(aJaJo(aJaJo(aJaJo(aJaJo(aJaJCJCJo(CJo(aJaJo(o(o(o(aJaJo(o(o(o(aJaJo(o(o(o(aJaJaJaJaJaJ3X^`p*,.xzJLþ{vqnjgc`\CJo(CJCJH*CJCJH*CJCJaJCJaJ CJaJ5 CJaJ50JCJaJ5 CJo(aJ CJo(aJCJaJ CJaJ5 CJaJ50JCJaJ50JaJCJaJCJaJCJaJCJaJCJo(CJo(o(aJaJo(aJaJo(aJaJo(aJaJo(aJaJo(aJaJ$FJLNHdjP R           "    þ{rjb]XSM CJaJ5CJaJCJaJCJaJCJaJ5\CJaJ5\CJaJ5\UCJaJ5mHsHnHtH\UCJaJ5\CJaJ5\CJaJ5\U0JCJaJ5 CJo(aJ CJo(aJCJaJCJaJCJaJCJaJCJaJ CJo(aJCJaJ CJo(aJCJaJCJaJCJaJCJCJCJH*CJXZ46Z\|~RTdh~BDRTzPJaJPJaJPJaJPJaJPJaJPJaJPJaJPJaJPJaJPJaJaJaJaJaJaJaJaJaJaJaJ0J0JaJCJaJCJaJCJaJCJaJCJaJ CJaJ5.^bxzXZ$*,jl46|tnfUCJaJ5 CJaJ5CJaJ5U 0J5aJ0JaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJCJaJ CJaJ5 CJaJ5 0J5aJ0JPJaJPJaJPJaJPJaJPJaJPJaJPJaJPJaJ(. 0 2 B D b d f h !!!!""$ $0$2$P$R$ƾ}voh`XRJUCJaJ5 CJaJ5CJaJ5U0JCJaJ5 CJOJQJ CJOJQJ CJOJQJ CJOJQJCJaJCJaJ CJaJ5 CJaJ5CJaJ5UCJaJ5mHsHnHtHUCJaJ5 CJaJ5CJaJ5U0JCJaJ50JaJCJaJCJaJ CJaJ5 CJaJ5CJaJ5UCJaJ5mHsHnHtHR$T$V$$$$$$$ %%%%(%*%& &8&<&&&&&&&&&j'l'''''''((`(b(.)0)n)p)* *l***D+F+++@,B,ýCJH*H*H* 0JaJ\ 0JaJ\ 0JaJ\ 0JaJ\ 0JaJ\ 0JaJ\0JCJaJ5 CJaJ5CJaJ5UCJaJ5mHsHnHtH5B,,,D-F---2.4...../ //h/l///////l0n0000000V1X1111111,2022242H2J2222222V3X33333&4*4D4H4z4|444444H*H*H*H*H*H*H*H*H*E44^5b5d5f5z5|55555Z6\666677777x7|777777788888899.929L9P9x9z9::D:H::: ;:;>;B;D;X;Z;;;;;;;<"<<<<<"=H*H*CJH*H*H*H*H*H*H*E"=&=*=,=@=B=R>V>Z>\>p>r>>>>>>> ?$?(?*?>?@???@@"@&@8@:@AA>A@AZA^AAAAAAAAAAA.B0BZB`BzB~BBB*C,CZC^CCCCCCCD DvDxDH*H*H*H*H*H*H*H*H*H*ExDDDE"E&E(EEFF>FBF^FbFFFGGGGGGGGG HHHLHPH}ld\UMOJ QJ ^J h OJ QJ ^J CJOJQJ5CJOJQJ5!B*`JphCJOJQJaJKHB*`JphCJo(aJKH"B*`JphCJo(aJ5KH\B*`JphCJaJ5KH\"B*`JphCJo(aJ5KH\"B*`JphCJo(aJ5KH\CJOJQJ5CJOJQJ5CJaJCJaJH*H*H*PHjHnHrHHHHLLLJMLMNMXMjMMNķq`M<!B*`JphOJ QJ ^J mH sH $B*`JphOJ QJ o(^J mH sH !B*`JphOJ QJ ^J mH sH $B*`JphOJ QJ o(^J mH sH B*`JphOJ QJ ^J OJ QJ ^J 5OJ QJ ^J 5 OJ QJ ^J B*`JphOJ QJ ^J hB*`JphOJ QJ ^J B*`JphOJ QJ ^J hOJ QJ ^J h OJ QJ ^J B*`JphOJ QJ ^J OJ QJ ^J hOJ QJ ^J hNNNHPJPPPPPPZQ^QbQQQQʹq`SD<4'B*`JphOJ QJ ^J OJ QJ ^J 5OJ QJ ^J 5B*`JphOJ QJ ^J hB*`JphOJ QJ ^J !B*`JphOJ QJ ^J mH sH $B*`JphOJ QJ o(^J mH sH !B*`JphOJ QJ ^J mH sH !B*`JphOJ QJ ^J mH sH $B*`JphOJ QJ o(^J mH sH !B*`JphOJ QJ ^J mH sH !B*`JphOJ QJ ^J mH sH $B*`JphOJ QJ o(^J mH sH !B*`JphOJ QJ ^J mH sH QjTnTrT[ [$[&[([*[,[.[0[2[4[6[8[:[<[>[@[ƹ|tld\TLD<CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5CJOJQJ5B*`JphOJ QJ ^J B*`JphOJ QJ ^J !B*`JphOJ QJ ^J mH sH OJ QJ ^J 5B*`JphOJ QJ ^J h!B*`JphOJ QJ ^J mH sH @[|[[[[[[[\\\\\\\z]|]]]]]re^VOG@8OJ QJ o(^J OJ QJ ^J OJ QJ o(^J OJ QJ ^J OJ QJ o(^J OJ QJ ^J B*`JphOJ QJ ^J B*`JphOJ QJ o(^J B*`JphOJ QJ ^J OJ QJ ^J 5B*`JphOJ QJ ^J B*`JphOJ QJ ^J !B*`JphOJ QJ ^J mH sH B*`JphOJ QJ ^J OJ QJ ^J hOJ QJ ^J hOJ QJ o(^J hOJ QJ ^J hOJ QJ ^J h OJ QJ ^J ]^^X_\_`_d_h_l______2`4`6`:`P`ŶsiaWME;OJ QJ o(^J hOJ QJ ^J hOJ QJ o(^J hOJ QJ o(^J hOJ QJ ^J hOJ QJ o(^J h'B*`JphOJ QJ o(^J hmH sH 'B*`JphOJ QJ o(^J hmH sH $B*`JphOJ QJ ^J hmH sH OJ QJ ^J hB*`JphOJ QJ ^J hB*`JphOJ QJ ^J h OJ QJ ^J OJ QJ ^J OJ QJ ^J OJ QJ ^J OJ QJ o(^J OJ QJ ^J P`R`T``````aa$a(a*a,a.a0a2a4aƼth\PD8CJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsH$B*`JphOJ QJ ^J hmHsHOJ QJ ^J hmHsHOJ QJ o(^J hmHsHCJaJOJ QJ o(^J hOJ QJ o(^J hOJ QJ ^J hOJ QJ o(^J hCJaJ$B*`JphOJ QJ ^J hmH sH B*`JphOJ QJ ^J h4a6a8a:aa@aBaDaFaHaJaLaNaPaRaTaVa÷{ocWK?3CJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHVaXaZa\a^a`abadapara|a~aaaaaa÷yk]OA5CJOJ QJ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJ OJ PJQJ ^J aJ 5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHCJOJQJ5mHsHaaaaaabb4b8bTbVbXbZb\b^bbbɻwk^QD7*CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJQJ^JaJ5bbbbbbbbbbbbbcc8c:cdZd\dxd|dddddddddde˾ynaTG:-CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJeee"eJeLeNeTeVeXeZeretevexeze~eeeĸrg\QF;0CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJeeeeeeeeff.f0fLfPfffhfjfpfƹxm`UJ>3CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ pfrfffffffffggg@gBgbgdgvi\OB5CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ dgggggggggggggggggµuj]PC6CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJ5CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJggh h"h(h4h:hoBoDoFooooooo˾maUI;-CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5'B*`JphCJOJ QJ ^J aJ5hCJOJ QJ ^J aJhCJOJ QJ ^J aJhCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJooooooooooopp(p*pJpɻugYK=/CJOJ QJ o(^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ o(^J aJ5CJOJ QJo(^J aJ5CJOJ QJ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ o(^J aJ5JpNptpvpxpzp|p~ppppppppppp̿vk`UJ=0CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ PJQJ ^J aJ5pq q&q*qDqFqHqPqRqrqtqqqqqqq·{naTGt@tXtZtntyl_RE8-CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJntrtttttttttttttuuu uźylaTI>2CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJ u(u*uTuVu`urutuuuuuuuuvvv¶yncWLA6CJOJ QJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ vv"v$v&v(v*v.v`vbvdvvvvvvvvĹzm`SF9.CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJvvvvvvwww2w4w6w8w:wzƻzodYNB6CJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJ>z@z\z^zzzzzzzzzzzzzz˾~qdWJ=1CJOJ QJ^J aJ5CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJ5\CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ zzz{{2{4{T{V{v{z{|{~{{{{{̿reXK>1CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJ5\CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJ5{{{{{{{{{{{{{{{{{|ymbWJ=0CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJ5CJOJ QJ^J aJ5||2|4|P|T|r|t|v|z|||~||||||||qf[NA4CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJ||||}}}"}$}&}(}B}D}^}`}z}|}}ĸ~qdWJ=2CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJ}}}}}}}}}}} ~~*~,~H~L~~Ź}reXM@5CJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJ~~~~~~~02NRtvx|~ĹzmbWK@4CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJOJ QJ ^J aJCJOJ QJ^J aJCJOJ QJ^J aJ~.ö}qeXK>1CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ PJQJ ^J aJCJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ .0LNjnprtvx|ĀƀȀ~qeYL?2CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJ5\CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJ  ,.NRTVXZ\^`bqcUG@92 OJ QJ ^J OJ QJ ^J OJ QJ ^J CJOJ QJ o(^J aJhCJOJ QJ o(^J aJhCJOJ QJ o(^J aJhCJOJ QJ o(^J aJhCJOJ QJ o(^J aJhCJOJ QJ o(^J aJhCJOJ QJ ^J aJhCJOJ QJ ^J aJhCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJ  ,.VXz|‚Ăzl^PB6*CJOJ QJ ^J aJhCJOJ QJ ^J aJhCJOJ QJ o(^J aJhCJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\ OJ QJ ^J ĂƂЂ҂܂ނ  DF|~˿{oaUG;-CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ 5CJ OJ QJ o(^J aJ 5CJ OJ PJQJ ^J aJ 5CJ OJ QJ o(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ^J aJ 5CJOJ QJ o(^J aJh   &µth]QF:/CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5&(JLnp„܄ބui^RG;0CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJo(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ  "HJnp…ąƅʅ̅öuj_TH=1CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ ̅΅Ѕ,.JNPµvk`TI=2CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ †"&(VXZ^`bdvk_TH=2CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ d‡Ƈȇ "&(˾ti^RG;0CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ (*HJhjڈ܈ވvk_TH=2CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ $&:<>@\`hj˾sh]RF;/CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ ĉƉ "tvxŹxk`UJ?2CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ ̊Ίxk^QF;0CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ  024PRnp˿reXK>2CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5\CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ  $&>@X\fǻ~qdWJ=1CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ fh܌ތǻ~qdWJ=2CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ xz|~čƍȍލŸxk_RE8CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ ލķ|qdWJ=1CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ  <>Z\xzЎҎԎ؎ڎ˾}qf[PD9-CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5\CJ OJ QJ ^J aJ 5ڎ܎ގ246:<>@BDöwj_TIFHPRXZ`dzm`TG;.CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ dfēƓȓʓ̓ΓƹzmbWI6OJ QJ o(^J OJ QJ o(^J OJ QJ o(^J OJ QJ o(^J CJOJ QJ ^J aJhCJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ <>@BDFܖޖ 68VX~ȺtfXJ<CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\OJ QJ o(^J OJ QJ ^J OJ QJ o(^J OJ QJ o(^J OJ QJ o(^J OJ QJ o(^J OJ QJ o(^J ΗЗޗ˿{m_SE7+CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ PJQJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ 5CJ OJ QJ o(^J aJ 5CJ OJ PJQJ ^J aJ 5CJ OJ QJ o(^J aJ 5CJ OJ PJQJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ^J aJ 5CJOJ QJ ^J aJhCJOJ QJ ^J aJhCJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\TVĘȘʘ̘ΘИҘ֘&(*,˽~qdXL?2CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJo(^J aJ 5,.04ΙЙ6:vxzµynaTI>1CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ z $&(.0JĹvj_SF;CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ JLfhԛ֛؛ @BbķzmbUJ?2CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ bfМҜ "BDHķ~qfYNC6CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ ܝޝ `bdĹ~sf[NC6CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ ƞȞʞJLNRTV\^~ƹui^SF;CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ ŸğDFlnĹ|odWLA6CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ   (*,.46¶|peYNB5CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ 6RTprȽreXL@3CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5\CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ rtvxz|~wlaUI>3CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ "$@B^b 8:RTf·|odWL?4CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ fh24NPRTnrڥĹ~qf[NA6CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ ڥܥޥ <>@Z\vxķ}qdYLA4CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ xTVXxz֧اܧĹ|qf[NC6CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ ܧ "$&(HJLfhlĹ~sf[PD9CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ >@^`b~ķ~qfYNC7CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ :<>VX\Ĺ~sf[NB6CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ ֪ت"rtv·|pdWJ=1CJ OJ QJ ^J aJ \CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ ګܫޫ 24BFĹzl^PB4CJ OJ QJ o(^J aJ 5CJOJ QJ o(^J aJ5CJ OJ PJQJ ^J aJ 5CJOJ QJ o(^J aJ5CJ OJ PJQJ ^J aJ 5CJOJ QJo(^J aJ5CJ OJ QJ ^J aJ 5CJOJ QJ^J aJ5 OJ QJ ^J OJ QJ ^J CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ FHJ(,.0246:˽}qdWJ=0CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJOJ QJo(^J aJ5CJ OJ QJ ^J aJ 5CJOJ QJo(^J aJ5CJ OJ QJ ^J aJ 5CJOJ QJo(^J aJ5CJ OJ QJ ^J aJ 5CJOJ QJo(^J aJ5CJ OJ PJQJ ^J aJ 5CJ OJ QJ ^J aJ 5:  xk`SH=2CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5|~ܮޮ8:<XƹwlaVK>3CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ XZz|~"$&*,.46ø}qfZOC7CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ 6RTVXxz̰ΰаĹzobWJ?3CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 46VZޱ$Ĺ|qeZOC6CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ $&*²IJƲ&(*DFJĹ~reYMB7CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ   .0246:Ĺuj^SG<0CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ ִش8:>rtv·{ocVK=2CJ OJ QJ ^J aJ CJ OJ PJQJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ µʵ̵ \^`~Ź|ocVJ=2CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ \CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ \CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ ֶڶܶ޶NP̿ui]PE:/CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5\CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ ·Ʒ ">@\ƺ{ocVK>2CJ OJ QJ ^J aJ \CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ 5CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ \^xz  *,HJfh·|odYL?3CJ OJ QJ ^J aJ 5CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ  .0LNŹseZMB5CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ PJQJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ CJ OJ QJ o(^J aJ CJ OJ QJ ^J aJ 5Njl*,.02>@`b÷zl^PB4CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\ OJ QJ ^J OJ QJ ^J OJ QJ o(^J OJ QJ o(^J OJ QJ ^J CJOJ QJ ^J aJhCJOJ QJ ^J aJhCJOJ QJ ^J aJhCJOJ QJ ^J aJhCJ OJ PJQJ ^J aJ CJ OJ PJQJ ^J aJ CJ OJ QJ ^J aJ CJ OJ QJ ^J aJ һԻ hjǹ~rdXL>2CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJo(^J aJ5CJOJ QJ ^J aJ5CJOJ QJ^J aJ5CJOJ QJ ^J aJh OJ QJ ^J CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\CJOJ PJQJ ^J aJ\ڼܼFHJNøwk]QC8-CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5NPRTVXZ\`½Ƚwl[NA6CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJ!B*`JphCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJȽʽ<@BRhͿ{odXMA6CJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ o(^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJƾȾʾ̾ 2468źuj^PD9CJOJ QJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ8TVprĿƿ ʽti^SH;.CJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ o(^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ PJQJ ^J aJ!B*`JphCJOJ QJ ^J aJ2468:<>@BX^`xzĹwl_TG<1CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJz(Ƚ{peZOD9CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ(*,.0246:>ƻvk`UJ?4CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJ2:ȽzobWL?4CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ:<>PXZ\^|Ĺuh[NA6CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ.46ǻylaVI>1CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ68:<>BXZ\`bdfhjlnprƻuj_TI>3CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJr·sh\QF;0CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJ  *,BD`dǼvj_TI=2CJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJ"$@DFHRT^`Ǽug[OA5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJQJ^J aJ5CJOJ QJo(^J aJ5CJOJ QJ ^J aJ5CJOJ QJ^J aJ5 OJ QJ ^J OJ QJ ^J CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ02PRprøwk]QC8-CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJ5CJOJ QJ ^J aJ5CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJ58wlaTI<1CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJ8:VXrtĹui]RG<0CJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJ2468:RTX|ƻwi]RG:CJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ5CJOJ QJ o(^J aJ5CJOJ QJ ^J aJ5CJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJ04Z\^`bd÷~sh]PC8CJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ o(^J aJdfhlƻyl_TI>3CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJ "$&(*,.0246:vxzȽ{peZOD9CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJz|~}rg\QF;0CJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJCJOJ PJQJ ^J aJ  :<>@BDƺwj_RF;/CJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ PJQJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJCJOJ QJ ^J aJCJOJ QJ o(^J aJ      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~